0001493152-22-008501.txt : 20220331 0001493152-22-008501.hdr.sgml : 20220331 20220331163559 ACCESSION NUMBER: 0001493152-22-008501 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 109 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 22793312 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 10-K 1 form10-k.htm
0001054102 false FY P7Y P2Y P3Y P3Y P3Y 0001054102 2021-01-01 2021-12-31 0001054102 2021-06-30 0001054102 2022-03-25 0001054102 2021-12-31 0001054102 2020-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001054102 2020-01-01 2020-12-31 0001054102 us-gaap:CommonStockMember 2020-12-31 0001054102 us-gaap:CommonStockMember 2019-12-31 0001054102 us-gaap:CommonStockMember 2021-03-31 0001054102 us-gaap:CommonStockMember 2020-03-31 0001054102 us-gaap:CommonStockMember 2021-09-30 0001054102 us-gaap:CommonStockMember 2020-09-30 0001054102 us-gaap:TreasuryStockMember 2020-12-31 0001054102 us-gaap:TreasuryStockMember 2019-12-31 0001054102 us-gaap:TreasuryStockMember 2021-03-31 0001054102 us-gaap:TreasuryStockMember 2020-03-31 0001054102 us-gaap:TreasuryStockMember 2021-06-30 0001054102 us-gaap:TreasuryStockMember 2020-06-30 0001054102 us-gaap:TreasuryStockMember 2021-09-30 0001054102 us-gaap:TreasuryStockMember 2020-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001054102 us-gaap:RetainedEarningsMember 2020-12-31 0001054102 us-gaap:RetainedEarningsMember 2019-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-03-31 0001054102 us-gaap:RetainedEarningsMember 2020-03-31 0001054102 us-gaap:RetainedEarningsMember 2021-06-30 0001054102 us-gaap:RetainedEarningsMember 2020-06-30 0001054102 us-gaap:RetainedEarningsMember 2021-09-30 0001054102 us-gaap:RetainedEarningsMember 2020-09-30 0001054102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001054102 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001054102 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001054102 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001054102 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001054102 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001054102 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001054102 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001054102 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001054102 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001054102 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001054102 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0001054102 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0001054102 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0001054102 us-gaap:TreasuryStockMember 2021-10-01 2021-12-31 0001054102 us-gaap:TreasuryStockMember 2020-10-01 2020-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001054102 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001054102 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001054102 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001054102 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001054102 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001054102 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001054102 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001054102 us-gaap:CommonStockMember 2021-06-30 0001054102 us-gaap:CommonStockMember 2020-06-30 0001054102 us-gaap:CommonStockMember 2021-12-31 0001054102 us-gaap:TreasuryStockMember 2021-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-12-31 0001054102 2019-12-31 0001054102 2020-01-13 2020-01-15 0001054102 2019-12-30 0001054102 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-01-01 2021-12-31 0001054102 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2021-01-01 2021-12-31 0001054102 IDXG:OfficeAndComputerEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001054102 IDXG:OfficeAndComputerEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001054102 IDXG:LabEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001054102 IDXG:LabEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001054102 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2021-01-01 2021-12-31 0001054102 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2021-01-01 2021-12-31 0001054102 IDXG:SoftwareForInternalUseMember srt:MinimumMember 2021-01-01 2021-12-31 0001054102 IDXG:SoftwareForInternalUseMember srt:MaximumMember 2021-01-01 2021-12-31 0001054102 IDXG:SoftwareForExternalUseMember 2021-01-01 2021-12-31 0001054102 IDXG:AmpersandNotesMember 2021-01-07 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-01-07 0001054102 IDXG:AmpersandNotesMember 2021-05-10 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-05-10 0001054102 IDXG:ComericaBankMember 2021-10-31 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember 2021-10-31 0001054102 IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001054102 IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:BroadOakLoanMember 2021-12-31 0001054102 IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001054102 IDXG:AsuragenMember 2021-01-01 2021-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2020-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2021-12-31 0001054102 IDXG:BroadOakLoanMember 2020-12-31 0001054102 IDXG:BroadOakLoanMember 2021-01-01 2021-12-31 0001054102 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember 2019-07-01 2019-07-31 0001054102 IDXG:BioPharmaAcquisitionMember 2019-07-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2021-01-01 2021-12-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2021-12-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2020-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2021-01-01 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2020-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2021-01-01 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2020-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2021-01-01 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2020-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2020-12-31 0001054102 IDXG:CLIALabMember 2021-01-01 2021-12-31 0001054102 IDXG:CLIALabMember 2021-12-31 0001054102 IDXG:CLIALabMember 2020-12-31 0001054102 IDXG:OpearatingLeaseMember 2021-12-31 0001054102 IDXG:FinancingLeaseMember 2021-12-31 0001054102 srt:MinimumMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember 2021-01-01 2021-12-31 0001054102 IDXG:SecurityPurchaseAndExchangeAgreementMember us-gaap:SeriesBPreferredStockMember 2020-01-09 2020-01-10 0001054102 IDXG:SecurityPurchaseAndExchangeAgreementMember us-gaap:SeriesBPreferredStockMember IDXG:OneThreeOneFiveCapitalMember 2020-01-09 2020-01-10 0001054102 IDXG:SecurityPurchaseAndExchangeAgreementMember us-gaap:SeriesBPreferredStockMember IDXG:AmpersandLimitedPartnershiMember 2020-01-09 2020-01-10 0001054102 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001054102 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001054102 IDXG:SeriesBPreferredStocksMember 2021-01-01 2021-12-31 0001054102 IDXG:SeriesBPreferredStocksMember 2020-06-08 2020-06-10 0001054102 IDXG:SeriesBPreferredStocksMember 2020-01-14 2020-01-15 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember 2021-10-29 0001054102 IDXG:TermLoanMember IDXG:AmpersandTwoThousandEighteenMember 2021-10-28 2021-10-29 0001054102 IDXG:TermLoanMember IDXG:AmpersandTwoThousandEighteenMember 2021-10-29 0001054102 IDXG:LoanAndSecurityAgreementMember IDXG:ComericaBankMember 2021-10-29 0001054102 IDXG:LoanAndSecurityAgreementMember IDXG:ComericaBankMember 2021-10-28 2021-10-29 0001054102 IDXG:SecurityAgreementMember IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-01-07 0001054102 IDXG:SeriesBConvertiblePreferredStockMember IDXG:AmpersandMember 2021-01-07 0001054102 IDXG:SeriesBConvertiblePreferredStockMember 2021-01-06 2021-01-07 0001054102 IDXG:OneThreeOneFiveCapitalMember IDXG:SeriesBConvertiblePreferredStockMember 2021-01-06 2021-01-07 0001054102 IDXG:SeriesBConvertiblePreferredStockMember IDXG:PromissoryNotesMember 2021-01-06 2021-01-07 0001054102 IDXG:PromissoryNotesMember 2021-01-06 2021-01-07 0001054102 IDXG:SecurityAgreementMember IDXG:AmpersandNoteMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember 2021-05-01 2021-05-10 0001054102 2021-01-06 2021-01-07 0001054102 IDXG:AmpersandMember IDXG:TermLoanMember 2021-09-28 2021-09-29 0001054102 IDXG:OneThousandThreeFifteenCapitalMember IDXG:TermLoanMember 2021-09-28 2021-09-29 0001054102 IDXG:PrivatePlacementWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2021-12-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2020-12-31 0001054102 IDXG:RedPathWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:RedPathWarrantsMember 2021-12-31 0001054102 IDXG:RedPathWarrantsMember 2020-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2021-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2020-12-31 0001054102 IDXG:WarrantsIssuedMember 2021-01-01 2021-12-31 0001054102 IDXG:WarrantsIssuedMember 2021-12-31 0001054102 IDXG:WarrantsIssuedMember 2020-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2021-01-01 2021-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2021-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2020-12-31 0001054102 us-gaap:WarrantMember 2021-12-31 0001054102 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001054102 IDXG:StockIncentivePlanMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001054102 IDXG:RSUsandRestrictedStockMember 2021-01-01 2021-12-31 0001054102 IDXG:RSUsandRestrictedStockMember 2020-01-01 2020-12-31 0001054102 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001054102 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0001054102 us-gaap:StockCompensationPlanMember 2021-01-01 2021-12-31 0001054102 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001054102 us-gaap:SalesRevenueNetMember IDXG:MedicareMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001054102 us-gaap:SalesRevenueNetMember IDXG:MedicareMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001054102 IDXG:MedicareCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:MedicareCustomerMember 2020-01-01 2020-12-31 0001054102 IDXG:MedicareAdvantageCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:MedicareAdvantageCustomerMember 2020-01-01 2020-12-31 0001054102 IDXG:CommercialPayersCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:CommercialPayersCustomerMember 2020-01-01 2020-12-31 0001054102 IDXG:ClientBillingsCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:ClientBillingsCustomerMember 2020-01-01 2020-12-31 0001054102 us-gaap:DomesticCountryMember 2021-12-31 0001054102 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001054102 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001054102 us-gaap:DomesticCountryMember 2019-07-07 2019-07-15 0001054102 us-gaap:DomesticCountryMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:DomesticCountryMember us-gaap:LatestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001054102 IDXG:WarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:WarrantsMember 2020-01-01 2020-12-31 0001054102 IDXG:ComericaLoanAgreementMember IDXG:ComericaBankMember IDXG:TermLoanMember 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember 2021-10-12 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember us-gaap:AccountsReceivableMember 2021-10-13 0001054102 srt:ScenarioForecastMember IDXG:LoanAndSecurityAgreementMember 2022-06-30 0001054102 IDXG:LoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-10-12 2021-10-13 0001054102 IDXG:RevolverMember 2021-12-31 0001054102 IDXG:SVBLoanAgreementMember IDXG:SiliconValleyBankMember 2018-11-13 0001054102 IDXG:SVBLoanAgreementMember IDXG:SiliconValleyBankMember IDXG:TermLoanMember 2018-11-13 0001054102 IDXG:RevolverMember 2020-12-31 0001054102 IDXG:PersonnelMember 2020-12-31 0001054102 IDXG:FacilitiesAndInfrastructureMember 2020-12-31 0001054102 IDXG:LegalMember 2020-12-31 0001054102 IDXG:PersonnelMember 2021-01-01 2021-12-31 0001054102 IDXG:FacilitiesAndInfrastructureMember 2021-01-01 2021-12-31 0001054102 IDXG:LegalMember 2021-01-01 2021-12-31 0001054102 IDXG:PersonnelMember 2021-12-31 0001054102 IDXG:FacilitiesAndInfrastructureMember 2021-12-31 0001054102 IDXG:LegalMember 2021-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2019-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2020-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2019-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2020-01-01 2020-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2020-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2019-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2020-01-01 2020-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2020-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2021-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2021-01-01 2021-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2021-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2021-01-01 2021-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure IDXG:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________to_________________

 

Commission file Number: 000-24249

 

Interpace Biosciences, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   22-2919486

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

Morris Corporate Center 1, Building C

300 Interpace Parkway, Parsippany, NJ 07054

(Address of principal executive offices and zip code)

 

(855) 776-6419
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.01 par value per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s common stock, $0.01 par value per share, held by non-affiliates of the registrant on June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was $42,186,849 (based on the closing sales price of the registrant’s common stock on that date). Shares of the registrant’s common stock held by each officer and director and each person who owns 10% or more of the outstanding common stock of the registrant have been excluded because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

 

As of March 25, 2022, 4,226,422 shares of the registrant’s common stock, $0.01 par value per share, were issued and outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant’s definitive proxy statement for the 2021 annual meeting of stockholders, or Proxy Statement, or will be included in an amendment hereto, to be filed within 120 days of the end of the fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.

 

 

 

 
 

 

Interpace Biosciences, Inc.

Annual Report on Form 10-K

 

      Page
PART I    
  Item 1. Business 5
  Item 1A. Risk Factors 30
  Item 1B. Unresolved Staff Comments 67
  Item 2. Properties 67
  Item 3. Legal Proceedings 67
  Item 4. Mine Safety Disclosures 67
     
PART II    
  Item 5. Market for our Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 68
  Item 6. Selected Financial Data 69
  Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 69
  Item 7A. Quantitative and Qualitative Disclosures about Market Risk 80
  Item 8. Financial Statements and Supplementary Data 80
  Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 80
  Item 9A. Controls and Procedures 80
  Item 9B. Other Information 81
  Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 81
     
PART III    
  Item 10. Directors, Executive Officers and Corporate Governance 82
  Item 11. Executive Compensation 82
  Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 82
  Item 13. Certain Relationships and Related Transactions, and Director Independence 82
  Item 14. Principal Accounting Fees and Services 82
     
PART IV    
  Item 15. Exhibits, Financial Statement Schedules 83
  Item 16. Form 10-K Summary 89
       
Signatures 90

 

 2 
 

 

FORWARD LOOKING STATEMENT INFORMATION

 

This Annual Report on Form 10-K, and the documents incorporated by reference in this document, our press releases and oral statements made from time to time by us or on our behalf, may contain “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (or the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In this context, forward-looking statements are not historical facts and include statements about our plans, objectives, beliefs and expectations. Forward-looking statements include statements preceded by, followed by, or that include the words “believes,” “expects,” “anticipates,” “seeks,” “plans,” “estimates,” “intends,” “projects,” “targets,” “should,” “could,” “may,” “will,” “can,” “can have,” “likely,” or the negatives thereof or other comparable words and expressions regarding beliefs, plans, expectations or intentions regarding the future, including risks and uncertainties associated with the coronavirus (COVID-19) pandemic. These forward-looking statements are contained throughout this Form 10-K, including, but not limited to, statements found in Part I – Item 1 – “Business” and Part II – Item 7 – “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

Forward-looking statements are only predictions and are not guarantees of future performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. These predictions are also affected by known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied by any forward-looking statement. Many of these factors are beyond our ability to control or predict. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors. Such factors include, but are not limited to, the following:

 

  ● the substantial doubt about our ability to continue as a going concern due to our history of operating losses, declining cash position and other liquidity factors, which in the absence of additional short term financing may cause us to cease or scale back operations;
     
  ● the effect of the Coronavirus (COVID-19) pandemic which has materially and adversely affected our business and financial results, particularly during portions of 2020, due to the slowdown in demand for our clinical services and pharma services, a reduction in samples received and testing volume and delayed third party collections and other factors and which may continue to have an adverse effect on our future business;
     
  ● our expectations of future revenues, expenditures, capital or other funding requirements;
     
  ● our reliance on Medicare reimbursement for our clinical services and our being subject to decisions of the Center for Medicare and Medicaid Services (“CMS”) regarding reimbursement and pricing of our clinical services which could have a material adverse effect on our business and financial results, which has temporarily had a material adverse effect on our business due to a new billing policy issued by CMS in January 2022 whereby CMS stated they would no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service; while this decision was subsequently reversed in February 2022, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS;
     
  ● our secured lenders have the right to foreclose on substantially all of our assets if we are unable to timely repay our outstanding obligations;
     
  ● our dependence on sales and reimbursements from our clinical services for more than 50% of our revenue; the ability to continue to generate sufficient revenue from these and other products and/or solutions that we develop in the future is important for our ability to meet our financial and other targets;
     
  ● our revenue recognition is based, in part, on our estimates for future collections and such estimates may prove to be incorrect;
     
  ● our ability to finance our business on acceptable terms in the future, which may limit the ability to grow our business, develop and commercialize products and services, develop and commercialize new molecular clinical service solutions and technologies and expand our pharma services offerings;

 

 3 
 

 

  ● our obligations to make royalty and milestone payments to our licensors;
     
  ● our dependence on third parties for the supply of some of the materials used in our clinical and pharma services tests;
     
  ● the potential adverse impact of current and future laws, licensing requirements and governmental regulations upon our business operations, including but not limited to the evolving U.S. regulatory environment related to laboratory developed tests (“LDTs”), pricing of our tests and services and patient access limitations;
     
  ● our reliance on our sales and marketing activities for future business growth and our ability to continue to expand our sales and marketing activities;
     
  ● our ability to implement our business strategy; and
     
  ● the potential impact of existing and future contingent liabilities on our financial condition.

 

Please see Part I - Item 1A – “Risk Factors” of this Form 10-K, as well as other documents we file with the U.S. Securities and Exchange Commission, or the SEC, from time-to-time, for other important factors that could cause our actual results to differ materially from our current expectations and from the forward-looking statements discussed herein. Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. In addition, these statements speak only as of the date of this Form 10-K and, except as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

In this Form 10-K, references to “we,” “our,” “us,” “Interpace” and the “Company” refer to Interpace Biosciences, Inc., including consolidated subsidiaries as of December 31, 2021.

 

 4 
 

 

PART I

 

ITEM 1. BUSINESS

 

Company Overview

 

We are an emerging leader in enabling precision medicine principally in oncology by offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications through our clinical and pharma services. Through our clinical services, we enable physicians to personalize the clinical management of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment. Our clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Through our pharma services, we develop, commercialize and provide molecular- and biomarker-based tests and services and provide companies with customized solutions for patient stratification and treatment selection through an extensive suite of molecular and biomarker-based testing services, DNA and RNA extraction and customized assay development and trial design consultation. Our pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine by partnering with pharmaceutical, academic and technology leaders to effectively integrate pharmacogenomics into drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

 

Customer Category   Types of Customers   Nature of Services
Clinical services   ● Hospitals
● Physicians
● Cancer Centers
● Clinics		   Clinical services provide information on diagnosis, prognosis and predicting treatment outcomes of cancers to guide patient management.
    ● Commercial laboratories    
    ● Pathology groups    
         
Pharma services   ● Pharmaceutical companies
● Biotech companies
● Contract Research Organizations
● Academic Researchers
● Diagnostic companies		   Pharma services provide expert-based collaborative solutions, customized assays and high quality services in support of their pharmaceutical and biotechnology clients’ therapeutic development programs. By deploying deep scientific and medical expertise, pharma services support all phases of drug development and accelerate their clients’ clinical programs.

 

Our clinical services’ customers consist primarily of physicians, hospitals, cancer centers, commercial laboratories, pathology groups and clinics. Our largest customer for ThyGeNEXT® and ThyraMIR® products in 2021 was [Laboratory Corporation of America® or LabCorp]. Our revenue channels include reimbursement by Medicare, Medicare Advantage, Medicaid, and direct client billings (for example, hospitals and clinics), and commercial payers such as Blue Cross Blue Shield, Aetna, Cigna, United Healthcare and others.

 

We partner with pharmaceutical and biotech companies and clinicians as oncology diagnostic specialists by supporting development and patient care from bench to bedside. Pharmaceutical and biotech companies work with us to provide molecular profiles on clinical trial participants. Similarly, we believe the oncology industry is undergoing a rapid evolution in its approach to diagnostic, prognostic and treatment outcome testing, embracing precision testing and individualized medicine as a means to drive higher standards of patient treatment and disease management. These profiles may help identify biomarker and genomic variations that may be targetable for developing novel personalized therapeutics or that may be responsible for differing responses to existing oncology therapies, thereby increasing the efficiency of trials while lowering costs. We believe tailored and combination therapies can revolutionize oncology care through molecular- and biomarker-based testing services, enabling physicians and researchers to target the factors that make each patient and disease unique. Our pharma services’ customers consist primarily of pharmaceutical and biotech companies.

 

To optimize the operations of laboratory operations within our pharma services, during late 2020 and the first quarter of 2021, we transitioned activities from our Rutherford, NJ facility to our Morrisville, NC facility. We invested several million dollars to facilitate this relocation, including but not limited to the transfer of personnel, expansion of the Morrisville facility and validation of transferred processes. We believe that this investment will result in a reduction in future operating costs. We have also undergone several other cost-cutting initiatives, primarily reductions in headcount, and those costs are categorized as transition expenses as well. It is not certain whether the transition will produce the predicted financial benefits. During Fiscal 2021, the Company experienced a fairly significant decrease in volume within pharma services. The decrease in revenue within pharma services was approximately 32% from the comparable prior year period.

 

In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica Bank (“Comerica”). In addition, also in October 2021, the Company entered into an $8.0 million term loan with BroadOak Fund V, L.P. (“BroadOak”). See Part II – Item 7 – “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” for more details.

 

 5 
 

 

Impact of COVID-19 Pandemic

 

The COVID-19 pandemic, together with related precautionary measures, continues to impact portions of the regions in which we operate. These regions are attempting to address the COVID-19 pandemic in varying ways, including stay-at-home orders, temporarily closing businesses, restricting gatherings, restricting travel, and mandating social distancing and face coverings. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location.

 

The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future.

 

We continue to monitor the COVID-19 pandemic and the guidance that is being provided by relevant federal, state and local public health authorities and may take additional actions based upon their recommendations. It is possible that we may have to make adjustments to our operating plans in reaction to developments that are beyond our control.

 

Lab closures experienced thus far by the Company have consisted of periodic, temporary work stoppages to clean and disinfect the labs; however, this could change in the future based upon conditions caused by the pandemic. It is also possible that we could experience supply chain shortages if the pandemic worsens and if one or more suppliers is unable to continue to provide us with supplies. For the foreseeable future, however, we do not anticipate supply chain shortages of critical supplies.

 

We have developed contingency plans and will continue to monitor and update them in order to mitigate pandemic-related, adverse financial impacts upon our business.

 

Market Overview

 

Global Molecular Diagnostic Market

 

The global molecular diagnostics market is estimated to be $11.77 billion (USD) in 2021 and is expected to grow to $18.1 billion (USD) by 2026 with a CAGR of 9.0% between 2021 and 2026, according to Market Data Forecast’s Molecular Diagnostics Market report (ID: 10293, published January 2022).

 

The global esoteric testing market size was valued at $20.2 billion in 2020, and is estimated to reach $66.2 billion by 2030, growing at a CAGR of 12.5% from 2021 to 2030, according to an August 2021 report by Allied Market Research. We believe that the specialty molecular diagnostics market offers significant growth and strong patient value given the substantial opportunity it affords to lower healthcare costs by helping to reduce unnecessary surgeries and ensuring the appropriate frequency of monitoring. We are keenly focused on growing our test volumes, securing additional insurance coverage and reimbursement, maintaining and growing our current reimbursement and supporting revenue growth for our molecular diagnostic tests, introducing related first line product and service extensions, as well as expanding our business by developing and promoting synergistic products in our markets. We also believe that BarreGEN® is a potentially significant pipeline product, and we are providing necessary resources to support the development process.

 

Contract Research Organization Market size was valued at over $43.9 billion in 2020 and is estimated to grow at a 7.8% CAGR between 2021 and 2027. Growing demand for clinical trials in emerging countries coupled with increasing prevalence of chronic diseases is escalating the market growth. The pharma services (clinical research) segment in the contract research organization market accounted for $25.2 billion in 2020 and is projected to showcase an 8% growth rate by 2027.

 

 6 
 

 

United States Clinical Oncology Market

 

Despite many advances in the treatment of cancer, it remains one of the greatest areas of unmet medical need. In 2020, the World Health Organization attributed nearly 10 million deaths globally to cancer, which is about one in six deaths. Within the United States, cancer is the second most common cause of death, exceeded only by heart disease, accounting for nearly one out of every five deaths. Of note, pancreatic cancer is now the third leading cause of cancer deaths in the United States. The Agency for Healthcare Research and Quality estimated that the direct medical treatment costs of cancer in the United States for 2015 were $80.2 billion. In the United States in 2022, it is expected that in total there will be approximately 1.9 million new cancer cases diagnosed, which is the equivalent of approximately 5,205 new cases each day, according to the American Cancer Society. The incidence, deaths and economic loss caused by cancer are staggering. The following table published by The American Cancer Society shows estimated new cases and deaths in 2020 in the United States for selected major cancer types:

 

Cancer Type   Estimated New Cases   Estimated Deaths
Bladder   81,180   17,100
Breast (Female – Male)   287,858 – 2,710   43,250 – 530
Colon and Rectal (Combined)   151,030   52,580
Kidney (Renal Cell and Renal Pelvis)   79,000   13,920
Leukemia (All Type)   60,650   24,000
Liver and Intrahepatic Bile Duct   41,260   30,520
Lung (Including Bronchus)   236,740   130,180
Melanoma   99,780   7,650
Non-Hodgkin’s Lymphoma   80,470   20,250
Pancreatic   62,210   49,830
Prostate   268,490   34,500
Thyroid   43,800   2,230

 

References

 

1. American Cancer Society: Cancer Facts and Figures 2022. Atlanta, GA: American Cancer Society, 2022. Also available online. Last accessed February 22, 2022.

 

United States and International Clinical Trials Market Overview

 

The United States is currently a world leader in biopharmaceutical research and development and manufacturing. In fiscal year 2021, the National Cancer Institute received a budget of $6.44 billion, an increase of $119 million over fiscal year 2020, to issue grants to support research, with a targeted investment in enhanced and early detection of disease through the analysis of circulating biomarkers using minimally invasive methods, as well as a focused investment in cancer prevention and treatment including research on new vaccines to prevent cancer-causing infections and investigational immuno-oncology drugs and drug combinations. The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that the average cost to develop a drug, including trial failures, can be as high as $2.6 billion and the approval process from development to market may be as long as 15 years. According to the National Cancer Institute, the overall cancer death rate in the United States continues to decline. Life expectancy increases can be attributed to earlier detection, new treatments and oncology medications.

 

Outside of the United States, particularly in potential target geographies of the European and Asia Pacific (“APAC”) regions, growth in the pharmaceuticals and clinical trials market is continuing. Medicines spending in the top five European markets (France, Germany, Italy, Spain, and the UK) is expected to increase at a CAGR of between 3% and 6%, or $51 billion, over the next five years (2022 to 2026), up from $44 billion in the past five years, according to the IQVIA Institute analysis. New brands were the largest driver of growth from 2016 to 2021 and are expected to continue in the next five years (2022 to 2026) but may be hampered by lingering effects of the pandemic on marketing operations and reimbursement decisions. APAC’s location provides access to large patient pools within favorable regulatory environments. The CRO market is valued at approximately $7.6 billion as of 2021 and is forecast to reach $11.9 billion by 2025. As a result of ease in regulatory approval, low worker rates, availability of a large patient pool, and the presence of key suppliers, the APAC region is anticipated to see a CAGR growth rate of 12% between 2017 and 2025.

 

While oncology drugs have the potential to be among the most personalized therapeutics, very few have successfully made it to market. The application of pharmacogenomics to oncology clinical trials enables researchers to better predict differences in drug response, efficacy and toxicity among trial participants, as well as to optimize treatment regimens based on these differences. According to IQVIA, in 2021, more than half (53%) of all pharmaceutical sales in the United States were from specialty drugs, a category of drugs including oncology treatments tailored to patients’ genomic profiles. We believe a growing demand for faster development of personalized medicines and more effective clinical trials are growth drivers of this market, and our core expertise is pharmacogenomics, or the study of genetic analysis based on a patient’s response to a particular therapy or drug.

 

 7 
 

 

Our Strategy

 

Our primary goal is to become a leader in providing high quality and dependable personalized medicine with exceptional growth. Our strategy is to grow our business both organically as well as by selective partnering, which could potentially include licensing, acquisitions or mergers, to generate positive returns for our shareholders and driving towards cash flow break-even. We expect to not only continue to further develop our existing gastrointestinal and endocrine assays but to also expand our presence in other markets where we have expertise and access. Our existing customer base and broad-based capabilities provide us a unique window not only into our current customers’ needs but also permit us to anticipate their future needs.

 

The key tactics to achieve our goals include:

 

  ● Expanding our existing commercial products, especially PancraGEN®, ThyGeNEXT® and ThyraMIR®, focusing on personalized medicine and early intervention related to cancer risk;
     
  ● Accelerating the clinical development and commercialization of BarreGEN®, our esophageal cancer risk classifier for Barrett’s Esophagus, working with our recently developed Key Opinion Leaders (“KOL’s”) and expanding clinical studies to seek key reimbursement support while seeking partners to collaborate with us;
     
  ● Implementation of automation and focus on improved operating efficiencies in the clinical laboratories to provide consistent superior quality testing and reporting at reduced costs;

 

  ● Broadening coverage and reimbursement for our clinical tests including:

 

  ○ Initiating and expanding studies to demonstrate that our tests are effective;
     
  ○ Meeting standards necessary to be consistent with leading clinical guidelines;
     
  ○ Executing by our internal managed care team;
     
  ○ Collaborating with KOL’s; and
     
  ○ Establishing payer relationship and in-network contracts serving our diagnostic customers.

 

  ● Targeting synergistic product and service opportunities developed for our clinical customers for use by our pharmaceutical and biotech customers;
     
  ● Developing and commercializing other related first-line clinical assays and expanding our service offerings such as PanDNA®, a DNA only version of PancraGEN®, and markers for aggressive thyroid cancer;
     
  ● Expanding our commercial sales staff rationally, while supporting our products with high quality data and studies;
     
  ● Exploring partnering opportunities to acquire new technologies;
     
  ● Expanding our bioinformatics data collected (currently from over 60,000 patients), utilizing registries to improve our assays and leveraging our data with potential collaborators;
     
  ● Expanding internationally; and
     
  ● Expanding our average contract revenue from pharmaceutical and biotech customers by growing our services and product offerings while providing dependable and timely service and unique solutions.

 

 8 
 

 

The reliability of the volume growth from our clinical customers combined with more variable but scalable revenue from our pharmaceutical and biotech customers, we believe, provides the opportunity to expand our services and grow our business. We also believe that the synergistic opportunities of our businesses are important especially in targeted product categories where we have a history of clinical data and sample biorepositories as we expand our roster of pharmaceutical client opportunities. We also believe that our LIM’s systems, with the current investments we are making, is already an important tool to support our future growth as we begin to convert data into usable and unique information and insights for our customers’ benefit. Our unique commercial infrastructure focused on clinical and pharmaceutical customers is one of our most important assets and we anticipate expanding it in the future with highly trained commercial personnel that have growth potential and can effectively communicate our value proposition to our sophisticated customers. The information and analytics that we have, we believe, will help further differentiate us from our competitors.

 

Our Service Offerings

 

Our business is based on demand for molecular- and biomarker-based characterization of cancers from three main sectors: (1) clinical services for physicians, hospitals and clinics, (2) pharma services for biotechnology and pharmaceutical companies, and (3) pharma services for the research community.

 

Clinicians and oncologists in cancer centers and hospitals seek molecular-based testing since these methods often produce higher value and more accurate cancer diagnostic information than traditional analytical methods. Our proprietary and unique disease-focused or esoteric tests aim to provide actionable information that can guide patient management decisions, potentially resulting in decreased costs.

 

We continue to pursue the strategy of trying to demonstrate increased value and efficacy with payers who wish to contain costs and academic collaborators seeking to develop new insights and treatments.

 

Our pharma services are sought by biotechnology and pharmaceutical companies engaged in designing and running clinical trials, from pre-clinical to post market surveillance, for their value and efficacy in oncology and immuno-oncology treatments and therapeutics.

 

We aim to provide physicians and patients with diagnostic options for detecting genomic and other molecular alterations that are associated with gastrointestinal, endocrine, and lung cancers. Our clinical services’ customers consist primarily of physicians, hospitals and clinics.

 

Clinical services

 

Our clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. We commercialize genomic tests and related first line assays principally focused on early detection of patients at high risk of cancer using the latest technology to help personalize medicine and improve patient diagnosis and management. Our tests and services provide mutational analysis of genomic material contained in suspicious cysts, nodules and lesions with the goal of better informing treatment decisions in patients at risk of thyroid, pancreatic, and other cancers. The molecular diagnostic tests we offer enable healthcare providers to better assess cancer risk, helping to avoid unnecessary surgical treatment in patients at low risk, while also helping to identify high risk patients that would benefit from surgical intervention.

 

Our mission is to provide personalized medicine through genomics-based diagnostics and innovation to advance patient care based on rigorous science. Our laboratories are licensed pursuant to federal law under Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) and are accredited by College of American Pathologists (“CAP”) and our products are approved by New York State. We are leveraging our licensed and accredited laboratories to refine and commercialize our assays and products. We aim to provide physicians and patients with diagnostic options for detecting genomic and other molecular alterations that are associated with gastrointestinal, endocrine, and other cancers. Our customers consist primarily of physicians, hospitals and clinics.

 

We currently have five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, which is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using our proprietary PathFinderTG® platform; PanDNA, a “molecular only” version of PancraGEN® that provides physicians a snapshot of a limited number of factors; ThyGeNEXT®, which is an expanded oncogenic mutation panel that helps identify malignant thyroid nodules; ThyraMIR®, which, in combination with ThyGeNEXT®, assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene expression assay. and RespriDx®, which is a genomic test that helps physicians differentiate metastatic or recurrent lung cancer from the presence of newly formed primary lung cancer and which also utilizes our PathFinderTG® platform.

 

 9 
 

 

Gastrointestinal Cancer Products

 

Our current gastrointestinal integrated pathology risk diagnostic assay, PancraGEN® is based on our PathFinderTG® platform. PathFinderTG® is designed to use advanced clinical algorithms to accurately stratify patients according to risk of pancreatic cancer by assessing panels of DNA abnormalities in patients who have pancreaticobiliary lesions (cysts or solid masses) with potential for cancer. PanDNA is a “molecular only” reporting option for physicians that perform their own integration of first line testing results. PathFinderTG® is supported by our state of the art CLIA certified, and CAP accredited laboratory in Pittsburgh, Pennsylvania. Our Pittsburgh laboratory is our largest clinical laboratory where we process the majority of our oncology related commercial tests; we also support our other gastrointestinal and endocrine commercial activities through this laboratory.

 

Early detection of pancreatic cancer is crucial. Based on the American Cancer Society Cancer 2022 Cancer Facts and Figures, pancreatic cancer is the third leading cause of cancer deaths in the U.S. (estimated) with an average five year survival rate of 11%. PancraGEN® and PanDNA® are designed to determine risk of malignancy in pancreatic cysts and pancreaticobiliary solid lesions, which are more often than not benign lesions but have potential for developing into cancer. We believe that PancraGEN® is the leader in the market for integrated molecular diagnostic tests for determining risk of pancreaticobiliary malignancy. We currently estimate that the immediate addressable market for PancraGEN® is approximately 115,000 indeterminate pancreaticobiliary lesions annually or approximately $200 million annually based on the current size of the patient population and reimbursement rates. To date, PancraGEN® testing has been used in more than 56,000 clinical cases. The National Pancreatic Cyst Registry study published in Endoscopy in 2015 demonstrated that PancraGEN® more accurately determines the malignant potential of pancreatic cysts than international consensus 2012 imaging criteria, helping to ensure that surgery is reserved for the most appropriate patients. When molecular analysis is not performed, the vast majority of all pancreatic cyst surgeries are performed on cystic lesions that do not harbor malignancy.

 

The American Gastroenterological Association 2015 Guidelines have cautioned that many pancreatic surgeries have been performed unnecessarily for lesions that will not progress to invasive adenocarcinoma. In addition, the 2016 guidelines published by the American Society of Gastroenterology Endoscopy (ASGE) in Gastrointestinal Endoscopy included a specific recommendation for use of molecular testing in specific circumstances where other types of testing and analysis have not provided sufficient data on which to determine the best course of action for patient treatment. Accordingly, we believe that PancraGEN® provides a highly reliable diagnostic and prognostic option that identifies cancer risk in circumstances where risk of cancer is otherwise uncertain.

 

Endocrine Cancer Products

 

We currently market and sell a dual platform endocrine cancer risk diagnostic assay. The incidence of thyroid nodules is on the rise. ThyGeNEXT® is a next generation DNA and RNA sequencing oncogene and mRNA fusion panel that is used to evaluate indeterminate thyroid biopsies. ThyGeNEXT® works synergistically with our second endocrine cancer diagnostic test ThyraMIR®, which is based on measuring the relative expression of ten distinct microRNAs. The combination of ThyGeNEXT® and ThyraMIR® is designed to provide a highly sensitive “rule-in” and “rule-out” test to accurately risk stratify indeterminate thyroid nodules.

 

We estimate the total market for our endocrine cancer assays is approximately $230 million annually based on the current size of the patient population, estimated numbers of indeterminate biopsies and reimbursement rates. ThyGeNEXT® plus ThyraMIR® is a combination testing platform. The mutational analysis provided by ThyGeNEXT can help inform treatment alone when strong BRAF V600E-like mutations are found. However, reflex to ThyraMIR occurs approximately 85% of the time to provide a greater understanding of malignancy risk and is especially helpful when weaker drivers of malignancy, such as RAS-like mutations, are found.

 

 10 
 

 

Endocrinologists and ear, nose and throat (“ENT”) specialists evaluate most thyroid nodules for possible cancer by collecting cells through Fine Needle Aspiration (“FNA”) that are then analyzed by cytopathologists to determine whether or not a thyroid nodule is cancerous. It is estimated that approximately 20% or well over 100,000 biopsies analyzed annually yield indeterminate results, meaning they cannot be diagnosed as definitely being malignant or benign by cytopathology alone. In the past, guidelines recommended that some patients with indeterminate cytopathology results undergo surgery to remove all or part of their thyroid to obtain an accurate diagnosis by looking directly at the thyroid tissue. According to a study published by Wang, et al. in 2011, in approximately 77% of these cases, the thyroid nodule proved to be benign. Current National Comprehensive Cancer Network (“NCCN”) and American Thyroid Association (“ATA”) guidelines support use of molecular analysis for nodules with indeterminate cytology results as this testing can prove beneficial to further characterize these lesions and support optimal patient management.

 

Lung Cancer Product—RespriDx® Test and Metastatic versus Primary Platform

 

RespriDx® compares the mutational fingerprint of two or more sites of cancer to determine whether the neoplastic deposits are representative of a recurrence (metastasis) of lung cancer or a new primary or independent tumor. The test, which currently provides only nominal revenues, defines the presence or absence of cancer in atypical cytology by comparing the mutational profile with that of known previous cancer. RespriDx® assists in determining the most appropriate course of treatment, whether chemotherapy, surgery, or other modalities.

 

CLIA Certified and CAP Accredited Laboratories

 

Our testing is performed in our state of the art Clinical Laboratory Improvement Amendments (“CLIA”) certified College of American Pathologists (“CAP”) accredited laboratory in Pittsburgh, Pennsylvania. CLIA is a federal law regulating clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Clinical laboratories must be certified under CLIA in order to perform testing on human specimens, unless they fall within an exception to CLIA certification, such as research laboratories that test human specimens but do not report patient-specific results for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of individual patients. CLIA certification is also required to be eligible to bill Federal and State healthcare programs, as well as many private third-party payers, for diagnostic testing and services. In addition, proprietary tests must also be recognized as part of an accredited program under CLIA so that they can be offered in a CLIA-certified laboratory. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. For renewal of CLIA certification, clinical laboratories are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of clinical laboratories outside of the renewal process.

 

Pharma services

 

We provide data driven solutions for pharmaceutical and biotech companies engaged in clinical trials and focus on providing these clients with oncology specific and non-oncology genetic testing services for phase I-IV clinical trials along with critical support of ancillary services. These ancillary services include: biorepository, clinical trial logistics, clinical trial design, bioinformatics analysis, customized assay development. DNA and RNA extraction and purification, genotyping, gene expression, flow cytometry, cytogenetic and FISH and biomarker analyses. We also seek to apply our expertise in laboratory developed tests to assist in developing and commercializing drug-specific companion diagnostics. We have established business relationships with key instrument manufacturers to provide a multi-omic approach, and to drive acceptance among biopharmaceutical sponsors developing innovative immuno-oncology therapies.

 

We also utilize our pharma services laboratories to provide clinical trial services to the pharmaceutical and biotech industries to improve the efficiency and economic viability of clinical trials. Our clinical trials services leverage our knowledge of clinical oncology and molecular diagnostics and our laboratories’ fully integrated capabilities. We believe our pharma services operates one of only a few laboratories with the capability to combine somatic and germline mutational analyses in clinical trials.

 

 11 
 

 

Our pharma services laboratory located in Morrisville, North Carolina has current certificates under CLIA to perform high complexity testing and are accredited by CAP, one of seven CLIA-approved accreditation organizations.

 

Industry research has shown many promising drugs have produced disappointing results in clinical trials. For example, a 2016 article by the University of Michigan reported that only 1 in 50 cancer drug candidates make it to the clinical market. Given such a high failure rate of oncology drugs, combined with constrained budgets for biotech and pharmaceutical companies, there is a significant need for drug developers to utilize molecular diagnostics to decrease these failure rates. For specific molecular-targeted therapeutics, the identification of appropriate biomarkers indicative of disease type or prognosis may help to optimize clinical trial patient selection and increase trial success rates by helping clinicians identify patients that are most likely to benefit from a therapy based on their individual genomic profile.

 

From a laboratory infrastructure standpoint, we possess capabilities in histology, immunohistochemistry (“IHC”), flow cytometry, cytogenetics and fluorescent in-situ hybridization (“FISH”), as well as sophisticated molecular analysis techniques, including next generation sequencing. This allows for comprehensive esoteric testing within one lab enterprise, with our CLIA-certified, CAP-accredited laboratory serving as a central hub for specimen tracking. Using this approach, we are able to support demanding clinical trial protocols requiring multiple assays and techniques aimed at capturing data on multiple biomarkers. Our suite of available testing platforms allows for highly customized clinical trial design which is supported by our dedicated group of development scientists and technical personnel.

 

Through this combination of a variety of testing platforms powered by a team of experienced scientists, we offer a comprehensive approach to clinical trial support. As trial design becomes increasingly complex to cater to more specific drug targets and patient populations, we believe that clinical result generation and reporting through a single-source solution for testing is becoming more valuable than ever. Examples of clinical trial services offered by our pharma services include:

 

Flow cytometry Selection of individual antibodies in multiple myeloma, leukemia, lymphomas, and therapy response.
   
Karyotyping Genome-wide detection of aberrations at low resolution that have a diagnostic or prognostic significance.
   
FISH Fluorescent in-situ hybridization (FISH) probe library for the detection of gene abnormalities in chromosomes indicated in hematological and solid tumors.
   
Anatomic pathology Full IHC library with over 180 antibodies available.
   
Exome sequencing Sequencing of the protein-encoding genes in a genome.
   
DNA and RNA sequencing Sequencing to determine the presence and quantity of RNA or DNA in a specimen.
   
Next Generation sequencing Proprietary and custom-designed panels to deep sequence genomic material to identify genetic mutations, substitutions, insertions and deletions, and rearrangements of genetic material.
   
Cell-free DNA analysis Multi-gene next generation sequencing panel for lung cancer to detect tumor-derived cell-free DNA obtained from a blood draw.
   
DNA and RNA microarray Measures select genomic information for large number of genes simultaneously.
   
Sanger sequencing DNA sequencing for validation of next generation sequencing results, and for smaller scale sequencing projects.
   
Fragment size analysis Analysis technique where DNA fragments are separated by size and used for mutation detection.
   
DNA and RNA extraction and purification Extraction and isolation of DNA and RNA from a wide variety of sample types for immediate testing or for storage.
   
Biostatistics and Bioinformatics Design and review of client assays and analysis of datasets.

 

 12 
 

 

In March of 2022, ClinicalTrials.gov reported over 80,000 clinical trials that are either preparing or recruiting patients. Molecular- and biomarker-based testing services have been altering the clinical trials landscape by providing biotech and pharmaceutical companies with information about trial subjects’ genetic profiles that may be able to inform researchers whether or not a subject will benefit from the trial drug or will experience adverse effects. We believe that streamlined subject selection and stratification and tailored therapies selected to maximally benefit each group of subjects may increase the number of trials that result in approved therapies and make conducting clinical trials more efficient and less costly for biotech and pharmaceutical companies. According to the United States Food and Drug Administration (“FDA”), 2021 produced over 50 new drug approvals and 20% of these drugs were oncology-focused, highlighting the potential value of incorporating genomic information into oncology clinical trial design.

 

We also provide genetic testing for drug metabolism to aid biotech and pharmaceutical companies identify subjects’ likely responses to treatment, allowing these companies to conduct more efficient and safer clinical trials. We believe pharmacogenomics drug metabolism testing helps deliver the promise of personalized medicine by enabling researchers to tailor therapies in development to differences in patients’ genomic profiles.

 

Sales and Marketing

 

Our sales and marketing efforts consist of both direct and indirect sales channels with the majority of efforts focused on direct sales in the United States as well as a collaborative arrangement with another laboratory services company. In the US, pharma services also execute an indirect channel partner strategy by partnering with clinical research organizations (“CROs”) to support demand for unique or esoteric testing, customized data management and individual development of unique biomarkers.

 

Our commercialization efforts for our clinical services are currently focused on endocrinology, gastroenterology and lung cancers. Communication of our marketing messaging and value proposition is done principally through our two field-based commercial sales teams of approximately 26 representatives and managers. In addition, we employ medical science liaisons or MSLs to respond to clinician inquiries. Additionally, we communicate through print, digital advertising, a web presence, peer-reviewed publications, and trade show exhibits. We believe that our molecular diagnostic tests provide value to payers, physicians and patients by improving patient care and lowering healthcare costs through avoidance of unnecessary surgeries, reducing the morbidity associated with unnecessary surgeries for patients, and providing better diagnostic and prognostic insights to physicians. We support the value propositions of our tests through rigorous science and the accumulation of bioinformatics data that demonstrate clinical and analytical validity as well as clinical utility, and how they actually impact physicians’ decisions. We believe our repository of bioinformatics data accumulated in over 37,000 cases using PancraGEN and over 30,000 cases using our thyroid assays is a valuable tool in developing our analytics and potentially an even more valuable tool in the future.

 

We communicate to payers, integrated delivery systems and hospital systems about our molecular diagnostic tests’ value through highly trained professionals who are experienced in reimbursement and business to business selling and through face to face meetings, phone calls, digital communications and advisory boards. We develop health economic analyses and budget impact models and incorporate these along with our clinical validation studies, and clinical utility studies to demonstrate our molecular diagnostic tests’ value to this distinct and important constituency.

 

 13 
 

 

Our U.S. pharma services business development and sales professionals have scientific backgrounds in hematology, pathology, and laboratory services, with many years of experience in biopharmaceutical and clinical oncology sales, esoteric laboratory sales from leading biopharmaceutical, pharmaceutical or specialty reference laboratory companies. We currently have a team of 4 business development and sales professionals in the United States. We support our sales force with scientific experts who bring deep domain knowledge in the design and use of our technologies and services.

 

Our pharma services team also executes an indirect channel partner strategy. As a result of this strategy, the pharma services team conducts project support for sponsors as a partner of such central labs as Covance, ICON Laboratories Inc. and Parexel International Corp. In addition to both direct and indirect sales channels, the pharma services team has formed a partnership with the China-based lab partner Genecast Biotechnology Co., Ltd. or, Genecast. Through our partnership with Genecast, we believe we are able to support our global pharmaceutical and biotechnology clients with their testing needs in the Chinese market.

 

We also promote our tests and services through marketing channels commonly used by the biopharma and pharmaceutical industries, such as internet, industry meetings and broad-based publication of our scientific and economic data. In addition, we provide easy to access information to our customers over the internet through dedicated websites. Our customers value easily accessible information in order to quickly review patient or study information. We do not, however, market our tests directly to individual patients or consumers.

 

Clinical Services Reimbursement Coverage

 

Additional Reimbursement Coverage During 2021

 

Reimbursement progress is key for our clinical services. We continued to expand the reimbursement of our products in 2021. Specifically, the most significant progress we have made regarding payers in 2021 is as follows:

 

● In January 2021, we announced an agreement with Blue Cross Blue Shield of Florida under which ThyGeNEXT® and ThyraMIR® tests are now covered in-network services for their 5 million members.
   
● In February 2021, we announced an agreement with Blue Cross Blue Shield of Illinois that makes ThyGeNEXT® and ThyraMIR® tests covered in-network services for their more than 8 million members in Illinois.
   
● In April 2021, we announced that Novitas, our Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (“PLA”) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimbursement level of $560.
   
● In May 2021, we announced that eviCore Healthcare (“eviCore”), a wholly owned subsidiary of Cigna, has updated their laboratory management guidelines to include positive coverage for ThyGeNEXT® and ThyraMIR®. This update, which impacts approximately 27 health plans nationwide covering 100 million lives, is effective on July 1, 2021. This means that after the effective date, claims for ThyGeNEXT and ThyraMIR which meet eviCore’s criteria for coverage will be considered medically necessary and processed as a covered service.
   
● In November 2021, CMS announced that it had assigned 0245U for Medicare rate-setting via the gapfill process. Under gapfill, the Medicare payment rate for 0245U will be established by Novitas during CY 2022. Effective January 1, 2023, the Medicare payment rate will be established as the median of the payment amounts established by all Medicare contractors.

 

 14 
 

 

Competition

 

We compete on the basis of factors such as reputation, scientific expertise, service quality, management experience, performance record, customer satisfaction, accessibility, flexibility, ability to respond to specific customer needs, integration skills, and product portfolio and price. Increased competition and/or a decrease in demand for our clinical and pharma services may also lead to other forms of competition. We believe that our business has a variety of competitive advantages that allow us to compete successfully in the marketplace. While we believe we compete effectively with respect to each of these factors, certain competitors of ours are substantially larger than us and have greater capital, personnel and other resources than we have. Many of our competitors also offer broader product lines outside of the molecular diagnostic testing market, and many have greater brand recognition than we do. Moreover, our competitors may make rapid technological developments that may result in our technologies and products becoming obsolete before we recover the expenses incurred to develop them or before they generate significant revenue. Increased competition may lead to pricing pressures and competitive practices that could have a material adverse effect on our market share and our ability to attract new business opportunities as well as our business, financial condition and results of operations.

 

We also compete with physicians and the medical community who use traditional methods to diagnose gastrointestinal and endocrine cancers. In many cases, practice guidelines in the United States have recommended therapies, surveillance or surgery to determine if a patient’s condition is malignant or benign. As a result, we believe that we will need to continue to educate physicians and the medical community on the value and benefits of our molecular diagnostic tests in order to change clinical practices and continue to support the use of molecular diagnostic tests in clinical guidelines.

 

Specifically, in regard to our thyroid diagnostic tests, Veracyte, Inc., or Veracyte, has a molecular thyroid nodule cancer diagnostic test (Afirma) that is the current market leader and competes with our ThyGeNEXT® and ThyraMir® tests. Quest Diagnostics Incorporated, or Quest, currently offers a diagnostic test similar to the earlier version of our ThyGeNEXT® test and announced an agreement to distribute the Afirma test in partnership with Veracyte. CBLPath, Inc., or CBL, offers ThyroSeq®, a diagnostic test that analyzes genetic alterations using next-generation sequencing. In addition, other thyroid based endocrine competitors include Accelerate Diagnostics, Inc., or other companies we are not aware of. Additionally, in February 2020, we entered into an arrangement to co-market our thyroid test for an additional two years with LabCorp on a reference laboratory basis. We are in the process of negotiating a renewal of the LabCorp contract.

 

We are currently not aware of any direct competitors to PancraGEN® that integrate clinical, imaging, cytology, and molecular information to stratify patients’ risk for malignancy and inform physicians on the best course of action, i.e., surgery or surveillance and surveillance interval length. The University of Pittsburgh Medical Center now offers PancreaSeq®, a Next Generation Sequencing “gene only” panel that focuses on the analysis of mutations in oncogenes and tumor suppressor genes, most of which may help establish the type of pancreatic cyst present and some of which may help establish the presence of malignancy. Some of these related genomic regions are included in PancraGEN®. This laboratory test however does not integrate any additional information to fully characterize a patient’s risk for pancreatic cancer. Importantly, there has been no long-term clinical validation or utility studies completed on any gene panel for pancreatic cyst fluid other than that associated with PancraGEN®. PancraGEN® has been validated in multiple studies and peer reviewed publications and has been used in over 45,000 patients. Additionally, we validated and launched a DNA only version of PancraGEN®, known as PanDNA®.

 

It is also possible that we face future competition from other laboratory-developed tests (LDT’s), developed by commercial laboratories such as Quest and other diagnostic companies developing new tests or technologies. Furthermore, we may be subject to competition as a result of new, unforeseen technologies that may be developed by our competitors in the gastrointestinal and endocrine cancer molecular diagnostic tests space.

 

We are aware of companies that are in the process of developing assays and LDTs for Barrett’s esophagus, such as Cernostics Inc. In addition, NeoGenomics Laboratories, Inc., or NeoGenomics, is marketing a Barrett’s assay, so it appears likely that this space will also be more competitive in the future.

 

With respect to pharma services, we also face competition from companies that currently offer or are developing products to profile genes, gene expression or protein biomarkers in various cancers. Precision medicine is a new area of science, and we cannot predict what tests others will develop that may compete with or provide results superior to the results we are able to achieve with the tests we develop. Our competitors include public companies such as NeoGenomics, and many private companies.

 

 15 
 

 

Research and Development

 

We conduct most of our research and development activities at our CLIA certified and CAP accredited laboratory in Pittsburgh, Pennsylvania. Our research and development efforts primarily focus on providing data and analyses necessary to support and improve our existing products on the market. Additionally, our research and development activities provide product line extension of our existing products as well as new product opportunities utilizing our proprietary platforms and extensive bioinformatics repositories and data bases.

 

Also, we use reagents for cross site validations and validations of new assays to be used in clinical trials. We may enter into collaborative relationships with research and academic institutions for the development of additional or enhanced tests to further increase the depth and breadth of our test offerings. Where appropriate, we may also enter into licensing agreements with our collaborative partners to both license intellectual property for use in our test panels as well as licensing such intellectual property out.

 

Our research and development costs are primarily clinical costs and were approximately $1.9 million and $2.8 million in 2021 and 2020, respectively.

 

We continue to generate and publish clinical evidence related to our key products, including ThyGeNEXT® and ThyraMIR® and PancraGEN® as well as our pipeline product, BarreGEN®.

 

Clinical Evidence

 

  ● The first manuscript reporting the clinical performance of ThyGeNEXT® and ThyraMIR® tests was accepted in July 2020 in the Diagnostic Cytopathology (Lupo M et al. Diagnostic Cytopathology. 2020; DOI: 10.10001/dc.24564.)

 

Intellectual Property

 

Patents, trademarks and other proprietary rights are important to us. We generate our own intellectual property portfolio and hold numerous patents and patent applications covering our existing and future products and technologies. As of December 31, 2021, we owned seven issued United States Patents. The U.S. patents are directed to, amongst other things, methods of measuring carcinoembryonic antigen in a biological sample; methods for treating subject with a high risk of disease progression from Barrett’s metaplasia to esophageal adenocarcinoma; and methods of treating a subject identified with a papillary thyroid carcinoma. As of December 31, 2021, we owned four issued patents outside of the United States, one each in Australia, Europe (validated in certain European countries), Japan, and Israel. As of December 31, 2021, we owned five pending patent applications in the United States. Provided all maintenance fees and annuities are paid, our issued United States patents expire from 2031 through 2034 and our foreign patents expire in 2027 or 2031, and our pending patent applications, if issued, are expected to expire between 2027 and 2038, absent any disclaimers, adjustments or extensions. On March 29, 2017 we were notified by the European Patent Office that our EP patent # 2772550 for diagnosing thyroid cancer from a sample based upon at least MIR-375 was issued (validated in Spain, France, United Kingdom, Ireland, Italy, Belgium, Switzerland, Germany, and the Netherlands) and, provided all maintenance fees and annuities are paid, expires in 2031. On January 16, 2018, we were notified that an Opposition had been filed against EP patent # 2772550 alleging that the patent is invalid. On February 25, 2019, the European Patent Office Opposition Division issued a decision revoking the patent on grounds that the claims were not supported by a valid basis. On April 25, 2019, we filed a Notice of Appeal challenging the European Patent Office Opposition Division and we are waiting for the appeal to be decided. We continue to believe that the patent is valid. Our patents are directed to certain of the technologies relating to detecting, diagnosing, and classifying thyroid tumors, pancreatic cysts and other forms of gastrointestinal disorders, such as Barrett’s esophagus.

 

 16 
 

 

On April 9, 2019 the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,255,410, supporting BarreGEN®. Additionally, United States Patent No. 10,444,239 issued on October 15, 2019, for methods measuring carcinoembryonic antigen in a biological sample.

 

In addition to our own molecular diagnostic test development efforts, we are currently using, and intend to use in the future, certain tests and biomarkers that have been developed by third parties or by us in collaboration with third parties. While a significant amount of intellectual property in the field of molecular diagnostic tests is already in the public domain, ThyraMIR®, ThyGeNEXT®, and some of the future tests developed by us, or by third parties on our behalf for use in our tests, may require, that we license the right to use certain intellectual property from third parties and pay customary royalties or make one time payments.

 

On August 13, 2014, we consummated an agreement to acquire certain fully developed thyroid and other tests in development for thyroid cancer, associated intellectual property and a biobank with more than 5,000 patient tissue samples pursuant to an asset purchase agreement, or the Asuragen Asset Purchase Agreement. We paid $8.0 million at closing and paid an additional $0.5 million to Asuragen for certain integral transition service obligations set forth in a transition services agreement, entered into concurrently with the Asuragen Asset Purchase Agreement. We also entered into two license agreements with Asuragen (the Asuragen License Agreement and the CPRIT License Agreement) relating to our ability to sell the fully developed diagnostic tests and other tests in development for thyroid cancer. Under the Asuragen License Agreement, we owed a $500,000 milestone payment, all of which was paid in installments throughout 2016 and paid in full as of January 13, 2017. We are further obligated to pay royalties on the future net sales of tests based on the miRInform® pancreas platform, if developed, on the future net sales of tests based on the miRInform® thyroid platform (i.e., ThyGeNEXT®) and potentially on certain other thyroid diagnostics tests. We rely on Asuragen as our sole supplier for certain components of our endocrine cancer diagnostic tests pursuant to our supply agreement with them.

 

In October 2014, we acquired RedPath Integrated Pathology Inc. (RedPath) which included its pancreatic and gastrointestinal assets. Additionally, we have a broad and growing trademark portfolio. We have secured trademark registrations for the marks AccuCEA® (or TM), PancraGEN®, PanDNA®, BarreGEN® and miRInform® in the United States, and miRInform® with the World Intellectual Property Organization. In July 2019, in connection with the acquisition of the pharma services business of Cancer Genetics we acquired certain know-how.

 

Our clinical and our pharma services rely on a combination of trade secrets and proprietary processes to protect our intellectual property. We enter into non-disclosure agreements with certain vendors and suppliers to attempt to ensure the confidentiality of our intellectual property. We also enter into non-disclosure agreements with our customers. In addition, we require that all our employees sign confidentiality and intellectual property assignment agreements.

 

Raw Material and Suppliers

 

We procure reagents, equipment and other materials that we use to perform our tests from sole suppliers. We also purchase components used in our collection kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. Our most significant suppliers for reagents and supplies include Thermo Fisher Scientific, Illumina, Inc., Qiagen, Asuragen, and F. Hoffmann-La Roche AG. While we have developed alternate sourcing strategies for most of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need to perform the tests and for our collection kits, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in test processing could occur, we may not be able to deliver patient reports and we may incur higher one-time switching costs. Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. If our test volume decreases or we switch suppliers, we may hold excess inventory with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new test, we may experience supply issues as we ramp test volume.

 

 17 
 

 

Government Regulations and Industry Guidelines

 

The healthcare industry, and thus our business, is subject to extensive Federal, State, local and foreign regulation. Both Federal and State governmental agencies continue to subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. We believe that we have structured our business operations and relationships with our customers to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could interpret these laws differently and assert otherwise. We discuss below the statutes and regulations that are most relevant to our business and most frequently cited in enforcement actions.

 

Regulations over Our Clinical Laboratories

 

The conduct and provision of our clinical services and pharma services are regulated under the Clinical Laboratory Improvements Amendments (“CLIA”). CLIA requires us to maintain Federal certification. CLIA imposes requirements relating to test processes, personnel qualifications, facilities and equipment, recordkeeping, quality assurance and participation in proficiency testing. CLIA compliance and certification are also a condition for participation by clinical laboratories in the Medicare Program and for eligibility to bill for services provided to governmental healthcare program beneficiaries. As a condition of CLIA certification, our laboratories are subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is typically conducted by a State agency, or, if the laboratory is accredited, a CMS-approved accreditation organization. Sanctions for failure to meet these certification, accreditation and licensure requirements include suspension, revocation or limitation of a laboratory’s CLIA certification, accreditation or license, which is necessary to conduct business, cancellation or suspension of the laboratory’s ability to receive Medicare or Medicaid reimbursement, as well as imposition of plans to correct deficiencies, injunctive actions and civil monetary and criminal penalties. The loss or suspension of a CLIA certification, imposition of a fine or other penalties, or future changes in the CLIA law or regulations (or interpretation of the law or regulations) could harm our business. In addition to CLIA requirements, we participate in the accreditation program of the College of American Pathologists (“CAP”). Under CMS requirements, accreditation by CAP is sufficient to satisfy the requirements of CLIA.

 

In addition to CLIA certification, we are required to hold state licenses in certain states. Some state licensing requirements differ from federal regulation and may be stricter. CLIA does not preempt state laws that are more stringent. If we were to lose our CLIA certification, CAP Accreditation, or required state licenses for our laboratories, whether as a result of revocation, suspension or limitation, we would no longer be able to provide our services, which would have a material adverse effect on our business, financial condition and results of operations.

 

Our laboratories are also subject to licensing and regulation under Federal, State and local laws relating to hazard communication and employee right-to-know regulations, and the safety and health of laboratory employees. Additionally, our laboratories are subject to applicable Federal and State laws and regulations and licensing requirements relating to the handling, storage and disposal of hazardous waste and laboratory specimens, including the regulations of the Environmental Protection Agency, the Department of Transportation, and the National Fire Protection Agency. The regulations of the United States Department of Transportation, Public Health Service and Postal Service apply to the surface and air transportation of laboratory specimens. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of hazardous waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.

 

In addition to its comprehensive regulation of safety in the workplace, the United States Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for healthcare employers whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis B virus, by preventing or minimizing any exposure through needle stick or similar penetrating injuries. Although we believe that we are currently in compliance in all material respects with such Federal, State and local laws, failure to comply with such laws could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions.

 

 18 
 

 

Potential U.S. Food and Drug Administration Regulation of Laboratory Developed Tests (“LDTs”)

 

Both United States Federal and State governmental agencies continue to subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. As indicated by work plans and reports issued by these agencies, the Federal government will continue to scrutinize, among other things, the marketing, labeling, promotion, and manufacturing of LDTs. While subject to oversight by CMS through its enforcement of CLIA, the FDA has claimed regulatory authority over all laboratories that produce LDTs, a type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory. The FDA has regulatory responsibility over, among other areas, instruments, test kits, reagents and other devices used in clinical laboratories to perform diagnostic testing in the United States.

 

Historically, the FDA has exercised enforcement discretion over most LDTs. However, in July 2014, the FDA issued two draft guidance documents: “Framework for Regulatory Oversight of Laboratory Developed Tests,” which provided an overview of how the FDA would regulate LDTs through a risk-based approach, and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests,” which provided guidance on how the FDA intends to collect information on existing LDTs, including adverse event reports. Pursuant to the Framework for Regulatory Oversight draft guidance, LDT manufacturers would be subject to medical device registration, listing, and adverse event reporting requirements. LDT manufacturers would be required to either submit a pre-market application and receive the FDA’s approval before an LDT may be marketed, or submit a pre-market notification in advance of marketing, unless subject to continued enforcement discretion. The Framework for Regulatory Oversight draft guidance states that within six months after the guidance documents are finalized, all laboratories will be required to give notice to the FDA and provide basic information concerning the nature of the LDTs offered. If the FDA were to regulate LDTs as proposed under the 2014 draft guidance documents, then it would classify LDTs into one of three classes according to the current system used to regulate medical devices. Class I devices are those for which reasonable assurance of the safety and effectiveness can be provided by adherence to the FDA’s general regulatory controls for medical devices. Class II devices are subject to the FDA’s general controls, and any other special controls as deemed necessary by the FDA to provide reasonable assurance of the safety and effectiveness of the devices. Class III devices are those devices which are deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device. Under the guidance documents, LDTs would also be subject to significant post-market requirements as well.

 

On January 13, 2017, the FDA released a discussion paper on LDTs outlining a possible, substantially-revised risk-based approach for FDA and CMS oversight of LDTs. According to the 2017 discussion paper, previously marketed LDTs would not be expected to comply with most or all FDA oversight requirements (grandfathering), except for adverse event and malfunction reporting. In addition, certain new and significantly modified LDTs would not be expected to comply with pre-market review unless the agency determines certain tests could lead to patient harm. Since many LDTs currently on the market would be grandfathered in, pre-market review of new and significantly modified LDTs could be phased-in over a four-year period, as opposed to the nine years proposed in the Framework for Regulatory Oversight draft guidance. In addition, tests introduced after the effective date, but before their phase-in date, could continue to be offered during pre-market review.

 

The discussion paper notes that FDA will focus on analytical and clinical validity as the basis for marketing authorization. The FDA anticipates laboratories that already conduct proper validation should not be expected to experience new costs for validating their tests to support marketing authorization and laboratories that conduct appropriate evaluations would not have to collect additional data to demonstrate analytical validity for FDA clearance or approval. The evidence of the analytical and clinical validity of all LDTs would be made publicly available. Laboratories developing LDTs would be encouraged to submit prospective change protocols in their pre-market submission that outline specific types of anticipated changes, the procedures that will be followed to implement them and the criteria that will be met prior to implementation.

 

Despite the FDA decision to not release the final guidance at this time, it can choose to regulate LDTs at any time. Failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. There are other regulatory and legislative proposals that would increase general FDA oversight of clinical laboratories and LDTs. The outcome and ultimate impact of such proposals on the business is difficult to predict at this time. We are monitoring developments and anticipate that our products will be able to comply with requirements if ultimately imposed by the FDA. In the meantime, we maintain our CLIA certification of accreditation, which permits the use of LDTs for diagnostic purposes.

 

 19 
 

 

In March 2017, members of Congress posted a discussion draft of “The Diagnostics Accuracy and Innovation Act” (DAIA). The discussion draft included language that, if enacted, would have established a new regulatory framework for the oversight of in vitro clinical tests (“IVCTs”) which include LDTs. In March 2020, members of Congress introduced “The Verifying Accurate, Leading-edge IVCT Development (VALID) Act”; this bill was re-introduced in substantially similar form in June 2021. Pursuant to VALID, a risk-based approach would be used to regulate IVCTs while grandfathering many existing IVCTs. Each test will be classified as high-risk or low-risk. Pre-market review will be required for high-risk tests. To market a high-risk IVCT, reasonable assurance of analytical and clinical validity for the intended use must be established. Under VALID, a precertification process would be established which will allow a laboratory to establish that the facilities, methods, and controls used in the development of certain IVCTs meet quality system requirements. If pre-certified, low-risk IVCTs it develops will not be subject to pre-market review. The new regulatory framework will include quality control and post-market reporting requirements. The FDA will have the authority to withdraw from the market IVCTs if it is reasonable possible that such tests will cause serious adverse health consequences (among other criteria). Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. It is unclear when, or if, the VALID Act will become law.

 

Healthcare, Fraud, Abuse and Anti-Kickback Laws

 

The Anti-Kickback Statute makes it a felony for a person or entity, including a laboratory, to knowingly and willfully offer, pay, solicit or receive remuneration, directly or indirectly, in order to induce business that is reimbursable under any Federal healthcare program. A violation of the Anti-Kickback Statute may result in imprisonment of up to five years and fines of up to $250,000 for each offense in the case of individuals and $500,000 for each offense in the case of organizations. Convictions under the Anti-Kickback Statute result in mandatory exclusion from federal healthcare programs for a minimum of five years. In addition, HHS has the authority to impose civil assessments and fines and to exclude healthcare providers and others engaged in prohibited activities from Medicare, Medicaid and other federal healthcare programs. Actions, which violate the Anti-Kickback Statute, also incur liability under the Federal False Claims Act, discussed in more detail below, which prohibits knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the U.S. Government.

 

Although the Anti-Kickback Statute applies only to federal healthcare programs, a number of states have passed statutes substantially similar to the Anti-Kickback Statute, which prohibits similar conduct toward all other health plans and third-party payers. Federal and state law enforcement authorities scrutinize arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. The law enforcement authorities, the courts and Congress have also demonstrated a willingness to look behind the formalities of a transaction to determine the underlying purpose of payments between healthcare providers and actual or potential referral sources. Generally, courts have taken a broad interpretation of the scope of the Anti-Kickback Statute, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases.

 

In addition to the Anti-Kickback Statute, the U.S. enacted the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). EKRA is an all-payer anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. The term “laboratory” is defined broadly and without reference to any connection to substance use disorder treatment. EKRA is a criminal statute and violations can result in fines of up to $200,000, up to 10 years in prison, or both, per violation. As drafted, EKRA prohibits incentive compensation to sales employees, a practice that is common in the industry.

 

 20 
 

 

Several other healthcare fraud and abuse laws could have an effect on our business. For example, provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal healthcare programs substantially in excess of its usual charges for its services. The terms “usual charge” and “substantially in excess” are ambiguous and subject to varying interpretations. Further, the Federal False Claims Act, discussed in more detail below, prohibits a person from knowingly submitting a claim, making a false record or statement in order to secure payment or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government’s involvement, then the plaintiff will receive a percentage of the recovery. Finally, the Social Security Act includes its own provisions that prohibit the filing of false claims or submitting false statements in order to obtain payment. Violation of these provisions may result in fines, imprisonment or both, and possible exclusion from Medicare or Medicaid programs.

 

We are also subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and state equivalents. These restrictions generally prohibit us from billing a patient or Medicare for any diagnostic services when the physician ordering the service, or any member of such physician’s immediate family, has an investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition. The government has also claimed in FCA litigation that the Stark Law applies to Medicaid claims. Some states have also enacted state Stark Law equivalents that can apply to that state’s Medicaid plan and/or commercial payors.

 

Persons or entities found to violate the Stark Law are required to refund any payments received pursuant to a referral prohibited by these laws to the patient, or the Medicare program, as applicable. Sanctions for a violation of the Stark Law include the following:

 

  ● denial of payment for the services provided in violation of the prohibition;
     
  ● refunds of amounts collected by an entity in violation of the Stark Law;
     
  ● a civil penalty of up to $26,125 for each service arising out of the prohibited referral;
     
  ● possible exclusion from federal healthcare programs, including Medicare and Medicaid; and
     
  ● a civil penalty of up to $174,172 against parties that enter into a scheme to circumvent the Stark Law’s prohibition.

 

These penalty amounts are adjusted each year for inflation. The Stark Law prohibitions apply regardless of the reasons for the financial relationship and the referral. No finding of intent to violate the Stark Law is required for a violation. In addition, violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act.

 

Additionally, the Federal Civil Monetary Penalties Law prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies.

 

We do retain healthcare practitioners as key opinion leaders providing consultation in various aspects of the business. These arrangements as any arrangement that includes compensation to a healthcare provider may trigger Federal or State anti-kickback and Stark Law liability. Our arrangements with healthcare providers are designed to meet available safe harbors and exceptions provided in the anti-kickback laws and Stark laws, respectively. There is no guarantee that the government will find that these arrangements are designed properly or that they do not trigger liability. Under existing laws, all arrangements must have a legitimate purpose and compensation must be fair market value. These terms require some subjective analysis and there is limited available case law or guidance for the application of these laws to the CLIA Laboratory industry. Safe harbors in the anti-kickback laws do not necessarily equate to exceptions in the Stark Law; and there is no guarantee that the government will not have issue with the relationships between the laboratories and the healthcare providers.

 

 21 
 

 

HIPAA, Fraud and Privacy Regulations

 

The Federal government’s efforts to combat fraud in the healthcare setting were consolidated and strengthened under Public Law 104-191, the Health Insurance Portability and Accountability Act of 1996, or HIPAA. HIPAA established a comprehensive program to combat fraud committed against all health plans, both public and private by, among other things creating two new Federal offenses: healthcare fraud (18 U.S. Code § 1347) and false statements relating to healthcare matters (18 U.S. Code § 1035). These provisions prohibit: (1) the knowing and willful execution, or attempted execution, of a scheme or artifice (a) to defraud any healthcare benefit program (including private payers), or (b) to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, in connection with the delivery of or payment for healthcare benefits, items, or services; and (2) the knowing and willful (a) falsification, concealment or covering up of a material fact by any trick, scheme or device, or (b) making of any materially false, fictitious or fraudulent statement or representation, or making or using any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits, items or services. A violation of these provisions is a felony and may result in fines, imprisonment and/or exclusion from government-sponsored programs.

 

HIPAA, along with the Health Information Technology for Economic and Clinical Health Act (HITECH) and the various regulations promulgated thereunder, also establish uniform standards governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of individually identifiable health information maintained or transmitted by certain healthcare providers, health plans and healthcare clearinghouses, which are referred to as “covered entities,” as well as individuals or entities to the extent they function as a business associate of a covered entity. The regulations promulgated under HIPAA govern: the Privacy of Individually Identifiable Health Information, restricting the use and disclosure of certain individually identifiable health information and establishing certain rights of individuals who are the subject of such information (45 C.F.R. §§ 164.500, et seq.); Administrative Requirements for electronic transactions, establishing standards for common healthcare transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures (45 C.F.R. §§ 162.100, et seq.); Security Standards for the Protection of Electronic Protected Health Information, requiring covered entities to implement and maintain certain security measures to safeguard certain electronic health information (45 C.F.R. §§ 164.302, et seq.); and Breach Notification, requiring covered entities and their business associates to provide certain notifications following a breach of unsecured protected health information (PHI) (45 C.F.R. §§ 164.400, et seq.). As a covered entity, and also in our capacity as a business associate to certain of our customers, we are subject to these standards. We may also be liable for violations of HIPAA by any individual or entity, which may include a business associate, that is acting as our agent under the federal common law of agency. While the government intended this legislation to reduce administrative expenses and burdens for the healthcare industry, our compliance with certain provisions of these standards entails significant costs for us and limits our performance of functions or activities that involve collecting, receiving, maintaining, transmitting, using, or disclosing PHI. Our failure to comply with HIPAA, HITECH, and their implementing regulations could lead to enforcement action that could have an adverse effect on our business. If we or our operations are found to be in violation of HIPAA, HITECH, or their respective implementing regulations, we may be subject to potentially significant penalties, including civil and criminal penalties, damages and fines, and may incur damage to our reputation.

 

In addition to Federal regulations issued under HIPAA and HITECH, many States and foreign jurisdictions have enacted privacy and security statutes or regulations that, in some cases, are more stringent than those issued under HIPAA. In those cases, it may be necessary to modify our planned operations and procedures to comply with the more stringent laws as HIPAA and HITECH do not supersede State laws to the extent such State laws are broader in scope, impose more stringent requirements for PHI, or give individuals more rights with respect to their PHI. If we fail to comply with applicable State or foreign laws, rules, or regulations, we could be subject to additional sanctions or other liabilities under those laws, rules, and regulations.

 

 22 
 

 

Federal and State Consumer Protection Laws

 

The Federal Trade Commission, or FTC, is an independent U.S. law enforcement agency charged with protecting consumers and enhancing competition across broad sectors of the economy. In 2022, the FTC has said that it will be evaluating new data privacy regulations, which, if adopted, could impact our operations. The FTC’s authority with respect to data privacy and security comes from Section 5 of the FTC Act. The FTC uses its broad grant of authority to regulate data privacy and security, using its powers to investigate and bring lawsuits. Where appropriate, the FTC can seek a variety of remedies, such as but not limited to requiring the implementation of comprehensive privacy and security programs, biennial assessments by independent experts, monetary redress to consumers, and provision of robust notice and choice mechanisms to consumers.

 

In addition to the FTC Act, many U.S. states have unfair and deceptive acts and practices statutes, known as UDAP statutes, that are substantively similar to the FTC Act and have been applied in the privacy and data security context. These UDAP statutes vary in substance and strength from state to state. Many have broad prohibitions against unfair and deceptive acts and practices. These statutes generally allow for private rights of action, and are enforced by the states’ Attorneys General.

 

California, Virginia, and Colorado have adopted comprehensive consumer privacy laws that are in effect or will take effect within the next 12 to 18 months, and regulate how certain for-profit businesses collect, use, and disclose the personal information of consumers who reside in those respective states. Among other things, these laws confer to their consumers the right to: receive notice of information collection and use practices; access, delete, correct, or transfer personal information and opt out of the “sale” of their personal information. These laws also require companies to adopt reasonable measures to safeguard the personal information that we collect and regulate categories of “sensitive” data such as information associated with minors, citizenship, and other personal data for which these state laws have designated special protection. These laws do not, however, apply to personal information that constitutes PHI under HIPAA, HIPAA-regulated entities to the extent that the entity maintains patient information in the same manner as PHI, and de-identified data as defined under HIPAA. As a result, we do not or likely will not have compliance obligations with respect to most testing and patient information we collect and process. However, we are required to comply with these consumer privacy laws insofar as we collect other categories of California, Virginia and Colorado consumers’ personal information. These laws are generally enforced by the respective state Attorney General. California’s law also includes a private right of action for certain data breaches.

 

Dozens of other states in the United States are currently considering similar, consumer data privacy laws, which could impact our operations if enacted.

 

Healthcare Reform

 

The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs.

 

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, or PPACA (also known as the Affordable Care Act), as amended by the Health Care and Education Reconciliation Act, a sweeping law intended to broaden access to health insurance and coverage for patients, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry, coordinate and promote research on comparative clinical effectiveness of different technologies and procedures, and impose additional health policy reforms. PPACA, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on pricing and implemented changes which significantly affect the pharmaceutical, medical device and clinical laboratory industries. There have been legislative and administrative actions to make changes to PPACA, including repeal and replacement of certain provisions.

 

 23 
 

 

The PPACA has also been subject to challenges in the courts however, the U.S. Supreme Court upheld the law in 2021.

 

Further changes to the PPACA remain possible, although the new Administration under President Biden has signaled that it plans to build on the Affordable Care Act and expand the number of people who are eligible for subsidies under it. President Biden has used executive orders to undo changes to the PPACA made by the Trump administration and indicated he would advocate for legislation to build on the PPACA. It is unknown what form any such changes or any law would take, and how or whether it may affect our business in the future. We expect that changes or additions to the PPACA, the Medicare and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.

 

We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.

 

Third Party Coverage and Reimbursement for our Clinical Services

 

Our customers’ bills are paid by many different payer groups. The majority of reimbursement dollars for traditional laboratory services are provided by traditional commercial insurance products, most notably preferred provider organizations, or PPOs, and other managed care plans, as well as government healthcare programs, such as Medicare and Medicaid. PPOs, HMOs and other managed care plans typically contract with a limited number of laboratories and then designate the laboratory or laboratories to be used for tests ordered by participating physicians. We are currently an out-of-network provider with most payers, which means we do not have a contract with payers to pay a specific rate for our tests. We did previously announce a new national agreement with Aetna through which the Company is now an in-network provider for Aetna’s members. We are subject to applicable state laws regarding who should be billed, how they should be billed, how business should be conducted, and how patient obligations regarding cost sharing should be handled. In addition, if we become an “in-network” provider for certain payers in the future, we will also be subject to the terms of contracts (which could include reduced reimbursement rates) and may be subject to discipline, breach of contract actions, non-renewal or other contractually provided remedies for non-compliance with the contract’s requirements and/or applicable laws.

 

We generally bill third-party payers and individual patients for testing services on a test-by-test basis. Third-party payers include Medicare, private insurance companies, institutional direct clients and Medicaid, each of which has different billing requirements. Medicare reimbursement programs are complex and often ambiguous, and are continuously being evaluated and modified by CMS. Our ability to receive timely reimbursements from third-party payers is dependent on our ability to submit accurate and complete billing statements, and/or correct and complete missing and incorrect billing information. Missing and incorrect information on reimbursement submissions slows down the billing process and increases the aging of accounts receivable. We must bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full. State Medicaid programs are generally prohibited from paying more than the Medicare fee schedule. Through February 2021, we were contracted with XIFIN, Inc. (“XIFIN”), a healthcare billing services management company, to work with our in-house staff and help manage our third-party billing. In early March 2021, we expanded our relationship with XIFIN to deploy XIFIN’s revenue cycle management solution enterprise-wide to support all of our diagnostics testing services. During January 2022, the Company became aware that CMS issued a new billing policy whereby CMS would no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. In February 2022, the Company announced that this billing policy determination by CMS had been changed retroactively to January 1, 2022. As a result, the Company will continue billing for both tests according to its LCD as originally set by Novitas.

 

 24 
 

 

Some billing arrangements require us to bill multiple payers, and there are several other factors that complicate billing (e.g., disparity in coverage and information requirements among various payers; and incomplete or inaccurate billing information provided by ordering physicians). Since 2018 several private payers implemented pre-authorization requirements for molecular and genetic testing, including Anthem Blue Cross Blue Shield and United Healthcare, as well as various lab benefit companies such as American Imaging Management, Inc., or AIM, and Beacon Lab Benefits Solutions, or Beacon. In addition, more commercial payers are contracting with and delegating risk for lab services costs to lab benefits management companies (e.g. eviCore healthcare, AIM, and Beacon). This requires us to go through their technology assessment process to secure coverage and obtain a contract as an in-network lab provider for our services. We incur additional costs as a result of our participation in Medicare and Medicaid programs because diagnostic testing services are subject to complex, stringent and frequently ambiguous federal and state laws and regulations, including those relating to coverage, billing and reimbursement. Additionally, auditing for compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further cost and complexity to the billing process. Further, our billing systems require significant technology investment and, as a result of marketplace demands, we need to continually invest in our billing systems. Changes in laws and regulations could further complicate our billing and increase our billing expense. CMS establishes procedures and continuously evaluates and implements changes to the reimbursement process and requirements for coverage.

 

As an integral part of our billing compliance program, we investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements. Any Medicare or Medicaid overpayments are reimbursed by us. As a result of these efforts, we have periodically identified and reported overpayments, reimbursed the payers for overpayments and taken appropriate corrective action.

 

Historically, due to the nature of our business, we have performed requested testing and have reported test results regardless of collectability or form of reimbursement. We submit claims for reimbursement on a best efforts basis including the use of a third-party revenue cycle management firm. If at times the billing information is incorrect or incomplete, we subsequently attempt to contact the healthcare provider or patient to obtain any missing information and to rectify incorrect billing information. Missing or incorrect information on requisitions complicates and slows down the billing process and may also impact revenue recognition. The increased use of electronic ordering reduces the incidence of missing or incorrect information, and we are seeking to electronically integrate with more and more payers and clients.

 

There are a number of factors that influence coverage and reimbursement for molecular diagnostic tests. In the United States, the American Medical Association assigns specific CPT codes, which are necessary for reimbursement of molecular diagnostic tests. Once the CPT code is established, CMS establishes reimbursement payment levels and coverage rules under Medicare, and private payers establish rates and coverage rules independently. However, the availability of a CPT code is not a guarantee of coverage or adequate reimbursement levels, and the revenues generated from our tests will depend, in part, on the extent to which third-party payers provide coverage and establish adequate reimbursement levels.

 

United States and other government regulations governing coverage and reimbursement for molecular diagnostic testing may affect, directly or indirectly, the design of our tests and the potential market for their use. The availability of third-party reimbursement for our tests and services may be limited or uncertain. Third-party payers may deny coverage if they determine that the tests or service has not received appropriate FDA or other government regulatory clearances, is not used in accordance with cost-effective treatment methods as determined by the payer, or is deemed by the third-party payer to be experimental, unnecessary or inappropriate. Furthermore, third-party payers, including Federal and State healthcare programs, government authorities, private managed care providers, private health insurers and other organizations, frequently challenge the prices, medical necessity, and cost-effectiveness of healthcare products and services, including laboratory tests. Such payers may limit coverage of our tests to specific, limited circumstances, may not provide coverage at all, or may not provide adequate reimbursement rates, if covered. Further, one payer’s determination to provide coverage does not assure that other payers will also provide coverage for the test. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to maintain our revenue and growth. Coverage policies and third-party reimbursement rates may change at any time.

 

Government payers, such as Medicare and Medicaid, have taken steps and are expected to continue to take steps to control the cost, utilization and delivery of healthcare services, including clinical test services. For example, Medicare has adopted policies under which it does not pay for many commonly ordered clinical tests unless the ordering physician has provided an appropriate diagnosis code supporting the medical necessity of the test. Physicians are required by law to provide diagnostic information when they order clinical tests for Medicare and Medicaid patients.

 

 25 
 

 

Currently, Medicare does not require the beneficiary to pay a co-payment for diagnostic information services reimbursed under the Clinical Laboratory Fee Schedule. Certain Medicaid programs require Medicaid recipients to pay co-payment amounts for diagnostic information services.

 

The Medicare Part B program contains fee schedule payment methodologies for clinical testing services performed for covered patients, including a national ceiling on the amount that carriers could pay under their local Medicare clinical testing fee schedules. Historically, the Medicare Clinical Laboratory Fee Schedule, or CLFS, has been subject to local variations in pricing. In April 2014, President Obama signed the Protecting Access to Medicare Act of 2014, or PAMA, which included a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, CLFS rates are based upon the weighted median of private payor rates reported for each type of laboratory test. PAMA requires laboratories that receive a majority of their Medicare revenue from payments made under the CLFS and the Physician Fee Schedule, and at least $12,500 in CLFS revenue during the six month data collection period to report private payor data collected from such 6-month period (January 1 through June 30 in the applicable year) to CMS between January 1 through March 31 of the following year. CMS posted the first new Medicare CLFS rates (based on weighted median private payer rates) in November 2017 and the new rates became effective on January 1, 2018. CMS published final rules implementing these changes in 2016 and 2018. The result of the PAMA calculations was an increase in our reimbursement rate for ThyGenX® of approximately 40% for our Medicare volume. However, on July 26, 2018, we received a coding update from CMS, which changed the billable procedure code (CPT) for ThyGeNEXT®. This code change resulted in a reduction of the fee schedule for payments to us. We have recently presented clinical data to CMS adding additional markers to the panel that we run that increase our gene families above 50. If approved, reimbursement for the new panel will exceed the previously approved rate. There can be no assurances that our request will be successful and that the rate will be escalated.

 

The Coronavirus Aid, Relief, and Economic Security (CARES) Act, as amended by the Protecting Medicare and American Farmers from Sequester Cuts Act, revised payment reductions and the data reporting schedule for CDLTs that are not ADLTs. Under these laws, the next data reporting period is January 1, 2023 through March 31, 2023, and will be based upon the data collected during the January 1, 2019 to June 30, 2019 period. Any reductions to payment rates resulting from the new methodology are limited to 10% per test per year in each of the years 2018 through 2020 and to 15% per test per year in each of the years 2023 through 2025. Payments will not be reduced for 2021 or 2022 for CDLTs.

 

Under the revised Medicare Clinical Laboratory Fee Schedule, reimbursement for clinical laboratory testing was reduced for most tests in 2018, 2019, and 2020. PAMA calls for further revisions of the Medicare Clinical Laboratory Fee Schedule for years after 2021, based on future surveys of market rates.

 

Penalties for violations of laws relating to billing government healthcare programs and for violations of federal and state fraud and abuse laws include: (1) exclusion from participation in Medicare/Medicaid programs; (2) asset forfeitures; (3) civil and criminal fines and penalties; and (4) the loss of various licenses, certificates and authorizations necessary to operate our business. Civil monetary penalties for a wide range of violations may be assessed on a per violation basis. A parallel civil remedy under the federal False Claims Act provides for penalties on a per violation basis, plus damages of up to three times the amount claimed.

 

Historically, most Medicare and Medicaid beneficiaries were covered under the traditional Medicare and Medicaid programs administered by the federal government. Reimbursement from traditional Medicare and Medicaid programs represented approximately 43% of our consolidated net revenues during 2020. Over the last several years, the federal government has continued to expand its contracts with private health insurance plans for Medicare beneficiaries and has encouraged such beneficiaries to switch from the traditional programs to the private programs, called “Medicare Advantage” programs. There has been growth of health insurance providers offering Medicare Advantage programs and of beneficiary enrollment in these programs. Commercial health plans that might not cover one or all of our tests for their commercially insured members are required to follow the Novitas LCD coverage policy for their Medicare Advantage members. To the extent we maintain the LCD coverage policies with Novitas for our products, any shift of members from traditional Medicare to Medicare Advantage plans doesn’t represent a risk of lost revenue. In recent years, in an effort to control costs, states also have mandated that Medicaid beneficiaries enroll in private managed care arrangements.

 

 26 
 

 

The current position of our laboratories is that they do not meet the definition of an “Applicable Manufacturer” under the “Sunshine Act” section of PPACA and therefore are not subject to the disclosure or tax requirements contained in PPACA. However, as new regulations are implemented and diagnostic tests reclassified, this may change and the laboratory business may be subject to PPACA as are other companies. There is no guarantee that our interpretation of the law is now or will be in the future consistent with government guidance and interpretation.

 

In December 2019, our Medicare Administrative Contractor (MAC) issued a new draft local coverage determination (LCD) for our ThyGeNEXT® test, representing an increase of approximately $2,400 per assay over previous reimbursement coverage. This increase in reimbursement rates reflects the expansion of the ThyGeNEXT® panel to aid in identifying the appropriate patients for surgery. Final approval is expected during the first half of 2020. Additionally, in February 2020, the CMS modified the reimbursement for ThyraMIR® retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR® from approximately $1,800 to $3,000 reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices.

 

In January 2022, the Company announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS.

 

Reporting Segments

 

We operate under one segment which is the business of developing and selling diagnostic clinical and pharma services.

 

Employees

 

As of February 28, 2022, we had approximately 147 full time employees and 147 total employees. We are not party to a collective bargaining agreement with any labor union.

 

Corporate Information

 

We were originally incorporated in New Jersey in 1986 and began commercial operations as PDI, Inc., a contract sales organization or CSO in 1987. In connection with PDI, Inc.’s initial public offering, it reincorporated in Delaware in 1998. In 2015 the CSO business and assets were sold, and we operated our molecular diagnostics business as Interpace Diagnostics Group, Inc. (IDXG). On July 15, 2019, we acquired the pharma services business from the secured creditors of CGI and Gentris, LLC, a wholly owned subsidiary of CGI and conduct that business as Interpace Pharma Solutions, Inc. We conduct our business through our wholly-owned subsidiaries, Interpace Diagnostics, LLC, which was formed in Delaware in 2013, Interpace Diagnostics Corporation (formerly known as RedPath Integrated Pathology, Inc.), which was formed in Delaware in 2007, and Interpace Pharma Solutions Inc. (formerly known as Interpace BioPharma, Inc.), which was formed in Delaware in 2019. On November 12, 2019, we changed the name of Interpace Diagnostics Group, Inc. to Interpace Biosciences, Inc. and that of our newly-formed subsidiary, Interpace BioPharma, Inc. to Interpace Pharma Solutions, Inc. Our executive offices are located at Morris Corporate Center 1, Building C, 300 Interpace Parkway, Parsippany, New Jersey 07054. Our telephone number is (855) 776-6419.

 

 27 
 

 

Business Development

 

Series B Investment by 1315 Capital and Ampersand

 

On January 10, 2020, we entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital II, L.P., a Delaware limited partnership (“1315 Capital”), and Ampersand 2018 Limited Partnership (“Ampersand” and together with 1315 Capital, the “Investors”) pursuant to which we sold to the Investors, in a private placement pursuant to Regulation D and Section 4(a)(2) under the Securities Act, an aggregate of $20,000,000 in Series B Preferred Stock, at an issuance price per share of $1,000. Pursuant to the Securities Purchase and Exchange Agreement, 1315 Capital purchased 19,000 shares of Series B Preferred Stock at an aggregate purchase price of $19,000,000 and Ampersand purchased 1,000 shares of Series B Preferred Stock at an aggregate purchase price of $1,000,000.

 

In addition, we exchanged $27,000,000 of the Company’s existing Series A Preferred Stock held by Ampersand, represented by 270 shares of Series A Preferred Stock, which represented all of the Company’s issued and outstanding Series A Preferred Stock, for 27,000 newly created shares of Series B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”). Following the Exchange, no shares of Series A Preferred Stock remain designated, authorized, issued or outstanding. Under the terms of the Securities Purchase and Exchange Agreement, Ampersand also agreed to waive all dividends and weighted-average anti-dilution adjustments accrued to date on the Series A Preferred Stock.

 

For so long as each of Ampersand and 1315 Capital holds at least sixty percent (60%) of the Series B Preferred Stock issued to it on January 15, 2020, such Investor will be entitled to elect two directors to the Board, provided that one of the directors qualifies as an “independent director” under Rule 5605(a)(2) of the listing rules of the Nasdaq Stock Market (or any successor rule or similar rule promulgated by another exchange on which the Company’s securities are then listed or designated) (“Independent Director”). However, if at any time such Investor holds less than sixty percent (60%), but at least forty percent (40%), of the Series B Preferred Stock issued to them on January 15, 2020, such Investor would only be entitled to elect one director to the Board. Any director elected pursuant to the terms of the Certificate of Designation may be removed without cause by, and only by, the affirmative vote of the holders of Series B Preferred Stock. A vacancy in any directorship filled by the holders of Series B Preferred Stock may be filled only by vote or written consent in lieu of a meeting of such holders of Series B Preferred Stock or by any remaining director or directors elected by such holders of Series B Preferred Stock.

 

The Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “Certificate of Designation”) provides that each share of Series B Preferred Stock is convertible, at any time and from time to time, at the option of the holder into a number of shares of our common stock equal to dividing the amount equal to the greater of the stated value of $1,000 of such Series B Preferred Stock, plus any dividends declared but unpaid thereon, or such amount per share as would have been payable had each such share been converted into our common stock immediately prior to a liquidation, by sixty cents ($0.60) (as adjusted to $6.00 following effectuation of the Reverse Stock Split in January 2020 and subject to further adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization affecting such shares). The aggregate number of shares of our common stock that may be issued through conversion of the currently outstanding Series B Preferred Stock is 78,333,334 shares (as adjusted to 7,833,334 shares following effectuation of the Reverse Stock Split and subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares). On any matter presented to our stockholders for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series B Preferred Stock will be entitled to cast the number of votes equal to the number of whole shares of our common stock into which the shares of Series B Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the Certificate of Designation, holders of Series B Preferred Stock will vote together with the holders of common stock as a single class and on an as-converted to common stock basis.

 

 28 
 

 

The Series B Preferred Stock entitles the holders thereof to certain protective provisions. In particular, for so long as any shares of Series B Preferred Stock are outstanding, the written consent of the holders of at least seventy five percent (75%) of the then outstanding shares of Series B Preferred Stock (voting as a single class) is required for us to amend, waive, alter or repeal the preferences, rights, privileges or powers of the holders of the Series B Preferred Stock, amend, alter or repeal any provision of the Certificate of Designation in a manner adverse to the holders of the Series B Preferred Stock, authorize, create or issue any equity securities senior to or pari passu with the Series B Preferred Stock, or increase or decrease the number of directors constituting the Board. Moreover, for so long as thirty percent (30%) of the Series B Preferred Stock outstanding as of January 15, 2020 remains outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares, including the Reverse Stock Split effected in January 2020), the written consent of the holders representing at least seventy-five percent (75%) of the of the outstanding shares of Series B Preferred Stock (voting as a single class) is required for us to: (A) authorize, create or issue any debt securities for borrowed money or funded debt (1) pursuant to which we issue shares, warrants or any other convertible security, or (2) in excess of $4,500,000 initially, with such amount to be increased in connection with an aggregate consolidated revenue milestone, but excluding certain specified permitted transactions; (B) merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess of $20,000,000, to be increased in connection with an aggregate consolidated revenue milestone; (C) materially change our business; (D) consummate any Liquidation (as defined in the Certificate of Designation); (E) transfer material intellectual property rights other than in the ordinary course of business; (F) declare or pay any cash dividend or make any cash distribution on any of our equity interests other than the Series B Preferred Stock; (G) repurchase or redeem any shares of our capital stock, except for the redemption of the Series B Preferred Stock pursuant to the terms of the Certificate of Designation, or repurchases of our common stock under agreements previously approved by the Board with employees, consultants, advisors or others who performed services for us in connection with the cessation of such employment or service; (H) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities pursuant to we issue shares, warrants or any other convertible security, or incur any individual debt, indebtedness for borrowed money or other liabilities pursuant to which we do not issue shares, warrants or any other convertible security exceeding, in each case, $4,500,000 initially, with such amount to be increased in connection with an aggregate consolidated revenue milestone, but excluding certain specified permitted transactions; (I) change any of our accounting methods, except for those changes required by GAAP or applicable regulatory agencies or authorities; or (J) conduct a public offering of common stock registered with the SEC, including any at-the-market offering of our common stock.

 

During April 2020, the Company applied for various federal stimulus loans, grants and advances made available under Title 1 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, including a loan request under the Small Business Administration (SBA) Paycheck Protection Program (PPP). In connection with the Company’s application for the PPP loan, both Ampersand and 1315 Capital consented to, and agreed to vote their shares of Series B Preferred Stock in favor of any “Fundamental Action” taken by the Company as determined by the Company’s Board of Directors. “Fundamental Actions” include the Company’s ability to a) authorize, create or issue any debt securities for borrowed money or funded debt; b) merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess of $20 million; c) transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Company or any of its direct or indirect subsidiaries, other than those accomplished in the ordinary course of business; d) declare or pay any cash dividend or make any cash distribution on any equity interests of the Company other than the Series B Shares; e) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities; and f) change any accounting methods or practices of the Company, except for those changes required by GAAP or applicable regulatory agencies or authorities. Subsequently, the Company and Ampersand agreed that Ampersand no longer was required to vote its shares of Series B Preferred Stock in favor of any “Fundamental Action” taken by the Company as determined by the Company’s Board of Directors.

 

Reverse Stock Split

 

At a Special Meeting of Stockholders held on December 13, 2019, our stockholders authorized our Board, in its discretion, to amend our certificate of incorporation, as amended, to effect a reverse split of our outstanding common stock at a ratio between one-for-five (1:5) and one-for-fifteen (1:15), with such final ratio to be determined by the Board following the special meeting (the “Reverse Stock Split”). On January 14, 2020, the Board determined to set the Reverse Stock Split ratio at one-for-ten (1:10) and approved the final form of the certificate of amendment to our certificate of incorporation to effectuate the Reverse Stock Split, which was filed with the Secretary of State of the State of Delaware on January 14, 2020. The Reverse Stock Split became effective in accordance with the terms of the certificate of amendment at 12:01a.m. Eastern Time on Wednesday, January 15, 2020, at which time every ten (10) shares of common stock issued and outstanding automatically combined into one (1) share of issued and outstanding common stock, without any change in the par value per share. Fractional shares were not issued as a result of the Reverse Stock Split. Instead, any fractional shares of our common stock that would have otherwise resulted from the Reverse Stock Split were rounded up to the nearest whole share.

 

 29 
 

 

The Reverse Stock Split resulted in a proportionate adjustment to the per share exercise price and the number of shares of common stock issuable upon the exercise of our outstanding stock options and warrants, as well as the number of shares of common stock eligible for issuance under the Interpace Biosciences, Inc. 2019 Equity Incentive Plan and the Interpace Biosciences, Inc. Employee Stock Purchase Plan.

 

Except as otherwise indicated, all share and per share information herein gives effect to the Reverse Stock Split.

 

Available Information

 

We maintain an internet website at www.interpace.com. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports are available free of charge through the “Investor Relations” portion of our website, as soon as reasonably practicable after they are filed with the SEC. The content contained in, or that can be accessed through, our website is not incorporated into this Form 10-K.

 

ITEM 1A. RISK FACTORS

 

In addition to the other information provided in this Annual Report on Form 10-K, including our financial statements and the related notes in Part II - Item 8, you should carefully consider the following factors in evaluating our business, operations and financial condition. Additional risks and uncertainties not presently known to us, which we currently deem immaterial or that are similar to those faced by other companies in our industry or businesses in general, such as competitive conditions, may also impair our business operations. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations or cash flows.

 

Summary of Risk Factors

 

Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:

 

  ●

Our operating history of net losses, negative working capital and insufficient cash flows, and lack of liquidity to pay our current obligations raise doubts about our ability to continue as a going concern.

     
  ● The COVID-19 global pandemic may continue to materially and adversely impact our business, financial condition and results of operations.
     
  ● We have and may continue to experience intangible asset or other long-lived asset impairment charges.
     
  ● We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
     
  ● Due to how we recognize revenue, our quarterly revenue and operating results are likely to fluctuate.
     
  ● A deterioration in the collectability of our accounts receivable could have a material adverse effect on our business, financial condition and results of operations.
     
  ● We depend on sales and reimbursements from our clinical services for more than 50% of our revenue, and we will need to generate sufficient revenue from these and other products and/or solutions that we develop or acquire to grow our business.
     
  ● Two private equity firms and their affiliates’ control, on an as-converted basis, an aggregate of 65% of our outstanding shares of common stock through their holdings of our Series B Preferred Stock, and this concentration of ownership along with their authority for designation rights for a majority of our directors and their right to approve certain of our actions has a substantial influence on our decisions.
     
  ● Our secured lenders have the right to foreclose on substantially all of our assets if we are unable to timely repay our outstanding obligations.
     
  ● Billing for our clinical services tests is complex, and we must dedicate substantial time and resources to the billing process to be paid for our clinical services tests.
     
  ● We depend on a few payers for a significant portion of our revenue for our clinical services, and if one or more significant payers, including CMS, stops providing reimbursement or decreases the amount of reimbursement for our tests, or if we are unable to successfully negotiate additional reimbursement contracts for our clinical services tests, our revenue could decline and our commercial success could be compromised. Our reliance on Medicare reimbursement for our clinical services and our being subject to decisions of the Center for Medicare and Medicaid Services (“CMS”) regarding reimbursement and pricing of our clinical services which could have a material adverse effect on our business and financial results, which has temporarily had a material adverse effect on our business due to a new billing policy issued by CMS in January 2022 whereby CMS stated they would no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service; while this decision was subsequently reversed in February 2022, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS;

 

 30 
 

 

  ● We rely on third-parties to process and transmit claims to payers for our clinical services, and any delay in processing or transmitting could have an adverse effect on our revenue and financial condition.
     
  ● We may experience a decline in demand for our clinical services tests and/or our pharma services products, which may result in a reduction in revenue.
     
  ● If we are unable to increase sales of our clinical services and the tests and services in our pharma services, we may be unable to achieve profitability.
     
  ● Our profitability will be impaired by our obligations to make royalty and milestone payments to our licensors for our clinical services tests.
     
  ● We depend on third parties for the supply of some of the materials used in our clinical and pharma services tests, and we may not be able to find replacements or transition to alternative suppliers in a timely manner.
     
  ● The markets that our clinical services and pharma services operate in is competitive, and our ability to compete successfully in this market depends on a variety of reasons, including our ability to keep up with rapid technological, medical, and scientific changes or our ability to enter into new clinical study collaborations. If we are unable to compete successfully in the markets our clinical services and pharma services operate in, we may be unable to increase or sustain our revenue or achieve profitability.
     
  ● If the FDA changes its enforcement policy as to laboratory developed tests (LDTs) or disagrees with our position that our clinical services tests are LDTs covered by the FDA’s current enforcement discretion policy, we could be subject to a number of enforcement actions, any of which could have a material adverse effect on our clinical services and/or incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and comply with applicable post-market requirements.
     
  ● A failure to comply with federal and state laws and regulations, including but not limited to those laws related to billing practices, fraud, abuse, and payer regulations, could result in our being excluded from participation in Medicare, Medicaid or other governmental payer programs and/or significant monetary fines, and additionally may decrease our revenues and adversely affect our results of operations and financial condition for our clinical services.
     
  ● We may not realize all of the anticipated benefits of the acquisition of our pharma services or those benefits may take longer to realize than expected.
     
  ● If we are unable to successfully utilize, integrate, and/or promote our pharma services in the market, we may be unable to generate sufficient revenue to sustain our pharma services.
     
  ● If we fail to perform our pharma services in accordance with contractual and regulatory requirements, and ethical considerations, we could be subject to significant costs, legal liabilities and could experience a decline in revenue.
     
  ● The loss of members of our senior management team or our inability to attract and retain key personnel could adversely affect our business.
     
  ● If we fail to comply with federal, state and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.
     
  ● Legislation reforming the U.S. healthcare system may have a material adverse effect on our financial condition and operations.

 

 31 
 

 

  ● If we do not increase our revenues and successfully manage the size of our operations, our business, financial condition and results of operations could be materially and adversely affected.
     
  ● The risks associated with penny stock classification could affect the marketability of the Company’s common stock and stockholders could find it difficult to sell their shares.
     
  ● We believe the delisting of our common stock from Nasdaq and trading on OTCQX® has adversely affected trading in our common stock and our ability to seek financing.
     
  ● If we are unable to maintain and implement effective internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.

 

Risks Related to our Business

 

There are substantial doubts about our ability to continue as a going concern due to our operating history of net losses, negative working capital and insufficient cash flows, and lack of liquidity to pay our current obligations and if we are unable to continue our business, our shares may have little or no value.

 

Our ability to become a profitable operating company is dependent upon our ability to generate revenues and/or obtain financing adequate to support our cost structure. We do not currently have enough cash on hand to meet our obligations over the next twelve months, and we cannot provide our stockholders any assurance that we will be able to raise sufficient funding from the generation of revenue, the sale of our common stock, or through financing to sustain us over the next twelve months.

 

For the fiscal year ended December 31, 2021, we had an operating loss of $14.0 million. As of December 31, 2021, we had cash and cash equivalents of $3.1 million and current liabilities of $15.7 million. The Company must fund its operating deficit until a sustainable level of revenue is achieved. These factors have raised substantial doubts about our ability to continue as a going concern. We may need to attempt to raise additional equity capital by selling shares of common stock or other dilutive or non-dilutive means, if necessary. However, the doubts raised, relating to our ability to continue as a going concern, may make investing in our securities an unattractive investment for potential investors. These factors, among others, may make it difficult to raise any additional capital.

 

Our results of operations have been adversely affected and, in the future, could be materially adversely impacted by the coronavirus (COVID-19) pandemic.

 

The world is currently suffering a COVID-19 pandemic which has resulted in governments around the world implementing stringent measures to help control the spread of the virus, including stay-at-home orders, temporarily closing businesses, restricting gatherings, restricting travel, and mandating social distancing and face coverings. The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. Such impact is a function of the scope of any new virus mutations and outbreaks, the nature of government public health guidelines and the public’s adherence to those guidelines, the rate of individuals becoming fully vaccinated, the public’s adherence to guidelines to receive booster shots, the success of business and economic recovery as the pandemic recedes, unemployment levels, the extent to which new shutdowns may be needed and the impact of any further government economic relief on the U.S. economy. In particular, the continued spread of the coronavirus globally is adversely affecting global economies and financial markets which has materially and adversely impacted our operations including, without limitation, the functioning of our laboratories, the availability of supplies including reagents, the progress and data collection of our pharma services, demand for our services and travel, customer demand and employee health and availability. Further, the impact of the COVID-19 pandemic in part caused us to reevaluate the carrying charge of our intangible assets and led us to restate certain of our financial statements to record impairment charges and amortization expense. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future.

 

The ongoing military conflict between Russia and Ukraine has caused geopolitical instability, economic uncertainty, financial markets volatility and capital markets disruption. Our business, financial condition and results of operations may be materially adversely affected by any negative impact on the capital markets resulting from the conflict in Ukraine or any other geopolitical tensions.

 

In late February 2022, Russia invaded Ukraine, significantly amplifying already existing geopolitical tensions among Russia and other countries in the region and in the west, including the U.S. Russia’s invasion, the responses of countries and political bodies to Russia’s actions, the larger overarching tensions, and Ukraine’s military response and the potential for wider conflict have resulted in financial market volatility and capital markets disruption, potentially increasing in magnitude, and could have severe adverse effects on regional and global economic markets and international relations. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial.

 

Following Russia’s actions, various countries, including the U.S., Canada and the United Kingdom, as well as the European Union, issued broad-ranging economic sanctions against Russia. Such sanctions included, among other things, a prohibition on doing business with certain Russian companies, officials and oligarchs; a commitment by certain countries and the European Union to remove selected Russian banks from the Society for Worldwide Interbank Financial Telecommunications (SWIFT) electronic banking network that connects banks globally; a ban on Russian oil and gas imports to the U.S.; and restrictive measures to prevent the Russian Central Bank from undermining the impact of the sanctions. The current sanctions (and potential further sanctions in response to continued Russian military activity) and other actions may have adverse effects on regional and global economic markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds and increasing the volatility of our stock price. Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results.

 

 32 
 

 

Actions that we have taken to restructure our business to strengthen the Company’s profile, enhance shareholder values, and increase revenue growth may not be as effective as anticipated.

 

During Fiscal 2020 and 2021, we implemented certain restructuring and reprioritization plans to strengthen the Company’s profile, enhance shareholder values, and increase revenue growth, by engaging in actions that included, but were not limited to, corporate reprioritization efforts and implementation of various cost saving measures. These plans included the transition of pharma activities from the Rutherford, NJ facility to our Morrisville, NC facility in order to optimize the operations of laboratory operations within our pharma services. We invested several million dollars to facilitate this relocation which was completed in March 2021, including but not limited to the transfer of personnel, expansion of the Morrisville facility and validation of transferred processes. While we expect to realize cost-saving benefits from these initiatives, these actions may not be successful and may not bring the cost saving benefits that we anticipate.

 

We have a history of operating losses, and our clinical and pharma services have generated limited revenue. We expect to incur net losses for the foreseeable future and may never achieve or sustain profitability.

 

Although we expect our revenue to grow in the future, there can be no assurance that we will achieve revenue sufficient to offset expenses. Over the next several years, we expect to (i) continue to devote resources to increase adoption of, and reimbursement for, our clinical services tests and assays and to use our bioinformatics data to develop and enhance our clinical services products and services, (ii) leverage and invest in our pharma services to expand and enhance our pharma services and (iii) develop and acquire additional products and services. However, our business may never achieve or sustain profitability, and our failure to achieve and sustain profitability in the future could have a material adverse effect on our business, financial condition and results of operations, as well as cause the market price of our common stock to decline.

 

We have and may continue to experience intangible asset impairment charges.

 

We are required to evaluate the carrying value of intangibles at least annually, and between annual tests if events or circumstances warrant such a test. We review the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. Writing down or reserving for other intangible assets or impairments has had and would have a negative and unexpected impact on our net worth.

 

In January 2021, we filed restated financial statements contained in the Company’s Annual Report on Form 10-K for the years ended December 31, 2014 through 2019 as well as the financial statements contained in the Quarterly Reports on Form 10-Q for each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2020 and June 30, 2020. Such restatements reflected a non-cash impairment charge and amortization expense related to our Barrett’s intangible asset of approximately $18 million.

 

We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

 

We began commercial sales of our molecular diagnostic tests in late 2014. On July 15, 2019, we acquired the pharma services business. We conduct our business through our wholly-owned subsidiaries, Interpace Diagnostics, LLC, which was formed in Delaware in 2013, Interpace Diagnostics Corporation (formerly known as RedPath Integrated Pathology, Inc.), which was formed in Delaware in 2007, and Interpace BioPharma, Inc., which was formed in Delaware in 2019. On November 12, 2019 we changed the name of Interpace Diagnostics Group, Inc. to Interpace Biosciences, Inc. and that of our newly-formed subsidiary, Interpace BioPharma, Inc. to Interpace Pharma Solutions, Inc. Consequently, any evaluations about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history.

 

 33 
 

 

Our quarterly and annual revenues and operating results may vary which may cause the price of our common stock to fluctuate.

 

Our quarterly and annual operating results may vary as a result of a number of factors, including:

 

  ● uncertainty of cash collections which could impact or affect net realizable values of sales of our tests and services;
     
  ● inability of one or more of our laboratories to perform tests;
     
  ● progress or lack of progress in developing and commercializing tests and services;
     
  ● favorable or unfavorable decisions about our tests or services or reimbursement rates from government regulators, insurances companies, customers, or other third party payers;
     
  ● the commencement, delay, cancellation or completion of sales and marketing programs;
     
  ● timing and amount of expenses for implementing new programs and accuracy of estimates of resources required for ongoing programs;
     
  ● adoption of and coverage and reimbursement for our tests;
     
  ● changes in our relationships with key collaborators, suppliers, customers and third parties;
     
  ● fluctuations in net revenue due to changes in the valuation of our patient accounts;
     
  ● periodic stock-based compensation and awards;
      
  ● mark to market fluctuations in the valuation of our warrant liabilities;
     
  ● changes in valuation for contingent consideration related to acquired assets;
     
  ● fluctuations in R&D, business development and spending for clinical trials;
     
  ● timing and integration of any acquisitions; and
     
  ● changes in regulations related to diagnostics, pharmaceutical, biotechnology and healthcare companies.

 

We believe that quarterly, and in certain instances annual, comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of future performance. Fluctuations in quarterly and annual results could materially and adversely affect the market price of our common stock in a manner unrelated to our long-term operating performance.

 

We depend on sales and reimbursements from our clinical services for more than 50% of our revenue, and we will need to generate sufficient revenue from these and other products and/or solutions that we develop or acquire to grow our business.

 

More than 50% of our revenue is derived from our clinical services. We have molecular diagnostics tests and complimentary service extensions that are in development, but there can be no assurance that we will be able to successfully commercialize or sufficiently increase revenues from those tests. If we are unable to increase sales of our molecular diagnostic tests, expand reimbursement for these tests, or successfully develop and commercialize other molecular diagnostic tests, our revenue and our ability to achieve and sustain profitability would be impaired, and this could have a material adverse effect on our business, financial condition and results of operations, and the market price of our common stock could decline.

 

 34 
 

 

We rely on third-parties to process and transmit claims to payers for our clinical services, and any delay in processing or transmitting could have an adverse effect on our revenue and financial condition.

 

We rely on third-parties to provide overall processing of claims and to transmit actual claims to payers based on specific payer billing formats. In 2019, we transitioned to a new third-party processor and there can be no assurance that we will not experience interruptions or collection delays with our future billings, an occurrence of which may adversely impact our revenue and financial condition. If claims for our clinical services are not submitted to payers on a timely basis, or if we are again required to switch to a different third-party processor to handle claim submissions, we may experience delays in our ability to process claims and receive payment from payers, which could have a material adverse effect on our business, financial condition and results of operations.

 

Due to how we recognize revenue, our quarterly revenue and operating results are likely to fluctuate.

 

We adopted Financial Accounting Standards Board (“FASB”) ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (or “ASC 606”) effective January 1, 2018. As of this date, all revenue is recognized on the accrual basis, based upon actual collection histories for tests and services and respective payers or payer groups. Due to this change in accounting and the estimations required under ASC 606, our quarterly revenue and operating results are likely to fluctuate. As we recognize revenue from payers under ASC 606, we may subsequently determine that certain judgments underlying estimated reimbursement change, or that the estimates we used at the time we accrued such revenue vary materially from the actual reimbursements subsequently realized, and our financial results could be negatively impacted in future quarters. We experienced an adjustment in our estimate for variable consideration under ASC 606 during the fourth quarter of 2019 which resulted in a $5.2 million reduction in revenue recognized year to date; however there have been no such adjustments since then.

 

As a result, comparing our operating results on a period-to-period basis may be difficult due to fluctuations resulting from the estimation process under ASC 606 and such comparisons may not be meaningful. You should not rely on our past results as an indication of our future performance. In addition, these fluctuations in revenue may make it difficult in the near term for us, research analysts and investors to accurately forecast our revenue and operating results. If our revenue or operating results fall below consensus expectations, the price of our common stock would likely decline.

 

A deterioration in the collectability of our accounts receivable could have a material adverse effect on our business, financial condition and results of operations.

 

Collection of accounts receivable from third-party payers and clients is critical to our operating performance. Our primary collection risks are (i) the risk of overestimating our net revenue at the time of billing, which may result in us receiving less than the recorded receivable, (ii) the risk of non-payment as a result of denied claims, (iii) in certain states, the risk that clients will fail to remit insurance payments to us when the commercial insurance company pays out-of-network claims directly to the client and (iv) resource and capacity constraints that may prevent us from handling the volume of billing and collection issues in a timely manner. Additionally, our ability to hire and retain experienced personnel affects our ability to bill and collect accounts in a timely manner. We routinely review accounts receivable balances in conjunction with these factors and other economic conditions that might ultimately affect the collectability of the client accounts and factor them into our estimation of collectability as warranted. Significant changes in business operations, payer mix or economic conditions, including changes resulting from legislation or other health reform efforts (including to repeal or significantly change the Affordable Care Act), could affect our collection of accounts receivable, cash flows and results of operations. In addition, increased client concentration in states that permit commercial insurance companies to pay out-of-network claims directly to the client instead of the provider, could adversely affect our collection of receivables. Unexpected changes in reimbursement rates by third-party payers could have a material adverse effect on our business, financial condition and results of operations.

 

Our business is substantially dependent on third-party reimbursement. Any change in the overall health care reimbursement system may adversely impact our business.

 

Our revenues are substantially dependent on third-party reimbursement. We are paid directly by private insurers and governmental agencies, often on a fixed fee basis. If the average fees allowable by private insurers or governmental agencies were reduced, the negative impact on revenues could have a material effect on our business, financial condition, results of operations and cash flows. Also, if amounts owed to us by payors are reduced or not paid on a timely basis, we may be required to increase our concessions and/or decrease our revenues. Changes to the health care reimbursement system that favor other technologies or treatment regimens and reduce our reimbursements may adversely affect our ability to market our services profitably. Overall, such dependency and potential changes could materially and adversely affect our business, financial condition, results of operations and cash flows.

 

 35 
 

 

Our inability to finance our business on acceptable terms in the future may limit our ability to develop and commercialize products and services and grow our business.

 

Our business is not currently operating on a cash flow breakeven or positive basis, and as a result, we may need to finance our business in the future through collaborations, equity offerings, debt financings, licensing arrangements or other dilutive or non-dilutive means. On January 7, 2021, we entered into promissory notes (“Notes”) with our two private equity investors in the aggregate amount of $5 million with a maturity date of June 30, 2021 which were secured by all of our assets. In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica Bank (“Comerica”). In addition, also in October 2021, the Company entered into an $8.0 million term loan with BroadOak Fund V, L.P. (“BroadOak”), the proceeds of which were used to repay in full at their maturity the Notes extended by our two private equity investors. The BroadOak loan agreement contains affirmative and negative restrictive covenants, including restrictions on certain mergers, acquisitions, investments and encumbrances which could adversely affect our ability to conduct our business. The BroadOak loan agreement also contains customary events of default. The Comerica loan agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica loan agreement. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The Comerica loan agreement also contains financial covenants requiring specified minimum liquidity and minimum revenue thresholds and also contains customary events of default.

 

We will need additional funding to repay the Comerica and BroadOak borrowings as well as to continue operations. Additional funding may not be available to us on acceptable terms, or at all. If we seek to raise funds by issuing additional equity securities, dilution to our stockholders could result. Any public offering of equity securities must be approved by the holders of our Series B Preferred Stock who are our private equity investors. In addition, we are currently ineligible to use a Form S-3 shelf registration statement. If we are unable to timely repay the Comerica and BroadOak borrowings when due, Comerica and BroadOak will have the right to foreclose on our assets (BroadOak being subordinated to Comerica). The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, limitations on our ability to enter into mergers or acquisition of assets, and other operating restrictions that could adversely affect our ability to conduct our business.

 

If we are unable to timely repay our outstanding obligations, our secured lenders will have the right to foreclose on our assets.

 

In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica and an $8.0 million term loan with BroadOak, which are secured by all of our assets. We will need additional funding to repay these outstanding obligations as well as to continue operations. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to timely repay these outstanding obligations, our secured lenders will have the right to foreclose on substantially all of our assets.

 

Risks Related to our Preferred Stock

 

We have issued and may issue additional preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.

 

We are authorized to issue up to five million shares of preferred stock in one or more series. Our Board may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue additional preferred stock, it could affect stockholder rights or reduce the market value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. We have designated, issued and sold an aggregate of 47,000 outstanding shares of Series B Preferred Stock.

 

Two private equity firms and their affiliate’s control, on an as-converted basis, an aggregate of 65% of our outstanding shares of common stock through their holdings of our Series B Preferred Stock, and this concentration of ownership along with their authority for designation rights for a majority of our directors and their right to approve certain of our actions has a substantial influence on our decisions.

 

Ampersand holds 28,000 shares of our Series B Preferred Stock and 1315 Capital holds 19,000 shares of our Series B Preferred Stock. Accordingly, on an as converted basis, Ampersand and its affiliates beneficially own 38.7% of the Company’s outstanding common stock of 4,217,063 and 1315 Capital and its affiliates beneficially own 26.3%. The conversion and sale by such holders of one or more large blocks of our common stock could have a negative impact on the market price of our common stock.

 

These stockholders, acting together, have control over the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. Holders of Series B Preferred Stock were granted director designation rights over a majority of our Board. Accordingly, these stockholders, acting together, have significant influence over our management and affairs. This concentration of ownership might harm the market price of our common stock by delaying, deterring or preventing a change in control, making some transactions more difficult or impossible to complete without the support of these shareholders, regardless of the impact of this transaction on our other shareholders. Such ownership interests could effectively deter a third party from making an offer to buy us, which might involve a premium over our current stock price or other benefits for our stockholders, or otherwise prevent changes in the control or management. For example, this concentration of ownership may have the effect of impeding a merger, consolidation, takeover or other business combination involving us or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

 

 36 
 

 

The holders of our Series B Preferred Stock have preferential rights that may be adverse to holders of our common stock.

 

The holders of our Series B Preferred Stock have preferential rights with respect to distributions upon a liquidation of the Company, including certain business combinations or sales of assets deemed to be a liquidation. Accordingly, no distributions upon liquidation may be made to the holders of common stock until the holders of the Series B Preferred Stock have been paid their liquidation preference. As a result, it is possible that, on a liquidation event and depending on the price thereof, all amounts available for the holders of equity of the Company would be paid to the holders of Series B Preferred Stock, and that the holders of common stock would not receive any payment. In addition, the holders of Series B Preferred Stock have the right to approve certain actions of the Company.

 

In April 2020, 1315 Capital consented to, and agreed to vote (by proxy or otherwise) their Series B Preferred Stock in favor of any “Fundamental Action” taken by the Company as determined by the Company’s Board of Directors. “Fundamental Actions” include the Company’s ability to a) authorize, create or issue any debt securities for borrowed money or funded debt; b) merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess of $20 million; c) transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Company or any of its direct or indirect subsidiaries, other than those accomplished in the ordinary course of business; d) declare or pay any cash dividend or make any cash distribution on any equity interests of the Company other than the Series B Shares; e) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities; and f) change any accounting methods or practices of the Company, except for those changes required by GAAP or applicable regulatory agencies or authorities.

 

Risks Related to our Clinical Services

 

Billing for our clinical services tests is complex, and we must dedicate substantial time and resources to the billing process to be paid for our clinical services tests.

 

Billing for clinical services is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, including Medicare, insurance companies and patients, all of which have different billing requirements. To the extent laws or contracts require us to bill patient co-payments or co-insurance; we must also comply with these requirements. We may also face increased risk in our collection efforts, including write-offs of doubtful accounts and long collection cycles, which could have a material adverse effect on our clinical services, results of operations and financial condition. Among others, the following factors make the billing process complex:

 

  ● differences between the list price for our molecular diagnostic tests and the reimbursement rates of payers;
     
  ● compliance with complex federal and state regulations related to billing Medicare;
     
  ● changes in billing policy reimbursement by CMS;
     
  ● disputes among payers as to which party is responsible for payment;
     
  ● differences in coverage among payers and the effect of patient co-payments or co-insurance;
     
  ● differences in information and billing requirements among payers;
     
  ● incorrect or missing billing information;
     
  ● the resources required to manage the billing and claims appeals process including those of our billing service providers;
     
  ● our inability to bill timely and accurate requisitions and process denials efficiently may result in delayed collections and reduced reimbursement rates; and
     
  ● the overall performance and effectiveness of our billing service providers.

 

 37 
 

 

As we grow and introduce new clinical services tests and other services, we will likely need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our revenue and cash flow from our clinical services. Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees or contractors, challenge coverage and payment denials, assist patients in appealing claims, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payers also conduct external audits to evaluate payments, which add further complexity to the billing process. These billing complexities, and the related uncertainty in obtaining payment for our diagnostic solutions, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.

 

We depend on a few payers for a significant portion of our revenue for our clinical services, and if one or more significant payers, including CMS, stops providing reimbursement or decreases the amount of reimbursement for our tests, or if we are unable to successfully negotiate additional reimbursement contracts for our clinical services tests, our revenue could decline and our commercial success could be compromised.

 

Revenue for clinical services tests performed on patients covered by Medicare was approximately 54% of our revenue for the fiscal year ended December 31, 2021. The percentage of our revenue derived from significant payers for our clinical services tests is expected to fluctuate from period to period as our revenue increases, as additional payers provide reimbursement for such tests, and in the event that one or more payers were to stop reimbursing for our clinical services tests or change their reimbursement amounts.

 

In January 2022, the Company announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS.

 

Novitas Solutions has been and is the current regional MAC that handles claims processing for Medicare services with jurisdiction for PancraGEN®, ThyGeNEXT®, ThyraMIR®, and RespriDx®. On a five-year rotational basis, Medicare requests bids for its regional MAC services. Any future changes in the MAC processing or coding for Medicare claims for our molecular diagnostic tests could result in a change in the coverage or reimbursement rates for such molecular diagnostic tests, or the loss of coverage.

 

Our PancraGEN®, ThyraMIR® and ThyGeNEXT® tests are reimbursed by Medicare based on applicable CPT codes. RespriDx® is currently only covered by the Medicare Advantage program and our BarreGEN® assay is not reimbursed at all. Any future reductions from the current reimbursement rates for our clinical services tests would have a material adverse effect on business and results of operations.

 

Although we have entered into contracts with certain third-party payers which establish allowable rates of reimbursement for our clinical services tests, payers may suspend or discontinue reimbursement at any time, may require or increase co-payments from patients, or may reduce the reimbursement rates paid to us. Any such actions could have a negative effect on our revenue for our clinical services tests.

 

If payers do not provide reimbursement, rescind or modify their reimbursement policies or delay payments for clinical services, or if we are unable to successfully negotiate additional reimbursement contracts for our clinical services tests, our commercial success could be compromised.

 

Physicians may generally not order our clinical services tests unless payers reimburse a substantial portion of the test price. There is uncertainty concerning third-party reimbursement of any test incorporating new molecular diagnostic technology. Reimbursement by a payer may depend on a number of factors, including a payer’s determination that tests such as our molecular diagnostic tests are: (a) not experimental or investigational; (b) pre-authorized and appropriate for the patient; (c) cost-effective; (d) supported by peer-reviewed publications; and (e) included in clinical practice guidelines. Since each payer generally makes its own decision as to whether to establish a policy or enter into a contract to reimburse our clinical services tests, seeking these approvals is a time-consuming and costly process. Although we have contracted rates of reimbursement with certain payers, which establishes allowable rates of reimbursement for our PancraGEN®, ThyGeNEXT®, ThyraMIR® and RespriDx® assays, payers may suspend or discontinue reimbursement at any time, may require or increase co-payments from patients, may impose pre-authorization requirements or may reduce the reimbursement rates paid to us. Any such actions could have a negative effect on our revenue for our clinical services tests.

 

 38 
 

 

We have contracted rates of reimbursement with select payers for PancraGEN®, ThyGeNEXT® and ThyraMIR® and to a limited extent, RespriDx®. Without a contracted rate for reimbursement, claims may be denied upon submission, and we may need to appeal the claims. The appeals process is time consuming and expensive, and may not result in payment. We expect to continue to focus resources on increasing adoption of and coverage and reimbursement for our molecular diagnostic tests. We cannot, however, predict whether, under what circumstances, or at what payment levels payers will reimburse us for our molecular diagnostic tests, if at all. In addition to our current commercial products on the market and in our pipeline, the launch of any new molecular diagnostic tests in the future may require that we expend substantial time and resources in order to obtain and retain reimbursement. Also, payer consolidation can create uncertainty as to whether coverage and contracts with existing payers will even remain in effect. Finally, commercial payers may tie their allowable rates to Medicare rates, and should Medicare reduce their rates, we may be negatively impacted. If we fail to establish broad adoption of and reimbursement for our assays, or if we are unable to maintain existing reimbursement from payers, our ability to generate revenue for our clinical services tests could be harmed and this could have a material adverse effect on our business, financial condition and results of operations.

 

We may experience a reduction in revenue if physicians decide not to order our clinical services tests.

 

If we are unable to create or maintain sufficient demand for our clinical services tests or if we are unable to expand our product offerings, we may not become profitable. To generate demand, we will need to continue to educate physicians and the medical community on the value and benefits of our clinical services tests in order to change clinical practices through clinical trials, published papers, presentations at scientific conferences and one-on-one education by our commercial sales force, which are costly and time-consuming. In addition, our ability to obtain and maintain adequate reimbursement from third-party payers for our clinical services tests will be critical to generating revenue.

 

In many cases, practice guidelines in the United States have recommended therapies or surgery to determine if a patient’s condition is malignant or benign. Accordingly, physicians may be reluctant to order a diagnostic test that may suggest surgery is unnecessary. In addition, our assays are performed at our laboratories rather than by a pathologist in a local laboratory, so pathologists may be reluctant to support our tests. Moreover, guidelines for the diagnosis and treatment of thyroid nodules may change to recommend another type of treatment protocol, and these changes may result in medical practitioners deciding not to use our molecular diagnostic tests. These facts may make physicians reluctant to use our assays, which could limit our ability to generate revenue from our clinical services tests and achieve profitability, which could have a material adverse effect on our business, financial condition and results of operations.

 

We may experience a reduction in revenue if patients decide not to use our clinical services tests.

 

Some patients may decide not to use our clinical services tests due to price, all or part of which may be payable directly by the patient if the patient’s insurer denies reimbursement in full or in part. Many insurers seek to shift more of the cost of healthcare to patients in the form of higher deductibles, co-payments, or premiums. In addition, the economic environment in the United States may result in the loss of healthcare coverage. Implementation of provisions of PPACA provided coverage for patients, particularly in the individual market, who were previously either uninsured or faced high premiums. However, premiums for many of the plans participating in the exchanges established as part of this legislation have increased and some health plans have chosen to drop out of these networks in specific markets or the program altogether. In 2018, Congress passed legislation revising certain provisions of PPACA and federal agencies also have issued final rules to repeal or revise regulations governing the implementation of certain provisions of PPACA which may negatively impact our revenues. Overall, the scope and timing of any further legislation, judicial action or federal regulations to limit, revise, or replace PPACA or regulations governing its implementation is uncertain, but if enacted could have a significant impact on the U.S. healthcare system and our revenues. These events may result in an increase of uninsured patients, increases in premiums, and reductions in coverage for some patients. Patients may therefore delay or forego medical checkups or treatment due to their inability to pay for our clinical services tests, which could have a negative effect on our revenues. We do have a Patient Assistance Program that allows eligible patients to apply for assistance in covering a portion of their out of pocket obligation or all costs for claims denied as non-covered for our clinical services tests if they meet the criteria for participation.

 

 39 
 

 

If our clinical services tests do not perform as expected, we may not be able to achieve widespread market adoption among physicians, which would cause our operating results, reputation, and business to suffer.

 

Our success depends in part on the market’s confidence that we can provide reliable, high-quality molecular information products. There is no guarantee that the accuracy and reproducibility we have demonstrated to date will continue, particularly for clinical samples, as our test volume increases. We believe that our customers are likely to be particularly sensitive to product defects and errors, including if our products fail to detect genomic alterations with high accuracy from clinical specimens or if we fail to list, or inaccurately include, certain treatment options and available clinical trials in our product reports. As a result, the failure of our products to perform as expected would significantly impair our operating results and our reputation. We may be subject to legal claims arising from any defects or errors in our clinical services tests.

 

Our profitability will be impaired by our obligations to make royalty and milestone payments to our licensors for our clinical services tests.

 

In connection with our acquisition of certain assets of Asuragen in 2014, we currently license certain patents and know-how from Asuragen relating to (i) miRInform® thyroid and pancreas cancer diagnostic tests and other tests in development for thyroid cancer (the “Asuragen License Agreement”), and (ii) the sale of diagnostic devices and the performance of certain services relating to thyroid cancer (the “CPRIT License Agreement”). Pursuant to the Asuragen License Agreement and the CPRIT License Agreement, we are obligated to make certain royalty and milestone payments to Asuragen and the Cancer Prevention & Research Institute of Texas, or CPRIT. Under the Asuragen License Agreement, we are obligated to pay royalties on the future net sales of tests utilizing the miRInform® thyroid platform (i.e., ThyGeNEXT®), potentially on certain other thyroid diagnostics tests and potentially on other tests in development for thyroid cancer. A similar obligation exists if we elect to launch any molecular tests utilizing the miRInform® pancreas platform. We are also required by the CPRIT License Agreement with Asuragen to make certain related royalty payments to CPRIT.

 

When performing the ThyraMIR® test, we use products supplied by Exiqon A/S (now a part of Qiagen), subject to a license agreement with Exiqon A/S. The license agreement obligates us to pay royalties on the future net sales of our assays that utilize licensed patents and know-how obtained from Exiqon A/S. Our profitability will be impaired by our obligations to make royalty payments to our licensors. Although we believe, under such circumstances, that the increase in revenue will exceed the corresponding royalty payments, our obligations to our licensors could have a material adverse effect on our business, financial condition and results of operations if we are unable to manage our operating costs and expenses at profitable levels.

 

If we breach certain agreements with Asuragen, it could have a material adverse effect on our sales and commercialization efforts for our thyroid cancer diagnostic tests as well as any potential tests in development for thyroid cancer utilizing their technology and the sale of diagnostic devices and the performance of certain services relating to thyroid cancer.

 

Under the CPRIT License Agreement, we are obligated to pay 5% of net sales on sales of certain diagnostic devices and the performance of services relating to thyroid cancer that incorporate technology developed and funded under an agreement between Asuragen and the Cancer Prevention and Research Institute of Texas, subject to a maximum deduction of 3.5% for royalties paid to third parties. Both of the Asuragen License Agreement and the CPRIT License Agreement continue until terminated by (i) mutual agreement of the parties or (ii) either party in the event of a material breach of the respective agreement by the other party.

 

If we materially breach or fail to perform any provision under the CPRIT License Agreement, Asuragen will have the right to terminate our license from CPRIT, and upon the effective date of such termination, our right to practice the licensed technology would end. To the extent such licensed technology rights relate to our molecular diagnostic tests currently on the market, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the technology licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under these license agreements could result in our loss of rights to practice the technology licensed to us under these license agreements, and to the extent such rights and other technology relate to our molecular diagnostic tests currently on the market, it could have a material adverse effect on our sales and commercialization efforts for NGS-based thyroid and pancreatic cancer molecular diagnostic tests and other tests in development for thyroid cancer, and the sale of molecular diagnostic tests and the performance of certain services relating to thyroid cancer.

 

 40 
 

 

Under the agreement, neither party will be held responsible for a default or breach for failure or delay in performing its obligations when such failure or delay is caused by or results from events beyond reasonable control of the non-performing party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics or pandemics, quarantines war, acts of war, etc.

 

Clinical utility studies are important in demonstrating to both customers and payers a molecular diagnostic test’s clinical relevance and value. If we are unable to identify collaborators willing to work with us to conduct clinical utility studies, or the results of those studies do not demonstrate that a molecular diagnostic test provides clinically meaningful information and value, commercial adoption of such test may be slow, which would negatively impact our business.

 

Clinical utility studies show when and how to use a molecular diagnostic clinical test and describe the particular clinical situations or settings in which it can be applied and the expected results. Clinical utility studies also show the impact of the molecular diagnostic test results on patient care and management. Clinical utility studies are typically performed with collaborating oncologists or other physicians at medical centers and hospitals, analogous to a clinical trial, and generally result in peer-reviewed publications. Sales and marketing representatives use these publications to demonstrate to customers how to use a molecular diagnostic clinical test, as well as why they should use it. These publications are also used with payers to obtain coverage for a molecular diagnostic test, helping to assure there is appropriate reimbursement. We will need to conduct additional studies for our molecular diagnostic tests and other diagnostic tests we plan to introduce, to increase the market adoption and obtain coverage and adequate reimbursement. Should we not be able to perform these studies, should the costs or length of time required for these studies exceed their value, or should their results not provide clinically meaningful data and value for oncologists and other physicians, adoption of our molecular diagnostic tests could be impaired, and we may not be able to obtain coverage and adequate reimbursement for them.

 

We rely on sole suppliers for some of the materials used in our tests and services, and we may not be able to find replacements or transition to alternative suppliers in a timely manner.

 

We rely on sole suppliers for certain materials that we use to perform our tests and services, including Asuragen, for our endocrine cancer diagnostic tests pursuant to our supply agreement with them. We also purchase reagents used in our tests and services from sole-source suppliers. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available in a timely manner. If these suppliers can no longer provide us with the materials we need to perform our tests and services, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing and services could occur. Any such interruption may directly impact our revenue and cause us to incur higher costs. In particular, the continued spread of the coronavirus globally could materially and adversely impact our operations including without limitation our supply chain, which may have a material and adverse effect on our business, financial condition and results of operations.

 

We may experience problems in scaling our operations, or delays or reagent and supply shortages for our tests and services that could limit the growth of our revenue.

 

If we encounter difficulties in scaling our operations as a result of, among other things, quality control and quality assurance issues and availability of reagents and raw material supplies, we will likely experience reduced sales of our tests and services, increased repair or re-engineering costs, and defects and increased expenses due to switching to alternate suppliers, any of which would reduce our revenues and gross margins. Although we attempt to match our capabilities to estimates of marketplace demand, to the extent demand materially varies from our estimates, we may experience constraints in our operations and delivery capacity, which could adversely impact revenue in a given fiscal period. Should our need for raw materials and reagents used in our tests and services fluctuate, we could incur additional costs associated with either expediting or postponing delivery of those materials or reagents.

 

 41 
 

 

If we are unable to support demand for our tests and services, or any of our future tests, services or solutions, our business could suffer.

 

As demand for our tests and services grow, we will also need to continue to scale up our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We will also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our tests and services. We cannot assure you that increases in scale, related improvements and quality assurance will be implemented successfully or that appropriate personnel will be available. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing and services on a timely basis at a level consistent with demand, or that our efforts to scale our operations will not negatively affect the quality of test results. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer, causing a material adverse effect on our business, financial condition and results of operations.

 

Developing new tests and related services and solutions involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other tests, assays, services and solutions under development.

 

Developing new tests, services and solutions will require us to devote considerable resources to research and development, which we may not be in a position to do. We may face challenges obtaining sufficient numbers of samples to validate a newly acquired or developed test or service. In order to develop and commercialize new tests and services, we need to:

 

  ● expend significant funds to conduct substantial research and development;
     
  ● conduct successful analytical and clinical studies;
     
  ● scale our laboratory processes to accommodate new tests and services; and
     
  ● build and maintain the commercial infrastructure to market and sell new tests and services.

 

Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a test, service or solutions or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating revenue from such test, service or solution. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study or if we fail to sufficiently demonstrate analytical validity, we might choose to abandon the development of the test, service or solution which could harm our business. In addition, competitors may develop and commercialize new competing tests, services and solutions faster than us or at a lower cost, which could have a material adverse effect on our business, financial condition and results of operations.

 

If we are unable to develop or acquire tests, services and solutions to keep pace with rapid technological, medical and scientific change, our operating results and competitive position in the market could be affected.

 

Recently, there have been numerous advances in technologies relating to diagnostics, particularly diagnostics that are based on genomic information. These advances require us to continuously develop our technology and to work to develop new solutions to keep pace with evolving standards of care. Our clinical services and pharma services could become obsolete unless we continually innovate and expand our product offerings to include new clinical applications. If we are unable to develop or acquire new tests, services and solutions or to demonstrate the applicability of our tests and services for other diseases, our sales could decline and our competitive position could be harmed.

 

 42 
 

 

If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed.

 

In the past, we have entered into clinical study collaborations related to our tests and services, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaboration with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Moreover, it may take longer to obtain the samples we need which could delay our trials, publications, and product launches and reimbursement. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed journals is a crucial step in commercializing and obtaining reimbursement for our diagnostic tests, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from them.

 

If the FDA changes its enforcement policy as to LDTs or disagrees with our position that our clinical services tests are LDTs covered by the FDA’s current enforcement discretion policy, we could be subject to a number of enforcement actions, any of which could have a material adverse effect on our clinical services and/or incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and comply with applicable post-market requirements.

 

Clinical laboratory tests like our clinical services tests are regulated under CLIA as well as by applicable state laws and may also be subject to FDA regulation, depending on how the test is classified. For example, the FDA regulates in vitro diagnostic tests (also called in vitro devices or “IVDs”), specimen collection kits, analyte specific reagents (ASRs), and instruments used in conducting diagnostic testing. Most tests that qualify as LDTs are currently subject to enforcement discretion by the FDA, but there is substantial uncertainty regarding the scope of the FDA’s enforcement discretion policy and the proper interpretation of the definition of LDTs (as set forth in the 2014 draft guidance described below, which defines LDTs as “those in vitro diagnostic devices (IVD) that are intended for clinical use and are designed, manufactured and used within a single laboratory”). In July 2014, the FDA issued two draft guidance documents: “Framework for Regulatory Oversight of Laboratory Developed Tests,” which provides an overview of how the FDA would regulate LDTs through a risk-based approach, and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests”, which provides guidance on how the FDA intends to collect information on existing LDTs, including adverse event reports. Pursuant to the Framework for Regulatory Oversight draft guidance, LDT manufacturers will be subject to medical device registration, listing, and adverse event reporting requirements. LDT manufacturers will be required to either submit a pre-market application and receive the FDA’s approval before an LDT may be marketed or submit a pre-market notification in advance of marketing unless subject to continued enforcement discretion. The Framework for Regulatory Oversight draft guidance states that within six months after the guidance documents are finalized, all laboratories will be required to give notice to the FDA and provide basic information concerning the nature of the LDTs offered.

 

On January 13, 2017, the FDA released a discussion paper on LDTs outlining a possible, substantially-revised risk-based approach for FDA and Centers for Medicare & Medicaid Services, or CMS, oversight of LDTs. According to the 2017 discussion paper, most previously marketed LDTs would not be expected to comply with most or all FDA oversight requirements (grandfathering), except for adverse event and malfunction reporting. In addition, certain new and significantly modified LDTs would not be expected to comply with pre-market review unless the agency determines certain tests could lead to patient harm. Since many LDTs currently on the market would be grandfathered in, pre-market review of new and significantly modified LDTs could be phased-in over a four-year period, as opposed to the nine years proposed in the Framework for Regulatory Oversight draft guidance. In addition, tests introduced after the effective date, but before their phase-in date, could continue to be offered during pre-market review.

 

The discussion paper notes that the FDA will focus on analytical and clinical validity as the basis for marketing authorization. The FDA anticipates laboratories that already conduct proper validation should not be expected to experience new costs for validating their tests to support marketing authorization and laboratories that conduct appropriate evaluations would not have to collect additional data to demonstrate analytical validity for FDA clearance or approval. The evidence of the analytical and clinical validity of all LDTs would be made publicly available. LDTs would be encouraged to submit prospective change protocols in their pre-market submission that outline specific types of anticipated changes, the procedures that will be followed to implement them and the criteria that will be met prior to implementation.

 

 43 
 

 

In March 2017, members of Congress posted a discussion draft of “The Diagnostics Accuracy and Innovation Act” (DAIA). The discussion draft included language that, if enacted, would have established a new regulatory framework for the oversight of in vitro clinical tests (“IVCTs”) which include LDTs. In 2020, members of Congress introduced “The Verifying Accurate, Leading-edge IVCT Development (VALID) Act”; this bill was re-introduced in substantially similar form in June 2021. If enacted, VALID would create a risk-based approach to regulate IVCTs while grandfathering many existing IVCTs. The new regulatory framework will include quality control and post-market reporting requirements. Each test will be classified as high-risk or low-risk. Pre-market review will be required for high-risk tests. To market a high-risk IVCT, reasonable assurance of analytical and clinical validity for the intended use must be established. Under VALID, a precertification process would be established which will allow a laboratory to establish that the facilities, methods, and controls used in the development of certain IVCTs meet quality system requirements. If pre-certified, low-risk IVCTs it develops will not be subject to pre-market review. The new regulatory framework will include quality control and post-market reporting requirements. The FDA will have the authority to withdraw from the market IVCTs if it is reasonably possible that such tests will cause serious adverse health consequences (among other criteria). We cannot predict whether this bill will become law or the ultimate impact of its passage, or other legislative or regulatory changes, would have on our business. If the FDA implements a new framework for enforcement of its regulations against LDTs, our existing products that are classified as LDTs, if any, and/or any of our future LDTs we seek to develop and market for clinical use, we may be required to obtain pre-certification or approval before continuing to market such tests in the U.S. We may not be able to obtain such pre-certifications or approvals on a timely basis or at all. Our business could be negatively impacted as a result of commercial delay that may be caused by any new requirements.

 

If we are required to submit applications for our currently-marketed clinical services tests, we may be required to conduct additional studies, which may be time-consuming and costly and could result in our currently-marketed tests being withdrawn from the market. Continued compliance with the FDA’s regulations would increase the cost of conducting our clinical services, and subject us to heightened regulation by the FDA and penalties for failure to comply with these requirements. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. Any other regulatory or legislative proposals that would increase general FDA oversight of clinical laboratories and LDTs could negatively impact our business if additional requirements are imposed. We are monitoring developments and anticipate that our clinical services products will be able to comply with requirements that are ultimately imposed by the FDA. In the meantime, we maintain our CLIA accreditation, which permits the use of LDTs for diagnostics purposes.

 

Similarly, notwithstanding any change in existing enforcement policies, if the FDA determines that any of our clinical services tests are IVDs, rather than LDTs and, accordingly, seeks to enforce the applicable medical device regulations against us, we could be subject to a wide range of penalties and would likely be prohibited from continuing to offer the applicable tests in interstate commerce until we have obtained FDA approval or clearance through the Premarket Approval (PMA) process or the 510(k) process, respectively, as applicable. Additionally, we could be subject to enforcement for noncompliance with the FDA’s regulations on marketing and promotional communications, manufacturing, quality and safety standards, labeling, storage, registration and listing, recordkeeping, adverse event reporting, and any other regulations applicable to IVDs. Any adverse enforcement action against us may have a material adverse effect on our clinical services and results of operations.

 

If we are sued for product liability or errors and omissions liability related to our tests and services, we could face substantial liabilities that exceed our resources.

 

The marketing, sale and use of our tests and services could lead to product liability claims if someone were to allege that the test or service failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. A product liability or errors and omissions liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain product liability and errors and omissions insurance, we cannot be certain that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of such claims. Any product liability or errors and omissions liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our products and solutions. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.

 

 44 
 

 

Our failure to comply with fraud and abuse laws or payer regulations could result in our being excluded from participation in Medicare, Medicaid, or other governmental payer programs, subject to fines, penalties, and repayment obligations, decrease our revenues and adversely affect our results of operations and financial condition for our clinical services.

 

The Medicare program is administered by CMS, which, like the states that administer their respective state Medicaid programs, imposes extensive and detailed requirements on diagnostic services providers, including, but not limited to, rules that govern how we structure our relationships with physicians, how and when we submit reimbursement claims and how we provide our specialized diagnostic services. In addition, federal and state laws prohibit fraudulent billing and provide for the recovery of overpayments. In particular, if we fail to comply with federal and state documentation, coding and billing rules, we could be subject to liability under the federal False Claims Act, including criminal and/or civil penalties, loss of licenses and exclusion from the Medicare and Medicaid programs. The False Claims Act prohibits individuals and companies from knowingly submitting false claims for payments to, or improperly retaining overpayments from, the government. Private payers also have complex documentation, coding, and billing rules, and can bring civil actions against laboratories. Our failure to comply with applicable Medicare, Medicaid and other third party payer rules could result in liability under the False Claims Act, our inability to participate in a governmental payer program, recoupment or returning funds already paid to us, civil monetary penalties, criminal penalties and/or limitations on the operational function of our laboratory, all of which could adversely affect our results of operations and financial condition.

 

Risks Related to our Pharma Services

 

We may not realize all of the anticipated benefits of the acquisition of our pharma services business or those benefits may take longer to realize than expected. We may also encounter significant unexpected difficulties in integrating the pharma services business.

 

Our ability to realize the anticipated benefits of the acquisition of the pharma services business depends, to a large extent, on our ability to integrate it successfully. The combination and integration of two independent operations is a complex, costly and time-consuming process. As a result, we have been required and are continuing to devote significant management attention and resources to integrating the business practices and operations of our pharma services with our clinical services practices and operations. The integration process, which includes moving laboratory locations, may disrupt the operations and, if implemented ineffectively or if impacted by unforeseen negative economic or market conditions or other factors, we may not realize the full anticipated benefits of the acquisition. Our failure to meet the challenges involved in integrating the two operations to realize the anticipated benefits of such acquisition could cause an interruption of, or a loss of momentum in, our activities and could adversely affect our results of operations.

 

In addition, the overall integration of the operations may result in material unanticipated problems, expenses, liabilities, competitive responses, loss of customer relationships, and diversion of management’s attention. The difficulties of combining the operations include but are not limited to:

 

  ● diversion of management’s attention from the management of daily operations to integration matters;
     
  ● difficulties in achieving anticipated cost savings, synergies, business opportunities and growth prospects from combining our pharma services with our clinical services operations;
     
  ● difficulties entering new markets or new laboratory or data management services where we have no or limited direct prior experience;

 

 45 
 

 

  ● difficulties in the integration of operations and systems;
     
  ● difficulties in the assimilation of employees and in the retention of key employees;
     
  ● difficulties in retaining employees who may be vital to the integration of departments, information technology systems, including accounting systems, technologies, books and records, and procedures, and maintaining uniform standards, such as internal accounting controls, procedures, and policies;
     
  ● difficulties in the assimilation of different corporate cultures and business practices;
     
  ● difficulties in managing the expanded operations of a significantly larger and more complex company;
     
  ● potential deterioration in the sales and revenues of the tests and services of our pharma services;
     
  ● costs and expenses associated with any undisclosed or potential liabilities;
     
  ● successfully managing relationships with our new strategic partners, suppliers and customer base;
     
  ● challenges in maintaining existing, and establishing new business relationships; and
     
  ● challenges as a result of the COVID-19 pandemic.

 

Many of these factors are outside of our control and any one of them could result in increased costs, decreases in the amount of expected revenues and diversion of management’s time and energy, which could materially impact the business, financial condition and our results of operations. In addition, even if the operations of our clinical services operations and our pharma services are integrated successfully, we may not realize the full benefits of the acquisition, including the synergies, cost savings or sales or growth opportunities that we expect. These benefits may not be achieved within the anticipated time frame, or at all.

 

Furthermore, additional unanticipated costs which may be incurred in the continuing integration of operations or unanticipated increases in expenses unrelated to the acquisition of our pharma services may offset the expected benefits from the acquisition of our pharma services. In addition, our acquisition of the pharma services business has resulted in the incurrence of additional amortization expenses related to intangible assets, which could have a material adverse effect on the Company’s financial condition, operating results, and cash flow. Further, the acquisition of the pharma services business resulted in the Company recording significant goodwill and other assets, and we may be required to incur impairment charges, which could adversely affect our consolidated financial position and results of operations. Since the acquisition, we have also undergone several cost-cutting initiatives with our pharma services business, including reductions in headcount. Further, during Fiscal 2021, the Company experienced a fairly significant decrease in volume within pharma services. The decrease in revenue within pharma services was approximately 32% from the comparable prior year period. Such revenue headwinds may continue in future periods. As such, all of these factors could decrease or delay the expected accretive effect of the pharma services business acquisition and negatively impact our business, financial condition and results of operations. As a result, we cannot be certain that the integration process and resulting combined operations will result in the realization of the full benefits anticipated from the acquisition.

 

If we are unable to increase sales of the tests and services in our pharma services or to successfully develop and commercialize other proprietary tests in our pharma services, we may be unable to achieve profitability.

 

Our pharma services provide pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials with lab testing services for patient stratification and treatment selection through an extensive suite of molecular- and biomarker-based testing services, DNA- and RNA- extraction and customized assay development and trial design consultation. It is unclear whether we will be able to maintain and grow the number of customers who will avail themselves of our tests and services, or how regular a flow of business we will be able to obtain from existing customers. If we are unable to increase sales of our tests and services or to successfully develop, validate and commercialize other diagnostic tests and services, our pharma services may not produce sufficient revenues to become profitable.

 

 46 
 

 

If pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials decide not to use our diagnostic tests and services, we may be unable to generate sufficient revenue to sustain our pharma services.

 

To generate demand for our pharma services, we need to educate pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials on the utility of our tests and services to improve the outcomes of clinical trials for new oncology drugs and more rapidly advance targeted therapies through the clinical development process through published papers, presentations at scientific conferences and one-on-one education sessions by members of our sales force. We may need to hire additional commercial, scientific, technical and other personnel to support this process. If we cannot convince pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials to order our diagnostic tests and services or other future tests and services we develop, we will likely be unable to create demand for our tests and services in sufficient volume for us to achieve sustained profitability of our pharma services.

 

As a result of our pharma services, our quarterly operating results may be subject to significant fluctuations and may be difficult to forecast.

 

The nature of the services of our pharma services is that they tend to come in relatively large projects but episodically, rather than providing steady sources of revenues. The timing, size and duration of our contracts with our customers depend on the size, pace and duration of such customer’s clinical trial, over which we have no control and sometimes limited visibility. In addition, our expense levels are based, in part, on expectation of future revenue levels. A shortfall in expected revenue could, therefore, result in a disproportionate decrease in our net income. As a result, our quarterly operating results may be subject to significant fluctuations and may be difficult to forecast.

 

If we fail to perform our pharma services in accordance with contractual and regulatory requirements, and ethical considerations, we could be subject to significant costs or liability.

 

Through our pharma services offerings, we contract with pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials to perform lab testing services for patient stratification and treatment selection through an extensive suite of molecular- and biomarker-based testing services, DNA- and RNA- extraction and customized assay development and trial design consultation. Such services are complex and subject to contractual requirements, regulatory standards and ethical considerations. If we fail to perform our services in accordance with these requirements, standards, and considerations regulatory authorities may take action against us or our customers. Such actions may include failure of such regulatory authority to grant marketing approval of our customers’ products, imposition of holds or delays, suspension or withdrawal of clearances or approvals, rejection of data collected, laboratory license revocation, product recalls, operational restrictions, civil or criminal penalties or prosecutions, damages or fines. Any such action could have a material adverse effect on our business, financial condition, and results of operations.

 

Risks Related to our Operations

 

The loss of members of our senior management team or our inability to attract and retain key personnel could adversely affect our business.

 

As a small company with less than 200 employees, the success of our business depends largely on the skills, experience and performance of members of our senior management team, including our chief executive officer and chief financial officer, and others in key management positions. During January and February 2021, we experienced turnover in our chief executive officer and chief financial officer positions. The efforts of these persons will be critical to us as we continue to grow our clinical services and develop and/or acquire additional molecular diagnostic tests, and increase or maintain pharma services tests and service revenue or to successfully develop and commercialize other pharma services proprietary tests and services. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. In addition, our commercial laboratory operations depend on our ability to attract and retain highly skilled scientists, including licensed clinical laboratory scientists. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel, and we may have to pay higher salaries to attract and retain qualified personnel. We may also be at a disadvantage in recruiting and retaining key personnel as our small size, limited resources, and limited liquidity may be viewed as providing a less stable environment, with fewer opportunities than would be the case at one of our larger competitors. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our clinical laboratory and commercialization.

 

 47 
 

 

If we lose the support of key opinion leaders or KOL’s, it may limit our revenue growth from our tests or services and our ability to achieve profitability.

 

We have established relationships with leading oncology opinion leaders at premier cancer institutions and oncology networks. If these key opinion leaders determine that our existing products and services or other products and services that we develop are not clinically effective, that alternative technologies are more effective, or if they elect to use internally developed products, we would encounter significant difficulty validating our testing platform, driving adoption, or establishing our tests as a standard of care, which would limit our revenue growth and our ability to achieve profitability.

 

If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies to leverage our bioinformatics data, we may be unable to recognize revenues from biopharmaceutical companies and our product development could be delayed.

 

We have limited experience in marketing and selling our products, and if we are unable to expand our direct sales and marketing force to adequately address our customer’s needs, our business may be adversely affected.

 

Although we have been selling commercial products since 2014, genomic diagnostics and pharma services are new areas of science, and we continue to focus and refine our efforts to sell, market and receive reimbursement for our clinical service products and to leverage our bioinformatics data. We may not be able to market, sell, or distribute our existing products or services or other products or services we may develop effectively enough to support our planned growth.

 

Our future sales will depend in large part on our ability to develop, and substantially expand, our sales force and to increase the scope of our marketing efforts. Our target market of physicians is a large and diverse market. As a result, we believe it is necessary to develop a sales force that includes sales representatives with specific technical backgrounds. We will also need to attract and develop marketing personnel with industry expertise. Competition for such employees is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales and marketing force, which could negatively impact sales and market acceptance of our products and services and limit our revenue growth and potential profitability.

 

Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, and integrate additional employees. Our future financial performance and our ability to commercialize our products and leverage our data and to compete effectively will depend in part on our ability to manage this potential future growth effectively, without compromising quality.

 

If our sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenues could be diminished. In addition, we have limited history selling our clinical services tests on a direct basis and operating our pharma services, and leveraging our bioinformatics data and our limited history makes forecasting difficult.

 

If our sales force is not successful, or new additions to our sales team fail to gain traction among our customers, we may not be able to increase market awareness and sales of our molecular diagnostic tests and pharma services. If we fail to establish our clinical services tests and pharma services in the marketplace, it could have a negative effect on our ability to sell subsequent products or services and hinder the desired expansion of our business. We have growing, however limited, historical experience forecasting the direct sales of our clinical services products, and no prior history operating our pharma services before our acquisition of pharma services in 2019. Our ability to produce product quantities that meet customer demand is dependent upon our ability to forecast accurately and plan production accordingly.

 

 48 
 

 

If we are unable to compete successfully in the markets our clinical services and pharma services operate in, we may be unable to increase or sustain our revenue or achieve profitability.

 

We compete with physicians and the medical community who use traditional methods to diagnose gastrointestinal, endocrine and lung cancers and to conduct clinical trials. In many cases, practice guidelines in the United States have recommended non-molecular testing like cytology or diagnostic surgery to determine if a patient’s condition is malignant or benign. As a result, we believe that we will need to continue to educate physicians and the medical community on the value and benefits of our clinical services tests in order to impact clinical practices. In addition, we face competition from other companies that offer diagnostic tests. Specifically, in regard to our thyroid diagnostic tests, Veracyte has thyroid nodule cancer diagnostic tests which are currently on the market that compete with our ThyGeNEXT® and ThyraMIR® tests. Quest currently offers Veracyte’s tests via a co-marketing agreement, and CBL is offering a diagnostic test performed via the University of Pittsburgh Medical Center (UPMC) that analyzes genetic alterations using next-generation sequencing mutation panel for pancreatic cysts. While we do not believe we currently have significant direct competition for PancraGEN® in the gastrointestinal market, technology such as a next-generation sequencing mutation panel could in the future lead to increased competition.

 

It is also possible that we face future competition from laboratory developed tests, or LDTs, developed by commercial laboratories such as Quest and/or other diagnostic companies developing new molecular diagnostic tests or technologies. Furthermore, we may be subject to competition as a result of the new, unforeseen technologies that can be developed by our competitors in the gastrointestinal and endocrine cancer molecular diagnostic testing space. To compete successfully, we must be able to demonstrate, among other things, that our test results are accurate and cost effective, and we must secure a meaningful level of reimbursement for our tests. Since our clinical services began in 2014, many of our potential competitors have stronger brand recognition and greater financial capabilities than we do. Others may develop a test with a lower price than ours that could be viewed by physicians and payers as functionally equivalent to our molecular diagnostic tests or offer a test at prices designed to promote market penetration, which could force us to lower the price of our clinical services tests and affect our ability to achieve and maintain profitability. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance of our clinical services tests and overall sales, which could prevent us from increasing our revenue or achieving profitability and cause the market price of our common stock to decline. As we add new clinical services tests and other products and services, we will likely face many of these same competitive risks that we do currently.

 

With respect to our pharma services, we also face competition from companies that currently offer or are developing products to profile genes, gene expression or protein biomarkers in various cancers. Precision medicine is a new area of science, and we cannot predict what tests others will develop that may compete with or provide results superior to the results we are able to achieve with the tests we develop. Our competitors for our pharma services include public companies such as NeoGenomics and many private companies.

 

If we cannot license rights to use third-party technologies on reasonable terms, we may not be able to commercialize new products or services in the future.

 

In the future, we may license third-party technology to develop or commercialize new products or offer new services. In return for the use of a third-party’s technology, we may agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of cost of revenue and affect the margins on our solutions. We may also need to negotiate licenses to patents and patent applications after introducing a commercial product. Our business may suffer if we are unable to enter into the necessary licenses on acceptable terms, or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the license or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable.

 

Unfavorable results of legal proceedings could have a material adverse effect on our business, financial condition and results of operations.

 

We are subject to various legal proceedings and claims that arise in or outside the ordinary course of business. The results of legal proceedings cannot be predicted with certainty. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in the legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that could have a material adverse effect on our business, financial condition and results of operations.

 

 49 
 

 

If a catastrophe strikes any of our laboratories or if any of our laboratories becomes inoperable for any other reason, we will be unable to perform our testing and pharma services and our business will be harmed.

 

The laboratories and equipment we use to perform our tests and services would be costly to replace and could require substantial lead time to replace and qualify for use if they became inoperable. Our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, flooding, power outages, and health epidemics or pandemics, including the outbreak of Coronavirus (COVID-19), which may render it difficult or impossible for us to perform our testing or services for some period of time or to receive and store samples. The inability to perform our tests or services for even a short period of time, including due to disruption in staffing, supplies, distribution, or transport or temporary closures related to an outbreak of disease such as COVID-19, may result in the loss of customers or harm our reputation, and we may be unable to regain those customers in the future. Although we maintain insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all. In addition, COVID-19 has materially and adversely impacted our operations particularly during portions of 2020. Further continued spread of COVID-19 globally and resulting travel and other restrictions that may be imposed could negatively impact our ability to obtain raw materials needed for manufacture of our clinical services testing, our ability to provide testing and our pharma services to patients, our financial condition and our results of operation. The extent to which COVID-19 and global efforts to contain its spread will impact our operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the outbreak and the actions taken to contain or treat the COVID-19 outbreak.

 

If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.

 

We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could have a significant impact on our operating results.

 

Security breaches, loss of data and other disruptions to us or our third-party service providers could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

 

Our business requires that we and our third-party service providers collect and store sensitive data, including PHI, personally identifiable information such as genetic information or credit card information about patients or other individuals, and our proprietary business and financial information. We must comply with the HIPAA and HITECH privacy, security, and breach notification regulations with respect to PHI in our capacity as a covered entity and business associate, and with consumer protection and consumer privacy laws that apply to our processing of this sensitive data, which may increase our operational costs. Furthermore, the privacy, security, and breach notification regulations implemented under HIPAA and HITECH as well as other federal and state consumer protection and consumer privacy laws and regulations that may apply to us provide for significant fines and other penalties, including potential civil and criminal fines and penalties, for non-compliance. We face a number of risks relative to our protection of, and our service providers’ protection of, this critical information, other personally identifiable information, and our proprietary business and financial information, including loss of access, fraudulent modifications, inappropriate disclosure and inappropriate access, as well as risks associated with our ability to identify and audit such events. The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. If such event would occur and cause interruptions in our operations, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, modified without our knowledge, lost or stolen. In 2017, we discovered malware installed on certain servers. After an internal investigation, we do not believe that any PHI or other sensitive data on the affected servers was accessed or compromised. We removed the malware, and enhanced our cybersecurity procedures.

 

 50 
 

 

Additionally, we engage third-party contractors who, insofar as they are our business associates, are contractually and legally obligated to safeguard and maintain the confidentiality of any PHI that they create, receive, maintain, transmit, use, or disclose on our behalf. Unauthorized persons may be able to gain access to PHI stored by such third-party contractors, including in their computer networks. Any wrongful use or disclosure of PHI by us or our third-party contractors, including disclosure due to data theft or unauthorized access to our or our third-party contractors’ computer networks, could subject us to fines or penalties that could adversely affect our business and results of operations. Although HIPAA and HITECH and their implementing regulations do not expressly provide for a private right of damages, they permit state attorneys general to bring civil actions and obtain damages on behalf of state residents for violations, and enjoin further violations, of the privacy and security regulations implemented under HIPAA. We also could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information or other private personal information by us or our third-party contractors. Unauthorized access, loss, modification or dissemination could disrupt our operations, including our ability to process tests, provide test results, bill payers or patients, process claims, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our solution and other patient and physician education and outreach efforts through our website, or manage the administrative aspects of our business and damage our reputation, any of which could adversely affect our business. In addition, the interpretation and application of consumer, health-related or other data protection laws in the United States are often uncertain, contradictory and in flux, particularly as more states enact comprehensive consumer privacy laws. It is possible that these various laws may be interpreted and applied in a manner that is inconsistent with our practices. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.

 

We may need to increase the size of our organization, and we may experience difficulties in managing this growth.

 

We are a small company with less than 200 employees. We may increase the number of employees in the future depending on the progress and growth of our business. Future growth will impose significant added responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate additional employees with the necessary skills to support the growing complexities of our business. Rapid and significant growth may place strain on our administrative, financial and operational infrastructure. Our future financial performance and our ability to sell or promote our existing tests and services and develop and commercialize new tests and services and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to:

 

  ● manage our clinical studies effectively;
     
  ● integrate additional management, administrative, manufacturing and regulatory personnel;
     
  ● maintain sufficient administrative, accounting and management information systems and controls; and
     
  ● hire and train additional qualified personnel.

 

We may not be able to accomplish these tasks, and our failure to accomplish any of them could harm our financial results. We may need to reduce the size of our organization in order to become profitable and we may experience difficulties in managing these reductions.

 

 51 
 

 

Risks Related to Regulation within our Markets

 

If we fail to comply with federal, state and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.

 

We are subject to CLIA regulations, a Federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of any disease, or impairment of, or the assessment of the health of, human beings. CLIA regulations mandate specific personnel qualifications, facilities administration, quality systems, inspections and proficiency testing. CLIA certification is also required in order for us to be eligible to bill federal and state healthcare programs, as well as many private third-party payers, for our molecular diagnostic tests. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories. We are also required to maintain State licenses to conduct testing in our Pittsburgh, Pennsylvania laboratory. Pennsylvania law requires that we maintain a license, and establish standards for the day-to-day operation of our clinical reference laboratory in Pittsburgh, Pennsylvania. In addition, our Pittsburgh laboratory is required to be licensed by certain states, including California, Maryland, New York and Rhode Island. New York law requires us to obtain test-specific approval before offering our tests as LDT. California, Maryland, New York and Rhode Island laws also mandate proficiency testing for laboratories licensed under the laws of each respective State regardless of whether such laboratories are located in California, Maryland, New York or Rhode Island. If we were unable to obtain or maintain our CLIA certificate for our laboratories, whether as a result of revocation, suspension or limitation, we would no longer be able to perform our current clinical services and pharma services, which could have a material adverse effect on our business, financial condition and results of operations. If we were to lose our licenses issued by States where we are required to hold licenses, if such licenses expired or were not renewed, or if we failed to obtain and maintain a State license that we are required to hold, we may be subject to significant fines, penalties and liability, and may be forced to cease testing (if Pennsylvania) or cease testing specimens from those States (if California, New York, Maryland, or Rhode Island), which could have a material adverse effect on our business, financial condition and results of operations. New molecular diagnostic tests and pharma services we may develop may be subject to new requirements by governmental bodies, including state governments, and we may not be able to offer our new molecular diagnostic tests or pharma services in such jurisdictions until such requirements are met.

 

Legislation reforming the U.S. healthcare system may have a material adverse effect on our financial condition and operations.

 

PPACA made changes that significantly affected the pharmaceutical, medical device and clinical laboratory industries. For example, PPACA includes coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. PPACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physicians, lower thresholds for violations and increasing potential penalties for such violations. The effect of PPACA and any potential changes that may be necessitated by the legislation is uncertain, any of which may potentially affect our business.

 

Our current position is that we do not meet the definition of an “Applicable Manufacturer” under the Physician Payments Sunshine Act of the PPACA and are therefore not subject to the disclosure or tax requirements contained in PPACA. If the government were to reach a different conclusion, our failure to disclose could result in significant monetary penalties and potential claims from certain third parties.

 

PPACA, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product or service, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our products. At the same time, there have been significant ongoing efforts to repeal, revise, or replace PPACA; however, the U.S. Supreme Court upheld the law in 2021.

 

 52 
 

 

President Biden has used executive orders to undo certain changes to the PPACA made by the Trump administration and has indicated it will advocate for legislation to build on the PPACA. It is unknown what form any such changes or any law would take, and how or whether it may affect our business in the future. We expect that changes or additions to the PPACA, the Medicare and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.

 

For example, Medicare payment rates have been – and in the future, will continue to be, to varying extents, subject to sequestration. Reductions resulting from the Congressional sequester are applied to total claim payments made; however, they do not currently result in a rebasing of the negotiated or established Medicare or Medicaid reimbursement rates.

 

State legislation on reimbursement applies to Medicaid reimbursement and Managed Medicaid reimbursement rates within that state. Some states have passed or proposed legislation that would revise reimbursement methodology for clinical laboratory payment rates under those Medicaid programs.

 

In April 2014, President Obama signed the Protecting Access to Medicare Act, or PAMA, which included a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, CLFS payment rates are based upon the weighted median of private payor rates for each type of laboratory test. To calculate these rates, PAMA requires CLIA-certified laboratories that receive a majority of their Medicare revenue from payments made under the CLFS and the Physician Fee Schedule, and receive at least $12,500 in CLFS revenue, within the 6-month reporting period, to report private payor rates and volumes for their tests with specific CPT codes based on final payments made during a 6-month period of data collection (from January 1 through June 30 of the applicable year). For most laboratory tests, the CLFS is updated every three years, but rates are updated annually for Advanced Diagnostic Laboratory Tests, or ADLTs. The first private payor rate-based CLFS was based on data collected from January 1 through June 30, 2016, and, following an initial, one-year delay became effective on January 1, 2018. CMS published final rules implementing these changes in 2016 and 2018.

 

Under the revised Medicare Clinical Laboratory Fee Schedule, reimbursement for clinical laboratory testing was reduced for most tests in 2018, 2019, and 2020. PAMA (as revised) calls for further revisions of the Medicare Clinical Laboratory Fee Schedule for years after 2022, based on future surveys of market rates. Further reductions in reimbursement may result from such revisions.

 

The Coronavirus Aid, Relief, and Economic Security (CARES) Act, as amended by the Protecting Medicare and American Farmers from Sequester Cuts Act, revised payment reductions and the data reporting schedule for CDLTs that are not ADLTs. Under these laws, the next data reporting period is January 1, 2023 through March 31, 2023, and will be based upon the data collected during the January 1, 2019 to June 30, 2019 period. Any reductions to payment rates resulting from the new methodology are limited to 10% per test per year in each of the years 2018 through 2020 and to 15% per test per year in each of the years 2023 through 2025. Payments will not be reduced for 2021 or 2022 for CDLTs.

 

We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business, or the effect any future legislation or regulation will have on us. There is additional uncertainty in light of the current Presidential administration. The taxes imposed by federal legislation, cost reduction measures and the expansion in the role of the U.S. government in the healthcare industry may result in decreased revenue, lower reimbursement by payers for our tests or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations.

 

 53 
 

 

Complying with numerous statutes and regulations pertaining to our clinical and pharma services is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.

 

We are subject to regulation by both the federal government and the governments of the states in which we conduct our operations. The federal and state laws which may apply to us include, but are not limited to:

 

  ● The Food, Drug and Cosmetic Act, as supplemented by various other statutes;
     
  ● CLIA and state licensing requirements;
     
  ● Manufacturing and promotion laws;
     
  ● Medicare and Medicaid billing and payment regulations applicable to clinical laboratories;
     
  ● The Eliminating Kickbacks in Recovery Act of 2018 (EKRA), which prohibits the solicitation, receipt, payment or offer of any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory for services covered by both government and private payers;
     
  ● The Federal Anti-Kickback Statute (and state equivalents), which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program;
     
  ● The Federal physician self-referral law, commonly referred to as the “Stark Law,” (and state equivalents), which prohibits a physician from making a referral for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition;
     
  ● HIPAA, which established comprehensive federal standards with respect to the privacy and security of PHI and requirements for the use of certain standardized electronic transactions, and amendments made in 2013 to HIPAA under the Health Information Technology for Economic and Clinical Health Act, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators, extend enforcement authority to state attorneys general, and impose requirements for breach notification;
     
  ● The FTC Act and various state consumer privacy laws, which require regulated entities to take reasonable steps to safeguard the personal information of consumers, minimize its use and provide consumers with certain rights as to their personal data such as the right to correct or delete their personal information;
     
  ● The Federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;
     
  ● The Federal False Claims Act (and state equivalents), which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;
     
  ● The federal transparency requirements under the PPACA, including the provisions commonly referred to as the Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or Children’s Health Insurance Program to report annually to CMS information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;
     
  ● Other federal and state fraud and abuse laws, prohibitions on self-referral and kickbacks, fee-splitting restrictions, prohibitions on the provision of products at no or discounted cost to induce physician or patient adoption, and false claims acts, transparency, reporting, and disclosure requirements, which may extend to services reimbursable by any third-party payer, including private insurers;

 

 54 
 

 

  ● The prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;
     
  ● The Protecting Access to Medicare Act of 2014, which requires us to report private payer rates and test volumes for specific CPT codes on a triennial basis and imposes penalties for failures to report, omissions, or misrepresentations;
     
  ● The rules regarding billing for diagnostic tests reimbursable by the Medicare program, which prohibit a physician or other supplier from marking up the price of the technical component or professional component of a diagnostic test ordered by the physician or other supplier and supervised or performed by a physician who does not “share a practice” with the billing physician or supplier; and
     
  ● State laws that prohibit other specified practices related to billing such as billing physicians for testing that they order, waiving coinsurance, co-payments, deductibles, and other amounts owed by patients, and billing a State Medicaid program at a price that is higher than what is charged to other payers.

 

In recent years U.S. Attorneys’ Offices have increased scrutiny of the healthcare industry, as have Congress, the Department of Justice, the Department of Health and Human Services’ Office of the Inspector General and the Department of Defense. These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation against, healthcare companies based on financial arrangements with health care providers, regulatory compliance, product promotional practices and documentation, and coding and billing practices. Whistleblowers have filed numerous qui tam lawsuits against healthcare companies under the federal and state False Claims Acts in recent years, in part because the whistleblower can receive a portion of the government’s recovery under such suits.

 

The growth of our business may increase the potential of violating these laws, regulations or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Violations of federal or state regulations may incur investigation or enforcement action by the FDA, Department of Justice, State agencies, or other legal authorities, and may result in substantial civil, criminal, or other sanctions. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to civil and criminal penalties, damages and fines, we could be required to refund payments received by us, we could face possible exclusion from Medicare, Medicaid and other federal or state healthcare programs and we could even be required to cease our operations. Any of the foregoing consequences could have a material adverse effect on our business, financial condition and results of operations.

 

A failure to comply with federal and state laws and regulations pertaining to our payment practices could result in substantial penalties.

 

We retain healthcare practitioners as key opinion leaders providing consultation in various aspects of our business, maintain a sales force, and contract for marketing services. These arrangements, like any arrangement that includes compensation to a healthcare provider or potential referral source, may trigger federal or state anti-kickback, Stark Law liability, and False Claims Act liability. There are no guarantees that the federal or state governments will find that these arrangements are designed properly or that they do not trigger liability under federal and state laws. Under existing laws, all arrangements must be commercially reasonable and compensation must be fair market value. These terms require some subjective analysis. Safe harbors in the anti-kickback laws do not necessarily equate to exceptions in the Stark Law, and there is no guarantee that the government will agree with our payment practices with respect to the relationships between our laboratories and the healthcare providers, sales force members, or other parties. A failure to comply with Federal and State laws and regulations pertaining to our payment practices could result in substantial penalties and adversely affect our business, financial condition and results of operations.

 

 55 
 

 

In addition, federal law prohibits any entity from offering or transferring to a Medicare or Medicaid beneficiary any remuneration that the entity knows or should know is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services, including waivers of copayments and deductible amounts (or any part thereof) and transfers of items or services for free or for other than fair market value. Entities found in violation may be liable for civil monetary penalties of up to $10,000 for each wrongful act. Further, federal and state anti-kickback statutes or similar laws may be implicated by arrangements with patients to waive, reduce, or limit copays or other payment amounts, such as our Patient Assistance Program. Third-party payers, including commercial payers and government payers, may prohibit, limit, or restrict certain financial arrangements with patients. Violation of these laws or payment policies could result in significant fines, penalties, liability, recoupment, and exclusion from Medicare and Medicaid, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.

 

In 2018, the U.S. enacted the Eliminating Kickbacks in Recovery Act, or EKRA, as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). EKRA is an all-payer anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. The term “laboratory” is defined broadly and without reference to any connection to substance use disorder treatment. EKRA is a criminal statute and violations can result in fines of up to $200,000, up to 10 years in prison, or both, per violation. As drafted, EKRA prohibits incentive compensation to sales employees, a practice that is common in the industry.

 

Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws.

 

Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, potentially including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.

 

Changes in governmental regulation could negatively impact our business operations and increase our costs.

 

The pharmaceutical, biotechnology and healthcare industries are subject to a high degree of governmental regulation. Significant changes in these regulations affecting our business could result in the imposition of additional restrictions on our business, additional costs to us in providing our tests or services to our customers or otherwise negatively impact our business operations. Changes in governmental regulations mandating price controls and limitations on patient access to our products could also reduce, eliminate or otherwise negatively impact our sales. Additional changes may be forthcoming in light of the current Presidential administration.

 

 56 
 

 

Risks Relating To Our Intellectual Property

 

If we are unable to protect our intellectual property effectively, our business would be harmed.

 

We rely on patent protection as well as trademark, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technology. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. While we apply for patents covering our products and technologies and uses thereof, we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in relevant jurisdictions. Others could seek to design around our current or future patented technologies. We may not be successful in defending any challenges made against our patents or patent applications. On January 16, 2018, we were notified that an Opposition had been filed against EP patent #2772550 alleging that the patent is invalid. On February 25, 2019, the European Patent Office Opposition Division issued a decision revoking the patent on grounds that the claims were not supported by a valid basis. On April 25, 2019, we filed a Notice of Appeal challenging the European Patent Office Opposition Division and we are waiting for the appeal to be decided. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents and increased competition to our business. The outcome of patent litigation, such as oppositions or post-grant reviews can be uncertain and any attempt by us to enforce our patent rights against others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.

 

Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. Further, competitors could willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that arguably fall outside of our intellectual property rights. Others may independently develop similar or alternative products and technologies or replicate any of our products and technologies. If our intellectual property does not adequately protect us against competitors’ products and methods, our competitive position could be adversely affected, as could our business and the results of our operations. To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of competition. If our intellectual property does not provide adequate coverage of our competitors’ products, our competitive position could be adversely affected, as could our overall business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.

 

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our molecular diagnostic tests.

 

As is the case with other companies operating in our industry, our success is somewhat dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents of molecular diagnostics tests, like our molecular diagnostic tests in our PancraGEN® and miRInform® platforms (including ThyGeNEXT®), involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. From time-to-time the U.S. Supreme Court, other Federal courts, the U.S. Congress or the United States Patent and Trademark Office, or the USPTO, may change the standards of patentability and any such changes could have a negative impact on our business. For instance, on October 30, 2008, the Court of Appeals for the Federal Circuit issued a decision that methods or processes cannot be patented unless they are tied to a machine or involve a physical transformation.

 

The U.S. Supreme Court later reversed that decision in Bilski v. Kappos, finding that the “machine-or-transformation” test is not the only test for determining patent eligibility. The Court, however, declined to specify how and when processes are patentable. On March 30, 2012, in the case Mayo Collaborative Services v. Prometheus Laboratories, Inc., the U.S. Supreme Court reversed the Federal Circuit’s application of Bilski and invalidated a patent focused on a process for identifying a proper dosage for an existing therapeutic because the patent claim embodied a law of nature. On July 3, 2012, the USPTO released a memorandum entitled “2012 Interim Procedure for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature,” with guidelines for determining patentability of diagnostic or other processes in line with the Mayo decision. On June 13, 2013, in Association for Molecular Pathology v. Myriad Genetics, the Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Supreme Court did not address the patentability of any innovative method claims involving the manipulation of isolated genes. On March 4, 2014, the USPTO released a memorandum entitled “2014 Procedure for Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products.” This memorandum provides guidelines for the USPTO’s new examination procedure for subject matter eligibility under 35 U.S.C. § 101 for claims embracing natural products or natural principles.

 

 57 
 

 

On June 12, 2015, the Federal Circuit issued a decision in Ariosa v. Sequenom holding that a method for detecting a paternally inherited nucleic acid of fetal origin performed on a maternal serum or plasma sample from a pregnant female were unpatentable as directed to a naturally occurring phenomenon. On July 30, 2015, the USPTO released a Federal Register Notice entitled, “July 2015 Update on Subject Matter Eligibility,” This Notice updated the USPTO guidelines for the USPTO’s procedure for subject matter eligibility under 35 U.S.C. § 101 for claims embracing natural products or natural principles phenomenon. On May 4, 2016, the USPTO released life science examples that were intended to be used in conjunction with the USPTO guidance on subject matter eligibility. Although the guidelines and examples do not have the force of law, patent examiners have been instructed to follow them. On February 6, 2019, the Federal Circuit for Court of Appeals issued a decision in Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, which relied on the decisions from Mayo and Ariosa, to find a claim directed to a method for diagnosing neurotransmission or developmental disorders related to muscle specific tyrosine kinase not eligible for patenting under 35 U.S.C. § 101. What constitutes a law of nature and a sufficient inventive concept continues to remain uncertain, and it is possible that certain aspects of diagnostic tests will continue to be considered natural laws and, therefore, ineligible for patent protection.

 

Some aspects of our technology involve processes that may be subject to this evolving standard and we cannot guarantee that any of our pending or issued claims will be patentable or upheld as valid as a result of such evolving standards. In addition, patents we own or license that issued before these recent cases may be subject to challenge in court or before the USPTO in view of these current legal standards. Accordingly, the evolving interpretation and application of patent laws in the United States governing the eligibility of diagnostics for patent protection may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned and licensed patents. Changes in either the patent laws or in interpretations and application of patent laws may also diminish the value of our existing intellectual property or intellectual property that we continue to develop. We cannot predict the breadth of claims that may be allowed or enforceable in our patents or in third-party patents.

 

We may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.

 

We may receive notices of claims of direct or indirect infringement or misappropriation or misuse of other parties’ proprietary rights from time to time and some of these claims may lead to litigation. We cannot assume that we will prevail in such actions, or that other actions alleging misappropriation or misuse by us of third-party trade secrets, infringement by us of third-party patents and trademarks or other rights, or the validity of our patents, trademarks or other rights, will not be asserted or prosecuted against us. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. No assurance can be given that other patent applications will not have priority over our patent applications. If third parties bring these proceedings against our patents, we could incur significant costs and experience management distraction. Litigation may be necessary for us to enforce our patents and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. Defending any litigation, and particularly patent litigation, is expensive and time-consuming, and the outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us. It is also possible that we might not be able to obtain licenses to technology that we require on acceptable terms or at all. In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, financial condition and operating results.

 

In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling our products. We may not be able to obtain these licenses on acceptable terms, if at all. We could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our financial results. In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could have a material adverse effect on our business, financial condition, and results of operations.

 

 58 
 

 

Other Risks Related to our Business

 

Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us.

 

We have incurred net losses since 2015 and may never achieve or sustain profitability. As of the fiscal year ended December 31, 2021, we had U.S. federal and state net operating losses, or NOLs, of approximately $118.6 million and $56.3 million respectively. Subject to the final two sentences of this paragraph, the federal and state NOL carryforwards will begin to expire, if not utilized, beginning in 2028 for certain states. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal taxable income.

 

To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any. We may be limited in the portion of NOL and tax credit carryforwards that we can use in the future to offset taxable income for U.S. federal and state income tax purposes. Sections 382 and 383 of Internal Revenue Code of 1986, or the Code, limit the use of NOLs and tax credits after a cumulative change in corporate ownership of more than 50% occurs within a three-year period. The limitation could prevent us from using some or all of our NOLs and tax credits, as it places a formula limit of how much of our NOL and tax credit carryforwards we would be permitted to use in a tax year. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. During the periods 2017 through 2019, the company experienced greater than 50% changes in ownership and as a result, NOLs attributable to the pre-ownership change are subject to a substantial annual limitation under Section 382 of the Code due to the ownership changes. The Company has adjusted their NOL carryforwards to address the impact of the Section 382 ownership changes. Federal Net Operating Losses of $71.2 million are subject to annual limitation as of the ownership changes for ownership changes. The remaining $47.4 million of NOLs incurred post July 15, 2019 are not subject to any annual limitation and can be carried forward indefinitely. Subsequent ownership changes may further affect the limitation in future years. In the event we have undergone or will undergo an ownership change under Section 382 of the Code, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may become subject to these limitations, which could potentially result in increased future tax liability to us.

 

Comprehensive tax reform could adversely affect our business and financial condition.

 

New income, sales and use or other tax laws or regulations could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws and regulations could be interpreted, modified or applied adversely to us. These events could require us to pay additional taxes on a prospective or retroactive basis, as well as penalties, interest and other costs for past amounts deemed to be due. New laws, or laws that are changed, modified or newly interpreted or applied, also could increase our compliance, operating and other costs, as well as the costs of our products. For example, the Tax Cuts and Jobs Act of 2017 enacted many significant changes to the U.S. tax laws, some of which were further modified by the Coronavirus Aid, Relief, and Economic Security Act, and may be modified in the future by the current or a future presidential administration. In addition, it is uncertain if and to what extent various states will conform to current federal law, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net operating losses, and other deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets and could increase our future tax expense.

 

 59 
 

 

If we do not increase our revenues and successfully manage the size of our operations, our business, financial condition and results of operations could be materially and adversely affected.

 

The majority of our operating expenses are personnel-related costs such as employee compensation and benefits, reagents and disposable supplies as well as the cost of infrastructure to support our operations, including facility space and equipment. We continuously review our personnel to determine whether we are fully utilizing their services. If we believe we are not in a position to fully utilize our personnel, we may make reductions to our workforce. If we are unable to achieve revenue growth in the future or fail to adjust our cost infrastructure to the appropriate level to support our revenues, our business, financial condition and results of operations could be materially and adversely affected.

 

We may acquire businesses or assets or make investments in other companies or testing, service or solution technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.

 

As part of our strategy, we may pursue acquisitions of synergistic businesses or other related assets. If we make any further acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisition by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results and financial condition. Integration of an acquired company or business will also likely require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition. To finance any acquisitions or investments, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. If these funds are raised through the sale of equity or convertible debt securities, dilution to our stockholders could result. The holders of our Series B Preferred Stock have the right to approve any public offering. Consummating an acquisition poses a number of risks including:

 

  ● we may not be able to accurately estimate the financial impact of an acquisition on our overall business;
     
  ● an acquisition may require us to incur debt or other obligations, incur large and immediate write-offs, issue capital stock potentially dilutive to our stockholders or spend significant cash, or may negatively affect our operating results and financial condition;
     
  ● if we spend significant funds or incur additional debt or other obligations, our ability to obtain financing for working capital or other purposes could decline;
     
  ● worse than expected performance of an acquired business may result in the impairment of intangible assets;
     
  ● we may be unable to realize the anticipated benefits and synergies from acquisitions as a result of inherent risks and uncertainties, including difficulties integrating acquired businesses or retaining key personnel, partners, customers or other key relationships, and risks that acquired entities may not operate profitably or that acquisitions may not result in improved operating performance;

 

 60 
 

 

  ● we may fail to successfully manage relationships with customers, distributors and suppliers;
     
  ● our customers may not accept new molecular diagnostic tests or pharma services from our acquired businesses;
     
  ● we may fail to effectively coordinate sales and marketing efforts of our acquired businesses;
     
  ● we may fail to combine product offerings and product lines of our acquired businesses timely and efficiently;
     
  ● an acquisition may involve unexpected costs or liabilities, including as a result of pending and future shareholder lawsuits relating to acquisitions or exercise by stockholders of their statutory appraisal rights, or the effects of purchase accounting may be different from our expectations;
     
  ● an acquisition may involve significant contingent payments that may adversely affect our future liquidity or capital resources;
     
  ● accounting for contingent payments requires significant judgment and changes to the assumptions used in determining the fair value of our contingent payments could lead to significant volatility in earnings;
     
  ● acquisitions and subsequent integration of these companies may disrupt our business and distract our management from other responsibilities; and
     
  ● the costs of an unsuccessful acquisition may adversely affect our financial performance.

 

Additional risks of integration of an acquired business include:

 

  ● differing information technology, internal control, financial reporting and record-keeping systems;
     
  ● differences in accounting policies and procedures;
     
  ● unanticipated additional transaction and integration-related costs;
     
  ● facilities or operations of acquired businesses in remote locations and the inherent risks of operating in unfamiliar legal and regulatory environments; and
     
  ● new products, including the risk that any underlying intellectual property associated with such products may not have been adequately protected or that such products may infringe on the proprietary rights of others.

 

If our information technology or communications systems fail or we experience a significant interruption in their operation, our reputation, business and results of operations could be materially and adversely affected.

 

The efficient operation of our business is dependent on our information technology and communications systems. Increasingly, we are also dependent upon our ability to electronically interface with our customers. The failure of these systems to operate as anticipated could disrupt our business and result in decreased revenue and increased overhead costs. In addition, we do not have complete redundancy for all of our systems and our disaster recovery planning cannot account for all eventualities. Our information technology and communications systems, including the information technology systems and services that are maintained by third party vendors, are vulnerable to damage or interruption from natural disasters, fire, terrorist attacks, epidemics, pandemics including COVID-19, malicious attacks by computer viruses or hackers, power loss, failure of computer systems, Internet, telecommunications or data networks. In 2017, we discovered malware installed on certain clinical services servers. We do not believe that any data on the affected servers was accessed or compromised. We removed the malware, and enhanced our cybersecurity procedures. Additionally, our clinical services and pharma services are largely dependent on our partially internally developed and partially purchased Laboratory Information Management Systems or LIMS, which is our automated basis of managing operations and storing data and customer information. If these systems or services become unavailable or suffer a security breach, or are uneconomical or impossible to update and modify, we may expend significant resources to address these problems, and our reputation, business and results of operations could be materially and adversely affected.

 

 61 
 

 

Risks Related To Our Common Stock Price

 

The price and trading volume of our common stock may be highly volatile and could be further affected by events not within our control, and an investment in our common stock could suffer a decline in value.

 

During 2021, our common stock traded at a low of $2.98 and a high of $10.51. During 2020, our common stock traded at a low of $2.57 and a high of $11.00. Volatility in our stock price or trading volume may be in response to various factors, some of which may be beyond our control. In addition to the other factors discussed or incorporated by reference herein, factors that may cause fluctuations in our stock price or trading volume, include, among others:

 

  ● general volatility in the trading markets;
     
  ● the impact of the delisting of our common stock from Nasdaq and listing on the OTCQX;
     
  ● adverse research and development results;
     
  ● significant fluctuations in our quarterly operating results;
     
  ● significant changes in our cash and cash equivalent reserves;
     
  ● our liquidity and ability to obtain additional capital, including the market’s reaction to any announced capital-raising transactions;
     
  ● market assessments of any announced strategic transaction, including the likelihood that it would be completed and the timing for completion;
     
  ● potential negative market reaction to the terms or volume of any issuance of shares of our common stock, preferred stock or other securities to new investors, pursuant to strategic or capital-raising transactions or to employees, directors or other service providers;
     
  ● sales of substantial amounts of our common stock, or the perception that substantial amounts of our common stock may be sold, by stockholders in the public market;
     
  ● announcements regarding our business or the business of our competitors;
     
  ● announcements regarding our equity offerings;
     
  ● strategic actions by us or our competitors, such as acquisitions or restructurings;
     
  ● industry and/or regulatory developments;
     
  ● changes in revenue mix;
     
  ● changes in revenue and revenue growth rates for us and for the industries in which we operate;
     
  ● changes in accounting standards, policies, guidance, interpretations or principles;
     
  ● statements or changes in opinions, ratings or earnings estimates made, or the failure to make, by brokerage firms or industry analysts relating to the markets in which we operate or expect to operate; and
     
  ● general market and economic conditions.

 

 62 
 

 

The issuance of additional shares of our common stock in any future offerings could be dilutive to stockholders.

 

The issuance of additional shares of our common stock in any future offerings could be dilutive to stockholders. In order to raise additional capital, such securities may be at prices that are not the same as the price per share in previous offerings. We cannot assure investors that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in previous offerings, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. Moreover, to the extent that we issue options or warrants to purchase, or securities convertible into or exchangeable for, shares of our common stock in the future (including our Series B Preferred Stock), and those options, warrants or other securities are exercised, converted or exchanged, stockholders may experience further dilution.

 

The delisting of our common stock from Nasdaq and subsequent trading on OTCQX® has adversely affected our common stock and business and financial condition.

 

On February 25, 2020, our common stock was delisted from the Nasdaq Capital Market (“Nasdaq”) and commenced trading on the OTCQX® Best Market tier of the OTC Markets Group Inc. (the “OTCQX”), an electronic quotation service operated by OTC Markets Group Inc.

 

Trading in stock quoted on the OTCQX is often thin, volatile, and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with the issuer’s operations, results or business prospects. The availability of buyers and sellers represented by this volatility could lead to a market price for our Common Stock that is unrelated to operating performance. Moreover, the OTCQX is not a stock exchange, and trading of securities quoted on the OTCQX is often more volatile than the trading of securities listed on a stock exchange like Nasdaq or the New York Stock Exchange. The OTCQX quotation system may provide less liquidity than Nasdaq.

 

Prices for securities traded solely on the OTCQX quotation system may be difficult to obtain, and holders of our common stock may be unable to resell their shares at or near their original acquisition price or at any price. Further, our delisting from Nasdaq and commencement of trading on the OTCQX has and may continue to have negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, the loss of federal preemption of state securities laws, greater difficulty in raising capital through the public or private sale of equity securities, deterring broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, a loss of current or future coverage by certain sell-side analysts, deterring certain institutions and persons from investing in our securities at all and a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.

 

The risks associated with penny stock classification could affect the marketability of the Company’s common stock and stockholders could find it difficult to sell their shares.

 

If the Company’s shares of Common Stock do not maintain a trading price of $5.00 or more per share, the Company’s common stock will be subject to “penny stock” rules as defined in Exchange Act Rule 3a51-1. The SEC adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Transaction costs associated with purchases and sales of penny stocks are likely to be higher than those for other securities. Penny stocks generally are equity securities with a price of less than $5.00.

 

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation.

 

 63 
 

 

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from such rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the Company’s common stock and stockholders may find it more difficult to sell their shares.

 

Risks Relating to Being a Public Company

 

We will continue to incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.

 

As a public company, we are incurring significant legal, accounting and other expenses. In addition to being required to comply with certain requirements of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), we are required to comply with certain requirements of the Dodd Frank Wall Street Reform and Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC, including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. We expect that compliance with these requirements will continue to increase our legal and financial compliance costs and will make some activities more time consuming and costly. In addition, we expect that our management and other personnel will continue to need to divert attention from operational and other business matters to devote substantial time to these public company requirements.

 

For example, in 2020, our Audit Committee conducted an independent investigation in accordance with Section 10A of the Exchange Act into complaints of certain employment and billing and compliance matters and concluded that the allegations made in the complaints were unsubstantiated and that there was no evidence of any illegal acts. The completion of the investigation caused us to be late in filing our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.

 

We also recently spent considerable management time in connection with our restatement of previously issued financial statements contained in our Annual Reports on Form 10-K for the years ended December 31, 2014 through 2019 as well as the financial statements contained in the Quarterly Reports on Form 10-Q for each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2020 and June 30, 2020. This was due to evaluating and recording an impairment charge and amortization expense relating to our BarreGen asset, as disclosed in Item 9A of our Report on Form 10-K for the fiscal year 2021.

 

Further, the Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. In addition, if we lose our status as a “smaller reporting company,” we will be required to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting. Our compliance with Section 404 of the Sarbanes-Oxley Act, as applicable, requires us to incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to continue to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. If we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.

 

 64 
 

 

If we are unable to maintain and implement effective internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.

 

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We will need to maintain and enhance these processes and controls as we grow, and we will require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed.

 

If we are unable to conclude that our internal control over financial reporting is effective, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.

 

Risks Relating to Our Corporate Structure and Our Common Stock

 

We have a substantial number of authorized shares of common and preferred stock available for future issuance that could cause dilution of our stockholders’ interest, adversely impact the rights of holders of our common stock and cause our stock price to decline.

 

We have a total of 100,000,000 shares of common stock and 5,000,000 shares of preferred stock authorized for issuance. As of December 31, 2021, we had 95,771,831 shares of common stock and 4,953,000 shares of preferred stock available for issuance. As of December 31, 2021, we have reserved 961,450 shares of our common stock for issuance under our 2019 Equity Incentive Plan and 25,715 shares of our common stock for issuance under our Employee Stock Purchase Plan and 602,077 additional shares available for future grants of awards under our 2019 Equity Incentive Plan as well as warrants for 1,404,648 shares of our common stock outstanding at prices ranging from $9.40 to $46.90 per warrant share. As of December 31, 2021, the aggregate number of shares of common stock that may be issued through conversion of all of the outstanding Series B Preferred Stock is 7,833,334. Provided that we have a sufficient number of unreserved authorized capital stock available, we may seek financing that could result in the issuance of additional shares of our capital stock and/or rights to acquire additional shares of our capital stock. We may also make acquisitions that result in issuances of additional shares of our capital stock. Those additional issuances of capital stock could result in substantial dilution of our existing stockholders. Furthermore, the book value per share of our common stock may be reduced. This reduction would occur if the exercise price of any issued warrants, the conversion price of any convertible notes or the conversion ratio of any issued preferred stock is lower than the book value per share of our common stock at the time of such exercise or conversion. Additionally, new investors in any subsequent issuances of our securities could gain rights, preferences and privileges senior to those of holders of common stock.

 

The addition of a substantial number of shares of our common stock into the market or the registration of any of our other securities under the Securities Act may significantly and negatively affect the prevailing market price for our common stock. The future sales of shares of our common stock issuable upon the exercise of outstanding warrants and options may have a depressive effect on the market price of our common stock, as such warrants and options would be more likely to be exercised at a time when the price of our common stock is greater than the exercise price.

 

 65 
 

 

We have anti-takeover defenses that could delay or prevent an acquisition and could adversely affect the price of our common stock.

 

Our certificate of incorporation, as amended, and amended and restated bylaws include provisions, such as providing for three classes of directors, which may make it more difficult to remove our directors and management and may adversely affect the price of our common stock. In addition, our certificate of incorporation, as amended, authorizes the issuance of “blank check” preferred stock, which allows our Board to create one or more classes of preferred stock with rights and preferences greater than those afforded to the holders of our common stock without separate shareholder approval. This provision could have the effect of delaying, deterring or preventing a future takeover or a change in control, unless the takeover or change in control is approved by our Board. We are also subject to laws that may have a similar effect. For example, Section 203 of the General Corporation Law of the State of Delaware prohibits us from engaging in a business combination with an interested stockholder for a period of three years from the date the person became an interested stockholder unless certain conditions are met. As a result of the foregoing, it will be difficult for another company to acquire us and, therefore, could limit the price that possible investors might be willing to pay in the future for shares of our common stock. In addition, the rights of our common stockholders are subject to, and may be adversely affected by, the rights of holders of our Series B Preferred Stock as well as any class or series of preferred stock that may be issued in the future and by the rights of holders of warrants currently outstanding or issued in the future.

 

We have not declared any cash dividends on our common stock and do not intend to declare or pay any cash dividends in the foreseeable future. Future earnings, if any, will be used to finance the future operation and growth of our business. As a result, capital appreciation, if any, will be your sole source of gain.

 

We have never paid cash dividends on our common stock. We do not currently anticipate paying cash dividends on our common stock in the foreseeable future and we may not have sufficient funds legally available to pay dividends. We are prohibited from paying dividends on our common stock without the approval of the holders of the Series B Preferred Stock for so long as 30% of the Series B Preferred Stock outstanding as of January 15, 2020 remains outstanding. We presently intend to retain all earnings for our operations. As a result, capital appreciation, if any, of our common stock will be an investor’s sole source of gain for the foreseeable future.

 

If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline.

 

The trading market for our common stock will depend in part on the research and reports that equity research analysts publish about us, our business and our competitors. We do not control these analysts or the content and opinions or financial models included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline.

 

We may be subject to securities litigation, which is expensive and could divert our management’s attention.

 

The market price of our securities may be volatile, and in the past companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

 

The indemnification rights provided to our directors, officers and employees may result in substantial expenditures by us and may discourage lawsuits against its directors, officers, and employees.

 

Our certificate of incorporation, as amended, contains provisions permitting us to enter into indemnification agreements with our directors, officers, and employees. The foregoing indemnification obligations could result in us incurring substantial expenditures to cover the cost of settlement or damage awards against directors and officers, which we may be unable to recoup. These provisions and resultant costs may also discourage us from bringing a lawsuit against our directors and officers for breaches of their fiduciary duties and may similarly discourage the filing of derivative litigation by our stockholders against our directors and officers even though such actions, if successful, might otherwise benefit us and our stockholders.

 

 66 
 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2. PROPERTIES

 

Our corporate headquarters are located in Parsippany, New Jersey where we lease approximately 6,000 square feet. The lease runs through September 2022. Our diagnostic laboratory facility is located in Pittsburgh, Pennsylvania where we lease approximately 21,400 square feet. Our Pittsburgh, Pennsylvania lease runs through June 30, 2023. Our pharma services laboratory facilities are located in Research Triangle Park (RTP) in Morrisville, North Carolina where we lease approximately 24,900 square feet. The Morrisville lease runs through May 2030.

 

Accordingly, we believe that our current facilities are adequate for our current and foreseeable operations and that suitable additional space will be available if needed.

 

ITEM 3. LEGAL PROCEEDINGS

 

We are not currently a party to any material legal proceedings. We may from time to time become involved in legal proceedings arising in the ordinary course of business.

 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 67 
 

 

PART II

 

ITEM 5. MARKET FOR OUR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Effective February 25, 2021, our common stock was delisted from The Nasdaq Capital Market and began trading on the OTCQX Best Market under the symbol “IDXG.” OTCQX Best Market quotations reflect inter-dealer prices and may not necessarily represent actual transactions.

 

Reverse Stock Split

 

On January 15, 2020, we effected a one-for-ten reverse split of our issued and outstanding shares of our common stock. At the effective time of the reverse split, every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. Our common stock began trading on a reverse stock split-adjusted basis on January 15, 2020.

 

Holders of Record

 

We had 197 stockholders of record as of February 28, 2022. Not reflected in the number of stockholders of record are persons who beneficially own shares of common stock held in nominee or street name.

 

Dividends

 

We have not declared any cash dividends and do not intend to declare or pay any cash dividends in the foreseeable future. Future earnings, if any, will be used to finance the future operation and growth of our businesses.

 

 68 
 

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and analysis includes certain forward-looking statements that involve risks, uncertainties and assumptions. You should review the Risk Factors sections of this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by such forward-looking statements. See Forward-Looking Statement Information at the beginning of this Form 10-K.

 

Company Overview

 

We are an emerging leader in enabling precision medicine principally in oncology by offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications through our clinical and pharma services. Through our clinical services, we enable physicians to personalize the clinical management of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment. Our clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Through our pharma services, we develop, commercialize and provide molecular- and biomarker-based tests and services and provide companies with customized solutions for patient stratification and treatment selection through an extensive suite of molecular and biomarker-based testing services, DNA- and RNA- extraction and customized assay development and trial design consultation. Our pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine by partnering with pharmaceutical, academic and technology leaders to effectively integrate pharmacogenomics into drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

 

Impact of COVID-19 pandemic

 

The COVID-19 pandemic, together with related precautionary measures, continues to impact portions of the regions in which we operate. These regions are attempting to address the COVID-19 pandemic in varying ways, including stay-at-home orders, temporarily closing businesses, restricting gatherings, restricting travel, and mandating social distancing and face coverings. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location.

 

The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future.

 

We continue to monitor the COVID-19 pandemic and the guidance that is being provided by relevant federal, state and local public health authorities and may take additional actions based upon their recommendations. It is possible that we may have to make adjustments to our operating plans in reaction to developments that are beyond our control.

 

 69 
 

 

Lab closures experienced thus far by the Company have consisted of periodic, temporary work stoppages to clean and disinfect the labs; however, this could change in the future based upon conditions caused by the pandemic. It is also possible that we could experience supply chain shortages if the pandemic worsens and if one or more suppliers is unable to continue to provide us with supplies. For the foreseeable future, however, we do not anticipate supply chain shortages of critical supplies.

 

We have developed contingency plans and will continue to monitor and update them in order to mitigate pandemic-related, adverse financial impacts upon our business.

 

Clinical services

 

Our clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating cancer risk by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. We develop and commercialize genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology to help personalized medicine and improve patient diagnosis and management. Our tests and services provide mutational analysis of genomic material contained in suspicious cysts, nodules and lesions with the goal of better informing treatment decisions in patients at risk of thyroid, pancreatic, and other cancers. The laboratory developed molecular diagnostic tests we offer are designed to enable healthcare providers to better assess cancer risk, helping to avoid unnecessary surgical treatment in patients at low risk. We currently have five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, which is a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a “molecular only” version of PancraGEN® that provides physicians a snapshot of a limited number of factors enabling physicians to better assess risk of pancreaticobiliary cancers using our proprietary PathFinderTG® platform; ThyGeNEXT®, which is an expanded oncogenic mutation panel that helps identify malignant thyroid nodules; ThyraMIR®, which assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene expression assay; and RespriDx®, which is a genomic test that helps physicians differentiate metastatic or recurrent lung cancer from the presence of newly formed primary lung cancer and which also utilizes our PathFinderTG® platform to compare the genomic fingerprint of two or more sites of lung cancer. In addition, BarreGEN®, a molecular based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a clinical evaluation program (CEP) whereby we gather information from physicians using BarreGEN® to assist us in gathering clinical evidence relative to the safety and performance of the test. We currently have a multicenter study underway to further assess the ability of BarreGEN® to accurately predict progression to high grade dysplasia or cancer and to assist us in positioning our product for full launch, partnering, and potentially supporting reimbursement with payers.

 

Our mission is to provide personalized medicine through genomics-based diagnostics and innovation to advance patient care based on rigorous science. Our laboratories are licensed pursuant to federal law under CLIA and are accredited by CAP and New York State.

 

We leverage our laboratories to develop and commercialize our assays and products. We aim to provide physicians and patients with diagnostic options for detecting genomic and other molecular alterations that are associated with gastrointestinal, endocrine, and lung cancers. Our customers consist primarily of physicians, hospitals and clinics.

 

The global molecular diagnostics market is estimated to be $11.77 billion (USD) in 2021 and is expected to grow to $18.1 billion (USD) by 2026 with a CAGR of 9.0% between 2021 and 2026, according to Market Data Forecast’s Molecular Diagnostics Market report (ID: 10293, published January 2022).

 

We believe that the molecular diagnostics market offers significant growth and strong patient value given the substantial opportunity it affords to lower healthcare costs by helping to reduce unnecessary surgeries and ensuring the appropriate frequency of monitoring. We are keenly focused on growing our test volumes, securing additional insurance coverage and reimbursement, maintaining and growing our current reimbursement and supporting revenue growth for our molecular diagnostic tests, introducing related first line product and service extensions, as well as expanding our business by developing and promoting synergistic products in our markets. We also believe that BarreGEN® is a potentially significant pipeline product, and we are providing necessary resources to accelerate our development process. Further, we believe BarreGEN® is synergistic with our capabilities in the gastrointestinal market, which is one of the sectors in which we operate.

 

In January 2022, we announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of our ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, we announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, we have not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS.

 

 70 
 

 

Pharma services

 

Our pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. Laboratory and testing services are performed for pharmaceutical and biotech companies engaged in clinical trials and focuses on providing these clients with oncology specific and non-oncology genetic testing services for phase I-IV clinical trials along with critical support of ancillary services. These services include: biorepository, clinical trial logistics, clinical trial design, bioinformatics analysis, customized assay development, DNA and RNA extraction and purification, genotyping, gene expression and biomarker analyses. We also seek to apply our expertise in laboratory developed tests to assist in developing and commercializing drug-specific companion diagnostics. We have established business relationships with key instrument manufacturers to support their platforms in the market, and to drive acceptance among biopharmaceutical sponsors developing innovative immuno-oncology therapies.

 

Molecular- and biomarker-based testing services have been altering the clinical trials landscape by providing biotech and pharmaceutical companies with information about trial subjects’ genetic profiles that may be able to inform researchers whether or not a subject will benefit from the trial drug or will experience adverse effects. Streamlined subject selection and stratification, and tailored therapies selected to maximally benefit each group of subjects may increase the number of trials that result in approved therapies and make conducting clinical trials more efficient and less costly for biotech and pharmaceutical companies. In 2021, over 50 new drugs were approved by the FDA, and 20% of these drugs were oncology-focused, highlighting the potential value of incorporating genomic information into oncology clinical trial design.

 

In addition to the tests and services provided to our pharma customers, we custom develop Next Generation Sequencing (NGS) panels for our customers focused on pharmacogenomics and oncology.

 

We also utilize our laboratories to provide clinical trial services to the pharmaceutical and biotech industries to improve the efficiency and economic viability of clinical trials. Our clinical trials services leverage our knowledge of clinical oncology and molecular diagnostics and our laboratories’ fully integrated capabilities. We believe our laboratory is one of a few with the capability to combine somatic and germline mutational analyses in clinical trials. We operate through a CLIA certificated and CAP accredited laboratory located in Morrisville, North Carolina.

 

Our laboratory possesses capabilities in histology, immunohistochemistry (IHC), flow cytometry, cytogenetics and fluorescent in-situ hybridization (FISH), as well as sophisticated molecular analysis techniques, including next generation sequencing. This allows for comprehensive customized testing within one lab enterprise, with our CAP-accredited biorepository laboratory serving as a central hub for specimen tracking. Using this approach, we are able to support demanding clinical trial protocols requiring multiple assays and techniques aimed at capturing data on multiple biomarkers. Our suite of available testing platforms allows for highly customized clinical trial design which is supported by our dedicated group of development scientists and technical personnel.

 

We also provide genetic testing for drug metabolism to aid biotech and pharmaceutical companies identify subjects’ likely responses to treatment, allowing these companies to conduct more efficient and safer clinical trials. We believe pharmacogenomics drug metabolism testing helps deliver the promise of personalized medicine by enabling researchers to tailor therapies in development to differences in patients’ genomic profiles.

 

Transition costs

 

To optimize the operations of laboratory operations within our pharma services, we transitioned activities from the Rutherford, NJ facility to our Morrisville, NC facility. We invested several million dollars to facilitate this relocation which was completed in March 2021, including but not limited to the transfer of personnel, expansion of the Morrisville facility and validation of transferred processes. We believe that this investment will result in a reduction in future operating costs; however, it is not certain whether we will fully realize the anticipated savings. We have also undergone several other cost-cutting initiatives, primarily reductions in headcount, and those costs are categorized as transition expenses as well.

 

 71 
 

 

Nasdaq Delisting

 

On February 16, 2021, the Company received a delisting determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Staff had determined to delist the Company’s common stock from Nasdaq due to the Company’s failure to regain compliance with the Nasdaq Capital Market’s minimum $2,500,000 stockholders’ equity requirement for continued listing as set forth in Nasdaq Listing Rule 5550(b) (the “Rule”) and the Company’s failure to timely execute its plan to regain compliance under the Rule.

 

Nasdaq commenced with delisting the Company’s common stock from the Nasdaq Capital Market and, suspended trading in the Company’s common stock effective at the open of business on February 25, 2021.

 

On February 24, 2021, the Company was approved to have its common stock quoted on the OTCQX® Best Market tier of the OTC Markets Group Inc. (the “OTCQX”), an electronic quotation service operated by OTC Markets Group Inc. The trading of the Company’s common stock commenced on OTCQX at the open of business on February 25, 2021 under the trading symbol IDXG.

 

DESCRIPTION OF REPORTING SEGMENTS

 

We operate under one segment which is the business of developing and selling diagnostic clinical and pharma services.

 

CRITICAL ACCOUNTING POLICIES

 

We prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or (“GAAP”). The preparation of financial statements and related disclosures in conformity with GAAP requires management to make judgments, estimates and assumptions at a specific point in time that affect the amounts reported in our consolidated financial statements and disclosed in the accompanying notes. These assumptions and estimates are inherently uncertain. Outlined below are accounting policies, which are important to our financial position and results of operations and require our management to make significant judgments in their application. Some of those judgments can be subjective and complex. Management’s estimates are based on historical experience, information from third-party professionals, facts and circumstances available at the time and various other assumptions that are believed to be reasonable. Actual results could differ from those estimates. Additionally, changes in estimates could have a material impact on our consolidated results of operations in any one period. For a summary of all of our significant accounting policies, including the accounting policies discussed below, see Note 1, Nature of Business and Significant Accounting Policies, to our consolidated financial statements included in this Annual Report on Form 10-K.

 

Revenue and Cost of Revenue

 

The Company’s revenue is primarily generated from the performance of its proprietary molecular diagnostic tests for its clinical customers and its DNA-based testing services in support of clinical trials for its pharma services customers. The Company’s performance obligation is fulfilled upon completion, review and release of test results and subsequent billing to the third-party payer, hospital or service provider, or biopharma companies.

 

Revenue Recognition

 

ASC 606 Revenue Recognition

 

Clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

 

 72 
 

 

For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.

 

For our pharma services customers, performance obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

 

Leases

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, Leases.

 

Long-Lived Assets, including Finite-Lived Intangible Assets

 

We review the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

 

As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have commenced upon acquisition of those assets as opposed to the Company’s previously disclosed policy of beginning asset amortization when the product was launched and generating revenue.

 

 73 
 

 

Contingencies

 

In the normal course of business, we are subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event we determine that a loss is not probable, but is reasonably possible, and it becomes possible to develop what we believe to be a reasonable range of possible loss, then we will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, we will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. We are currently a party to legal proceedings that are incidental to our business. As required, we have accrued our estimate of the probable costs for the resolution of these claims. These estimates are developed in consultation with outside counsel and are based upon an analysis of potential results, assuming a combination of litigation and settlement strategies. Predicting the outcome of claims and litigation, and estimating related costs and exposures, involves substantial uncertainties that could cause actual costs to vary materially from estimates.

 

Income Taxes

 

Income taxes are based on income for financial reporting purposes calculated using our expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes.

 

We account for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of our assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized.

 

We operate in multiple tax jurisdictions and provide taxes in each jurisdiction where we conduct business and are subject to taxation. The breadth of our operations and the complexity of the various tax laws require assessments of uncertainties and judgments in estimating the ultimate taxes we will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. We have established estimated liabilities for uncertain federal and state income tax positions. Uncertain tax positions are recognized in the financial statements when it is more likely than not (for example, a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. We adjust our accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. We believe that any potential audit adjustments will not have a material adverse effect on our financial condition or liquidity. However, any adjustments made may be material to our consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense.

 

Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. We currently have significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences. The realization of these assets is dependent on generating future taxable income. We perform an analysis quarterly to determine whether the expected future income will more likely than not be sufficient to realize the deferred tax assets. Our recent operating results and projections of future income weighed heavily in our overall assessment. The existing and forecasted levels of pretax earnings for financial reporting purposes are not sufficient to generate future taxable income and realize our deferred tax assets and, as a result, we established a full federal and state valuation allowance for the net deferred tax assets at December 31, 2021 and 2020, as we determined that it was more likely than not that these assets would not be realized.

 

 74 
 

 

The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL, and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as similar state tax provisions. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carry forwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. . During 2021, the Company completed a 382 assessment of the available NOLs under Section 382 and determined that the Company underwent an ownership change on September 30, 2017 and July 15, 2019, and as a result, NOLs attributable to the pre-ownership change are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code due to the multiple ownership changes. The Company has adjusted their NOL carryforwards to address the impact of the 382 ownership change.

 

Stock Compensation Costs

 

The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. We recognize the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period-to-period.

 

We primarily use the Black-Scholes option pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by our stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: our expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield.

 

Changes in the valuation assumptions could result in a significant change to the cost of an individual award. However, the total cost of an award is also a function of the number of awards granted, and as result, we have the ability to manage the cost and value of our equity awards by adjusting the number of awards granted.

 

 75 
 

 

CONSOLIDATED RESULTS OF OPERATIONS

 

The following table sets forth the selected statements of operations data ($ in thousands) as a percentage of revenue for the periods indicated. The trends illustrated in this table may not be indicative of future operating results.

 

 

   Years Ended December 31, 
   2021   2021   2020   2020 
                 
Revenue, net  $41,314    100.0%  $32,398    100.0%
Cost of revenue   23,369    56.6%   21,673    66.9%
Gross profit   17,945    43.4%   10,725    33.1%
Operating expenses:                    
Sales and marketing   10,067    24.4%   9,254    28.6%
Research and development   1,882    4.6%   2,795    8.6%
General and administrative   13,669    33.1%   18,192    56.2%
Transition expense   2,585    6.3%   2,578    8.0%
Loss on DiamiR transaction   13    0.0%   -    0.0%
Acquisition related amortization expense   4,064    9.8%   4,461    13.8%
Change in fair value of contingent consideration   (338)   -0.8%   (489)   -1.5%
Total operating expenses   31,942    77.3%   36,791    113.6%
                     
Operating loss   (13,997)   -33.9%   (26,066)   -80.5%
Interest accretion expense   (496)   -1.2%   (549)   -1.7%
Related party interest   (424)   -1.0%   -    0.0%
Other (expense) income, net   (496)   -1.2%   467    1.4%
Loss from continuing operations before tax   (15,413)   -37.3%   (26,148)   -80.7%
(Benefit) provision for income taxes   (667)   -1.6%   53    0.2%
Loss from continuing operations   (14,746)   -35.7%   (26,201)   -80.9%
                     
Loss from discontinued operations, net of tax   (197)   -0.5%   (250)   -0.8%
                     
Net loss  $(14,943)   -36.2%  $(26,451)   -81.6%

 

Revenue, net

 

Consolidated revenue for the year ended December 31, 2021 increased by $8.9 million, or 28%, to $41.3 million, compared to $32.4 million for the year ended December 31, 2020. The increase in net revenue was driven by increased reimbursement rates and increased clinical services volume as the year ended December 31, 2020 was impacted by the pandemic. This increase was partially offset by a fairly significant decrease in volume within pharma services. The decrease in revenue within pharma services was approximately 32% from the comparable prior year period.

 

Cost of revenue

 

Consolidated cost of revenue for the year ended December 31, 2021 increased by $1.7 million, or 8%, to $23.4 million, compared to $21.7 million for the year ended December 31, 2020. This increase is primarily attributed to the increased volume associated with the clinical services business.

 

Gross Profit

 

Consolidated gross profit for the year ended December 31, 2021 increased $7.2 million, or 67%, to $17.9 million, compared to $10.7 million for the year ended December 31, 2020. The increase can be attributed to increased reimbursement rates as well as the change in the gross profit mix.

 

 76 
 

 

Sales and marketing expense

 

Consolidated sales and marketing expense was $10.1 million for the year ended December 31, 2021, as compared to $9.3 million for the year ended December 31, 2020. As a percentage of revenue, sales and marketing expense decreased to 24% from 29% in the comparable prior year period due to the higher revenue for the year ended December 31, 2021.

 

Research and development

 

Research and development expense was $1.9 million for the year ended December 31, 2021 and $2.8 million for the year ended December 31, 2020 due to lower professional services and employee costs. As a percentage of revenue, research and development expense decreased to 5% from 9% in the comparable prior year period.

 

General and administrative

 

General and administrative expense for the year ended December 31, 2021 was $13.7 million as compared to $18.2 million for the year ended December 31, 2020. The decrease can be primarily attributed to the closing of the Rutherford, NJ office as well as employee and consulting costs associated with the closure. The year ended December 31, 2020 also included approximately $1.1 million in executive severance costs. As a percentage of net revenue, general and administrative expense was 33% for the year ended December 31, 2021 as compared to 56% for the year ended December 31, 2020.

 

Transition expense

 

Transition expense was approximately $2.6 million for the year ended December 31, 2021 and $2.6 million for the year ended December 31, 2020. These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount and the implementation of a new laboratory information system.

 

Loss on DiamiR transaction

 

During the year ended December 31, 2021 there was a loss of $0.01 million on the disposition of New Haven, CT laboratory to DiamiR in April 2021.

 

Acquisition related amortization expense

 

During the years ended December 31, 2021 and December 31, 2020, we recorded amortization expense of approximately $4.1 million and $4.5 million, respectively, which is related to intangible assets associated with our acquisitions.

 

Change in fair value of contingent consideration

 

During the year ended December 31, 2021, there was a $0.3 million decrease in the contingent consideration liability. During the year ended December 31, 2020, there was a $0.5 million decrease in the contingent consideration liability related thereto.

 

Operating loss

 

There were consolidated operating losses from continuing operations of $14.0 million and $26.1 million during the years ended December 31, 2021 and 2020, respectively.

 

(Benefit) provision for income taxes

 

The income tax benefit was approximately $0.7 million for the year ended December 31, 2021 and which primarily pertained to the Company’s sale of NOLs of approximately $0.7 million under the State of New Jersey’s Technology Business Tax Certificate Transfer Program. Income tax expense of $0.1 million for the year ended December 31, 2020 was primarily driven by minimum state and local taxes.

 

 77 
 

 

Loss from discontinued operations, net of tax

 

We had a loss from discontinued operations of $0.2 million for the year ended December 31, 2021 as compared to a loss from discontinued operations of $0.3 million for the year ended December 31, 2020.

 

Non-GAAP Financial Measures

 

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.

 

In this 10-K, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, acquisition related expenses, transition expenses, non-cash stock based compensation, interest and taxes, and other non-cash expenses including asset impairment costs, bad debt expense, loss on extinguishment of debt, goodwill impairment and change in fair value of contingent consideration, and warrant liability. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

 

   Years Ended 
   December 31, 
   2021   2020 
Loss from continuing operations (GAAP Basis)  $(14,746)  $(26,201)
Bad debt (recovery) expense   (140)   585 
Loss on DiamiR transaction   13    - 
Receipt of HHS stimulus grant   -    (650)
Transition expenses   2,585    2,578 
Legal and professional services   -    495 
Depreciation and amortization   5,374    5,501 
Stock-based compensation   1,368    2,242 
Taxes (benefit)/expense   (667)   53 
Interest accretion expense   496    549 
Financing interest and related costs   

950

    

-

 
Mark to market on warrant liability   50    (61)
Change in fair value of note payable   (58)   - 
Change in fair value of contingent consideration   (338)   (489)
Adjusted EBITDA  $(5,113)  $(15,398)

 

LIQUIDITY AND CAPITAL RESOURCES

 

For the fiscal year ended December 31, 2021, we had an operating loss of $14.0 million. As of December 31, 2021, we had cash, cash equivalents and restricted cash of $3.3 million, total current assets of $12.2 million and current liabilities of $15.7 million. As of March 18, 2022, we had approximately $2.7 million of cash on hand, excluding restricted cash.

 

 78 
 

 

During the year ended December 31, 2021, net cash used in operating activities was $8.7 million. The main component of cash used in operating activities was our net loss of $14.9 million which was partially offset by non-cash depreciation, amortization and stock compensation expenses of $6.6 million. During the year ended December 31, 2020, net cash used in operating activities was $14.0 million. The main component of cash used in operating activities was our net loss of $26.5 million which was partially offset by non-cash expenses of $7.7 million.

 

For the year ended December 31, 2021, cash provided from financing activities was $9.0 million, of which $7.7 million were the net proceeds from the BroadOak loan and $1.5 million borrowed under our line of credit. See Note 13, Notes Payable, for more details. For the year ended December 31, 2020, cash provided from financing activities was $16.6 million, $19.2 million which resulted from the issuance of preferred stock in January 2020 and $0.4 million from sales of Common Stock, partially offset by the repayment of $3.0 million of borrowed funds under our now terminated revolving line of credit with Silicon Valley Bank.

 

For the year ended December 31, 2021, cash used in investing activities was $0.4 million, primarily related to the purchase of lab equipment. For the year ended December 31, 2020, cash used in investing activities was $1.6 million, primarily related to capital expenditures associated with the moving of our Rutherford, New Jersey lab to North Carolina.

 

On January 7, 2021, the Company entered into secured promissory notes in the amount of $3 million and $2 million with Ampersand and 1315 Capital, respectively. See Note 13, Notes Payable of the notes to the financial statements. On May 10, 2021, the Company amended the Ampersand Note to increase the principal amount to $4.5 million and amended the 1315 Capital Note to increase the principal amount to $3.0 million. The maturity dates of the Notes were the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

In October 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “Comerica Loan Agreement”) with Comerica Bank (“Comerica”), providing for a revolving credit facility of up to $7,500,000 (the “Credit Facility”). The Company may use the proceeds of the Credit Facility for working capital and other general corporate purposes.

 

The amount that may be borrowed under the Credit Facility is the lower of (i) the revolving limit of $7,500,000 (the “Revolving Line”) and (ii) 80% of the Company’s eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close not based upon the Company’s eligible accounts receivable, with such additional availability reducing by $250,000 per quarter beginning with the quarter ending June 30, 2022. Borrowings on the Credit Facility are limited to $5,000,000 until 80% of the Company’s and its subsidiaries’ customers are paying into a collection account or segregated governmental account with Comerica. The Revolving Line can also include, at the Company’s option, credit card services with a sublimit of $300,000. Borrowings on the Revolving Line are subject to an interest rate equal to prime plus 0.50%, with prime being the greater of (x) Comerica’s stated prime rate or (y) the sum of (A) the daily adjusting LIBOR rate plus (B) 2.5% per annum. The Company is also required to pay an unused facility fee quarterly in arrears in an amount equal to 0.25% per annum on the average unused but available portion of the Revolving Line for such quarter. See Note 19, Line of Credit, for more details. Comerica has a first priority security interest in substantially all of the Company’s and its subsidiaries’ assets.

 

In addition, also in October 2021, the Company entered into a Loan and Security Agreement (the “BroadOak Loan Agreement”) with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000 (the “Term Loan”). Funding of the Term Loan took place on November 1, 2021. The Term Loan matures upon the earlier of (i) October 31, 2024 or (ii) the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is secured by a security interest in substantially all of the Company’s and its subsidiaries’ assets and is subordinate to the Company’s recently established $7,500,000 revolving credit facility with Comerica Bank. The Term Loan has an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date. Upon receipt of the term loan, the proceeds were used to repay in full at their maturity the notes extended by Ampersand and 1315 Capital discussed above. See Note 13, Notes Payable, for more details. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents and availability on the revolving credit facility with Comerica will be sufficient to meet its anticipated operating cash requirements through at least the end of the first quarter of fiscal 2023.

 

The BroadOak Loan Agreement contains affirmative and negative restrictive covenants, including restrictions on certain mergers, acquisitions, investments and encumbrances which could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default. The Comerica Loan Agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica loan agreement. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The Comerica Loan Agreement also contains financial covenants requiring specified minimum liquidity and minimum revenue thresholds and also contains customary events of default. However, if we are unable to meet the financial covenants under the Comerica Loan Agreement, the revolving line of credit and notes payable will become due and payable immediately.

 

As of December 31, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows:

 

       Less than   1 to 3   3 to 5   After 
   Total   1 Year   Years   Years   5 Years 
Operating lease obligations  $5,085   $1,295   $1,464   $816   $1,510 
Total  $5,085   $1,295   $1,464   $816   $1,510 

 

 79 
 

 

Although the Company is targeting to achieve adjusted EBITDA and cash flow breakeven during Fiscal 2022, we may not generate positive cash flows from operations for the year ending December 31, 2022. We intend to meet our ongoing capital needs by using our available cash and availability under the Comerica Loan Agreement, as well as through revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options.

 

The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity and expand the business through acquisitions or other strategic transactions. With the Company’s delisting from Nasdaq in February 2021, its ability to raise additional capital on terms acceptable to the Company may be adversely impacted. In January 2022, the Company’s registration statement for a rights offering become effective. The rights offering was subsequently terminated in January 2022. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to the Company or at all.

 

As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be insufficient to meet its anticipated cash requirements through the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a “smaller reporting company” for purposes of the disclosure requirements of Item 305 of Regulation S-K and, therefore, we are not required to provide this information.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Financial statements and the financial statement schedule specified by this Item 8, together with the report thereon of BDO USA, LLP, are presented following Item 15 of this Annual Report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.

 

 80 
 

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

As of December 31, 2021, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December 31, 2021, our internal control over financial reporting was effective based on those criteria.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION
   
  None.
   
ITEM 9C.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

   
  Not applicable.

 

 81 
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
   
  Information relating to directors and executive officers of the registrant that is responsive to Item 10 of this Annual Report on Form 10-K will be included in an amendment hereto or will be included in our Proxy Statement for our 2022 annual meeting of stockholders and such information is incorporated by reference herein.

 

ITEM 11. EXECUTIVE COMPENSATION
   
  Information relating to executive compensation of the registrant that is responsive to Item 11 of this Annual Report on Form 10-K will be included in an amendment hereto or will be included in our Proxy Statement for our 2022 annual meeting of stockholders, and such information is incorporated by reference herein.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
   
  Information relating to security ownership of certain beneficial owners and management of the registrant that is responsive to Item 12 of this Annual Report on Form 10-K will be included in an amendment hereto or will be included in our Proxy Statement for our 2022 annual meeting of stockholders and such information is incorporated by reference herein.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
   
  Information relating to certain relationships and related transactions of the registrant that is responsive to Item 13 of this Annual Report on Form 10-K will be included in an amendment hereto or will be included in our Proxy Statement for our 2022 annual meeting of stockholders and such information is incorporated by reference herein.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
   
  Information relating to principal accounting fees and services of the registrant that is responsive to Item 14 of this Annual Report on Form 10-K will be included in an amendment hereto or will be included in our Proxy Statement for our 2022 annual meeting of stockholders and such information is incorporated by reference herein.

 

 82 
 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

(a) The following documents are filed as part of this Form 10-K:

 

  (1) Financial Statements – See Index to Financial Statements on page F-1 of this Form 10-K.
  (2) Financial Statement Schedule

 

Schedule II: Valuation and Qualifying Accounts

 

All other schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

 

  (3) Exhibits

 

Exhibit

No.

   Description
     
2.1   Asset Purchase Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 2.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014.
2.2   Asset Purchase Agreement, dated as of October 30, 2015, by and between Publicis Touchpoint Solutions, Inc. and PDI, Inc., incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 2, 2015.
2.3   Asset Purchase Agreement by and among the Company and Diamir Biosciences Corp. dated March 16, 2021,incorporated by reference to Exhibit 2.1 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.
3.1+   Conformed version of Certificate of Incorporation of Interpace Biosciences, Inc., as amended by the Certificate of Amendment, effective January 15, 2020, and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed January 17, 2020, incorporated by reference to Exhibit 3.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
3.2   Amended and Restated Bylaws of Interpace Biosciences, Inc., incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 14, 2019.
4.1   Description of Securities, incorporated by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2021.
4.2   Specimen Certificate Representing the Common Stock, incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-3 (File No. 333-227728), filed with the SEC on October 5, 2018.
4.3   Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 20, 2017.
4.4   Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.3 of the Company’s Current Report on Form 8-K, as amended, filed with the SEC on March 24, 2017.
4.5   Form of PreFunded Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017.
4.6   Form of Underwriters’ Warrants, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017.
4.7   Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.3 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017.
4.8   Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 12, 2017.
4.9   Loan and Security Agreement, dated November 13, 2018, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC, incorporated by reference to Exhibit 4.9 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
4.10   Form of Underwriter Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 29, 2019.
4.11   Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc., incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on July 19, 2019.
10.1*   Amended and Restated 2004 Stock Award and Incentive Plan, incorporated by reference to Annex A of the Company’s definitive proxy statement, filed with the SEC on August 14, 2017.
10.2*   Form of Restricted Stock Unit Agreement for Employees, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018.

 

 83 
 

 

Exhibit
No.		   Description
10.3*   Form of Restricted Stock Unit Agreement for Directors, incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018.
10.4*   Form of Non-Qualified Stock Option Agreement, incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018.
10.5*   Form of Incentive Stock Option Agreement, incorporated by reference to Exhibit 10.4 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018.
10.6*   Interpace Diagnostics Group, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.1 of the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.
10.7*   Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 10.8 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on June 26, 2020.
10.8*   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.3 of the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.
10.9*   Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement, incorporated by reference to Exhibit 10.9 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on June 26, 2020.
10.10*   Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.4 of the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.
10.11*   Interpace Diagnostics Group, Inc. Employee Stock Purchase Plan, incorporated by reference to Exhibit 4.2 of the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.
10.12*   Employment agreement entered into May 10, 2021, effective February 1, 2021, between Thomas Freeburg and the Company, incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.
10.15*   Severance agreement and General Release, dated January 31, 2021, by and between the Company and Fred Knechtel, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on February 4, 2021.
10.16*   Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and Jack E. Stover, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 20, 2016.
10.17*   Amended and Restated Employment Agreement dated December 5, 2018, between the Company and Jack E. Stover, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2018.
10.18*   First Amendment to Amended and Restated Employment Agreement, dated January 29, 2020, by and between Interpace Biosciences, Inc. and Jack E. Stover, incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.
10.20*   Employment Agreement, dated November 23, 2020, between Thomas W. Burnell and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 25, 2020.
10.21*   Separation and Consulting Agreement and General Release, dated November 23, 2020, between Jack E. Stover and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 25, 2020.
10.22*   Form of Indemnification Agreement by and between Interpace Diagnostics Group, Inc. and its directors and executive officers, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on August 8, 2016.
10.23*   Form of Indemnification Agreement by and between Interpace Biosciences, Inc. and Indemnitee, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020.
10.24   License Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 10.31 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014.

 

 84 
 

 

Exhibit
No.		   Description
10.25   CPRIT License Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 10.32 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014.
10.26   Supply Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 10.33 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014.
10.27   Guaranty, dated August 13, 2014 by the Company in favor of Asuragen, Inc., incorporated by reference to Exhibit 10.34 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014.
10.28   Morris Corporate Center Lease, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, filed with the SEC on November 5, 2009.
10.29   First Amendment to Lease, dated May 24, 2017, by and between Brookwood MC Investors, LLC, Brookwood MC II, LLC, and the Company, incorporated by reference to Exhibit 10.52 of the Company’s Registration Statement on Form S-1 (333-218140), as amended, filed with the SEC on June 13, 2017.
10.39   Lease Agreement, dated March 31, 2017, by and between Saddle Lane Realty, LLC and the Company, incorporated by reference to Exhibit 10.53 of the Company’s Registration Statement on Form S-1 (333-218140), as amended on June 13, 2017.
10.40   First Amendment, dated September 26, 2017, by and between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, incorporated by reference to Exhibit 10.36 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time
10.41   Amendment No. 2 to Lease, dated March 15, 2018, between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, incorporated by reference to Exhibit 10.45 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 23, 2018.
10.42   Form of Securities Purchase Agreement, dated January 20, 2017, by and between Interpace Diagnostics Group, Inc. and certain purchasers named therein, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 20, 2017.
10.43   Warrant Agency Agreement, dated June 21, 2017, by and between Interpace Diagnostics Group, Inc. and American Stock Transfer & Trust Company, LLC, incorporated by reference to Exhibit 1.2 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017.

 

 85 
 

 

Exhibit
No.		   Description
10.44   Form of Warrant Exercise Agreement dated October 12, 2017, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 12, 2017.
10.45   Securities Purchase Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on July 19, 2019.
10.46   Transition Services Agreement, dated July 15, 2019, by and between Interpace BioPharma, Inc. and Cancer Genetics, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on July 19, 2019.
10.47   Form of Voting Agreement, incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K, filed with the SEC on July 19, 2019.
10.50   Consent to Assignment, dated July 19, 2019, by and among Meadows Landmark LLC, Cancer Genetics, Inc., and Interpace BioPharma, Inc, incorporated by reference to Exhibit 10.46 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.51   Lease Agreement, dated June 12, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.47 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.52   Letter Amendment, dated October 21, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.48 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.53   Second Amendment to Lease, dated June 17, 2005, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.49 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.54   Third Amendment to Lease, dated May 25, 2006, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.50 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.55   Fourth Amendment to Lease, dated December 20, 2007, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.51 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.56   Fifth Amendment to Lease, dated June 15, 2009, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.52 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.

 

 86 
 

 

Exhibit
No.		   Description
10.57   Sixth Amendment to Lease, dated June 3, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.53 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.58   Seventh Amendment to Lease, dated October 26, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.54 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.59   Eighth Amendment to Lease, dated July 27, 2011, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.55 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.60   Ninth Amendment to Lease, dated November 7, 2012, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.56 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.61   Tenth Amendment to Lease, dated July 15, 2014, by and among Southport Business Park Limited Partnership, Gentris Corporation, and Gentris, LLC, incorporated by reference to Exhibit 10.57 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.62   Eleventh Amendment to Lease, effective as of June 1, 2020, by and between Southport Business Park Limited Partnership and Interpace Pharma Solutions, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 9, 2020.
10.63   Assignment of Lease, dated July 15, 2019, by and between Cancer Genetics, Inc. and Interpace BioPharma, Inc., incorporated by reference to Exhibit 10.58 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.64   Guaranty of Lease, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Southport Business Park Limited Partnership, incorporated by reference to Exhibit 10.59 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
10.65   Equity Distribution Agreement, dated September 20, 2019, by and between Interpace Diagnostics Group, Inc. and Oppenheimer & Co. Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on September 20, 2019.
10.66   Securities Purchase and Exchange Agreement, dated January 10, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 14, 2020.
10.67   Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020.
10.68   Support Agreement, dated April 7, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on October 19, 2020.
10.69   Termination Agreement, dated July 9, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.3 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on October 19, 2020.
10.70   Support Agreement, dated April 2, 2020, by and between 1315 Capital II, L.P. and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on October 19, 2020.
10.71   First Loan Modification Agreement, dated March 18, 2019, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc. (n/k/a Interpace Biosciences, Inc.), Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC, incorporated by reference to Exhibit 10.6 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on October 19, 2020.

 

 87 
 

 

Exhibit
No.		   Description
10.72   Joinder and Second Loan Modification Agreement, dated October 19, 2020, by and among the Company, Interpace Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma Solutions, Inc. and Silicon Valley Bank, incorporated by reference to Exhibit 4.3 of the Company’s Current Report on Form 8-K, filed with the SEC on October 23, 2020.
10.73   Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021,incorporated by reference to Exhibit 10.3 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.
10.74   Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021, incorporated by reference to Exhibit 10.4 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.
10.75   Security Agreement entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021, incorporated by reference to Exhibit 10.5 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.
10.76   Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.
10.77   Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P., incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.
10.78   Amendment to Security Agreement dated May 10, 2021 by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.3 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.
10.79   Second Amendment to Secured Promissory Note dated June 24, 2021 with Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 29, 2021.
10.80   Second Amendment to Secured Promissory Note dated June 25, 2021 with 1315 Capital II, L.P., incorporated by reference to Exhibit 99.2 of the Company’s Current Report on Form 8-K, filed with the SEC on June 29, 2021.
10.81   Third Amendment to Secured Promissory Note dated August 31, 2021 with Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K, filed with the SEC on August 31, 2021.
10.82   Third Amendment to Secured Promissory Note dated August 31, 2021 with 1315 Capital II, L.P., incorporated by reference to Exhibit 99.2 of the Company’s Current Report on Form 8-K, filed with the SEC on August 31, 2021.
10.83   Fourth Amendment to Secured Promissory Note dated September 29, 2021 with Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 1, 2021.
10.84   Fourth Amendment to Secured Promissory Note dated September 29, 2021 with 1315 Capital II, L.P., incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on October 1, 2021.
10.85   Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 13, 2021, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 19, 2021.
10.86   Subordination Agreement by and between Ampersand 2018 Limited Partnership, 1315 Capital II. L.P., Comerica Bank Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 13, 2021, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on October 19, 2021.
10.87   Loan and Security Agreement by and between BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 29, 2021, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021.

 

 88 
 

 

Exhibit
No.		   Description
10.88   First Amendment to Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated November 1, 2021, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021.
10.89   Subordination and Intercreditor Agreement by and between Comerica Bank, BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated as of November 1, 2021, incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021.
21.1   Subsidiaries of the Registrant, incorporated by reference to Exhibit 21.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.
23.1   Consent of BDO USA, LLP, filed herewith.
31.1   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
31.2   Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
32.1   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.
32.2   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.
     
*   Denotes compensatory plan, compensation arrangement or management contract.

 

ITEM 16. Form 10-K Summary

 

The Company has opted to not provide a summary.

 

 89 
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INTERPACE BIOSCIENCES, INC.
   
Date: March 31, 2022 /s/ Thomas W. Burnell
  Thomas W. Burnell
  President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated and on the dates indicated.

 

Name   Title   Date
         
/s/ Thomas W. Burnell   President, Chief Executive Officer and Director   March 31, 2022
Thomas W. Burnell   (Principal Executive Officer)    
         
/s/ Thomas Freeburg   Chief Financial Officer and Treasurer   March 31, 2022
Thomas Freeburg   (Principal Financial and Accounting Officer)    
         
/s/ Stephen J. Sullivan   Director   March 31, 2022
Stephen J. Sullivan        
         
/s/ Joseph Keegan   Director   March 31, 2022
Joseph Keegan        
         
/s/ Vijay Aggarwal   Director   March 31, 2022
Vijay Aggarwal        
         
/s/ Robert Gorman   Chairman of the Board of Directors   March 31, 2022
Robert Gorman        
         
/s/ Edward Chan   Director   March 31, 2022
Edward Chan        
         
/s/ Fortunato Ron Rocca   Director   March 31, 2022
Fortunato Ron Rocca        

 

 90 
 

 

Interpace Biosciences, Inc.

Index to Consolidated Financial Statements

and Financial Statement Schedules

 

  Page
   
Report of Independent Registered Public Accounting Firm (BDO USA, LLP; Woodbridge, NJ; PCAOB ID #243) F-2
   
Consolidated Financial Statements  
   
Consolidated Balance Sheets at December 31, 2021 and 2020 F-4
   
Consolidated Statements of Operations for the years ended December 31, 2021 and 2020 F-5
   
Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2021 and 2020 F-6
   
Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020 F-7
   
Notes to Consolidated Financial Statements F-8
   
Schedule II. Valuation and Qualifying Accounts F-32

 

 F-1 
 

 

Report of Independent Registered Public Accounting Firm

 

Shareholders and Board of Directors

Interpace Biosciences, Inc.

Parsippany, New Jersey

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Interpace Biosciences, Inc. and Subsidiaries (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders’ deficit, and cash flows for each of the two years in the period ended December 31, 2021, and the related notes and schedules (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Uncertainty

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has suffered operating losses, has negative operating cash flows and is dependent upon its ability to generate profitable operations in the future and/or obtain additional financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. These conditions raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

 F-2 
 

 

Revenue Recognition

 

As described in Note 1 of the consolidated financial statements, the Company’s clinical services derive revenue from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

 

We identified revenue recognition related to the measurement of the Company’s clinical services revenue recognized for each specified test based on an estimated transaction price or NRV as a critical audit matter. The principal considerations for our determination included the following: (i) the judgment applied by management based on historical collection rates, (ii) the estimation of the amount of variable consideration using the expected value method based on historical experience, and (iii) the expected collection for each test, as the estimate is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from the third-party payors Auditing these elements involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed.

 

The primary procedures we performed to address this critical audit matter included:

 

  ● Evaluating the consistency and reasonableness of management’s judgments and estimates of variable consideration utilizing the expected value method based on its historical experience in its calculation of net realizable value.
     
  ● Comparing the significant assumptions and inputs used by management to the Company’s fee schedule, third-party payor collection trends, and assessing the historical accuracy of the cash collections used in the Company’s revenue models and assessing the completeness of adjustments to estimates of future cash collections as a result of significant subsequent contract amendments, changes in collection trends and changes in payor behavior.

 

We have served as the Company’s auditor since 2012.

 

/s/ BDO USA, LLP

 

Woodbridge, New Jersey

March 31, 2022

 

 F-3 
 

 

INTERPACE BIOSCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

   December 31,   December 31, 
   2021   2020 
         
ASSETS          
Current assets:          
Cash and cash equivalents  $3,064   $2,772 
Restricted cash   250    600 
Accounts receivable, net of allowance for doubtful accounts of $72 and $275, respectively   6,158    8,028 
Other current assets   2,694    2,722 
Total current assets   12,166    14,122 
Property and equipment, net   6,349    7,349 
Other intangible assets, net   7,287    11,351 
Goodwill   8,433    8,433 
Operating lease right of use assets   4,032    4,384 
Other long-term assets   160    42 
Total assets  $38,427   $45,681 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $2,694   $4,511 
Accrued salary and bonus   3,024    3,161 
Other accrued expenses   9,198    9,795 
Current liabilities from discontinued operations   766    766 
Total current liabilities   15,682    18,233 
Contingent consideration   1,383    1,818 
Operating lease liabilities, net of current portion   3,154    3,540 
Line of credit   1,500    - 
Note payable at fair value   7,942    - 
Other long-term liabilities   4,648    4,637 
Total liabilities   34,309    28,228 
           
Commitments and contingencies (Note 11)   -    - 
           
Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding   46,536    46,536 
           
Stockholders’ deficit:          
Common stock, $.01 par value; 100,000,000 shares authorized; 4,228,169 and 4,075,257 shares issued, respectively; 4,195,412 and 4,055,593 shares outstanding, respectively   403    402 
Additional paid-in capital   186,106    184,404 
Accumulated deficit   (227,059)   (212,116)
Treasury stock, at cost (32,757 and 19,664 shares, respectively)   (1,868)   (1,773)
Total stockholders’ deficit   (42,418)   (29,083)
Total liabilities and stockholders’ deficit  $(8,109)  $(855)
           
Total liabilities, preferred stock and stockholders’ deficit  $38,427   $45,681 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-4 
 

 

INTERPACE BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for per share data)

 

   2021   2020 
   For The Years Ended December 31, 
   2021   2020 
         
Revenue, net  $41,314   $32,398 
Cost of revenue (excluding amortization of $4,064 and $4,461, respectively)   23,369    21,673 
Gross profit   17,945    10,725 
Operating expenses:          
Sales and marketing   10,067    9,254 
Research and development   1,882    2,795 
General and administrative   13,669    18,192 
Transition expense   2,585    2,578 
Loss on DiamiR transaction   13    - 
Acquisition related amortization expense   4,064    4,461 
Change in fair value of contingent consideration   (338)   (489)
Total operating expenses   31,942    36,791 
           
Operating loss   (13,997)   (26,066)
Interest accretion expense   (496)   (549)
Related party interest   (424)   - 
Other (expense) income, net   (496)   467 
Loss from continuing operations before tax   (15,413)   (26,148)
(Benefit) provision for income taxes   (667)   53 
Loss from continuing operations   (14,746)   (26,201)
           
Loss from discontinued operations, net of tax   (197)   (250)
           
Net loss   (14,943)   (26,451)
           
Less adjustment for preferred stock deemed dividend   -    (3,033)
           
Net loss attributable to common stockholders  $(14,943)  $(29,484)
           
Basic and diluted loss per share of common stock:          
From continuing operations  $(3.57)  $(7.26)
From discontinued operations   (0.04)   (0.06)
Net loss per basic and diluted share of common stock  $(3.61)  $(7.32)
Weighted average number of common shares and common share equivalents outstanding:          
Basic   4,135    4,029 
Diluted   4,135    4,029 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-5 
 

 

INTERPACE BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(in thousands)

 

   For The Year Ended   For The Year Ended 
   December 31, 2021   December 31, 2020 
   Shares   Amount   Shares   Amount 
Common stock:                    
Balance at January 1   4,075   $402    3,932   $393 
Common stock issued   9    -    37    1 
Restricted stock issued   12    -    6    - 
Common stock issued through market sales   -    -    80    8 
Common stock issued through ESPP   36    -    -    - 
Balance at March 31   4,132    402    4,055    402 
Common stock issued   10    -    -    - 
Balance at June 30   4,142    402    4,055    402 
Common stock issued   13    -    5    - 
Common stock issued through ESPP   39    1    -    - 
Balance at September 30   4,194    403    4,060    402 
Common stock issued   34    -    15    - 
Balance at December 31   4,228    403    4,075    402 
Treasury stock:                    
Balance at January 1   20    (1,773)   12    (1,721)
Treasury stock purchased   -    -    -    - 
Balance at March 31   20    (1,773)   12    (1,721)
Treasury stock purchased   -    -    7    (49)
Balance at June 30   20    (1,773)   19    (1,770)
Treasury stock purchased   -    -    -    - 
Balance at September 30   20    (1,773)   19    (1,770)
Treasury stock purchased   13    (95)   1    (3)
Balance at December 31   33    (1,868)   20    (1,773)
Additional paid-in capital:                    
Balance at January 1        184,404         182,514 
Common stock issued        108         - 
Extinguishment of Series A Shares        -         (828)
Beneficial Conversion Feature in connection with Series B Issuance        -         2,205 
Amortization of Beneficial Conversion Feature        -         (2,205)
Common stock issued through market sales        -         476 
Stock-based compensation expense        286         418 
Balance at March 31        184,798         182,580 
Stock-based compensation expense        551         400 
Balance at June 30        185,349         182,980 
Common stock issued        226         - 
Stock-based compensation expense        477         563 
Balance at September 30        186,052         183,543 
Common stock issued through market sales, net of expenses        -         - 
Stock-based compensation expense        54         861 
Balance at December 31        186,106         184,404 
Accumulated deficit:                    
Balance at January 1        (212,116)        (185,665)
Net loss        (4,207)        (6,494)
Adoption of ASC 842        -         - 
Balance at March 31        (216,323)        (192,159)
Net loss        (3,446)        (5,580)
Balance at June 30        (219,769)        (197,739)
Net loss        (3,561)        (6,234)
Balance at September 30        (223,330)        (203,973)
Net loss        (3,729)        (8,143)
Balance at December 31        (227,059)        (212,116)
                     
Total stockholders’ deficit       $(42,418)       $(29,083)

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-6 
 

 

INTERPACE BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

   2021   2020 
   For The Years Ended December 31, 
   2021   2020 
         
Cash Flows From Operating Activities          
Net loss  $(14,943)  $(26,451)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   5,374    5,501 
Interest accretion expense   496    549 
Bad debt (recovery) expense   (140)   585 
Reversal of 2019 bonus accrual   -    (1,156)
Mark to market on warrants   50    (61)
Amortization of deferred financing fees   122    - 
Accrued interest - note payable   120    - 
Note payable fees   312    - 
Stock-based compensation   1,255    2,187 
ESPP expense   113    55 
Change in fair value of note payable   (58)   - 
Deferred income taxes   38    37 
Loss on DiamiR transaction   13    - 
Change in fair value of contingent consideration   (338)   (489)
Asset impairment   -    37 
Other gains and expenses, net   (2)   - 
Other changes in operating assets and liabilities:          
Decrease in accounts receivable   2,148    1,725 
Decrease in other current assets   28    241 
Increase in other long-term assets   (118)   - 
Decrease in accounts payable   (1,817)   (198)
(Decrease) increase in accrued salaries and bonus   (137)   1,976 
(Decrease) increase in accrued liabilities   (1,086)   1,395 
(Decrease) increase in long-term liabilities   (149)   88 
Net cash used in operating activities   (8,719)   (13,979)
           
Cash Flows From Investing Activity          
Purchase of property and equipment   (354)   (1,575)
Sale of property and equipment   39    - 
Net cash used in investing activities   (315)   (1,575)
           
Cash Flows From Financing Activities          
Issuance of common stock, net of expenses   335    434 
Issuance of Series B preferred stock, net of expenses   -    19,223 
Loan proceeds - related parties   7,500    - 
Loan proceeds - BroadOak   8,000    - 
Loan expenses - BroadOak   (312)   - 
Payment of related party note and related interest   (7,924)   - 
Financing fees - related party   (123)   - 
Borrowings (payments) on Line of Credit   1,500    (3,000)
Cash paid for repurchase of restricted shares   -    (52)
Net cash provided by financing activities   8,976    16,605 
           
Net (decrease) increase in cash, cash equivalents and restricted cash   (58)   1,051 
Cash, cash equivalents and restricted cash – beginning   3,372    2,321 
Cash, cash equivalents and restricted cash – ending  $3,314   $3,372 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-7 
 

 

1. Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.

 

Principles of Consolidation

 

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc.

 

Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation.

 

The Company has one reporting segment: the Company’s clinical and pharma services business. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

 

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.

 

Reverse stock split

 

On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company’s issued and outstanding stock decreased from 39,323,701 to 3,932,370 and 39,205,895 to 3,920,589 at December 31, 2019. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the reverse stock split for all periods presented.

 

 F-8 
 

 

Cash and Cash Equivalents

 

Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.

 

Accounts Receivable, Net

 

The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.

 

Other current assets

 

Other current assets consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Lab supply inventory  $1,786   $2,052 
Prepaid expenses   800    625 
Other   108    45 
Total other current assets  $2,694   $2,722 

 

Property and Equipment, net

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven to twelve years for furniture and fixtures; two to five years for office and computer equipment; three to twelve years for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently three to ten years. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations.

 

Software Costs

 

Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three to seven years. Software costs that do not meet capitalization criteria are expensed immediately.

 

External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years. Software costs that do not meet capitalization criteria are expensed immediately.

 

See Note 6, Property and Equipment, for further information.

 

Long-Lived Assets, including Finite-Lived Intangible Assets

 

Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition related amortization expense in the Consolidated Statements of Operations.

 

 F-9 
 

 

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

 

As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment.

 

Contingencies

 

In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.

 

Revenue Recognition

 

Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

 

For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.

 

 F-10 
 

 

For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

 

The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.

 

Deferred Revenue

 

For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.

 

Cost of revenue

 

Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.

 

Stock-Based Compensation

 

The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert.

 

See Note 15, Stock-Based Compensation, for further information.

 

Treasury Stock

 

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.

 

Leases

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, Leases.

 

 F-11 
 

 

Income taxes

 

Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense.

 

The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized.

 

The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense.

 

Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.

 

Income (Loss) per Share

 

Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2021 and 2020, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.

 

 F-12 
 

 

2. Recent Accounting Standards

 

Recently Adopted Accounting Guidance

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment was effective for annual periods beginning after December 15, 2020.

 

The Company adopted this pronouncement on January 1, 2021 and the impact was not material to the Company’s Consolidated Financial Statements.

 

Accounting Pronouncements Pending Adoption

 

In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company does not expect this will have any impact on its unaudited consolidated financial statements.

 

3. Going Concern

 

The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.

 

For the fiscal year ended December 31, 2021, we had an operating loss of $14.0 million. As of December 31, 2021, we had cash, cash equivalents and restricted cash of $3.3 million, total current assets of $12.2 million and current liabilities of $15.7 million. As of March 18, 2022, we had approximately $2.7 million of cash on hand, excluding restricted cash.

 

In January 2022, the Company announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be insufficient to meet its anticipated cash requirements through the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. 

 

On January 7, 2021, the Company entered into secured promissory notes in the amount of $3 million and $2 million with Ampersand (“Ampersand Note”) and 1315 Capital (“1315 Capital Note”), respectively. See Note 13, Notes Payable, of the notes to the financial statements. On May 10, 2021, the Company amended the Ampersand Note to increase the principal amount to $4.5 million and amended the 1315 Capital Note to increase the principal amount to $3.0 million. The maturity dates of the Notes were the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

 F-13 
 

 

On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica. See Note 19, Revolving Line of Credit, for more details. In addition, also in October 2021, the Company entered into the $8.0 million BroadOak Term Loan, the proceeds of which were used to repay in full at their maturity the notes extended by Ampersand and 1315 Capital discussed above. See Note 13, Notes Payable, for more details.

 

Although the Company is targeting to achieve adjusted EBITDA and cash flow breakeven during Fiscal 2022, we may not generate positive cash flows from operations for the year ending December 31, 2022. We intend to meet our ongoing capital needs by using our available cash and availability under the Comerica Loan Agreement, as well as through revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options. However, if we are unable to meet the financial covenants under the Comerica Loan Agreement, the revolving line of credit and notes payable will become due and payable immediately.

 

The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity and expand the business through acquisitions or other strategic transactions. With the Company’s delisting from Nasdaq in February 2021, its ability to raise additional capital on terms acceptable to the Company may be adversely impacted. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to the Company. In January 2022, the Company’s registration statement for a rights offering become effective. The rights offering was subsequently terminated in January 2022.

 

4. Discontinued Operations

 

The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods.

 

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2021 and December 31, 2020:

 

   December 31,
2021		   December 31,
2020		 
         
Accrued liabilities  $   766   $   766 
Current liabilities from discontinued operations   766    766 
Total liabilities  $766   $766 

 

The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2021 and 2020.

 

   2021   2020 
   Years Ended 
   December 31, 
   2021   2020 
Income from discontinued operations, before tax  $-   $- 
Income tax expense   197    250 
Loss from discontinued operations, net of tax  $(197)  $(250)

 

 F-14 
 

 

5. Fair Value Measurements

 

Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the consolidated financial statements include contingent consideration, notes payable, and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

 

  Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
     
  Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
     
  Level 3: Valuations for assets and liabilities include certain unobservable inputs in the assumptions and projections used in determining the fair value assigned to such assets or liabilities.

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 

   As of December 31, 2021   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2021 
   Amount   Value   Level 1   Level 2   Level 3 
Liabilities:                         
Contingent consideration:                         
Asuragen  $1,871   $1,871   $     -   $    -   $1,871 
Other accrued expenses:                         
Warrant liability   71    71    -    -    71 
Note payable:                         
BroadOak loan   7,942    7,942    -    -    7,942 
   $9,884   $9,884   $-   $-   $9,884 

 

 F-15 
 

 

   As of December 31, 2020   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2020 
   Amount   Value   Level 1   Level 2   Level 3 
                     
Liabilities:                         
Contingent consideration:                         
Asuragen  $2,216   $2,216   $    -   $    -   $2,216 
Other long-term liabilities:                         
Warrant liability   21    21    -    -    21 
   $2,237   $2,237   $-   $-   $2,237 

 

In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

 

In connection with the BroadOak loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted approach regarding the loan’s change in control feature. See Note 13, Notes Payable, for more details. The fair value measurement is based on the estimated probability of a change in control and thus represents a Level 3 measurement.

 

                            Adjustment        
                      Accretion/     to Fair Value/        
   

December 31,

2020

    

Loan

Received

     Payments    

Interest

Accrued

    

Mark to

Market

    

December 31,

2021

  
                                     
Asuragen   $ 2,216       -      $ (503 )   $ 496     $ (338 )   $ 1,871  
                                                 
Underwriters Warrants     21       -        -       -       50       71  
                                                 
BroadOak Loan     -       8,000       -       -       (58 )     7,942  
    $ 2,237     $ 8,000     $ (503 )   $ 496     $ (346 )   $ 9,884  

 

Certain of the Company’s non-financial assets, such as other intangible assets are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

 

6. Property and Equipment

 

Property and equipment consisted of the following as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Furniture and fixtures  $339   $339 
Lab and office equipment   7,837    7,536 
Computer equipment   331    339 
Internal-use software   1,572    1,572 
Leasehold improvements   506    505 
Property and equipment   10,585    10,291 
Less accumulated depreciation and amortization   (4,236)   (2,942)
Net property and equipment  $6,349   $7,349 

 

Depreciation and amortization expense from continuing operations was approximately $1.2 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. There was internal-use software amortization expense included in depreciation and amortization expense in 2021 of approximately $0.3 million. As of December 31, 2021, capitalized external-use software was fully amortized.

 

 F-16 
 

 

7. Goodwill and Other Intangible Assets

 

Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at December 31, 2021 was $8.4 million. The net carrying value of the identifiable intangible assets as of December 31, 2021 and December 31, 2020 is as follows:

 

       As of December 31, 2021   As of December 31, 2020 
   Life   Carrying   Carrying 
   (Years)   Amount   Amount 
             
Asuragen acquisition:              
Thyroid  9   $8,519   $8,519 
RedPath acquisition:              
Pancreas test  7    16,141    16,141 
Barrett’s test  9    6,682    6,682 
BioPharma acquisition:              
Trademarks  10    1,600    1,600 
Customer relationships  8    5,700    5,700 
               
CLIA Lab  2.3   $609   $609 
               
Total      $39,251   $39,251 
               
Accumulated Amortization      $(31,964)  $(27,900)
               
Net Carrying Value      $7,287   $11,351 

 

The following table displays a roll forward of the carrying amount of goodwill from January 1, 2020 to December 31, 2021:

 

   Carrying 
   Amount 
Balance as of January 1, 2020  $8,433 
Adjustments   - 
Balance as of December 31, 2020  $8,433 
Adjustments   - 
Balance as of December 31, 2021  $8,433 

 

Amortization expense was approximately $4.1 million and $4.5 million for the years ended December 31, 2021 and 2020, respectively. Estimated amortization expense for the next five years is as follows:

 

2022   2023   2024   2025   2026 
                       
$2,143   $1,734   $873   $873   $873 

 

 F-17 
 

 

8. Leases

 

Finance lease assets are included in fixed assets, net of accumulated depreciation.

 

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

 

   Classification on the Balance Sheet  December 31, 2021 
       
Assets        
Financing lease assets  Property and equipment, net  $636 
Operating lease assets  Operating lease right of use assets   4,032 
Total lease assets     $4,668 
         
Liabilities        
Current        
Financing lease liabilities  Other accrued expenses  $79 
Operating lease liabilities  Other accrued expenses   1,041 
Total current lease liabilities     $1,120 
Noncurrent        
Financing lease liabilities  Other long-term liabilities   59 
Operating lease liabilities  Operating lease liabilities, net of current portion   3,154 
Total long-term lease liabilities      3,213 
Total lease liabilities     $4,333 

 

The weighted average remaining lease term for the Company’s operating leases was 6.4 years as of December 31, 2021 and 7.1 years as of December 31, 2020 and the weighted average discount rate for those leases was 6.5% and 6.0% as of December 31, 2021 and December 31, 2020, respectively. The Company’s operating lease expenses are recorded within “Cost of revenue” and “General and administrative expenses.”

 

The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2021:

 

   Operating Leases   Financing Leases 
2022  $1,295   $86 
2023   897    60 
2024   567    - 
2025   402    - 
2026-2030   1,924    - 
Total minimum lease payments   5,085    146 
Less: amount of lease payments representing effects of discounting   890    8 
Present value of future minimum lease payments   4,195    138 
Less: current obligations under leases   1,041    79 
Long-term lease obligations  $3,154   $59 

 

 F-18 
 

 

9. Retirement Plans

 

The Company offers an employee 401(k) saving plan. Under the Interpace Biosciences, Inc. 401(k) Plan, employees may contribute up to 50% of their pre- or post-tax base compensation. The Company currently offers a safe harbor matching contribution equal to 100% of the first 3% of the participant’s contributed base salary plus 50% of the participant’s base salary contributed exceeding 3% but not more than 5%. Participants are not allowed to invest any of their 401(k) funds in the Company’s common stock. The Company’s total contribution expense from continuing operations related to the 401(k) plan for the years ended December 31, 2021 and December 31, 2020 was approximately $0.3 million and $0.4 million, respectively.

 

10. Accrued Expenses and Other Long-Term Liabilities

 

Other accrued expenses consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Accrued royalties  $3,890   $2,710 
Contingent consideration   488    398 
Upfront Medicare payment   -    2,066 
Operating lease liability   1,041    1,027 
Financing lease liability   79    177 
Deferred revenue   40    54 
Interest payable   

120

    - 
Warrant liability   71    - 
Accrued sales and marketing - diagnostics   47    51 
Accrued lab costs - diagnostics   228    161 
Accrued professional fees   932    854 
Taxes payable   245    334 
Unclaimed property   565    565 
All others   1,452    1,398 
Total other accrued expenses  $9,198   $9,795 

 

Other long-term liabilities consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Warrant liability  $-   $21 
Uncertain tax positions   4,577    4,342 
Deferred revenue   13    136 
Other   58    138 
Total other long-term liabilities  $4,648   $4,637 

 

 

11. Commitments and Contingencies

 

The Company leases facilities and certain equipment under agreements classified as operating leases, which expire at various dates through May 2030. Substantially all of the property leases provide for increases based upon use of utilities and landlord’s operating expenses as well as pre-defined rent escalations. Total expense from continuing operations under these agreements for the years ended December 31, 2021 and 2020 was approximately $1.2 million and $2.1 million, respectively.

 

 F-19 
 

 

As of December 31, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows:

 

       Less than   1 to 3   3 to 5   After 
   Total   1 Year   Years   Years   5 Years 
Operating lease obligations  $5,085   $1,295   $1,464   $816   $1,510 
Total  $5,085   $1,295   $1,464   $816   $1,510 

 

Litigation

 

Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products.

 

The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

 

12. Equity

 

Preferred Stock Issuance: Securities Purchase and Exchange Agreement

 

On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $20.0 million in Series B Preferred Stock of the Company, at an issuance price per share of $1,000. Pursuant to the Securities Purchase and Exchange Agreement, 1315 Capital agreed to purchase 19,000 shares of Series B Preferred Stock at an aggregate purchase price of $19.0 million and Ampersand agreed to purchase 1,000 shares of Series B Preferred Stock at an aggregate purchase price of $1.0 million.

 

In addition, the Company agreed to exchange $27.0 million of the Company’s existing Series A convertible preferred stock, par value $0.01 per share, held by Ampersand (the “Series A Preferred Stock”), represented by 270 shares of Series A Preferred Stock with a stated value of $100,000 per share, which represents all of the Company’s issued and outstanding Series A Preferred Stock, for 27,000 newly issued shares of Series B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”). Following the Exchange, no shares of Series A Preferred Stock remained designated, authorized, issued or outstanding. The Series B Preferred Stock has a conversion price of $6.00 as compared to a conversion price of $8.00 on the Series A Preferred Stock, but did not include certain rights applicable to the Series A Preferred Stock, including a six-percent (6%) dividend and a conversion price adjustment for any failure by the Company to achieve a revenue target of $34.0 million in 2020 related to its clinical services or a weighted-average anti-dilution adjustment. Under the terms of the Securities Purchase and Exchange Agreement, Ampersand also agreed to waive all dividends and weighted-average anti-dilution adjustments accrued to date on the Series A Preferred Stock.

 

 F-20 
 

 

A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $2.2 million, which the Company recorded as a reduction to additional paid-in capital upon the sale of the Series B Preferred stock. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the Common Stock on January 15, 2020 of $6.79 per share and the effective conversion price per share of $6.00 multiplied by the number of shares of common stock issuable upon conversion. The Company fully amortized the beneficial conversion feature during the three months ended March 31, 2020 in accordance with GAAP. The beneficial conversion feature resulted in an increase in the loss attributable to common shareholders for the three months ended March 31, 2020 in the Condensed Consolidated Statement of Operations, as it represented a deemed dividend to the preferred shareholders.

 

In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect. During October 2021, Ampersand and 1315 Capital provided consent to the Company to enter into the Comerica Loan Agreement and the BroadOak Term Loan.

 

As of December 31, 2021 and 2020, there were 47,000 Series B issued and outstanding shares of preferred stock, respectively.

 

13. Notes Payable

 

BroadOak Loan and Repayment of Promissory Notes

 

On October 29, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “BroadOak Loan Agreement”) with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000 (the “Term Loan”). Funding of the Term Loan took place on November 1, 2021. The Term Loan matures upon the earlier of (i) October 31, 2024 or (ii) the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is secured by a security interest in substantially all of the Company’s and its subsidiaries’ assets and is subordinate to the Company’s recently established $7,500,000 revolving credit facility with Comerica Bank. The Term Loan has an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date.

 

The BroadOak Loan Agreement contains affirmative and negative restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default.

 

In connection with the BroadOak Loan Agreement, the Company and its subsidiaries entered into that certain First Amendment to Loan and Security Agreement and Consent with Comerica, dated as of November 1, 2021 (the “Comerica Amendment”), pursuant to which Comerica consented to the Company’s and its subsidiaries’ entry into the BroadOak Loan Agreement, and amended that certain Loan and Security Agreement among Comerica, the Company and its subsidiaries (the “Comerica Loan Agreement”) to, among other things, permit the indebtedness, liens and encumbrances contemplated by the BroadOak Loan Agreement.

 

 F-21 
 

 

As a condition for BroadOak to extend the Term Loan to the Company and its subsidiaries, the Company’s existing creditor, Comerica, and BroadOak entered into that certain Subordination and Intercreditor Agreement, dated as of November 1, 2021, pursuant to which BroadOak agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to BroadOak to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Intercreditor Agreement”). BroadOak further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Intercreditor Agreement provides that it is solely for the benefit of BroadOak and Comerica and is not for the benefit of the Company or any of its subsidiaries.

 

The Company concluded that the Note met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5 that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to shareholders’ equity. Accordingly, the Company elected the fair value option for the Note.

 

Secured Promissory Notes – Related Parties

 

On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $3 million, and 1315 Capital, in the amount of $2 million, respectively (together, the “Notes”) and a related security agreement (the “Security Agreement”).

 

Ampersand holds 28,000 shares of the Company’s Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 4,666,666 shares of our Common Stock, and 1315 Capital holds 19,000 shares of the Company Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 3,166,668 shares of our Common Stock. On an as-converted basis, such shares would represent approximately 38.7% and 26.3% of our fully-diluted shares of Common Stock, respectively. In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 12, Equity). As a result, the Company considers the Notes and Security Agreement to be a related party transaction.

 

The rate of interest on the Notes was equal to eight percent (8.0%) per annum and their maturity date was the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. No interest payments were due on the Notes until their maturity date. All payments on the Notes were pari passu.

 

On May 10, 2021, (i) the Company and Ampersand amended the Ampersand Note to increase its principal amount to $4.5 million, (ii) the Company and 1315 Capital amended the 1315 Capital Note to increase its principal amount to $3.0 million and (iii) the Company and Ampersand amended the Security Agreement to include the new total principal amount of the Notes of $7.5 million. The maturity date of the Notes remained the earlier of June 30, 2021 and the date on which all amounts become due upon the occurrence of any event of default and the interest rate remained 8%, and except with respect to their respective principal amounts, the terms of the Notes and the Security Agreement were otherwise unchanged.

 

On June 24, 2021, August 31, 2021, and September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021, September 30, 2021, and October 31, 2021, respectively and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, August 31, 2021, and September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remained in full force and effect, and was not amended in connection with the amendments to the Notes.

 

In the case of the amendments, the Company reviewed the changes in accordance with ASC 470 and determined they should be treated as modifications.

 

 F-22 
 

 

The Notes contained certain negative covenants which prevented the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.

 

The Company used the proceeds of the BroadOak Term Loan discussed above to repay in full at their maturity all outstanding indebtedness under the promissory notes with Ampersand, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $4.5 million, and 1315 Capital, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $3 million, respectively. The Company, Ampersand, and 1315 Capital also terminated a related security agreement.

 

14. Warrants

 

Warrants outstanding and warrant activity for the year ended December 31, 2021 are as follows:

Description  Classification   Exercise
Price		   Expiration
Date		   Warrants
Issued		  

Balance

December 31,

2020

   Warrants
Cancelled/
Expired		  

Balance

December 31,

2021

 
                             
Private Placement Warrants, issued January 25, 2017  Equity   $46.90   June 2022    85,500    85,500    -    85,500 
RedPath Warrants, issued March 22, 2017  Equity   $46.90   September 2022    10,000    10,000    -    10,000 
Underwriters Warrants, issued June 21, 2017  Liability   $13.20   December 2022    57,500    53,500    -    53,500 
Base & Overallotment Warrants, issued June 21, 2017  Equity   $12.50   June 2022    1,437,500    870,214    -    870,214 
Warrants issued October 12, 2017  Equity   $18.00   April 2022    320,000    320,000    -    320,000 
Underwriters Warrants, issued January 25, 2019  Equity   $9.40   January 2022    65,434    65,434    -    65,434 
                                  
                 1,975,934    1,404,648          -    1,404,648 

 

The weighted average exercise price of the warrants is $15.97 and the weighted average remaining contractual life is approximately 0.4 years.

 

 F-23 
 

 

15. Stock-Based Compensation

 

The Company’s stock-incentive program is a long-term retention program that is intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. Currently, the Company is able to grant options, stock appreciation rights (“SARs”) and restricted shares from the Interpace Biosciences, Inc. 2019 Equity Incentive Plan. No new grants may be made under the Company’s prior stock incentive plan, the Interpace Diagnostics Group, Inc. (now known as Interpace Biosciences, Inc.) Amended and Restated 2004 Stock Award and Incentive Plan (the “2004 Plan”). Unless earlier terminated by action of the Company’s board of directors, the 2004 Plan will remain in effect until such time as no stock remains available for delivery and the Company has no further rights or obligations under the 2004 Plan with respect to outstanding awards thereunder.

 

Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

 

The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the Company’s expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility is based on historical volatility. As there is no trading volume for the Company’s options, implied volatility is not representative of the Company’s current volatility so the historical volatility of the Company’s common stock is determined to be more indicative of the Company’s expected future stock performance. The expected life is determined using the safe-harbor method. The Company expects to use this simplified method for valuing employee options until more detailed information about exercise behavior becomes available over time. The Company bases the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option valuation model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest. The Company recognizes compensation cost, net of estimated forfeitures, arising from the issuance of stock options on a straight-line basis over the vesting period of the grant.

 

The Company began an employee stock purchase plan in 2020 and recognized approximately $0.1 million and $0.04 million in expense related to that plan for the years ended December 31, 2021 and 2020, respectively.

 

The estimated compensation cost associated with the granting of restricted stock and restricted stock units is based on the fair value of the Company’s common stock on the date of grant. The Company recognizes the compensation cost, net of estimated forfeitures, arising from the issuance of restricted stock and restricted stock units on a straight-line basis over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved.

 

The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2021 and December 31, 2020.

 

   December 31, 2021   December 31, 2020 
    
Risk-free interest rate   0.79%   0.75%
Expected life   6.0 years    6.5 years 
Expected volatility   134.73%   123.71%
Dividend yield   -    - 

 

The weighted-average fair value of stock options granted during the year ended December 31, 2021 was estimated to be $4.64. The weighted-average fair value of stock options granted during the year ended December 31, 2020 was estimated to be $5.36. There were 13,042 options exercised in 2021. There were no options exercised in 2020. Historically, shares issued upon the exercise of options have been new shares and have not come from treasury shares.

 

 F-24 
 

 

Stock-based compensation for the years ended December 31, 2021 and 2020 is as follows:

 

   2021   2020 
RSUs and restricted stock  $433   $176 
Performance-based awards   107    265 
Common stock awards   -    116 
Options   715    1,630 
Total stock-based compensation expense  $1,255   $2,187 

 

A summary of stock option activity for the year ended December 31, 2021, and changes during such year, is presented below:

 

                Weighted-Average  
          Weighted-     Remaining        
          Average     Contractual     Aggregate  
          Grant     Period     Intrinsic  
    Shares     Price     (in years)     Value  
Outstanding at January 1, 2021     848,819     $ 8.76       8.59     $ -  
Granted     347,500       6.00       9.21       -  
Exercised     (13,042 )     9.45                  
Forfeited or expired     (550,766 )     9.15               -  
Outstanding at December 31, 2021     632,511       6.89       8.40       -  
                                 
Exercisable at December 31, 2021     206,732       9.14       7.53                -  
                                 
Vested and expected to vest     537,520       7.15       8.36       -  

 

A summary of the status of the Company’s non-vested options for the year ended December 31, 2021, and changes during such year, is presented below:

   Shares   Weighted-
Average
Grant Date
Fair Value		 
         
Nonvested at January 1, 2021   487,318   $5.81 
Granted   347,500    4.64 
Vested   (127,696)   6.54 
Forfeited   (284,646)   5.72 
Nonvested at December 31, 2021   422,476   $4.78 

 

The aggregate fair value of options vested during the years ended December 31, 2021 and 2020 was $0.8 million and $1.5 million, respectively. The weighted-average grant date fair value of options vested during the year ended December 31, 2020 was $7.34.

 

 F-25 
 

 

A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2021, and changes during such year, is presented below:

                Average        
          Weighted-     Remaining        
          Average     Vesting     Aggregate  
          Grant Date     Period     Intrinsic  
    Shares     Fair Value     (in years)     Value  
Nonvested at January 1, 2021     239,457     $ 10.00       1.75     $ 1,348,781  
Granted     207,438       5.46       -       -  
Vested     (65,577 )     4.65       -       -  
Forfeited     (52,379 )     5.23       -       -  
Nonvested at December 31, 2021     328,939     $ 3.67       1.34     $ 2,467,043  

 

The aggregate fair value of restricted stock units vested during each of the years ended December 31, 2021 and 2020 was $0.3 million and $0.4 million, respectively.

 

As of December 31, 2021, there was approximately $2.0 million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock units.

 

16. Revenue Sources

 

The Company’s clinical services customers consist primarily of physicians, hospitals and clinics. Its revenue channels include Medicare, Medicare Advantage, Medicaid, Client Billings (hospitals, etc.), and commercial payers. The following sets forth the net revenue generated by revenue channel accounted for more than 10% of the Company’s revenue from continuing operations during the years ended December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and December 31, 2020, revenue from Medicare was approximately 54% and 50% of total revenue, respectively.

 

   Years Ended December 31, 
Customer  2021   2020 
Medicare  $17,778   $10,186 
Medicare Advantage  $5,859   $3,566 
Commercial Payors  $5,555   $4,136 
Client Billings  $3,752   $2,582 

 

 

17. Income Taxes

 

The benefit from income taxes on continuing operations for the years ended December 31, 2021 and 2020 is comprised of the following:

 

   2021   2020 
Current:          
Federal  $-   $- 
State   (705)   16 
Total current   (705)   16 
           
Deferred:          
Federal   24    23 
State   14    14 
Total deferred   38    37 
(Benefit) provision from income taxes  $(667)  $53 

 

 F-26 
 

 

The Company performs an analysis each year to determine whether the expected future income will more likely than not be sufficient to realize the deferred tax assets. The Company’s recent operating results and projections of future income weighed heavily in the Company’s overall assessment. As a result of this analysis, the Company continues to maintain a full valuation allowance against its federal and state net deferred tax assets at December 31, 2021 as the Company believes that it is more likely than not that these assets will not be realized. In the current year, the company maintains a full valuation allowance in consolidation and no separate company deferred tax liability recorded will be recorded.

 

The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2021 and 2020 are as follows:

 

   2021   2020 
Deferred tax assets:          
Federal net operating loss carryforwards  $24,923   $17,015 
State net operating loss carryforwards   3,498    2,953 
Compensation   1,844    1,492 
Allowances and reserves   

585

    436 
Intangible assets   571    292 
State taxes   942    900 
Credit carryforward   2    229 
163(j) interest   1,047    745 
Leases   41    54 
Deferred revenue   95    95 
Valuation allowance   (33,170)   (23,684)
Gross deferred tax assets   378    527 
Deferred tax liability:          
           
Property and equipment   (471)   (582)
Deferred tax liability-net valuation allowance  $(93)  $(55)

 

The Company’s deferred tax asset and deferred tax liabilities are included within Other long-term liabilities, respectively, within the consolidated balance sheet as of December 31, 2021 and 2020. Federal tax attribute carryforwards at December 31, 2021, consist primarily of approximately $118.6 million of federal net operating losses. In addition, the Company has approximately $56.3 million of state net operating losses carryforwards post 382 ownership change. The utilization of the federal carryforwards as an available offset to future taxable income is subject to limitations under federal income tax laws. Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year.

 

The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL, and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as similar state tax provisions. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carry forwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. During 2021, the Company completed a 382 assessment of the available NOLs under Section 382 and determined that the Company underwent an ownership change on March 30, 2017 and July 15, 2019 and as a result, NOLs attributable to the pre-ownership change are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code due to the multiple ownership changes. The Company has adjusted their NOL carryforwards to address the impact of the 382 ownership change. Federal Net Operating Losses of $71.2 million are subject to annual limitation as of the ownership changes for ownership changes. The remaining $47.4M of NOLs incurred post July 15, 2019 are not subject to any annual limitation and can be carried forward indefinitely.

 

 F-27 
 

 

A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows:

 

   2021   2020 
Federal statutory rate   21.0%   21.0%
State income tax rate, net of Federal tax benefit   4.2%   4.0%
Meals and entertainment   (0.1%)   (0.1%)
Valuation allowance   (25.3)%   (25.0%)
Naked credit   (0.2%)   (0.1%)
NJ NOL credit sale   4.7%   0.0%
Effective tax rate   4.3%   (0.2%)

 

The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020:

 

   Unrecognized 
   Tax Benefits 
     
Balance of unrecognized benefits as of January 1, 2020  $877 
Additions for tax positions of prior years              - 
Balance as of January 1, 2021  $877 
Additions for tax positions of prior years   - 
Balance as of December 31, 2021  $877 

 

As of December 31, 2021 and 2020, the total amount of gross unrecognized tax benefits was $0.9 million and $0.9 million, respectively. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of December 31, 2021 and 2020 was $0.9 million and $0.9 million, respectively.

 

The Company recognized interest and penalties of $0.2 million and $0.3 million, respectively, related to uncertain tax positions in income tax expense during each of the years ended December 31, 2021 and 2020. At December 31, 2021 and 2020, accrued interest and penalties, net were $3.6 million and $3.4 million, respectively, and included in the Other long-term liabilities in the consolidated balance sheets.

 

The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2021:

 

Jurisdiction  Tax Years
Federal  2017 – 2021
State and Local  2016 – 2021

 

To the extent there was a failure to file a tax return in a previous year; the statute of limitation will not begin until the return is filed. There were no examinations in process by the Internal Revenue Service as of December 31, 2021.

 

 F-28 
 

 

18. Basic and Diluted Net Loss per Share

 

A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2021 and 2020 are as follows (rounded to thousands):

 

   Years Ended December 31, 
   2021   2020 
Basic weighted average number of common shares   4,135    4,029 
Potential dilutive effect of stock-based awards   -    - 
Diluted weighted average number of common shares   4,135    4,029 

 

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

 

   Years Ended December 31, 
   2021   2020 
Options   632    849 
Restricted stock units (RSUs)   329    238 
Warrants   1,405    1,405 
    2,366    2,492 

 

 

19. Revolving Line of Credit

 

On October 13, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “Comerica Loan Agreement”) with Comerica Bank (“Comerica”), providing for a revolving credit facility of up to $7,500,000 (the “Credit Facility”). The Company may use the proceeds of the Credit Facility for working capital and other general corporate purposes.

 

The amount that may be borrowed under the Credit Facility is the lower of (i) the revolving limit of $7,500,000 (the “Revolving Line”) and (ii) 80% of the Company’s eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close not based upon the Company’s eligible accounts receivable, with such additional availability reducing by $250,000 per quarter beginning with the quarter ending June 30, 2022. Borrowings on the Credit Facility are limited to $5,000,000 until 80% of the Company’s and its subsidiaries’ customers are paying into a collection account or segregated governmental account with Comerica. The Revolving Line can also include, at the Company’s option, credit card services with a sublimit of $300,000. Borrowings on the Revolving Line are subject to an interest rate equal to prime plus 0.50%, with prime being the greater of (x) Comerica’s stated prime rate or (y) the sum of (A) the daily adjusting LIBOR rate plus (B) 2.5% per annum. The Company is also required to pay an unused facility fee quarterly in arrears in an amount equal to 0.25% per annum on the average unused but available portion of the Revolving Line for such quarter.

 

 F-29 
 

 

The Credit Facility matures on September 30, 2023, and is secured by a first priority lien on substantially all of the assets of the Company and its subsidiaries. As of December 31, 2021, the balance of the revolving line was $1.5 million.

 

The Comerica Loan Agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica Loan Agreement. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The Comerica Loan Agreement also contains financial covenants requiring specified minimum liquidity and minimum revenue thresholds and also contains customary events of default.

 

As a condition for Comerica to extend the Credit Facility to the Company and its subsidiaries, the Company’s existing creditors, Ampersand and 1315 Capital (the “Existing Creditors”), entered into that certain Subordination Agreement, dated as of October 13, 2021, pursuant to which each Existing Creditor agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to such Existing Creditor to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Subordination Agreement”). Each Existing Creditor further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Subordination Agreement provides that it is solely for the benefit of Comerica and each of the Existing Creditors and is not for the benefit of the Company or any of its subsidiaries.

 

Revolving Line of Credit – Silicon Valley Bank

 

On November 13, 2018 the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”), which provided for up to $4.0 million of debt financing consisting of a term loan of up to $850,000 and a revolving line of credit based on its outstanding accounts receivable (the “Revolving Line”) of up to $3.75 million. As of December 31, 2020, the balance of the Revolving Line with SVB was zero.

 

On January 5, 2021, the Company terminated the SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company.

 

20. Transition Expenses

 

These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain legal expenses. The following is a roll forward of the transition expenses liabilities:

 

       Facilities/         
   Personnel   Infrastructure   Legal   Total 
    
Balance at December 31, 2020  $885   $269   $-   $1,154 
Transition expenses   1,044    1,036    505    2,585 
Payments   (1,929)   (1,305)   (505)   (3,739)
Balance at December 31, 2021  $-   $-   $-   $- 

 

 

 F-30 
 

 

21. Supplemental Cash Flow Information

 

Supplemental Disclosure of Other Cash Flow Information

(in thousands)

 

Cash paid for taxes  $369   $218 
Cash paid for interest  $424   $60 

 

Supplemental Disclosures of Non Cash Activities

(in thousands)

 

   Years Ended 
   December 31, 
   2021   2020 
Operating          
Taxes accrued for repurchase of restricted shares  $95   $- 
           
Investing          
Preferred Stock Deemed Dividend  $-   $3,033 
Investment in DiamiR   248    - 
           
Financing          
           
Accrued financing costs  $-   $31 

 

 

22. Subsequent Events

 

Centers for Medicare & Medicaid Services (CMS) Billing Policy Notice & Rights Offering

 

On January 28, 2022, the Company announced that the Centers for Medicare & Medicaid Services (CMS) issued a new billing policy whereby CMS would no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service and that the Company was terminating its previously announced rights offering and the mutual termination of the standby purchase agreement with 3K Limited Partnership. The CMS billing policy decision was subsequently reversed in February 2022, however the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS.

 

 F-31 
 

 

INTERPACE BIOSCIENCES, INC.

VALUATION AND QUALIFYING ACCOUNTS

YEARS ENDED DECEMBER 31, 2021 AND 2020

($ in thousands)

 

       Additions         
   Balance at   (Reductions)   (1)   Balance at 
   Beginning   Charged to   Deductions   end 
Description  of Period   Operations   Other   of Period 
2020                    
Allowance for doubtful accounts  $25          -    250   $275 
Allowance for doubtful notes  $869    -    -   $869 
Tax valuation allowance  $17,027    -    6,657   $23,684 
                     
2021                    
Allowance for doubtful accounts  $275    -    (203)  $72 
Allowance for doubtful notes  $869    -    -   $869 
Tax valuation allowance  $23,684    -    9,486   $33,170 

 

(1) Includes payments and actual write offs, as well as changes in estimates in the reserves.

 

 

 F-32 

 EX-23.1 2 ex23-1.htm

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

Interpace Biosciences, Inc.

Parsippany, New Jersey

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-207263 and 333-227728) and Form S-8 (Nos. 333-61231, 333-60512, 333-177969, 333-201070, 333-214260, 333-252574 and 333-234284) of Interpace Biosciences, Inc. of our report dated March 31, 2022, relating to the consolidated financial statements and schedule, which appear in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

/s/BDO USA, LLP

 

Woodbridge, New Jersey

March 31, 2022

 

 

 

 

 EX-31.1 3 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Thomas W. Burnell, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2021 of Interpace Biosciences, Inc. (the “registrant”);
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022 /s/ Thomas W. Burnell
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 EX-31.2 4 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Thomas Freeburg, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2021 of Interpace Biosciences, Inc. (the “registrant”);
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022 /s/ Thomas Freeburg
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 EX-32.1 5 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Interpace Biosciences, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas W. Burnell, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 31, 2022 /s/ Thomas W. Burnell
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 EX-32.2 6 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Interpace Biosciences, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Freeburg, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 31, 2022 /s/ Thomas Freeburg
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 EX-101.SCH 7 idxg-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Recent Accounting Standards link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Retirement Plans link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Accrued Expenses and Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Revenue Sources link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Basic and Diluted Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Revolving Line of Credit link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Transition Expenses link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Accrued Expenses and Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Revenue Sources (Tables) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Basic and Diluted Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Transition Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Financial Instrument Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Schedule of Identifiable Intangible Assets Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Schedule of Goodwill Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Future Estimated Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Goodwill and Other Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Schedule of Financing and Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Retirement Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Schedule of Other Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Schedule of Long Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Schedule of Warrants Outstanding and Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - Schedule of Non Vested Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000077 - Disclosure - Schedule of Revenue by Major Customers (Details) link:presentationLink link:calculationLink link:definitionLink 00000078 - Disclosure - Revenue Sources (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000079 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 00000080 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000081 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000082 - Disclosure - Schedule of Unrecognized Tax Benefits Roll Forward (Details) link:presentationLink link:calculationLink link:definitionLink 00000083 - Disclosure - Schedule of Tax Years Subject to Examination (Details) link:presentationLink link:calculationLink link:definitionLink 00000084 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000085 - Disclosure - Schedule of Weighted Average Number of Shares (Details) link:presentationLink link:calculationLink link:definitionLink 00000086 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000087 - Disclosure - Basic and Diluted Net Loss per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000088 - Disclosure - Revolving Line of Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000089 - Disclosure - Schedule of Transition Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000090 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000091 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 idxg-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 idxg-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 idxg-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Long-Lived Tangible Asset [Axis] Furniture and Fixtures [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Office and Computer Equipment [Member] Lab Equipment [Member] Leasehold Improvements [Member] Software for Internal Use [Member] Software for External Use [Member] Debt Instrument [Axis] Ampersand Notes [Member] 1315 Capital Note [Member] Lender Name [Axis] Comerica Bank [Member] Term Loan [Member] Legal Entity [Axis] Broad Oak [Member] Asuragen [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] BroadOak Loan [Member] Underwriter Warrants [Member] Software Development [Member] Business Acquisition [Axis] BioPharma Acquisition [Member] Asuragen Acquisition [Member] Finite-Lived Intangible Assets by Major Class [Axis] Thyroid [Member] RedPath Acquisition [Member] Pancreas Test [Member] Barrett's Test [Member] Trademarks [Member] Customer Relationships [Member] CLIA Lab [Member] Lease Contractual Term [Axis] Operating Leases [Member] Financing Leases [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Security Purchase and Exchange Agreement [Member] 1315 Capital [Member] Ampersand 2018 Limited Partnership [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Ampersand 2018 [Member] Credit Facility [Axis] Loan And Security Agreement [Member] Security Agreement [Member] Series B Convertible Preferred Stock [Member] Ampersand [Member] Promissory Notes [Member] Ampersand Note [Member] 1315 Capital [Member] Private Placement Warrants[Member] RedPath Warrants [Member] Base & Overallotment Warrants [Member] Warrants Issued [Member] Underwriters Warrants [Member] Warrant [Member] Plan Name [Axis] Stock Incentive Plan [Member] Sale of Stock [Axis] Employee Stock [Member] Award Type [Axis] RSUs and Restricted Stock [Member] Performance Shares [Member] Share-based Payment Arrangement [Member] Share-based Payment Arrangement, Option [Member] Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Medicare [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Medicare Customer [Member] Medicare Advantage Customer [Member] Commercial Payers Customer [Member] Client Billings Customer [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Tax Period [Axis] Earliest Tax Year [Member] Latest Tax Year [Member] Antidilutive Securities [Axis] Warrants [Member] Comerica Loan Agreement [Member] Product and Service [Axis] Accounts Receivable [Member] Scenario [Axis] Forecast [Member] Variable Rate [Axis] London Interbank Offered Rate (LIBOR) [Member] Title of Individual [Axis] Revolver [Member] SVB Loan Agreement [Member] Silicon Valley Bank [Member] Balance Sheet Location [Axis] Personnel [Member] Facilities And Infrastructure [Member] Legal [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Allowance, Credit Loss [Member] Allowance for Doubtful Notes [Member] SEC Schedule, 12-09, Valuation Allowance, Other Tax Carryforward [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Restricted cash Accounts receivable, net of allowance for doubtful accounts of $72 and $275, respectively Other current assets Total current assets Property and equipment, net Other intangible assets, net Goodwill Operating lease right of use assets Other long-term assets Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable Accrued salary and bonus Other accrued expenses Current liabilities from discontinued operations Total current liabilities Contingent consideration Operating lease liabilities, net of current portion Line of credit Note payable at fair value Other long-term liabilities Total liabilities Commitments and contingencies (Note 11) Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding Stockholders’ deficit: Common stock, $.01 par value; 100,000,000 shares authorized; 4,228,169 and 4,075,257 shares issued, respectively; 4,195,412 and 4,055,593 shares outstanding, respectively Additional paid-in capital Accumulated deficit Treasury stock, at cost (32,757 and 19,664 shares, respectively) Total stockholders’ deficit Total liabilities and stockholders’ deficit Total liabilities, preferred stock and stockholders’ deficit Statement [Table] Statement [Line Items] Allowance for doubtful accounts Temporary equity, par value Temporary equity, shares authorized Temporary equity, shares issued Temporary equity, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenue, net Cost of revenue (excluding amortization of $4,064 and $4,461, respectively) Gross profit Operating expenses: Sales and marketing Research and development General and administrative Transition expense Loss on DiamiR transaction Acquisition related amortization expense Change in fair value of contingent consideration Total operating expenses Operating loss Interest accretion expense Related party interest Other (expense) income, net Loss from continuing operations before tax (Benefit) provision for income taxes Loss from continuing operations Loss from discontinued operations, net of tax Net loss Less adjustment for preferred stock deemed dividend Net loss attributable to common stockholders Basic and diluted loss per share of common stock: From continuing operations From discontinued operations Net loss per basic and diluted share of common stock Weighted average number of common shares and common share equivalents outstanding: Basic Diluted Amortization Balance, shares Balance,value Common stock issued, shares Common stock issued Restricted stock issued, shares Restricted stock issued Common stock issued through market sales, shares Common stock issued through market sales Common stock issued through ESPP, shares Common stock issued through ESPP Treasury stock purchased, shares Treasury stock purchased Extinguishment of series A shares Beneficial Conversion Feature in connection with Series B Issuance Amortization of beneficial conversion feature Stock-based compensation expense Net income (loss) attributable to parent Adoption of Asc Adoption of Asc 842 Balance,shares Balance,value Balance, value Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Interest accretion expense Bad debt (recovery) expense Reversal of 2019 bonus accrual Mark to market on warrants Amortization of deferred financing fees Accrued interest - note payable Note payable fees Stock-based compensation ESPP expense Change in fair value of note payable Deferred income taxes Loss on DiamiR transaction Asset impairment Other gains and expenses, net Other changes in operating assets and liabilities: Decrease in accounts receivable Decrease in other current assets Increase in other long-term assets Decrease in accounts payable (Decrease) increase in accrued salaries and bonus (Decrease) increase in accrued liabilities (Decrease) increase in long-term liabilities Net cash used in operating activities Cash Flows From Investing Activity Purchase of property and equipment Sale of property and equipment Net cash used in investing activities Cash Flows From Financing Activities Issuance of common stock, net of expenses Issuance of Series B preferred stock, net of expenses Loan proceeds - related parties Loan proceeds - BroadOak Loan expenses - BroadOak Payment of related party note and related interest Financing fees - related party Borrowings (payments) on Line of Credit Cash paid for repurchase of restricted shares Net cash provided by financing activities Net (decrease) increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning Cash, cash equivalents and restricted cash – ending Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business and Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recent Accounting Standards Going Concern Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Fair Value Disclosures [Abstract] Fair Value Measurements Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Other Intangible Assets Leases Leases Retirement Benefits [Abstract] Retirement Plans Payables and Accruals [Abstract] Accrued Expenses and Other Long-Term Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Equity Debt Disclosure [Abstract] Notes Payable Warrants Warrants Share-based Payment Arrangement [Abstract] Stock-Based Compensation Risks and Uncertainties [Abstract] Revenue Sources Income Tax Disclosure [Abstract] Income Taxes Earnings Per Share [Abstract] Basic and Diluted Net Loss per Share Revolving Line of Credit Transition Expenses Transition Expenses Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Information Subsequent Events [Abstract] Subsequent Events Nature of Business Principles of Consolidation Accounting Estimates Reverse stock split Cash and Cash Equivalents Accounts Receivable, Net Other current assets Property and Equipment, net Software Costs Long-Lived Assets, including Finite-Lived Intangible Assets Contingencies Revenue Recognition Deferred Revenue Cost of revenue Stock-Based Compensation Treasury Stock Leases Income taxes Income (Loss) per Share Schedule of Current Assets Schedule of Discontinued Operations Schedule of Financial Instrument Measured on Recurring Basis Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Schedule of Property and Equipment Schedule of Identifiable Intangible Assets Carrying Value Schedule of Goodwill Carrying Value Schedule of Future Estimated Amortization Expense Schedule of Financing and Operating Leases Schedule of Maturities of Operating and Financing Lease Liabilities Schedule of Other Accrued Expenses Schedule of Long Term Liabilities Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases Schedule of Warrants Outstanding and Warrants Activity Schedule of Stock Options, Valuation Assumptions Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award Schedule of Stock Option Activity Schedule of Non Vested Option Activity Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity Schedule of Revenue by Major Customers Schedule of Components of Income Tax Expense (Benefit) Schedule of Deferred Tax Assets and Liabilities Schedule of Effective Income Tax Rate Reconciliation Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Tax Years Subject to Examination Schedule of Weighted Average Number of Shares Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share Schedule of Transition Expenses Supplemental Cash Flow Information Schedule II - Valuation and Qualifying Accounts Lab supply inventory Prepaid expenses Other Total other current assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Reverse stock split description Shares issued Shares outstanding Property, plant and equipment, useful life Finite-lived intangible asset, useful life Income tax examination, likelihood of unfavorable settlement Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Operating Income (Loss) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Assets, Current Liabilities, Current Cash Secured Debt Long-term Line of Credit Debt Instrument, Face Amount Accrued liabilities Current liabilities from discontinued operations Total liabilities Income from discontinued operations, before tax Income tax expense Loss from discontinued operations, net of tax Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Contingent consideration Warrant liability Notes Payable Fair value of liabilities Beginning Balance Loan proceeds Payments Accretion/Interest Accrued Adjustment to Fair Value/Mark to Market Ending Balance Furniture and fixtures Lab and office equipment Computer equipment Internal-use software Leasehold improvements Property and equipment Less accumulated depreciation and amortization Net property and equipment Depreciation and amortization expense Amortization expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Asset, Useful Life Finite-lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Goodwill, Beginning Balance Adjustments Goodwill, Ending Balance 2022 2023 2024 2025 2026 Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Finite-lived Intangible Assets Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Amortization expense Schedule Of Financing And Operating Leases Finance lease assets Operating lease assets Total lease assets Finance Lease, Liability, Current Operating Lease, Liability, Current Total current lease liabilities Finance Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Total long-term lease liabilities Total lease liabilities Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Operating Leases 2022 Finance Lease 2022 Operating Leases 2023 Finance Lease 2023 Operating Leases 2024 Finance Lease 2024 Operating Leases 2025 Finance Lease 2025 Operating Leases 2026-2030 Operating Leases 2026-2030 Operating Leases,Total minimum lease payments Financing Leases,Total minimum lease payments Operating Leases, Less: amount of lease payments representing effects of discounting Finance Leases, Less: amount of lease payments representing effects of discounting Operating Leases, Present value of future minimum lease payments Finance Leases, Present value of future minimum lease payments Operating Leases, Less: current obligations under leases Finance Leases, Less: current obligations under leases Operating Leases, Long-term lease obligations Finance Leases, Long-term lease obligations Operating Lease, Weighted Average Remaining Lease Term Operating lease, weighted average discount rate, percent Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Defined contribution plan, maximum annual contributions per employee, percent Defined contribution plan, employer matching contribution, percent Defined contribution plan employer matching contribution at fifty percent Contribution expense Accrued royalties Contingent consideration Upfront Medicare payment Operating lease liability Financing lease liability Deferred revenue Interest payable Warrant liability Accrued sales and marketing - diagnostics Accrued lab costs - diagnostics Accrued professional fees Taxes payable Unclaimed property All others Total other accrued expenses Warrant liability Uncertain tax positions Deferred revenue Other Total other long-term liabilities Operating lease obligations, Total Operating lease obligations, Less than 1 Year Operating lease obligations, 1 to 3 Years Operating lease obligations, 3 to 5 Years Operating lease obligations, After 5 Years Operating lease expire date description Expense Schedule of Stock by Class [Table] Class of Stock [Line Items] Value of preferred stock exchanged Issuance price of preferred stock Aggregate of shares issued Preferred stock par/stated value Preferred shares stated value Preferred stock adjusted conversion Preferred stock dividend percentage Company achieve revenue target Intrinsic value of beneficial conversion feature Intrinsic value of effective conversion price per share Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Line of Credit Facility [Table] Line of Credit Facility [Line Items] Debt instrument, face amount Maturity date Debt interest percentage Debt instrument interest, description Percentage of debt origination fee Promissory note Convertible Preferred Stock, Shares Issued upon Conversion Stock Issued During Period, Shares, Conversion of Convertible Securities [custom:NumberOfHoldsShares] [custom:FullyDilutedPercentageOfCommonStock] Interest rate [custom:DescriptionOfFundedDebtAmount] Repayment of notes Description Classification Exercise Price Expiration Date Warrants Issued Warrants Warrants Cancelled/Expired Weighted average exercise price Weighted average remaining contractual life Risk-free interest rate Expected life Expected volatility Dividend yield Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense Shares outstanding beginning balance Weighted average grant price outstanding beginning balance Weighted average remaining contractual period outstanding beginning balance Aggregate intrinsic value outstanding beginning balance Shares granted Weighted average grant price granted Weighted average remaining contractual period granted Aggregate intrinsic value granted Shares exercised Weighted average grant price exercised Shares forfeited or expired Weighted average grant price forfeited or expired Aggregate intrinsic value forfeited or expired Shares outstanding ending balance Weighted average grant price outstanding ending balance Weighted average remaining contractual period outstanding ending balance Aggregate intrinsic value outstanding ending balance Shares exercisable ending balance Weighted average grant price exercisable ending balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate intrinsic value exercisable ending balance Shares vested and expected to vest Weighted average grant price vested and expected to vest Weighted average remaining contractual period vested and expected to vest Aggregate intrinsic value vested and expected to vest Non-vested Shares outstanding beginning balance Non-vested weighted average grant date fair value outstanding beginning balance Non-vested Shares granted Non-vested weighted average grant date fair value granted Non-vested Shares vested Non-vested weighted average grant date fair value vested Non-vested Shares forfeited Non-vested weighted average grant date fair value forfeited Non-vested Shares outstanding ending balance Non-vested weighted average grant date fair value outstanding ending balance Non-vested Shares beginning balance Non-vested Weighted Average Grant Date Fair Value beginning balance Non-vested Average Remaining Vesting Period Beginning balance Non-vested Aggregate Intrinsic Value Beginning balance Non-vested Shares granted Non-vested Weighted Average Grant Date Fair Value Granted Non-vested Aggregate Intrinsic Value Granted Non-vested Shares Vested Non-vested Weighted Average Grant Date Fair Value Vested Non-vested Aggregate Intrinsic Value Vested Non-vested Shares Forfeited Non-vested Weighted Average Grant Date Fair Value Forfeited Non-vested Aggregate Intrinsic Value Forfeited Non-vested Shares ending balance Non-vested Weighted Average Grant Date Fair Value Ending balance Non-vested Average Remaining Vesting Period Ending balance Non-vested Aggregate Intrinsic Value Ending balance Share-based compensation arrangement by share-based payment award, description Share-based compensation expense Weighted-average fair value of stock options granted Options exercised Share-based compensation aggregate fair value of option Weighted-average grant date fair value of options vested Aggregate fair value of restricted stock units Total unrecognized compensation cost related to unvested stock options and restricted stock units Revenue Concentration Risk [Table] Concentration Risk [Line Items] Revenue from continuing operations Federal State Total current Federal State Total deferred (Benefit) provision from income taxes Federal net operating loss carryforwards State net operating loss carryforwards Compensation Allowances and reserves Intangible assets State taxes Credit carryforward 163(j) interest Leases Deferred revenue Valuation allowance Gross deferred tax assets Property and equipment Deferred tax liability-net valuation allowance Federal statutory rate State income tax rate, net of Federal tax benefit Meals and entertainment Valuation allowance Naked credit NJ NOL credit sale Effective tax rate Unrecognized tax benefits beginning balance Additions for tax positions of prior years Unrecognized tax benefits ending balance Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Open Tax Year Operating Loss Carryforwards Operating Loss Carryforwards, Limitations on Use [custom:ReductionInOperatingLossCarryforwards] [custom:RemainingReductionInOperatingLossCarryforwards] Unrecognized tax benefits Unrecognized tax benefits would affect the effective tax rate Income tax examination penalties and interest expense Income tax examination penalties and interest accrued Basic weighted average number of common shares Potential dilutive effect of stock-based awards Diluted weighted average number of common shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from earning per share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Number preferred stocks on converted basis Percentage of accounts receivable Line of credit reductions Line of credit Revolving Line option credit card services borrowing limit InterestRate Percentage of line of credit unused facility fee Line of credit, maturity date Line of credit outstanding accounts receivable Balance at December 31, 2020 Transition expenses Payments Balance at December 31, 2021 Cash paid for taxes Cash paid for interest Taxes accrued for repurchase of restricted shares Preferred Stock Deemed Dividend Investment in DiamiR Accrued financing costs SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Balance at Beginning of Period Additions (Reductions) Charged to Operations Deductions Other Balance at end of Period Security Purchase and Exchange Agreement [Member] Issuance prices of preferred stock. 1315 Capital [Member] Ampersand 2018 Limited Partnership [Member] Value of preferred stock exchanged during period. Preferred shares stated value. Preferred stock adjusted conversion. Company achieve revenue target. Series B Preferred Stock [Member] Intrinsic value of beneficial conversion feature. Intrinsic value of effective conversion price per share. Security Agreement [Member] Number of holds shares . Series B Convertible Preferred Stock [Member] Liabilities and stockholder equity. Fully diluted percentage of common stock. Asuragen [Member] Deferred tax assets attributable to interest. Deferred tax assets attributable to leases. Warrant Liability. Gain on transaction Loss on transaction. Reduction in operating loss carryforwards. Description of funded debt amount. Effective Income Tax Rate Reconciliation Naked Credit. Common stock issued through market sales, shares. Common stock issued through market sales. Number preferred stocks on converted basis. Warrants [Member] Broad Oak [Member] Ampersand Two Thousand Eighteen [Member] SVB Loan Agreement [Member] Silicon Valley Bank [Member] Loan And Security Agreement [Member] Percentage of debt origination fee. Revolver [Member] Adoption of ASC 842 - right of use asset. Preferred stock deemed dividend. Warrent description. Private Placement Warrants[Member] RedPath Warrants [Member] Accrued financing costs. Base & Overallotment Warrants [Member] Warrants Issued [Member] Underwriters Warrants [Member] Warraants classification. Adjustments to additional paid in capital extinguishment of series shares. Allowance for Doubtful Notes [Member] Adjustments to additional paid in capital amortization of beneficial conversion feature. Expiration date, description. BioPharma Acquisition [Member] Asuragen Acquisition [Member] Thyroid [Member] RedPath Acquisition [Member] Pancreas Test [Member] Barrett's Test [Member] CLIA Lab [Member] New accounting pronouncement. Transition Expenses Liabilities. Transition expense. Payment transition expenses. Transition Expenses [Text Block] Stock Incentive Plan [Member] Total lease assets. Total lease liabilities. Accrued interest related parties. increase decrease in longterm liabilities. Percentage Of Accounts Receivable. Revolving line option credit card services borrowing limit. Operating Leases [Member] Financing Leases [Member] Remaining Reduction In Operating Loss Carryforwards Credit sale. BroadOak Loan [Member] Ampersand [Member] Term Loan [Member] Underwriter Warrants [Member] Comerica Loan Agreement [Member] Comerica Bank [Member] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion. Revolving Credit Facility. Warrants [Text Block] Taxes Accrued For Repurchase Of Restricted Shares. Investment In Diamir. Schedule Of Transition Expenses [Table Text Block] Percentage of employees' gross pay for which the employer contributes a matching contribution of fifty percent to a defined contribution plan. Weighted average remaining contractual period granted. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual period vested and expected to vest. Schedule of long term liabilities [Table Text Block] Aggregate instrinsic value forfeited or expired. Schedule Of Tax Years Subject To Examination [Table Text Block] Personnel [Member] Facilities And Infrastructure [Member] Legal [Member] Schedule Of Financing And Operating Leases [Table Text Block] Reversal Of Bonus Accrual. Employee Stock Purchase Plan Expense. Increase Decrease In Accrued Salaries And Bonus Proceeds From Loan. Accrued Interest Notes Payable. Note Payable Fees. Change In Fair Value Of Note Payable. Deferred Income Taxes. Schedule Of Maturities Of Operating And Financing Lease Liabilties [Table Text Block] Lessee Operating Lease Liability Payments Due Year Four And Thereafter Financing Fees Related Party. Loan Proceeds. Loan Expenses. RSUs and Restricted Stock [Member] Nature Of Business [Policy Text Block] Reverse Stock Split [Policy Text Block] Finance Lease Liability Payments Due Year Four And Thereafter. New Accounting Pronouncement Adoption. Upfront Medicare payment advance. Accrued lab costs. Unclaimed property current. Others accrued expenses current. Warrant liability noncurrent. Other accrued expenses and long term liabilities. Other current assets [Policy Text Block] Operating lease expire date description. Other. Schedule of future minimum lease payment under noncancelable leases [Table Text Block] Operating lease obligations, 3 to 5 Years. Non vested Average Remaining Vesting Period Beginning balance. Non vested Average Remaining Vesting Period. Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options. Intrinsic value of forfeited award under share-based payment arrangement. Excludes share and unit options. Medicare [Member] Cost of revenue [Policy Text Block] Medicare Customer [Member] Office and Computer Equipment [Member]. Lab Equipment [Member]. Software for External Use [Member]. Software for Internal Use [Member]. Commercial Payers Customer [Member] Medicare Advantage Customer [Member] Client Billings Customer [Member] Treasury stock [Policy Text Block] Promissory Notes [Member] Ampersand limited partnership [Member] Business combination warrant liability Borrowings payments on line of credit Lessee operating lease liability payments due one to three years Lessee operating lease liability payments due three to five years Ampersand Notes [Member] 1315 Capital Note [Member] Ampersand Note [Member] 1315 Capital [Member] Warrant classification. Share based compensation on weighted average remaining contractual terms. Warrant liability current. Aggregate intrinsic value granted. Finance lease liabilities current. Finance lease liabilities noncurrent. Finance lease right of use assets. Finance lease right of use assets classified under property and equipment net. Operating lease liabilities current. Deferred Revenue [Policy Text Block] Series B Preferred Stock [Member] [Default Label] 1315 Capital [Member] [Default Label] Assets Liabilities Treasury Stock, Value Liabilities and Equity Gross Profit LossOnTransaction Operating Expenses Operating Income (Loss) Interest Expense, Other Interest Expense, Related Party Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Preferred Stock Conversions, Inducements Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Treasury Stock, Value, Acquired, Cost Method ReversalOfBonusAccrual AccruedInterestNotesPayable NotePayableFees ChangeInFairValueOfNotePayable DeferredIncomeTaxes Gain (Loss) on Disposition of Property Plant Equipment Other Noncash Income (Expense) Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Current Assets Increase (Decrease) in Other Noncurrent Assets IncreaseDecreaseInAccruedSalariesAndBonus IncreaseDecreaseInLongtermLiabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities LoanExpenses Repayments of Notes Payable FinancingFeesRelatedParty Payments for Repurchase of Other Equity Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Lessee, Operating Leases [Text Block] Warrants [Text Block] TransitionExpensesTextBlock OtherCurrentAssetsPolicyTextBlock Share-based Payment Arrangement [Policy Text Block] Lessee, Leases [Policy Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Disposal Group, Including Discontinued Operation, Liabilities Business Combination, Contingent Consideration, Liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter Business Combination, Contingent Consideration, Liability, Current WarrantLiabilityCurrent WarrantLiabilityNoncurrent Deferred Revenue, Noncurrent OtherAccruedExpensesAndLongTermLiabilities Class of Warrant or Right, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) DeferredTaxAssetsTaxCreditLeases Deferred Tax Assets, Deferred Income Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Net Line of Credit Facility, Maximum Borrowing Capacity TransitionExpensesLiabilities SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount EX-101.PRE 11 idxg-20211231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 25, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 000-24249    
Entity Registrant Name Interpace Biosciences, Inc.    
Entity Central Index Key 0001054102    
Entity Tax Identification Number 22-2919486    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One Morris Corporate Center 1    
Entity Address, Address Line Two Building C    
Entity Address, Address Line Three 300 Interpace Parkway    
Entity Address, City or Town Parsippany    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07054    
City Area Code (855)    
Local Phone Number 776-6419    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 42,186,849
Entity Common Stock, Shares Outstanding   4,226,422  
Documents Incorporated by Reference [Text Block] Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant’s definitive proxy statement for the 2021 annual meeting of stockholders, or Proxy Statement, or will be included in an amendment hereto, to be filed within 120 days of the end of the fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part hereof    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 243    
Auditor Name BDO USA, LLP    
Auditor Location Woodbridge, New Jersey    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 3,064 $ 2,772
Restricted cash 250 600
Accounts receivable, net of allowance for doubtful accounts of $72 and $275, respectively 6,158 8,028
Other current assets 2,694 2,722
Total current assets 12,166 14,122
Property and equipment, net 6,349 7,349
Other intangible assets, net 7,287 11,351
Goodwill 8,433 8,433
Operating lease right of use assets 4,032 4,384
Other long-term assets 160 42
Total assets 38,427 45,681
Current liabilities:    
Accounts payable 2,694 4,511
Accrued salary and bonus 3,024 3,161
Other accrued expenses 9,198 9,795
Current liabilities from discontinued operations 766 766
Total current liabilities 15,682 18,233
Contingent consideration 1,383 1,818
Operating lease liabilities, net of current portion 3,154 3,540
Line of credit 1,500
Note payable at fair value 7,942
Other long-term liabilities 4,648 4,637
Total liabilities 34,309 28,228
Commitments and contingencies (Note 11)
Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding 46,536 46,536
Stockholders’ deficit:    
Common stock, $.01 par value; 100,000,000 shares authorized; 4,228,169 and 4,075,257 shares issued, respectively; 4,195,412 and 4,055,593 shares outstanding, respectively 403 402
Additional paid-in capital 186,106 184,404
Accumulated deficit (227,059) (212,116)
Treasury stock, at cost (32,757 and 19,664 shares, respectively) (1,868) (1,773)
Total stockholders’ deficit (42,418) (29,083)
Total liabilities and stockholders’ deficit (8,109) (855)
Total liabilities, preferred stock and stockholders’ deficit $ 38,427 $ 45,681
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Allowance for doubtful accounts $ 72 $ 275
Temporary equity, par value $ 0.01 $ 0.01
Temporary equity, shares authorized 5,000,000 5,000,000
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 4,228,169 4,075,257
Common stock, shares outstanding 4,195,412 4,055,593
Treasury stock, shares 32,757 19,664
Series B Preferred Stock [Member]    
Temporary equity, shares issued 47,000 47,000
Temporary equity, shares outstanding 47,000 47,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Revenue, net $ 41,314 $ 32,398
Cost of revenue (excluding amortization of $4,064 and $4,461, respectively) 23,369 21,673
Gross profit 17,945 10,725
Operating expenses:    
Sales and marketing 10,067 9,254
Research and development 1,882 2,795
General and administrative 13,669 18,192
Transition expense 2,585 2,578
Loss on DiamiR transaction 13
Acquisition related amortization expense 4,064 4,461
Change in fair value of contingent consideration (338) (489)
Total operating expenses 31,942 36,791
Operating loss (13,997) (26,066)
Interest accretion expense (496) (549)
Related party interest (424)
Other (expense) income, net (496) 467
Loss from continuing operations before tax (15,413) (26,148)
(Benefit) provision for income taxes (667) 53
Loss from continuing operations (14,746) (26,201)
Loss from discontinued operations, net of tax (197) (250)
Net loss (14,943) (26,451)
Less adjustment for preferred stock deemed dividend (3,033)
Net loss attributable to common stockholders $ (14,943) $ (29,484)
Basic and diluted loss per share of common stock:    
From continuing operations $ (3.57) $ (7.26)
From discontinued operations (0.04) (0.06)
Net loss per basic and diluted share of common stock $ (3.61) $ (7.32)
Weighted average number of common shares and common share equivalents outstanding:    
Basic 4,135 4,029
Diluted 4,135 4,029
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Amortization $ 4,064 $ 4,461
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Stockholders' Deficit - USD ($)
$ in Thousands
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Balance, value $ 393 $ (1,721) $ 182,514 $ (185,665)
Balance, shares at Dec. 31, 2019 3,932 12    
Balance,value at Dec. 31, 2019 $ 393 $ (1,721) 182,514 (185,665)
Common stock issued, shares 37      
Common stock issued $ 1    
Restricted stock issued, shares 6      
Restricted stock issued      
Common stock issued through market sales, shares 80      
Common stock issued through market sales $ 8   476  
Common stock issued through ESPP, shares      
Common stock issued through ESPP      
Treasury stock purchased, shares      
Treasury stock purchased      
Extinguishment of series A shares     (828)  
Beneficial Conversion Feature in connection with Series B Issuance     2,205  
Amortization of beneficial conversion feature     (2,205)  
Stock-based compensation expense     418  
Net income (loss) attributable to parent       (6,494)
Adoption of Asc 842      
Balance,shares at Mar. 31, 2020 4,055 12    
Balance,value at Mar. 31, 2020 $ 402 $ (1,721) 182,580 (192,159)
Balance, shares at Dec. 31, 2019 3,932 12    
Balance,value at Dec. 31, 2019 $ 393 $ (1,721) 182,514 (185,665)
Balance,shares at Dec. 31, 2020 4,075 20    
Balance,value at Dec. 31, 2020 $ 402 $ (1,773) 184,404 (212,116)
Balance, value $ 402 $ (1,721) 182,580 (192,159)
Balance, shares at Mar. 31, 2020 4,055 12    
Balance,value at Mar. 31, 2020 $ 402 $ (1,721) 182,580 (192,159)
Common stock issued, shares      
Common stock issued      
Treasury stock purchased, shares   7    
Treasury stock purchased   $ (49)    
Stock-based compensation expense     400  
Net income (loss) attributable to parent       (5,580)
Balance,shares at Jun. 30, 2020 4,055 19    
Balance,value at Jun. 30, 2020 $ 402 $ (1,770) 182,980 (197,739)
Balance, value $ 402 $ (1,770) 182,980 (197,739)
Common stock issued, shares 5      
Common stock issued    
Common stock issued through ESPP, shares      
Common stock issued through ESPP      
Treasury stock purchased, shares      
Treasury stock purchased      
Stock-based compensation expense     563  
Net income (loss) attributable to parent       (6,234)
Balance,shares at Sep. 30, 2020 4,060 19    
Balance,value at Sep. 30, 2020 $ 402 $ (1,770) 183,543 (203,973)
Balance, value $ 402 $ (1,770) 183,543 (203,973)
Common stock issued, shares 15      
Common stock issued      
Common stock issued through market sales      
Treasury stock purchased, shares   1    
Treasury stock purchased   $ (3)    
Stock-based compensation expense     861  
Net income (loss) attributable to parent       (8,143)
Balance,shares at Dec. 31, 2020 4,075 20    
Balance,value at Dec. 31, 2020 $ 402 $ (1,773) 184,404 (212,116)
Balance, value $ 402 $ (1,773) 184,404 (212,116)
Common stock issued, shares 9      
Common stock issued   108  
Restricted stock issued, shares 12      
Restricted stock issued      
Common stock issued through market sales, shares      
Common stock issued through market sales    
Common stock issued through ESPP, shares 36      
Common stock issued through ESPP      
Treasury stock purchased, shares      
Treasury stock purchased      
Extinguishment of series A shares      
Beneficial Conversion Feature in connection with Series B Issuance      
Amortization of beneficial conversion feature      
Stock-based compensation expense     286  
Net income (loss) attributable to parent       (4,207)
Adoption of Asc      
Balance,shares at Mar. 31, 2021 4,132,000 20    
Balance,value at Mar. 31, 2021 $ 402 $ (1,773) 184,798 (216,323)
Balance, shares at Dec. 31, 2020 4,075 20    
Balance,value at Dec. 31, 2020 $ 402 $ (1,773) 184,404 (212,116)
Balance,shares at Dec. 31, 2021 4,228 33    
Balance,value at Dec. 31, 2021 $ 403 $ (1,868) 186,106 (227,059)
Balance, value $ 402 $ (1,773) 184,798 (216,323)
Balance, shares at Mar. 31, 2021 4,132,000 20    
Balance,value at Mar. 31, 2021 $ 402 $ (1,773) 184,798 (216,323)
Common stock issued, shares 10      
Common stock issued      
Treasury stock purchased, shares      
Treasury stock purchased      
Stock-based compensation expense     551  
Net income (loss) attributable to parent       (3,446)
Balance,shares at Jun. 30, 2021 4,142 20    
Balance,value at Jun. 30, 2021 $ 402 $ (1,773) 185,349 (219,769)
Balance, value $ 402 $ (1,773) 185,349 (219,769)
Common stock issued, shares 13      
Common stock issued   226  
Common stock issued through ESPP, shares 39      
Common stock issued through ESPP $ 1      
Treasury stock purchased, shares      
Treasury stock purchased      
Stock-based compensation expense     477  
Net income (loss) attributable to parent       (3,561)
Balance,shares at Sep. 30, 2021 4,194 20    
Balance,value at Sep. 30, 2021 $ 403 $ (1,773) 186,052 (223,330)
Balance, value $ 403 $ (1,773) 186,052 (223,330)
Common stock issued, shares 34      
Common stock issued      
Common stock issued through market sales      
Treasury stock purchased, shares   13    
Treasury stock purchased   $ (95)    
Stock-based compensation expense     54  
Net income (loss) attributable to parent       (3,729)
Balance,shares at Dec. 31, 2021 4,228 33    
Balance,value at Dec. 31, 2021 $ 403 $ (1,868) 186,106 (227,059)
Balance, value $ 403 $ (1,868) $ 186,106 $ (227,059)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash Flows From Operating Activities    
Net loss $ (14,943) $ (26,451)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 5,374 5,501
Interest accretion expense 496 549
Bad debt (recovery) expense (140) 585
Reversal of 2019 bonus accrual (1,156)
Mark to market on warrants 50 (61)
Amortization of deferred financing fees 122
Accrued interest - note payable 120
Note payable fees 312
Stock-based compensation 1,255 2,187
ESPP expense 113 55
Change in fair value of note payable (58)
Deferred income taxes 38 37
Loss on DiamiR transaction 13
Change in fair value of contingent consideration (338) (489)
Asset impairment 37
Other gains and expenses, net (2)
Other changes in operating assets and liabilities:    
Decrease in accounts receivable 2,148 1,725
Decrease in other current assets 28 241
Increase in other long-term assets (118)
Decrease in accounts payable (1,817) (198)
(Decrease) increase in accrued salaries and bonus (137) 1,976
(Decrease) increase in accrued liabilities (1,086) 1,395
(Decrease) increase in long-term liabilities (149) 88
Net cash used in operating activities (8,719) (13,979)
Cash Flows From Investing Activity    
Purchase of property and equipment (354) (1,575)
Sale of property and equipment 39
Net cash used in investing activities (315) (1,575)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 335 434
Issuance of Series B preferred stock, net of expenses 19,223
Loan proceeds - related parties 7,500
Loan proceeds - BroadOak 8,000
Loan expenses - BroadOak (312)
Payment of related party note and related interest (7,924)
Financing fees - related party (123)
Borrowings (payments) on Line of Credit 1,500 (3,000)
Cash paid for repurchase of restricted shares (52)
Net cash provided by financing activities 8,976 16,605
Net (decrease) increase in cash, cash equivalents and restricted cash (58) 1,051
Cash, cash equivalents and restricted cash – beginning 3,372 2,321
Cash, cash equivalents and restricted cash – ending $ 3,314 $ 3,372
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business and Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Significant Accounting Policies

 

1. Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.

 

Principles of Consolidation

 

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc.

 

Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation.

 

The Company has one reporting segment: the Company’s clinical and pharma services business. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

 

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.

 

Reverse stock split

 

On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company’s issued and outstanding stock decreased from 39,323,701 to 3,932,370 and 39,205,895 to 3,920,589 at December 31, 2019. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the reverse stock split for all periods presented.

 

 

Cash and Cash Equivalents

 

Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.

 

Accounts Receivable, Net

 

The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.

 

Other current assets

 

Other current assets consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Lab supply inventory  $1,786   $2,052 
Prepaid expenses   800    625 
Other   108    45 
Total other current assets  $2,694   $2,722 

 

Property and Equipment, net

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven to twelve years for furniture and fixtures; two to five years for office and computer equipment; three to twelve years for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently three to ten years. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations.

 

Software Costs

 

Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three to seven years. Software costs that do not meet capitalization criteria are expensed immediately.

 

External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years. Software costs that do not meet capitalization criteria are expensed immediately.

 

See Note 6, Property and Equipment, for further information.

 

Long-Lived Assets, including Finite-Lived Intangible Assets

 

Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition related amortization expense in the Consolidated Statements of Operations.

 

 

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

 

As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment.

 

Contingencies

 

In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.

 

Revenue Recognition

 

Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

 

For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.

 

 

For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

 

The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.

 

Deferred Revenue

 

For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.

 

Cost of revenue

 

Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.

 

Stock-Based Compensation

 

The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert.

 

See Note 15, Stock-Based Compensation, for further information.

 

Treasury Stock

 

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.

 

Leases

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, Leases.

 

 

Income taxes

 

Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense.

 

The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized.

 

The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense.

 

Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.

 

Income (Loss) per Share

 

Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2021 and 2020, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Recent Accounting Standards
 12 Months Ended
Dec. 31, 2021
Accounting Changes and Error Corrections [Abstract]  
Recent Accounting Standards

 

2. Recent Accounting Standards

 

Recently Adopted Accounting Guidance

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment was effective for annual periods beginning after December 15, 2020.

 

The Company adopted this pronouncement on January 1, 2021 and the impact was not material to the Company’s Consolidated Financial Statements.

 

Accounting Pronouncements Pending Adoption

 

In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company does not expect this will have any impact on its unaudited consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Going Concern
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

 

3. Going Concern

 

The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.

 

For the fiscal year ended December 31, 2021, we had an operating loss of $14.0 million. As of December 31, 2021, we had cash, cash equivalents and restricted cash of $3.3 million, total current assets of $12.2 million and current liabilities of $15.7 million. As of March 18, 2022, we had approximately $2.7 million of cash on hand, excluding restricted cash.

 

In January 2022, the Company announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be insufficient to meet its anticipated cash requirements through the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. 

 

On January 7, 2021, the Company entered into secured promissory notes in the amount of $3 million and $2 million with Ampersand (“Ampersand Note”) and 1315 Capital (“1315 Capital Note”), respectively. See Note 13, Notes Payable, of the notes to the financial statements. On May 10, 2021, the Company amended the Ampersand Note to increase the principal amount to $4.5 million and amended the 1315 Capital Note to increase the principal amount to $3.0 million. The maturity dates of the Notes were the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

 

On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica. See Note 19, Revolving Line of Credit, for more details. In addition, also in October 2021, the Company entered into the $8.0 million BroadOak Term Loan, the proceeds of which were used to repay in full at their maturity the notes extended by Ampersand and 1315 Capital discussed above. See Note 13, Notes Payable, for more details.

 

Although the Company is targeting to achieve adjusted EBITDA and cash flow breakeven during Fiscal 2022, we may not generate positive cash flows from operations for the year ending December 31, 2022. We intend to meet our ongoing capital needs by using our available cash and availability under the Comerica Loan Agreement, as well as through revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options. However, if we are unable to meet the financial covenants under the Comerica Loan Agreement, the revolving line of credit and notes payable will become due and payable immediately.

 

The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity and expand the business through acquisitions or other strategic transactions. With the Company’s delisting from Nasdaq in February 2021, its ability to raise additional capital on terms acceptable to the Company may be adversely impacted. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to the Company. In January 2022, the Company’s registration statement for a rights offering become effective. The rights offering was subsequently terminated in January 2022.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Discontinued Operations
 12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

 

4. Discontinued Operations

 

The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods.

 

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2021 and December 31, 2020:

 

   December 31,
2021		   December 31,
2020		 
         
Accrued liabilities  $   766   $   766 
Current liabilities from discontinued operations   766    766 
Total liabilities  $766   $766 

 

The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2021 and 2020.

 

   2021   2020 
   Years Ended 
   December 31, 
   2021   2020 
Income from discontinued operations, before tax  $-   $- 
Income tax expense   197    250 
Loss from discontinued operations, net of tax  $(197)  $(250)

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

 

5. Fair Value Measurements

 

Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the consolidated financial statements include contingent consideration, notes payable, and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

 

  Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
     
  Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
     
  Level 3: Valuations for assets and liabilities include certain unobservable inputs in the assumptions and projections used in determining the fair value assigned to such assets or liabilities.

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 

   As of December 31, 2021   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2021 
   Amount   Value   Level 1   Level 2   Level 3 
Liabilities:                         
Contingent consideration:                         
Asuragen  $1,871   $1,871   $     -   $    -   $1,871 
Other accrued expenses:                         
Warrant liability   71    71    -    -    71 
Note payable:                         
BroadOak loan   7,942    7,942    -    -    7,942 
   $9,884   $9,884   $-   $-   $9,884 

 

 

   As of December 31, 2020   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2020 
   Amount   Value   Level 1   Level 2   Level 3 
                     
Liabilities:                         
Contingent consideration:                         
Asuragen  $2,216   $2,216   $    -   $    -   $2,216 
Other long-term liabilities:                         
Warrant liability   21    21    -    -    21 
   $2,237   $2,237   $-   $-   $2,237 

 

In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

 

In connection with the BroadOak loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted approach regarding the loan’s change in control feature. See Note 13, Notes Payable, for more details. The fair value measurement is based on the estimated probability of a change in control and thus represents a Level 3 measurement.

 

                            Adjustment        
                      Accretion/     to Fair Value/        
   

December 31,

2020

    

Loan

Received

     Payments    

Interest

Accrued

    

Mark to

Market

    

December 31,

2021

  
                                     
Asuragen   $ 2,216       -      $ (503 )   $ 496     $ (338 )   $ 1,871  
                                                 
Underwriters Warrants     21       -        -       -       50       71  
                                                 
BroadOak Loan     -       8,000       -       -       (58 )     7,942  
    $ 2,237     $ 8,000     $ (503 )   $ 496     $ (346 )   $ 9,884  

 

Certain of the Company’s non-financial assets, such as other intangible assets are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

 

6. Property and Equipment

 

Property and equipment consisted of the following as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Furniture and fixtures  $339   $339 
Lab and office equipment   7,837    7,536 
Computer equipment   331    339 
Internal-use software   1,572    1,572 
Leasehold improvements   506    505 
Property and equipment   10,585    10,291 
Less accumulated depreciation and amortization   (4,236)   (2,942)
Net property and equipment  $6,349   $7,349 

 

Depreciation and amortization expense from continuing operations was approximately $1.2 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. There was internal-use software amortization expense included in depreciation and amortization expense in 2021 of approximately $0.3 million. As of December 31, 2021, capitalized external-use software was fully amortized.

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets

 

7. Goodwill and Other Intangible Assets

 

Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at December 31, 2021 was $8.4 million. The net carrying value of the identifiable intangible assets as of December 31, 2021 and December 31, 2020 is as follows:

 

       As of December 31, 2021   As of December 31, 2020 
   Life   Carrying   Carrying 
   (Years)   Amount   Amount 
             
Asuragen acquisition:              
Thyroid  9   $8,519   $8,519 
RedPath acquisition:              
Pancreas test  7    16,141    16,141 
Barrett’s test  9    6,682    6,682 
BioPharma acquisition:              
Trademarks  10    1,600    1,600 
Customer relationships  8    5,700    5,700 
               
CLIA Lab  2.3   $609   $609 
               
Total      $39,251   $39,251 
               
Accumulated Amortization      $(31,964)  $(27,900)
               
Net Carrying Value      $7,287   $11,351 

 

The following table displays a roll forward of the carrying amount of goodwill from January 1, 2020 to December 31, 2021:

 

   Carrying 
   Amount 
Balance as of January 1, 2020  $8,433 
Adjustments   - 
Balance as of December 31, 2020  $8,433 
Adjustments   - 
Balance as of December 31, 2021  $8,433 

 

Amortization expense was approximately $4.1 million and $4.5 million for the years ended December 31, 2021 and 2020, respectively. Estimated amortization expense for the next five years is as follows:

 

2022   2023   2024   2025   2026 
                       
$2,143   $1,734   $873   $873   $873 

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
 12 Months Ended
Dec. 31, 2021
Leases  
Leases

 

8. Leases

 

Finance lease assets are included in fixed assets, net of accumulated depreciation.

 

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

 

   Classification on the Balance Sheet  December 31, 2021 
       
Assets        
Financing lease assets  Property and equipment, net  $636 
Operating lease assets  Operating lease right of use assets   4,032 
Total lease assets     $4,668 
         
Liabilities        
Current        
Financing lease liabilities  Other accrued expenses  $79 
Operating lease liabilities  Other accrued expenses   1,041 
Total current lease liabilities     $1,120 
Noncurrent        
Financing lease liabilities  Other long-term liabilities   59 
Operating lease liabilities  Operating lease liabilities, net of current portion   3,154 
Total long-term lease liabilities      3,213 
Total lease liabilities     $4,333 

 

The weighted average remaining lease term for the Company’s operating leases was 6.4 years as of December 31, 2021 and 7.1 years as of December 31, 2020 and the weighted average discount rate for those leases was 6.5% and 6.0% as of December 31, 2021 and December 31, 2020, respectively. The Company’s operating lease expenses are recorded within “Cost of revenue” and “General and administrative expenses.”

 

The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2021:

 

   Operating Leases   Financing Leases 
2022  $1,295   $86 
2023   897    60 
2024   567    - 
2025   402    - 
2026-2030   1,924    - 
Total minimum lease payments   5,085    146 
Less: amount of lease payments representing effects of discounting   890    8 
Present value of future minimum lease payments   4,195    138 
Less: current obligations under leases   1,041    79 
Long-term lease obligations  $3,154   $59 

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Retirement Plans
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Retirement Plans

 

9. Retirement Plans

 

The Company offers an employee 401(k) saving plan. Under the Interpace Biosciences, Inc. 401(k) Plan, employees may contribute up to 50% of their pre- or post-tax base compensation. The Company currently offers a safe harbor matching contribution equal to 100% of the first 3% of the participant’s contributed base salary plus 50% of the participant’s base salary contributed exceeding 3% but not more than 5%. Participants are not allowed to invest any of their 401(k) funds in the Company’s common stock. The Company’s total contribution expense from continuing operations related to the 401(k) plan for the years ended December 31, 2021 and December 31, 2020 was approximately $0.3 million and $0.4 million, respectively.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Long-Term Liabilities
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses and Other Long-Term Liabilities

 

10. Accrued Expenses and Other Long-Term Liabilities

 

Other accrued expenses consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Accrued royalties  $3,890   $2,710 
Contingent consideration   488    398 
Upfront Medicare payment   -    2,066 
Operating lease liability   1,041    1,027 
Financing lease liability   79    177 
Deferred revenue   40    54 
Interest payable   

120

    - 
Warrant liability   71    - 
Accrued sales and marketing - diagnostics   47    51 
Accrued lab costs - diagnostics   228    161 
Accrued professional fees   932    854 
Taxes payable   245    334 
Unclaimed property   565    565 
All others   1,452    1,398 
Total other accrued expenses  $9,198   $9,795 

 

Other long-term liabilities consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Warrant liability  $-   $21 
Uncertain tax positions   4,577    4,342 
Deferred revenue   13    136 
Other   58    138 
Total other long-term liabilities  $4,648   $4,637 

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

 

11. Commitments and Contingencies

 

The Company leases facilities and certain equipment under agreements classified as operating leases, which expire at various dates through May 2030. Substantially all of the property leases provide for increases based upon use of utilities and landlord’s operating expenses as well as pre-defined rent escalations. Total expense from continuing operations under these agreements for the years ended December 31, 2021 and 2020 was approximately $1.2 million and $2.1 million, respectively.

 

 

As of December 31, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows:

 

       Less than   1 to 3   3 to 5   After 
   Total   1 Year   Years   Years   5 Years 
Operating lease obligations  $5,085   $1,295   $1,464   $816   $1,510 
Total  $5,085   $1,295   $1,464   $816   $1,510 

 

Litigation

 

Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products.

 

The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Equity

 

12. Equity

 

Preferred Stock Issuance: Securities Purchase and Exchange Agreement

 

On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $20.0 million in Series B Preferred Stock of the Company, at an issuance price per share of $1,000. Pursuant to the Securities Purchase and Exchange Agreement, 1315 Capital agreed to purchase 19,000 shares of Series B Preferred Stock at an aggregate purchase price of $19.0 million and Ampersand agreed to purchase 1,000 shares of Series B Preferred Stock at an aggregate purchase price of $1.0 million.

 

In addition, the Company agreed to exchange $27.0 million of the Company’s existing Series A convertible preferred stock, par value $0.01 per share, held by Ampersand (the “Series A Preferred Stock”), represented by 270 shares of Series A Preferred Stock with a stated value of $100,000 per share, which represents all of the Company’s issued and outstanding Series A Preferred Stock, for 27,000 newly issued shares of Series B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”). Following the Exchange, no shares of Series A Preferred Stock remained designated, authorized, issued or outstanding. The Series B Preferred Stock has a conversion price of $6.00 as compared to a conversion price of $8.00 on the Series A Preferred Stock, but did not include certain rights applicable to the Series A Preferred Stock, including a six-percent (6%) dividend and a conversion price adjustment for any failure by the Company to achieve a revenue target of $34.0 million in 2020 related to its clinical services or a weighted-average anti-dilution adjustment. Under the terms of the Securities Purchase and Exchange Agreement, Ampersand also agreed to waive all dividends and weighted-average anti-dilution adjustments accrued to date on the Series A Preferred Stock.

 

 

A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $2.2 million, which the Company recorded as a reduction to additional paid-in capital upon the sale of the Series B Preferred stock. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the Common Stock on January 15, 2020 of $6.79 per share and the effective conversion price per share of $6.00 multiplied by the number of shares of common stock issuable upon conversion. The Company fully amortized the beneficial conversion feature during the three months ended March 31, 2020 in accordance with GAAP. The beneficial conversion feature resulted in an increase in the loss attributable to common shareholders for the three months ended March 31, 2020 in the Condensed Consolidated Statement of Operations, as it represented a deemed dividend to the preferred shareholders.

 

In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect. During October 2021, Ampersand and 1315 Capital provided consent to the Company to enter into the Comerica Loan Agreement and the BroadOak Term Loan.

 

As of December 31, 2021 and 2020, there were 47,000 Series B issued and outstanding shares of preferred stock, respectively.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Notes Payable

 

13. Notes Payable

 

BroadOak Loan and Repayment of Promissory Notes

 

On October 29, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “BroadOak Loan Agreement”) with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000 (the “Term Loan”). Funding of the Term Loan took place on November 1, 2021. The Term Loan matures upon the earlier of (i) October 31, 2024 or (ii) the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is secured by a security interest in substantially all of the Company’s and its subsidiaries’ assets and is subordinate to the Company’s recently established $7,500,000 revolving credit facility with Comerica Bank. The Term Loan has an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date.

 

The BroadOak Loan Agreement contains affirmative and negative restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default.

 

In connection with the BroadOak Loan Agreement, the Company and its subsidiaries entered into that certain First Amendment to Loan and Security Agreement and Consent with Comerica, dated as of November 1, 2021 (the “Comerica Amendment”), pursuant to which Comerica consented to the Company’s and its subsidiaries’ entry into the BroadOak Loan Agreement, and amended that certain Loan and Security Agreement among Comerica, the Company and its subsidiaries (the “Comerica Loan Agreement”) to, among other things, permit the indebtedness, liens and encumbrances contemplated by the BroadOak Loan Agreement.

 

 

As a condition for BroadOak to extend the Term Loan to the Company and its subsidiaries, the Company’s existing creditor, Comerica, and BroadOak entered into that certain Subordination and Intercreditor Agreement, dated as of November 1, 2021, pursuant to which BroadOak agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to BroadOak to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Intercreditor Agreement”). BroadOak further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Intercreditor Agreement provides that it is solely for the benefit of BroadOak and Comerica and is not for the benefit of the Company or any of its subsidiaries.

 

The Company concluded that the Note met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5 that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to shareholders’ equity. Accordingly, the Company elected the fair value option for the Note.

 

Secured Promissory Notes – Related Parties

 

On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $3 million, and 1315 Capital, in the amount of $2 million, respectively (together, the “Notes”) and a related security agreement (the “Security Agreement”).

 

Ampersand holds 28,000 shares of the Company’s Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 4,666,666 shares of our Common Stock, and 1315 Capital holds 19,000 shares of the Company Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 3,166,668 shares of our Common Stock. On an as-converted basis, such shares would represent approximately 38.7% and 26.3% of our fully-diluted shares of Common Stock, respectively. In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 12, Equity). As a result, the Company considers the Notes and Security Agreement to be a related party transaction.

 

The rate of interest on the Notes was equal to eight percent (8.0%) per annum and their maturity date was the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. No interest payments were due on the Notes until their maturity date. All payments on the Notes were pari passu.

 

On May 10, 2021, (i) the Company and Ampersand amended the Ampersand Note to increase its principal amount to $4.5 million, (ii) the Company and 1315 Capital amended the 1315 Capital Note to increase its principal amount to $3.0 million and (iii) the Company and Ampersand amended the Security Agreement to include the new total principal amount of the Notes of $7.5 million. The maturity date of the Notes remained the earlier of June 30, 2021 and the date on which all amounts become due upon the occurrence of any event of default and the interest rate remained 8%, and except with respect to their respective principal amounts, the terms of the Notes and the Security Agreement were otherwise unchanged.

 

On June 24, 2021, August 31, 2021, and September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021, September 30, 2021, and October 31, 2021, respectively and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, August 31, 2021, and September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remained in full force and effect, and was not amended in connection with the amendments to the Notes.

 

In the case of the amendments, the Company reviewed the changes in accordance with ASC 470 and determined they should be treated as modifications.

 

 

The Notes contained certain negative covenants which prevented the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.

 

The Company used the proceeds of the BroadOak Term Loan discussed above to repay in full at their maturity all outstanding indebtedness under the promissory notes with Ampersand, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $4.5 million, and 1315 Capital, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $3 million, respectively. The Company, Ampersand, and 1315 Capital also terminated a related security agreement.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Warrants
 12 Months Ended
Dec. 31, 2021
Warrants  
Warrants

 

14. Warrants

 

Warrants outstanding and warrant activity for the year ended December 31, 2021 are as follows:

Description  Classification   Exercise
Price		   Expiration
Date		   Warrants
Issued		  

Balance

December 31,

2020

   Warrants
Cancelled/
Expired		  

Balance

December 31,

2021

 
                             
Private Placement Warrants, issued January 25, 2017  Equity   $46.90   June 2022    85,500    85,500    -    85,500 
RedPath Warrants, issued March 22, 2017  Equity   $46.90   September 2022    10,000    10,000    -    10,000 
Underwriters Warrants, issued June 21, 2017  Liability   $13.20   December 2022    57,500    53,500    -    53,500 
Base & Overallotment Warrants, issued June 21, 2017  Equity   $12.50   June 2022    1,437,500    870,214    -    870,214 
Warrants issued October 12, 2017  Equity   $18.00   April 2022    320,000    320,000    -    320,000 
Underwriters Warrants, issued January 25, 2019  Equity   $9.40   January 2022    65,434    65,434    -    65,434 
                                  
                 1,975,934    1,404,648          -    1,404,648 

 

The weighted average exercise price of the warrants is $15.97 and the weighted average remaining contractual life is approximately 0.4 years.

 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

 

15. Stock-Based Compensation

 

The Company’s stock-incentive program is a long-term retention program that is intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. Currently, the Company is able to grant options, stock appreciation rights (“SARs”) and restricted shares from the Interpace Biosciences, Inc. 2019 Equity Incentive Plan. No new grants may be made under the Company’s prior stock incentive plan, the Interpace Diagnostics Group, Inc. (now known as Interpace Biosciences, Inc.) Amended and Restated 2004 Stock Award and Incentive Plan (the “2004 Plan”). Unless earlier terminated by action of the Company’s board of directors, the 2004 Plan will remain in effect until such time as no stock remains available for delivery and the Company has no further rights or obligations under the 2004 Plan with respect to outstanding awards thereunder.

 

Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

 

The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the Company’s expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility is based on historical volatility. As there is no trading volume for the Company’s options, implied volatility is not representative of the Company’s current volatility so the historical volatility of the Company’s common stock is determined to be more indicative of the Company’s expected future stock performance. The expected life is determined using the safe-harbor method. The Company expects to use this simplified method for valuing employee options until more detailed information about exercise behavior becomes available over time. The Company bases the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option valuation model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest. The Company recognizes compensation cost, net of estimated forfeitures, arising from the issuance of stock options on a straight-line basis over the vesting period of the grant.

 

The Company began an employee stock purchase plan in 2020 and recognized approximately $0.1 million and $0.04 million in expense related to that plan for the years ended December 31, 2021 and 2020, respectively.

 

The estimated compensation cost associated with the granting of restricted stock and restricted stock units is based on the fair value of the Company’s common stock on the date of grant. The Company recognizes the compensation cost, net of estimated forfeitures, arising from the issuance of restricted stock and restricted stock units on a straight-line basis over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved.

 

The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2021 and December 31, 2020.

 

   December 31, 2021   December 31, 2020 
    
Risk-free interest rate   0.79%   0.75%
Expected life   6.0 years    6.5 years 
Expected volatility   134.73%   123.71%
Dividend yield   -    - 

 

The weighted-average fair value of stock options granted during the year ended December 31, 2021 was estimated to be $4.64. The weighted-average fair value of stock options granted during the year ended December 31, 2020 was estimated to be $5.36. There were 13,042 options exercised in 2021. There were no options exercised in 2020. Historically, shares issued upon the exercise of options have been new shares and have not come from treasury shares.

 

 

Stock-based compensation for the years ended December 31, 2021 and 2020 is as follows:

 

   2021   2020 
RSUs and restricted stock  $433   $176 
Performance-based awards   107    265 
Common stock awards   -    116 
Options   715    1,630 
Total stock-based compensation expense  $1,255   $2,187 

 

A summary of stock option activity for the year ended December 31, 2021, and changes during such year, is presented below:

 

                Weighted-Average  
          Weighted-     Remaining        
          Average     Contractual     Aggregate  
          Grant     Period     Intrinsic  
    Shares     Price     (in years)     Value  
Outstanding at January 1, 2021     848,819     $ 8.76       8.59     $ -  
Granted     347,500       6.00       9.21       -  
Exercised     (13,042 )     9.45                  
Forfeited or expired     (550,766 )     9.15               -  
Outstanding at December 31, 2021     632,511       6.89       8.40       -  
                                 
Exercisable at December 31, 2021     206,732       9.14       7.53                -  
                                 
Vested and expected to vest     537,520       7.15       8.36       -  

 

A summary of the status of the Company’s non-vested options for the year ended December 31, 2021, and changes during such year, is presented below:

   Shares   Weighted-
Average
Grant Date
Fair Value		 
         
Nonvested at January 1, 2021   487,318   $5.81 
Granted   347,500    4.64 
Vested   (127,696)   6.54 
Forfeited   (284,646)   5.72 
Nonvested at December 31, 2021   422,476   $4.78 

 

The aggregate fair value of options vested during the years ended December 31, 2021 and 2020 was $0.8 million and $1.5 million, respectively. The weighted-average grant date fair value of options vested during the year ended December 31, 2020 was $7.34.

 

 

A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2021, and changes during such year, is presented below:

                Average        
          Weighted-     Remaining        
          Average     Vesting     Aggregate  
          Grant Date     Period     Intrinsic  
    Shares     Fair Value     (in years)     Value  
Nonvested at January 1, 2021     239,457     $ 10.00       1.75     $ 1,348,781  
Granted     207,438       5.46       -       -  
Vested     (65,577 )     4.65       -       -  
Forfeited     (52,379 )     5.23       -       -  
Nonvested at December 31, 2021     328,939     $ 3.67       1.34     $ 2,467,043  

 

The aggregate fair value of restricted stock units vested during each of the years ended December 31, 2021 and 2020 was $0.3 million and $0.4 million, respectively.

 

As of December 31, 2021, there was approximately $2.0 million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock units.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Sources
 12 Months Ended
Dec. 31, 2021
Risks and Uncertainties [Abstract]  
Revenue Sources

 

16. Revenue Sources

 

The Company’s clinical services customers consist primarily of physicians, hospitals and clinics. Its revenue channels include Medicare, Medicare Advantage, Medicaid, Client Billings (hospitals, etc.), and commercial payers. The following sets forth the net revenue generated by revenue channel accounted for more than 10% of the Company’s revenue from continuing operations during the years ended December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and December 31, 2020, revenue from Medicare was approximately 54% and 50% of total revenue, respectively.

 

   Years Ended December 31, 
Customer  2021   2020 
Medicare  $17,778   $10,186 
Medicare Advantage  $5,859   $3,566 
Commercial Payors  $5,555   $4,136 
Client Billings  $3,752   $2,582 

 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

 

17. Income Taxes

 

The benefit from income taxes on continuing operations for the years ended December 31, 2021 and 2020 is comprised of the following:

 

   2021   2020 
Current:          
Federal  $-   $- 
State   (705)   16 
Total current   (705)   16 
           
Deferred:          
Federal   24    23 
State   14    14 
Total deferred   38    37 
(Benefit) provision from income taxes  $(667)  $53 

 

 

The Company performs an analysis each year to determine whether the expected future income will more likely than not be sufficient to realize the deferred tax assets. The Company’s recent operating results and projections of future income weighed heavily in the Company’s overall assessment. As a result of this analysis, the Company continues to maintain a full valuation allowance against its federal and state net deferred tax assets at December 31, 2021 as the Company believes that it is more likely than not that these assets will not be realized. In the current year, the company maintains a full valuation allowance in consolidation and no separate company deferred tax liability recorded will be recorded.

 

The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2021 and 2020 are as follows:

 

   2021   2020 
Deferred tax assets:          
Federal net operating loss carryforwards  $24,923   $17,015 
State net operating loss carryforwards   3,498    2,953 
Compensation   1,844    1,492 
Allowances and reserves   

585

    436 
Intangible assets   571    292 
State taxes   942    900 
Credit carryforward   2    229 
163(j) interest   1,047    745 
Leases   41    54 
Deferred revenue   95    95 
Valuation allowance   (33,170)   (23,684)
Gross deferred tax assets   378    527 
Deferred tax liability:          
           
Property and equipment   (471)   (582)
Deferred tax liability-net valuation allowance  $(93)  $(55)

 

The Company’s deferred tax asset and deferred tax liabilities are included within Other long-term liabilities, respectively, within the consolidated balance sheet as of December 31, 2021 and 2020. Federal tax attribute carryforwards at December 31, 2021, consist primarily of approximately $118.6 million of federal net operating losses. In addition, the Company has approximately $56.3 million of state net operating losses carryforwards post 382 ownership change. The utilization of the federal carryforwards as an available offset to future taxable income is subject to limitations under federal income tax laws. Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year.

 

The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL, and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as similar state tax provisions. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carry forwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. During 2021, the Company completed a 382 assessment of the available NOLs under Section 382 and determined that the Company underwent an ownership change on March 30, 2017 and July 15, 2019 and as a result, NOLs attributable to the pre-ownership change are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code due to the multiple ownership changes. The Company has adjusted their NOL carryforwards to address the impact of the 382 ownership change. Federal Net Operating Losses of $71.2 million are subject to annual limitation as of the ownership changes for ownership changes. The remaining $47.4M of NOLs incurred post July 15, 2019 are not subject to any annual limitation and can be carried forward indefinitely.

 

 

A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows:

 

   2021   2020 
Federal statutory rate   21.0%   21.0%
State income tax rate, net of Federal tax benefit   4.2%   4.0%
Meals and entertainment   (0.1%)   (0.1%)
Valuation allowance   (25.3)%   (25.0%)
Naked credit   (0.2%)   (0.1%)
NJ NOL credit sale   4.7%   0.0%
Effective tax rate   4.3%   (0.2%)

 

The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020:

 

   Unrecognized 
   Tax Benefits 
     
Balance of unrecognized benefits as of January 1, 2020  $877 
Additions for tax positions of prior years              - 
Balance as of January 1, 2021  $877 
Additions for tax positions of prior years   - 
Balance as of December 31, 2021  $877 

 

As of December 31, 2021 and 2020, the total amount of gross unrecognized tax benefits was $0.9 million and $0.9 million, respectively. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of December 31, 2021 and 2020 was $0.9 million and $0.9 million, respectively.

 

The Company recognized interest and penalties of $0.2 million and $0.3 million, respectively, related to uncertain tax positions in income tax expense during each of the years ended December 31, 2021 and 2020. At December 31, 2021 and 2020, accrued interest and penalties, net were $3.6 million and $3.4 million, respectively, and included in the Other long-term liabilities in the consolidated balance sheets.

 

The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2021:

 

Jurisdiction  Tax Years
Federal  2017 – 2021
State and Local  2016 – 2021

 

To the extent there was a failure to file a tax return in a previous year; the statute of limitation will not begin until the return is filed. There were no examinations in process by the Internal Revenue Service as of December 31, 2021.

 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Share
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Basic and Diluted Net Loss per Share

 

18. Basic and Diluted Net Loss per Share

 

A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2021 and 2020 are as follows (rounded to thousands):

 

   Years Ended December 31, 
   2021   2020 
Basic weighted average number of common shares   4,135    4,029 
Potential dilutive effect of stock-based awards   -    - 
Diluted weighted average number of common shares   4,135    4,029 

 

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

 

   Years Ended December 31, 
   2021   2020 
Options   632    849 
Restricted stock units (RSUs)   329    238 
Warrants   1,405    1,405 
    2,366    2,492 

 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Revolving Line of Credit
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Revolving Line of Credit

 

19. Revolving Line of Credit

 

On October 13, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “Comerica Loan Agreement”) with Comerica Bank (“Comerica”), providing for a revolving credit facility of up to $7,500,000 (the “Credit Facility”). The Company may use the proceeds of the Credit Facility for working capital and other general corporate purposes.

 

The amount that may be borrowed under the Credit Facility is the lower of (i) the revolving limit of $7,500,000 (the “Revolving Line”) and (ii) 80% of the Company’s eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close not based upon the Company’s eligible accounts receivable, with such additional availability reducing by $250,000 per quarter beginning with the quarter ending June 30, 2022. Borrowings on the Credit Facility are limited to $5,000,000 until 80% of the Company’s and its subsidiaries’ customers are paying into a collection account or segregated governmental account with Comerica. The Revolving Line can also include, at the Company’s option, credit card services with a sublimit of $300,000. Borrowings on the Revolving Line are subject to an interest rate equal to prime plus 0.50%, with prime being the greater of (x) Comerica’s stated prime rate or (y) the sum of (A) the daily adjusting LIBOR rate plus (B) 2.5% per annum. The Company is also required to pay an unused facility fee quarterly in arrears in an amount equal to 0.25% per annum on the average unused but available portion of the Revolving Line for such quarter.

 

 

The Credit Facility matures on September 30, 2023, and is secured by a first priority lien on substantially all of the assets of the Company and its subsidiaries. As of December 31, 2021, the balance of the revolving line was $1.5 million.

 

The Comerica Loan Agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica Loan Agreement. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The Comerica Loan Agreement also contains financial covenants requiring specified minimum liquidity and minimum revenue thresholds and also contains customary events of default.

 

As a condition for Comerica to extend the Credit Facility to the Company and its subsidiaries, the Company’s existing creditors, Ampersand and 1315 Capital (the “Existing Creditors”), entered into that certain Subordination Agreement, dated as of October 13, 2021, pursuant to which each Existing Creditor agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to such Existing Creditor to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Subordination Agreement”). Each Existing Creditor further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Subordination Agreement provides that it is solely for the benefit of Comerica and each of the Existing Creditors and is not for the benefit of the Company or any of its subsidiaries.

 

Revolving Line of Credit – Silicon Valley Bank

 

On November 13, 2018 the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”), which provided for up to $4.0 million of debt financing consisting of a term loan of up to $850,000 and a revolving line of credit based on its outstanding accounts receivable (the “Revolving Line”) of up to $3.75 million. As of December 31, 2020, the balance of the Revolving Line with SVB was zero.

 

On January 5, 2021, the Company terminated the SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Transition Expenses
 12 Months Ended
Dec. 31, 2021
Transition Expenses  
Transition Expenses

 

20. Transition Expenses

 

These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain legal expenses. The following is a roll forward of the transition expenses liabilities:

 

       Facilities/         
   Personnel   Infrastructure   Legal   Total 
    
Balance at December 31, 2020  $885   $269   $-   $1,154 
Transition expenses   1,044    1,036    505    2,585 
Payments   (1,929)   (1,305)   (505)   (3,739)
Balance at December 31, 2021  $-   $-   $-   $- 

 

 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

 

21. Supplemental Cash Flow Information

 

Supplemental Disclosure of Other Cash Flow Information

(in thousands)

 

Cash paid for taxes  $369   $218 
Cash paid for interest  $424   $60 

 

Supplemental Disclosures of Non Cash Activities

(in thousands)

 

   Years Ended 
   December 31, 
   2021   2020 
Operating          
Taxes accrued for repurchase of restricted shares  $95   $- 
           
Investing          
Preferred Stock Deemed Dividend  $-   $3,033 
Investment in DiamiR   248    - 
           
Financing          
           
Accrued financing costs  $-   $31 

 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

 

22. Subsequent Events

 

Centers for Medicare & Medicaid Services (CMS) Billing Policy Notice & Rights Offering

 

On January 28, 2022, the Company announced that the Centers for Medicare & Medicaid Services (CMS) issued a new billing policy whereby CMS would no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service and that the Company was terminating its previously announced rights offering and the mutual termination of the standby purchase agreement with 3K Limited Partnership. The CMS billing policy decision was subsequently reversed in February 2022, however the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS.

 

 

INTERPACE BIOSCIENCES, INC.

VALUATION AND QUALIFYING ACCOUNTS

YEARS ENDED DECEMBER 31, 2021 AND 2020

($ in thousands)

 

       Additions         
   Balance at   (Reductions)   (1)   Balance at 
   Beginning   Charged to   Deductions   end 
Description  of Period   Operations   Other   of Period 
2020                    
Allowance for doubtful accounts  $25          -    250   $275 
Allowance for doubtful notes  $869    -    -   $869 
Tax valuation allowance  $17,027    -    6,657   $23,684 
                     
2021                    
Allowance for doubtful accounts  $275    -    (203)  $72 
Allowance for doubtful notes  $869    -    -   $869 
Tax valuation allowance  $23,684    -    9,486   $33,170 

 

(1) Includes payments and actual write offs, as well as changes in estimates in the reserves.

 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business and Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business

Nature of Business

 

Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.

 
Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc.

 

Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation.

 

The Company has one reporting segment: the Company’s clinical and pharma services business. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

 
Accounting Estimates

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.

 
Reverse stock split

Reverse stock split

 

On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company’s issued and outstanding stock decreased from 39,323,701 to 3,932,370 and 39,205,895 to 3,920,589 at December 31, 2019. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the reverse stock split for all periods presented.

 

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.

 
Accounts Receivable, Net

Accounts Receivable, Net

 

The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.

 
Other current assets

Other current assets

 

Other current assets consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Lab supply inventory  $1,786   $2,052 
Prepaid expenses   800    625 
Other   108    45 
Total other current assets  $2,694   $2,722 

 
Property and Equipment, net

Property and Equipment, net

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven to twelve years for furniture and fixtures; two to five years for office and computer equipment; three to twelve years for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently three to ten years. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations.

 
Software Costs

Software Costs

 

Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three to seven years. Software costs that do not meet capitalization criteria are expensed immediately.

 

External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years. Software costs that do not meet capitalization criteria are expensed immediately.

 

See Note 6, Property and Equipment, for further information.

 
Long-Lived Assets, including Finite-Lived Intangible Assets

Long-Lived Assets, including Finite-Lived Intangible Assets

 

Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition related amortization expense in the Consolidated Statements of Operations.

 

 

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

 

As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment.

 
Contingencies

Contingencies

 

In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.

 
Revenue Recognition

Revenue Recognition

 

Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

 

For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.

 

 

For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

 

The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.

 
Deferred Revenue

Deferred Revenue

 

For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.

 
Cost of revenue

Cost of revenue

 

Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.

 
Stock-Based Compensation

Stock-Based Compensation

 

The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert.

 

See Note 15, Stock-Based Compensation, for further information.

 
Treasury Stock

Treasury Stock

 

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.

 
Leases

Leases

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, Leases.

 

 
Income taxes

Income taxes

 

Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense.

 

The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized.

 

The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense.

 

Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.

 
Income (Loss) per Share

Income (Loss) per Share

 

Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2021 and 2020, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business and Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Current Assets

Other current assets consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Lab supply inventory  $1,786   $2,052 
Prepaid expenses   800    625 
Other   108    45 
Total other current assets  $2,694   $2,722 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operations

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2021 and December 31, 2020:

 

   December 31,
2021		   December 31,
2020		 
         
Accrued liabilities  $   766   $   766 
Current liabilities from discontinued operations   766    766 
Total liabilities  $766   $766 

 

The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2021 and 2020.

 

   2021   2020 
   Years Ended 
   December 31, 
   2021   2020 
Income from discontinued operations, before tax  $-   $- 
Income tax expense   197    250 
Loss from discontinued operations, net of tax  $(197)  $(250)
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

 

   As of December 31, 2021   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2021 
   Amount   Value   Level 1   Level 2   Level 3 
Liabilities:                         
Contingent consideration:                         
Asuragen  $1,871   $1,871   $     -   $    -   $1,871 
Other accrued expenses:                         
Warrant liability   71    71    -    -    71 
Note payable:                         
BroadOak loan   7,942    7,942    -    -    7,942 
   $9,884   $9,884   $-   $-   $9,884 

 

 

   As of December 31, 2020   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2020 
   Amount   Value   Level 1   Level 2   Level 3 
                     
Liabilities:                         
Contingent consideration:                         
Asuragen  $2,216   $2,216   $    -   $    -   $2,216 
Other long-term liabilities:                         
Warrant liability   21    21    -    -    21 
   $2,237   $2,237   $-   $-   $2,237 
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

                            Adjustment        
                      Accretion/     to Fair Value/        
   

December 31,

2020

    

Loan

Received

     Payments    

Interest

Accrued

    

Mark to

Market

    

December 31,

2021

  
                                     
Asuragen   $ 2,216       -      $ (503 )   $ 496     $ (338 )   $ 1,871  
                                                 
Underwriters Warrants     21       -        -       -       50       71  
                                                 
BroadOak Loan     -       8,000       -       -       (58 )     7,942  
    $ 2,237     $ 8,000     $ (503 )   $ 496     $ (346 )   $ 9,884  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment consisted of the following as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Furniture and fixtures  $339   $339 
Lab and office equipment   7,837    7,536 
Computer equipment   331    339 
Internal-use software   1,572    1,572 
Leasehold improvements   506    505 
Property and equipment   10,585    10,291 
Less accumulated depreciation and amortization   (4,236)   (2,942)
Net property and equipment  $6,349   $7,349 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

 

       As of December 31, 2021   As of December 31, 2020 
   Life   Carrying   Carrying 
   (Years)   Amount   Amount 
             
Asuragen acquisition:              
Thyroid  9   $8,519   $8,519 
RedPath acquisition:              
Pancreas test  7    16,141    16,141 
Barrett’s test  9    6,682    6,682 
BioPharma acquisition:              
Trademarks  10    1,600    1,600 
Customer relationships  8    5,700    5,700 
               
CLIA Lab  2.3   $609   $609 
               
Total      $39,251   $39,251 
               
Accumulated Amortization      $(31,964)  $(27,900)
               
Net Carrying Value      $7,287   $11,351 
Schedule of Goodwill Carrying Value

The following table displays a roll forward of the carrying amount of goodwill from January 1, 2020 to December 31, 2021:

 

   Carrying 
   Amount 
Balance as of January 1, 2020  $8,433 
Adjustments   - 
Balance as of December 31, 2020  $8,433 
Adjustments   - 
Balance as of December 31, 2021  $8,433 
Schedule of Future Estimated Amortization Expense

 

2022   2023   2024   2025   2026 
                       
$2,143   $1,734   $873   $873   $873 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Leases  
Schedule of Financing and Operating Leases

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

 

   Classification on the Balance Sheet  December 31, 2021 
       
Assets        
Financing lease assets  Property and equipment, net  $636 
Operating lease assets  Operating lease right of use assets   4,032 
Total lease assets     $4,668 
         
Liabilities        
Current        
Financing lease liabilities  Other accrued expenses  $79 
Operating lease liabilities  Other accrued expenses   1,041 
Total current lease liabilities     $1,120 
Noncurrent        
Financing lease liabilities  Other long-term liabilities   59 
Operating lease liabilities  Operating lease liabilities, net of current portion   3,154 
Total long-term lease liabilities      3,213 
Total lease liabilities     $4,333 
Schedule of Maturities of Operating and Financing Lease Liabilities

The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2021:

 

   Operating Leases   Financing Leases 
2022  $1,295   $86 
2023   897    60 
2024   567    - 
2025   402    - 
2026-2030   1,924    - 
Total minimum lease payments   5,085    146 
Less: amount of lease payments representing effects of discounting   890    8 
Present value of future minimum lease payments   4,195    138 
Less: current obligations under leases   1,041    79 
Long-term lease obligations  $3,154   $59 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Long-Term Liabilities (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Other Accrued Expenses

Other accrued expenses consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Accrued royalties  $3,890   $2,710 
Contingent consideration   488    398 
Upfront Medicare payment   -    2,066 
Operating lease liability   1,041    1,027 
Financing lease liability   79    177 
Deferred revenue   40    54 
Interest payable   

120

    - 
Warrant liability   71    - 
Accrued sales and marketing - diagnostics   47    51 
Accrued lab costs - diagnostics   228    161 
Accrued professional fees   932    854 
Taxes payable   245    334 
Unclaimed property   565    565 
All others   1,452    1,398 
Total other accrued expenses  $9,198   $9,795 
Schedule of Long Term Liabilities

Other long-term liabilities consisted of the following as of December 31, 2021 and 2020:

 

   December 31, 2021   December 31, 2020 
Warrant liability  $-   $21 
Uncertain tax positions   4,577    4,342 
Deferred revenue   13    136 
Other   58    138 
Total other long-term liabilities  $4,648   $4,637 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases

As of December 31, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows:

 

       Less than   1 to 3   3 to 5   After 
   Total   1 Year   Years   Years   5 Years 
Operating lease obligations  $5,085   $1,295   $1,464   $816   $1,510 
Total  $5,085   $1,295   $1,464   $816   $1,510 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Warrants (Tables)
 12 Months Ended
Dec. 31, 2021
Warrants  
Schedule of Warrants Outstanding and Warrants Activity

Warrants outstanding and warrant activity for the year ended December 31, 2021 are as follows:

Description  Classification   Exercise
Price		   Expiration
Date		   Warrants
Issued		  

Balance

December 31,

2020

   Warrants
Cancelled/
Expired		  

Balance

December 31,

2021

 
                             
Private Placement Warrants, issued January 25, 2017  Equity   $46.90   June 2022    85,500    85,500    -    85,500 
RedPath Warrants, issued March 22, 2017  Equity   $46.90   September 2022    10,000    10,000    -    10,000 
Underwriters Warrants, issued June 21, 2017  Liability   $13.20   December 2022    57,500    53,500    -    53,500 
Base & Overallotment Warrants, issued June 21, 2017  Equity   $12.50   June 2022    1,437,500    870,214    -    870,214 
Warrants issued October 12, 2017  Equity   $18.00   April 2022    320,000    320,000    -    320,000 
Underwriters Warrants, issued January 25, 2019  Equity   $9.40   January 2022    65,434    65,434    -    65,434 
                                  
                 1,975,934    1,404,648          -    1,404,648 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Options, Valuation Assumptions

 

   December 31, 2021   December 31, 2020 
    
Risk-free interest rate   0.79%   0.75%
Expected life   6.0 years    6.5 years 
Expected volatility   134.73%   123.71%
Dividend yield   -    - 
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

Stock-based compensation for the years ended December 31, 2021 and 2020 is as follows:

 

   2021   2020 
RSUs and restricted stock  $433   $176 
Performance-based awards   107    265 
Common stock awards   -    116 
Options   715    1,630 
Total stock-based compensation expense  $1,255   $2,187 
Schedule of Stock Option Activity

A summary of stock option activity for the year ended December 31, 2021, and changes during such year, is presented below:

 

                Weighted-Average  
          Weighted-     Remaining        
          Average     Contractual     Aggregate  
          Grant     Period     Intrinsic  
    Shares     Price     (in years)     Value  
Outstanding at January 1, 2021     848,819     $ 8.76       8.59     $ -  
Granted     347,500       6.00       9.21       -  
Exercised     (13,042 )     9.45                  
Forfeited or expired     (550,766 )     9.15               -  
Outstanding at December 31, 2021     632,511       6.89       8.40       -  
                                 
Exercisable at December 31, 2021     206,732       9.14       7.53                -  
                                 
Vested and expected to vest     537,520       7.15       8.36       -  
Schedule of Non Vested Option Activity

A summary of the status of the Company’s non-vested options for the year ended December 31, 2021, and changes during such year, is presented below:

   Shares   Weighted-
Average
Grant Date
Fair Value		 
         
Nonvested at January 1, 2021   487,318   $5.81 
Granted   347,500    4.64 
Vested   (127,696)   6.54 
Forfeited   (284,646)   5.72 
Nonvested at December 31, 2021   422,476   $4.78 
Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2021, and changes during such year, is presented below:

                Average        
          Weighted-     Remaining        
          Average     Vesting     Aggregate  
          Grant Date     Period     Intrinsic  
    Shares     Fair Value     (in years)     Value  
Nonvested at January 1, 2021     239,457     $ 10.00       1.75     $ 1,348,781  
Granted     207,438       5.46       -       -  
Vested     (65,577 )     4.65       -       -  
Forfeited     (52,379 )     5.23       -       -  
Nonvested at December 31, 2021     328,939     $ 3.67       1.34     $ 2,467,043  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Sources (Tables)
 12 Months Ended
Dec. 31, 2021
Risks and Uncertainties [Abstract]  
Schedule of Revenue by Major Customers

   Years Ended December 31, 
Customer  2021   2020 
Medicare  $17,778   $10,186 
Medicare Advantage  $5,859   $3,566 
Commercial Payors  $5,555   $4,136 
Client Billings  $3,752   $2,582 
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)

The benefit from income taxes on continuing operations for the years ended December 31, 2021 and 2020 is comprised of the following:

 

   2021   2020 
Current:          
Federal  $-   $- 
State   (705)   16 
Total current   (705)   16 
           
Deferred:          
Federal   24    23 
State   14    14 
Total deferred   38    37 
(Benefit) provision from income taxes  $(667)  $53 
Schedule of Deferred Tax Assets and Liabilities

The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2021 and 2020 are as follows:

 

   2021   2020 
Deferred tax assets:          
Federal net operating loss carryforwards  $24,923   $17,015 
State net operating loss carryforwards   3,498    2,953 
Compensation   1,844    1,492 
Allowances and reserves   

585

    436 
Intangible assets   571    292 
State taxes   942    900 
Credit carryforward   2    229 
163(j) interest   1,047    745 
Leases   41    54 
Deferred revenue   95    95 
Valuation allowance   (33,170)   (23,684)
Gross deferred tax assets   378    527 
Deferred tax liability:          
           
Property and equipment   (471)   (582)
Deferred tax liability-net valuation allowance  $(93)  $(55)
Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows:

 

   2021   2020 
Federal statutory rate   21.0%   21.0%
State income tax rate, net of Federal tax benefit   4.2%   4.0%
Meals and entertainment   (0.1%)   (0.1%)
Valuation allowance   (25.3)%   (25.0%)
Naked credit   (0.2%)   (0.1%)
NJ NOL credit sale   4.7%   0.0%
Effective tax rate   4.3%   (0.2%)
Schedule of Unrecognized Tax Benefits Roll Forward

The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020:

 

   Unrecognized 
   Tax Benefits 
     
Balance of unrecognized benefits as of January 1, 2020  $877 
Additions for tax positions of prior years              - 
Balance as of January 1, 2021  $877 
Additions for tax positions of prior years   - 
Balance as of December 31, 2021  $877 
Schedule of Tax Years Subject to Examination

The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2021:

 

Jurisdiction  Tax Years
Federal  2017 – 2021
State and Local  2016 – 2021
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Share (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares

A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2021 and 2020 are as follows (rounded to thousands):

 

   Years Ended December 31, 
   2021   2020 
Basic weighted average number of common shares   4,135    4,029 
Potential dilutive effect of stock-based awards   -    - 
Diluted weighted average number of common shares   4,135    4,029 
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

 

   Years Ended December 31, 
   2021   2020 
Options   632    849 
Restricted stock units (RSUs)   329    238 
Warrants   1,405    1,405 
    2,366    2,492 
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Transition Expenses (Tables)
 12 Months Ended
Dec. 31, 2021
Transition Expenses  
Schedule of Transition Expenses

These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain legal expenses. The following is a roll forward of the transition expenses liabilities:

 

       Facilities/         
   Personnel   Infrastructure   Legal   Total 
    
Balance at December 31, 2020  $885   $269   $-   $1,154 
Transition expenses   1,044    1,036    505    2,585 
Payments   (1,929)   (1,305)   (505)   (3,739)
Balance at December 31, 2021  $-   $-   $-   $- 

 
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

Supplemental Disclosure of Other Cash Flow Information

(in thousands)

 

Cash paid for taxes  $369   $218 
Cash paid for interest  $424   $60 

 

Supplemental Disclosures of Non Cash Activities

(in thousands)

 

   Years Ended 
   December 31, 
   2021   2020 
Operating          
Taxes accrued for repurchase of restricted shares  $95   $- 
           
Investing          
Preferred Stock Deemed Dividend  $-   $3,033 
Investment in DiamiR   248    - 
           
Financing          
           
Accrued financing costs  $-   $31 
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Tables)
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Schedule II - Valuation and Qualifying Accounts

 

       Additions         
   Balance at   (Reductions)   (1)   Balance at 
   Beginning   Charged to   Deductions   end 
Description  of Period   Operations   Other   of Period 
2020                    
Allowance for doubtful accounts  $25          -    250   $275 
Allowance for doubtful notes  $869    -    -   $869 
Tax valuation allowance  $17,027    -    6,657   $23,684 
                     
2021                    
Allowance for doubtful accounts  $275    -    (203)  $72 
Allowance for doubtful notes  $869    -    -   $869 
Tax valuation allowance  $23,684    -    9,486   $33,170 

 

(1) Includes payments and actual write offs, as well as changes in estimates in the reserves.
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Lab supply inventory $ 1,786 $ 2,052
Prepaid expenses 800 625
Other 108 45
Total other current assets $ 2,694 $ 2,722
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business and Significant Accounting Policies (Details Narrative) - shares
 12 Months Ended
Jan. 15, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 30, 2019
Property, Plant and Equipment [Line Items]          
Reverse stock split description the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share        
Shares issued   4,228,169 4,075,257 3,932,370 39,323,701
Shares outstanding   4,195,412 4,055,593 3,920,589 39,205,895
Income tax examination, likelihood of unfavorable settlement   Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement      
Furniture and Fixtures [Member] | Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   7 years      
Furniture and Fixtures [Member] | Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   12 years      
Office and Computer Equipment [Member] | Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   2 years      
Office and Computer Equipment [Member] | Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   5 years      
Lab Equipment [Member] | Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   3 years      
Lab Equipment [Member] | Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   12 years      
Leasehold Improvements [Member] | Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   3 years      
Leasehold Improvements [Member] | Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Finite-lived intangible asset, useful life   10 years      
Software for Internal Use [Member] | Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   3 years      
Software for Internal Use [Member] | Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   7 years      
Software for External Use [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, useful life   3 years      
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Going Concern (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2021
Oct. 29, 2021
May 10, 2021
Jan. 07, 2021
Short-term Debt [Line Items]            
Operating Income (Loss) $ 13,997,000 $ 26,066,000        
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3,300,000          
Assets, Current 12,166,000 14,122,000        
Liabilities, Current 15,682,000 18,233,000        
Cash 2,700,000          
Long-term Line of Credit $ 1,500,000        
Comerica Bank [Member]            
Short-term Debt [Line Items]            
Long-term Line of Credit     $ 7,500,000      
Ampersand Notes [Member]            
Short-term Debt [Line Items]            
Secured Debt         $ 4,500,000 $ 3,000,000
1315 Capital Note [Member]            
Short-term Debt [Line Items]            
Secured Debt         $ 3,000,000.0 $ 2,000,000
Term Loan [Member] | Broad Oak [Member]            
Short-term Debt [Line Items]            
Debt Instrument, Face Amount     $ 8,000,000.0 $ 8,000,000    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Discontinued Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]    
Accrued liabilities $ 766 $ 766
Current liabilities from discontinued operations 766 766
Total liabilities 766 766
Income from discontinued operations, before tax
Income tax expense 197 250
Loss from discontinued operations, net of tax $ (197) $ (250)
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Financial Instrument Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability $ 71 $ 21
Notes Payable 7,942
Fair value of liabilities 9,884 2,237
Fair Value Measured at Net Asset Value Per Share [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability 71 21
Fair value of liabilities 9,884 2,237
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability
Fair value of liabilities
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability 71 21
Fair value of liabilities 9,884 2,237
Asuragen [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 1,871 2,216
Asuragen [Member] | Fair Value Measured at Net Asset Value Per Share [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 1,871 2,216
Asuragen [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration
Asuragen [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration
Asuragen [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 1,871 $ 2,216
BroadOak Loan [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes Payable 7,942  
BroadOak Loan [Member] | Fair Value Measured at Net Asset Value Per Share [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes Payable 7,942  
BroadOak Loan [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes Payable  
BroadOak Loan [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes Payable  
BroadOak Loan [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes Payable $ 7,942  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Beginning Balance $ 2,237  
Loan proceeds 8,000
Payments (5)  
Accretion/Interest Accrued 496  
Adjustment to Fair Value/Mark to Market (346)  
Ending Balance 9,884 2,237
Underwriter Warrants [Member]    
Beginning Balance 21  
Loan proceeds  
Payments  
Accretion/Interest Accrued  
Adjustment to Fair Value/Mark to Market 50  
Ending Balance 71 21
Asuragen [Member]    
Beginning Balance 2,216  
Loan proceeds  
Payments (503)  
Accretion/Interest Accrued 496  
Adjustment to Fair Value/Mark to Market (338)  
Ending Balance 1,871 2,216
BroadOak Loan [Member]    
Beginning Balance  
Loan proceeds 8,000  
Payments  
Accretion/Interest Accrued  
Adjustment to Fair Value/Mark to Market (58)  
Ending Balance $ 7,942
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Furniture and fixtures $ 339 $ 339
Lab and office equipment 7,837 7,536
Computer equipment 331 339
Internal-use software 1,572 1,572
Leasehold improvements 506 505
Property and equipment 10,585 10,291
Less accumulated depreciation and amortization (4,236) (2,942)
Net property and equipment $ 6,349 $ 7,349
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Depreciation and amortization expense $ 1,200 $ 800
Amortization expense 4,064 $ 4,461
Software Development [Member]    
Property, Plant and Equipment [Line Items]    
Amortization expense $ 300  
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Finite-lived Intangible Assets, Gross $ 39,251 $ 39,251
Finite-Lived Intangible Assets, Accumulated Amortization (31,964) (27,900)
Finite-Lived Intangible Assets, Net $ 7,287 11,351
CLIA Lab [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 2 years 3 months 18 days  
Finite-lived Intangible Assets, Gross $ 609 609
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 9 years  
Finite-lived Intangible Assets, Gross $ 8,519 8,519
RedPath Acquisition [Member] | Pancreas Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 7 years  
Finite-lived Intangible Assets, Gross $ 16,141 16,141
RedPath Acquisition [Member] | Barrett's Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 9 years  
Finite-lived Intangible Assets, Gross $ 6,682 6,682
BioPharma Acquisition [Member] | Trademarks [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 10 years  
Finite-lived Intangible Assets, Gross $ 1,600 1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 8 years  
Finite-lived Intangible Assets, Gross $ 5,700 $ 5,700
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Goodwill Carrying Value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Goodwill, Beginning Balance $ 8,433 $ 8,433
Adjustments
Goodwill, Ending Balance $ 8,433 $ 8,433
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Future Estimated Amortization Expense (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2022 $ 2,143
2023 1,734
2024 873
2025 873
2026 $ 873
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Other Intangible Assets (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jul. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]        
Goodwill   $ 8,433 $ 8,433 $ 8,433
Amortization expense   $ 4,100 $ 4,500  
BioPharma Acquisition [Member]        
Restructuring Cost and Reserve [Line Items]        
Finite-lived Intangible Assets Acquired $ 15,600      
Goodwill 8,300      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 7,300      
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Financing and Operating Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Leases    
Finance lease assets $ 636  
Operating lease assets 4,032 $ 4,384
Total lease assets 4,668  
Finance Lease, Liability, Current 79 177
Operating Lease, Liability, Current 1,041 1,027
Total current lease liabilities 1,120  
Finance Lease, Liability, Noncurrent 59  
Operating Lease, Liability, Noncurrent 3,154 $ 3,540
Total long-term lease liabilities 3,213  
Total lease liabilities $ 4,333  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Maturities of Operating and Financing Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Lessee, Lease, Description [Line Items]    
Operating Leases 2022 $ 1,295  
Operating Leases,Total minimum lease payments 5,085  
Operating Leases, Less: current obligations under leases 1,041 $ 1,027
Finance Leases, Less: current obligations under leases 79 177
Operating Leases, Long-term lease obligations 3,154 $ 3,540
Finance Leases, Long-term lease obligations 59  
Operating Leases [Member]    
Lessee, Lease, Description [Line Items]    
Operating Leases 2022 1,295  
Operating Leases 2023 897  
Operating Leases 2024 567  
Operating Leases 2025 402  
Operating Leases 2026-2030 1,924  
Operating Leases,Total minimum lease payments 5,085  
Operating Leases, Less: amount of lease payments representing effects of discounting 890  
Operating Leases, Present value of future minimum lease payments 4,195  
Operating Leases, Less: current obligations under leases 1,041  
Operating Leases, Long-term lease obligations 3,154  
Financing Leases [Member]    
Lessee, Lease, Description [Line Items]    
Finance Lease 2022 86  
Finance Lease 2023 60  
Finance Lease 2024  
Finance Lease 2025  
Operating Leases 2026-2030  
Financing Leases,Total minimum lease payments 146  
Finance Leases, Less: amount of lease payments representing effects of discounting 8  
Finance Leases, Present value of future minimum lease payments 138  
Finance Leases, Less: current obligations under leases 79  
Finance Leases, Long-term lease obligations $ 59  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details Narrative)
Dec. 31, 2021
Dec. 31, 2020
Leases    
Operating Lease, Weighted Average Remaining Lease Term 6 years 4 months 24 days 7 years 1 month 6 days
Operating lease, weighted average discount rate, percent 6.50% 6.00%
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Retirement Plans (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]    
Defined contribution plan, maximum annual contributions per employee, percent 50.00%  
Defined contribution plan, employer matching contribution, percent 100.00%  
Defined contribution plan employer matching contribution at fifty percent 50.00%  
Contribution expense $ 0.3 $ 0.4
Minimum [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined contribution plan, employer matching contribution, percent 3.00%  
Defined contribution plan employer matching contribution at fifty percent 3.00%  
Maximum [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined contribution plan employer matching contribution at fifty percent 5.00%  
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Other Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accrued royalties $ 3,890 $ 2,710
Contingent consideration 488 398
Upfront Medicare payment 2,066
Operating lease liability 1,041 1,027
Financing lease liability 79 177
Deferred revenue 40 54
Interest payable 120
Warrant liability 71
Accrued sales and marketing - diagnostics 47 51
Accrued lab costs - diagnostics 228 161
Accrued professional fees 932 854
Taxes payable 245 334
Unclaimed property 565 565
All others 1,452 1,398
Total other accrued expenses $ 9,198 $ 9,795
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Long Term Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Warrant liability $ 21
Uncertain tax positions 4,577 4,342
Deferred revenue 13 136
Other 58 138
Total other long-term liabilities $ 4,648 $ 4,637
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Operating lease obligations, Total $ 5,085
Operating lease obligations, Less than 1 Year 1,295
Operating lease obligations, 1 to 3 Years 1,464
Operating lease obligations, 3 to 5 Years 816
Operating lease obligations, After 5 Years $ 1,510
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]    
Operating lease expire date description expire at various dates through May 2030  
Expense $ 1.2 $ 2.1
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Jun. 10, 2020
Jan. 15, 2020
Jan. 10, 2020
Dec. 31, 2021
Dec. 31, 2020
Class of Stock [Line Items]          
Preferred stock dividend percentage       6.00%  
Series B Preferred Stock [Member]          
Class of Stock [Line Items]          
Preferred stock adjusted conversion   $ 6.00      
Company achieve revenue target       $ 34.0  
Intrinsic value of beneficial conversion feature $ 2.2        
Intrinsic value of effective conversion price per share   $ 6.79      
Series B Preferred Stock [Member]          
Class of Stock [Line Items]          
Aggregate of shares issued       27,000  
Preferred stock adjusted conversion       $ 6.00  
Preferred Stock, Shares Issued       47,000 47,000
Preferred Stock, Shares Outstanding       47,000 47,000
Series A Preferred Stock [Member]          
Class of Stock [Line Items]          
Value of preferred stock exchanged       $ 27.0  
Aggregate of shares issued       270  
Preferred stock par/stated value       $ 0.01  
Preferred shares stated value       100,000  
Preferred stock adjusted conversion       $ 8.00  
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member]          
Class of Stock [Line Items]          
Value of preferred stock exchanged     $ 20.0    
Issuance price of preferred stock     $ 1,000    
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | 1315 Capital [Member]          
Class of Stock [Line Items]          
Value of preferred stock exchanged     $ 19.0    
Aggregate of shares issued     19,000    
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | Ampersand 2018 Limited Partnership [Member]          
Class of Stock [Line Items]          
Value of preferred stock exchanged     $ 1.0    
Aggregate of shares issued     1,000    
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable (Details Narrative) - USD ($)
Oct. 29, 2021
Sep. 29, 2021
May 10, 2021
Jan. 07, 2021
Dec. 31, 2021
Oct. 31, 2021
Oct. 13, 2021
Dec. 31, 2020
Line of Credit Facility [Line Items]                
Long-term Line of Credit         $ 1,500,000    
[custom:DescriptionOfFundedDebtAmount]       The Notes contained certain negative covenants which prevented the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year        
Series B Convertible Preferred Stock [Member]                
Line of Credit Facility [Line Items]                
Stock Issued During Period, Shares, Conversion of Convertible Securities       4,666,666        
Security Agreement [Member]                
Line of Credit Facility [Line Items]                
Maturity date     Jun. 30, 2021          
Promissory note     $ 7,500,000          
Interest rate     8.00%          
Comerica Bank [Member]                
Line of Credit Facility [Line Items]                
Long-term Line of Credit           $ 7,500,000    
Loan And Security Agreement [Member]                
Line of Credit Facility [Line Items]                
Long-term Line of Credit             $ 7,500,000  
Loan And Security Agreement [Member] | Comerica Bank [Member]                
Line of Credit Facility [Line Items]                
Long-term Line of Credit $ 7,500,000              
Debt instrument interest, description The Term Loan has an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date              
1315 Capital [Member] | Series B Convertible Preferred Stock [Member]                
Line of Credit Facility [Line Items]                
Stock Issued During Period, Shares, Conversion of Convertible Securities       3,166,668        
[custom:NumberOfHoldsShares]       19,000        
[custom:FullyDilutedPercentageOfCommonStock]       26.30%        
1315 Capital Note [Member] | Security Agreement [Member]                
Line of Credit Facility [Line Items]                
Promissory note     $ 3,000,000.0          
Term Loan [Member] | Broad Oak [Member]                
Line of Credit Facility [Line Items]                
Debt instrument, face amount $ 8,000,000         $ 8,000,000.0    
Term Loan [Member] | Ampersand 2018 [Member]                
Line of Credit Facility [Line Items]                
Maturity date Oct. 31, 2024              
Debt interest percentage 9.00%              
Percentage of debt origination fee 3.00%              
Term Loan [Member] | Ampersand [Member]                
Line of Credit Facility [Line Items]                
Repayment of notes   $ 4,500,000            
Term Loan [Member] | 1315 Capital [Member]                
Line of Credit Facility [Line Items]                
Repayment of notes   $ 3,000,000            
Ampersand Notes [Member]                
Line of Credit Facility [Line Items]                
Promissory note     4,500,000 $ 3,000,000        
1315 Capital Note [Member]                
Line of Credit Facility [Line Items]                
Promissory note     3,000,000.0 2,000,000        
1315 Capital Note [Member] | Security Agreement [Member]                
Line of Credit Facility [Line Items]                
Promissory note       $ 2,000,000        
Ampersand [Member] | Series B Convertible Preferred Stock [Member]                
Line of Credit Facility [Line Items]                
Convertible Preferred Stock, Shares Issued upon Conversion       28,000        
Promissory Notes [Member]                
Line of Credit Facility [Line Items]                
Interest rate       8.00%        
Promissory Notes [Member] | Series B Convertible Preferred Stock [Member]                
Line of Credit Facility [Line Items]                
[custom:FullyDilutedPercentageOfCommonStock]       38.70%        
Ampersand Note [Member] | Security Agreement [Member]                
Line of Credit Facility [Line Items]                
Promissory note     $ 4,500,000          
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Warrants Outstanding and Warrants Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Warrants Issued 1,975,934  
Warrants 1,404,648 1,404,648
Warrants Cancelled/Expired  
Private Placement Warrants[Member]    
Description Private Placement Warrants, issued January 25, 2017  
Classification Equity  
Exercise Price $ 46.90  
Expiration Date June 2022  
Warrants Issued 85,500  
Warrants 85,500 85,500
Warrants Cancelled/Expired  
RedPath Warrants [Member]    
Description RedPath Warrants, issued March 22, 2017  
Classification Equity  
Exercise Price $ 46.90  
Expiration Date September 2022  
Warrants Issued 10,000  
Warrants 10,000 10,000
Warrants Cancelled/Expired  
Underwriter Warrants [Member]    
Description Underwriters Warrants, issued June 21, 2017  
Classification Liability  
Exercise Price $ 13.20  
Expiration Date December 2022  
Warrants Issued 57,500  
Warrants 53,500 53,500
Warrants Cancelled/Expired  
Base & Overallotment Warrants [Member]    
Description Base & Overallotment Warrants, issued June 21, 2017  
Classification Equity  
Exercise Price $ 12.50  
Expiration Date June 2022  
Warrants Issued 1,437,500  
Warrants 870,214 870,214
Warrants Cancelled/Expired  
Warrants Issued [Member]    
Description Warrants issued October 12, 2017  
Classification Equity  
Exercise Price $ 18.00  
Expiration Date April 2022  
Warrants Issued 320,000  
Warrants 320,000 320,000
Warrants Cancelled/Expired  
Underwriters Warrants [Member]    
Description Underwriters Warrants, issued January 25, 2019  
Classification Equity  
Exercise Price $ 9.40  
Expiration Date January 2022  
Warrants Issued 65,434  
Warrants 65,434 65,434
Warrants Cancelled/Expired  
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.22.1
Warrants (Details Narrative) - Warrant [Member]
 12 Months Ended
Dec. 31, 2021
$ / shares
Weighted average exercise price $ 15.97
Weighted average remaining contractual life 4 months 24 days
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Options, Valuation Assumptions (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Risk-free interest rate 0.79% 0.75%
Expected life 6 years 6 years 6 months
Expected volatility 134.73% 123.71%
Dividend yield
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 1,255 $ 2,187
RSUs and Restricted Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 433 176
Performance Shares [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 107 265
Share-based Payment Arrangement [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 116
Share-based Payment Arrangement, Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 715 $ 1,630
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Option Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Shares outstanding beginning balance 848,819  
Weighted average grant price outstanding beginning balance $ 8.76  
Weighted average remaining contractual period outstanding beginning balance 8 years 7 months 2 days  
Aggregate intrinsic value outstanding beginning balance  
Shares granted 347,500  
Weighted average grant price granted $ 6.00  
Weighted average remaining contractual period granted 9 years 2 months 15 days  
Aggregate intrinsic value granted  
Shares exercised (13,042) 0
Weighted average grant price exercised $ 9.45  
Shares forfeited or expired (550,766)  
Weighted average grant price forfeited or expired $ 9.15  
Aggregate intrinsic value forfeited or expired  
Shares outstanding ending balance 632,511 848,819
Weighted average grant price outstanding ending balance $ 6.89 $ 8.76
Weighted average remaining contractual period outstanding ending balance 8 years 4 months 24 days  
Aggregate intrinsic value outstanding ending balance
Shares exercisable ending balance 206,732  
Weighted average grant price exercisable ending balance $ 9.14  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 7 years 6 months 10 days  
Aggregate intrinsic value exercisable ending balance  
Shares vested and expected to vest 537,520  
Weighted average grant price vested and expected to vest $ 7.15  
Weighted average remaining contractual period vested and expected to vest 8 years 4 months 9 days  
Aggregate intrinsic value vested and expected to vest  
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Non Vested Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Non-vested Shares outstanding beginning balance 487,318  
Non-vested weighted average grant date fair value outstanding beginning balance $ 5.81  
Non-vested Shares granted 347,500  
Non-vested weighted average grant date fair value granted $ 4.64 $ 5.36
Non-vested Shares vested (127,696)  
Non-vested weighted average grant date fair value vested $ 6.54 $ 7.34
Non-vested Shares forfeited (284,646)  
Non-vested weighted average grant date fair value forfeited $ 5.72  
Non-vested Shares outstanding ending balance 422,476 487,318
Non-vested weighted average grant date fair value outstanding ending balance $ 4.78 $ 5.81
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Non-vested Aggregate Intrinsic Value Vested $ 800 $ 1,500
Restricted Stock Units (RSUs) [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Non-vested Shares beginning balance 239,457  
Non-vested Weighted Average Grant Date Fair Value beginning balance $ 10.00  
Non-vested Average Remaining Vesting Period Beginning balance 1 year 9 months  
Non-vested Aggregate Intrinsic Value Beginning balance $ 1,348,781  
Non-vested Shares granted 207,438  
Non-vested Weighted Average Grant Date Fair Value Granted $ 5.46  
Non-vested Aggregate Intrinsic Value Granted  
Non-vested Shares Vested (65,577)  
Non-vested Weighted Average Grant Date Fair Value Vested $ 4.65  
Non-vested Aggregate Intrinsic Value Vested  
Non-vested Shares Forfeited (52,379)  
Non-vested Weighted Average Grant Date Fair Value Forfeited $ 5.23  
Non-vested Aggregate Intrinsic Value Forfeited  
Non-vested Shares ending balance 328,939 239,457
Non-vested Weighted Average Grant Date Fair Value Ending balance $ 3.67 $ 10.00
Non-vested Average Remaining Vesting Period Ending balance 1 year 4 months 2 days  
Non-vested Aggregate Intrinsic Value Ending balance $ 2,467,043 $ 1,348,781
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 1,255 $ 2,187
Weighted-average fair value of stock options granted $ 4.64 $ 5.36
Options exercised 13,042 0
Share-based compensation aggregate fair value of option $ 800 $ 1,500
Weighted-average grant date fair value of options vested $ 6.54 $ 7.34
Aggregate fair value of restricted stock units $ 300 $ 400
Total unrecognized compensation cost related to unvested stock options and restricted stock units 2,000  
Employee Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 100 $ 40
Stock Incentive Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation arrangement by share-based payment award, description stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances  
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Revenue by Major Customers (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue $ 41,314 $ 32,398
Medicare Customer [Member]    
Revenue 17,778 10,186
Medicare Advantage Customer [Member]    
Revenue 5,859 3,566
Commercial Payers Customer [Member]    
Revenue 5,555 4,136
Client Billings Customer [Member]    
Revenue $ 3,752 $ 2,582
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Sources (Details Narrative)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue Benchmark [Member] | Medicare [Member] | Customer Concentration Risk [Member]    
Concentration Risk [Line Items]    
Revenue from continuing operations 54.00% 50.00%
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal
State (705) 16
Total current (705) 16
Federal 24 23
State 14 14
Total deferred 38 37
(Benefit) provision from income taxes $ (667) $ 53
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal net operating loss carryforwards $ 24,923 $ 17,015
State net operating loss carryforwards 3,498 2,953
Compensation 1,844 1,492
Allowances and reserves 585 436
Intangible assets 571 292
State taxes 942 900
Credit carryforward 2 229
163(j) interest 1,047 745
Leases 41 54
Deferred revenue 95 95
Valuation allowance (33,170) (23,684)
Gross deferred tax assets 378 527
Property and equipment (471) (582)
Deferred tax liability-net valuation allowance $ (93) $ (55)
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal statutory rate 21.00% 21.00%
State income tax rate, net of Federal tax benefit 4.20% 4.00%
Meals and entertainment (0.10%) (0.10%)
Valuation allowance (25.30%) (25.00%)
Naked credit (0.20%) (0.10%)
NJ NOL credit sale 4.70% 0.00%
Effective tax rate 4.30% (0.20%)
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Unrecognized tax benefits beginning balance $ 877 $ 877
Additions for tax positions of prior years
Unrecognized tax benefits ending balance $ 877 $ 877
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Tax Years Subject to Examination (Details)
 12 Months Ended
Dec. 31, 2021
Domestic Tax Authority [Member] | Earliest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2017
Domestic Tax Authority [Member] | Latest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2021
State and Local Jurisdiction [Member] | Earliest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2016
State and Local Jurisdiction [Member] | Latest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2021
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Jul. 15, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Loss Carryforwards [Line Items]        
Operating Loss Carryforwards, Limitations on Use   Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year    
Unrecognized tax benefits   $ 877 $ 877 $ 877
Unrecognized tax benefits would affect the effective tax rate   900 900  
Income tax examination penalties and interest expense   200 300  
Income tax examination penalties and interest accrued   3,600 $ 3,400  
Domestic Tax Authority [Member]        
Operating Loss Carryforwards [Line Items]        
Operating Loss Carryforwards   118,600    
[custom:ReductionInOperatingLossCarryforwards]   71,200    
[custom:RemainingReductionInOperatingLossCarryforwards] $ 47,400      
State and Local Jurisdiction [Member]        
Operating Loss Carryforwards [Line Items]        
Operating Loss Carryforwards   $ 56,300    
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Weighted Average Number of Shares (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share [Abstract]    
Basic weighted average number of common shares 4,135 4,029
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares 4,135 4,029
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from earning per share 2,366 2,492
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from earning per share 632 849
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from earning per share 329 238
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from earning per share 1,405 1,405
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Share (Details Narrative)
 12 Months Ended
Dec. 31, 2021
shares
Series B Preferred Stock [Member]  
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]  
Number preferred stocks on converted basis 7,833,334
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.22.1
Revolving Line of Credit (Details Narrative) - USD ($)
Oct. 13, 2021
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Nov. 13, 2018
Line of Credit Facility [Line Items]          
Line of credit     $ 1,500,000  
Revolver [Member]          
Line of Credit Facility [Line Items]          
Line of credit     $ 1,500,000 $ 0  
Loan And Security Agreement [Member]          
Line of Credit Facility [Line Items]          
Line of credit $ 7,500,000        
Percentage of accounts receivable 80.00%        
Line of credit $ 5,000,000        
Revolving Line option credit card services borrowing limit $ 300,000        
InterestRate 0.50%        
Percentage of line of credit unused facility fee 0.25%        
Line of credit, maturity date Sep. 30, 2023        
Loan And Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]          
Line of Credit Facility [Line Items]          
InterestRate 2.50%        
Loan And Security Agreement [Member] | Forecast [Member]          
Line of Credit Facility [Line Items]          
Line of credit reductions   $ 250,000      
Loan And Security Agreement [Member] | Accounts Receivable [Member]          
Line of Credit Facility [Line Items]          
Line of credit $ 2,000,000        
Comerica Loan Agreement [Member] | Comerica Bank [Member] | Term Loan [Member]          
Line of Credit Facility [Line Items]          
Line of credit $ 7,500,000        
SVB Loan Agreement [Member] | Silicon Valley Bank [Member]          
Line of Credit Facility [Line Items]          
Line of credit         $ 4,000,000.0
Line of credit outstanding accounts receivable         3,750,000
SVB Loan Agreement [Member] | Silicon Valley Bank [Member] | Term Loan [Member]          
Line of Credit Facility [Line Items]          
Line of credit         $ 850,000
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Transition Expenses (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Balance at December 31, 2020 $ 1,154
Transition expenses 2,585
Payments (3,739)
Balance at December 31, 2021
Personnel [Member]  
Balance at December 31, 2020 885
Transition expenses 1,044
Payments (1,929)
Balance at December 31, 2021
Facilities And Infrastructure [Member]  
Balance at December 31, 2020 269
Transition expenses 1,036
Payments (1,305)
Balance at December 31, 2021
Legal [Member]  
Balance at December 31, 2020
Transition expenses 505
Payments (505)
Balance at December 31, 2021
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]    
Cash paid for taxes $ 369 $ 218
Cash paid for interest 424 60
Taxes accrued for repurchase of restricted shares 95
Preferred Stock Deemed Dividend 3,033
Investment in DiamiR 248
Accrued financing costs $ 31
XML 102 R91.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
SEC Schedule, 12-09, Allowance, Credit Loss [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Balance at Beginning of Period $ 275 $ 25
Additions (Reductions) Charged to Operations
Deductions Other [1] (203) 250
Balance at end of Period 72 275
Allowance for Doubtful Notes [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Balance at Beginning of Period 869 869
Additions (Reductions) Charged to Operations
Deductions Other [1]
Balance at end of Period 869 869
SEC Schedule, 12-09, Valuation Allowance, Other Tax Carryforward [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Balance at Beginning of Period 23,684 17,027
Additions (Reductions) Charged to Operations
Deductions Other [1] 9,486 6,657
Balance at end of Period $ 33,170 $ 23,684
[1] Includes payments and actual write offs, as well as changes in estimates in the reserves.
XML 103 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001054102 2021-01-01 2021-12-31 0001054102 2021-06-30 0001054102 2022-03-25 0001054102 2021-12-31 0001054102 2020-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001054102 2020-01-01 2020-12-31 0001054102 us-gaap:CommonStockMember 2020-12-31 0001054102 us-gaap:CommonStockMember 2019-12-31 0001054102 us-gaap:CommonStockMember 2021-03-31 0001054102 us-gaap:CommonStockMember 2020-03-31 0001054102 us-gaap:CommonStockMember 2021-09-30 0001054102 us-gaap:CommonStockMember 2020-09-30 0001054102 us-gaap:TreasuryStockMember 2020-12-31 0001054102 us-gaap:TreasuryStockMember 2019-12-31 0001054102 us-gaap:TreasuryStockMember 2021-03-31 0001054102 us-gaap:TreasuryStockMember 2020-03-31 0001054102 us-gaap:TreasuryStockMember 2021-06-30 0001054102 us-gaap:TreasuryStockMember 2020-06-30 0001054102 us-gaap:TreasuryStockMember 2021-09-30 0001054102 us-gaap:TreasuryStockMember 2020-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001054102 us-gaap:RetainedEarningsMember 2020-12-31 0001054102 us-gaap:RetainedEarningsMember 2019-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-03-31 0001054102 us-gaap:RetainedEarningsMember 2020-03-31 0001054102 us-gaap:RetainedEarningsMember 2021-06-30 0001054102 us-gaap:RetainedEarningsMember 2020-06-30 0001054102 us-gaap:RetainedEarningsMember 2021-09-30 0001054102 us-gaap:RetainedEarningsMember 2020-09-30 0001054102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001054102 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001054102 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001054102 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001054102 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001054102 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001054102 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001054102 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001054102 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001054102 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001054102 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001054102 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0001054102 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0001054102 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0001054102 us-gaap:TreasuryStockMember 2021-10-01 2021-12-31 0001054102 us-gaap:TreasuryStockMember 2020-10-01 2020-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001054102 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001054102 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001054102 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001054102 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001054102 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001054102 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001054102 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001054102 us-gaap:CommonStockMember 2021-06-30 0001054102 us-gaap:CommonStockMember 2020-06-30 0001054102 us-gaap:CommonStockMember 2021-12-31 0001054102 us-gaap:TreasuryStockMember 2021-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-12-31 0001054102 2019-12-31 0001054102 2020-01-13 2020-01-15 0001054102 2019-12-30 0001054102 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001054102 srt:MinimumMember IDXG:OfficeAndComputerEquipmentMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember IDXG:OfficeAndComputerEquipmentMember 2021-01-01 2021-12-31 0001054102 srt:MinimumMember IDXG:LabEquipmentMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember IDXG:LabEquipmentMember 2021-01-01 2021-12-31 0001054102 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001054102 srt:MinimumMember IDXG:SoftwareForInternalUseMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember IDXG:SoftwareForInternalUseMember 2021-01-01 2021-12-31 0001054102 IDXG:SoftwareForExternalUseMember 2021-01-01 2021-12-31 0001054102 IDXG:AmpersandNotesMember 2021-01-07 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-01-07 0001054102 IDXG:AmpersandNotesMember 2021-05-10 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-05-10 0001054102 IDXG:ComericaBankMember 2021-10-31 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember 2021-10-31 0001054102 IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001054102 IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:BroadOakLoanMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:BroadOakLoanMember 2021-12-31 0001054102 IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2020-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2020-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001054102 IDXG:AsuragenMember 2021-01-01 2021-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2020-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2021-12-31 0001054102 IDXG:BroadOakLoanMember 2020-12-31 0001054102 IDXG:BroadOakLoanMember 2021-01-01 2021-12-31 0001054102 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember 2019-07-01 2019-07-31 0001054102 IDXG:BioPharmaAcquisitionMember 2019-07-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2021-01-01 2021-12-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2021-12-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2020-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2021-01-01 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2020-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2021-01-01 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2020-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2021-01-01 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2020-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2020-12-31 0001054102 IDXG:CLIALabMember 2021-01-01 2021-12-31 0001054102 IDXG:CLIALabMember 2021-12-31 0001054102 IDXG:CLIALabMember 2020-12-31 0001054102 IDXG:OpearatingLeaseMember 2021-12-31 0001054102 IDXG:FinancingLeaseMember 2021-12-31 0001054102 srt:MinimumMember 2021-01-01 2021-12-31 0001054102 srt:MaximumMember 2021-01-01 2021-12-31 0001054102 us-gaap:SeriesBPreferredStockMember IDXG:SecurityPurchaseAndExchangeAgreementMember 2020-01-09 2020-01-10 0001054102 us-gaap:SeriesBPreferredStockMember IDXG:SecurityPurchaseAndExchangeAgreementMember IDXG:OneThreeOneFiveCapitalMember 2020-01-09 2020-01-10 0001054102 us-gaap:SeriesBPreferredStockMember IDXG:SecurityPurchaseAndExchangeAgreementMember IDXG:AmpersandLimitedPartnershiMember 2020-01-09 2020-01-10 0001054102 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001054102 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001054102 IDXG:SeriesBPreferredStocksMember 2021-01-01 2021-12-31 0001054102 IDXG:SeriesBPreferredStocksMember 2020-06-08 2020-06-10 0001054102 IDXG:SeriesBPreferredStocksMember 2020-01-14 2020-01-15 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember 2021-10-29 0001054102 IDXG:TermLoanMember IDXG:AmpersandTwoThousandEighteenMember 2021-10-28 2021-10-29 0001054102 IDXG:TermLoanMember IDXG:AmpersandTwoThousandEighteenMember 2021-10-29 0001054102 IDXG:LoanAndSecurityAgreementMember IDXG:ComericaBankMember 2021-10-29 0001054102 IDXG:LoanAndSecurityAgreementMember IDXG:ComericaBankMember 2021-10-28 2021-10-29 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember IDXG:SecurityAgreementMember 2021-01-07 0001054102 IDXG:AmpersandMember IDXG:SeriesBConvertiblePreferredStockMember 2021-01-07 0001054102 IDXG:SeriesBConvertiblePreferredStockMember 2021-01-06 2021-01-07 0001054102 IDXG:SeriesBConvertiblePreferredStockMember IDXG:OneThreeOneFiveCapitalMember 2021-01-06 2021-01-07 0001054102 IDXG:PromissoryNotesMember IDXG:SeriesBConvertiblePreferredStockMember 2021-01-06 2021-01-07 0001054102 IDXG:PromissoryNotesMember 2021-01-06 2021-01-07 0001054102 IDXG:AmpersandNoteMember IDXG:SecurityAgreementMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember 2021-05-01 2021-05-10 0001054102 2021-01-06 2021-01-07 0001054102 IDXG:TermLoanMember IDXG:AmpersandMember 2021-09-28 2021-09-29 0001054102 IDXG:TermLoanMember IDXG:OneThousandThreeFifteenCapitalMember 2021-09-28 2021-09-29 0001054102 IDXG:PrivatePlacementWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2021-12-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2020-12-31 0001054102 IDXG:RedPathWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:RedPathWarrantsMember 2021-12-31 0001054102 IDXG:RedPathWarrantsMember 2020-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2021-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2020-12-31 0001054102 IDXG:WarrantsIssuedMember 2021-01-01 2021-12-31 0001054102 IDXG:WarrantsIssuedMember 2021-12-31 0001054102 IDXG:WarrantsIssuedMember 2020-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2021-01-01 2021-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2021-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2020-12-31 0001054102 us-gaap:WarrantMember 2021-12-31 0001054102 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001054102 IDXG:StockIncentivePlanMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001054102 IDXG:RSUsandRestrictedStockMember 2021-01-01 2021-12-31 0001054102 IDXG:RSUsandRestrictedStockMember 2020-01-01 2020-12-31 0001054102 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001054102 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0001054102 us-gaap:StockCompensationPlanMember 2021-01-01 2021-12-31 0001054102 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001054102 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember IDXG:MedicareMember 2021-01-01 2021-12-31 0001054102 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember IDXG:MedicareMember 2020-01-01 2020-12-31 0001054102 IDXG:MedicareCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:MedicareCustomerMember 2020-01-01 2020-12-31 0001054102 IDXG:MedicareAdvantageCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:MedicareAdvantageCustomerMember 2020-01-01 2020-12-31 0001054102 IDXG:CommercialPayersCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:CommercialPayersCustomerMember 2020-01-01 2020-12-31 0001054102 IDXG:ClientBillingsCustomerMember 2021-01-01 2021-12-31 0001054102 IDXG:ClientBillingsCustomerMember 2020-01-01 2020-12-31 0001054102 us-gaap:DomesticCountryMember 2021-12-31 0001054102 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001054102 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001054102 us-gaap:DomesticCountryMember 2019-07-07 2019-07-15 0001054102 us-gaap:DomesticCountryMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:DomesticCountryMember us-gaap:LatestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001054102 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001054102 IDXG:WarrantsMember 2021-01-01 2021-12-31 0001054102 IDXG:WarrantsMember 2020-01-01 2020-12-31 0001054102 IDXG:ComericaBankMember IDXG:TermLoanMember IDXG:ComericaLoanAgreementMember 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember 2021-10-12 2021-10-13 0001054102 us-gaap:AccountsReceivableMember IDXG:LoanAndSecurityAgreementMember 2021-10-13 0001054102 srt:ScenarioForecastMember IDXG:LoanAndSecurityAgreementMember 2022-06-30 0001054102 IDXG:LoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-10-12 2021-10-13 0001054102 IDXG:RevolverMember 2021-12-31 0001054102 IDXG:SiliconValleyBankMember IDXG:SVBLoanAgreementMember 2018-11-13 0001054102 IDXG:SiliconValleyBankMember IDXG:TermLoanMember IDXG:SVBLoanAgreementMember 2018-11-13 0001054102 IDXG:RevolverMember 2020-12-31 0001054102 IDXG:PersonnelMember 2020-12-31 0001054102 IDXG:FacilitiesAndInfrastructureMember 2020-12-31 0001054102 IDXG:LegalMember 2020-12-31 0001054102 IDXG:PersonnelMember 2021-01-01 2021-12-31 0001054102 IDXG:FacilitiesAndInfrastructureMember 2021-01-01 2021-12-31 0001054102 IDXG:LegalMember 2021-01-01 2021-12-31 0001054102 IDXG:PersonnelMember 2021-12-31 0001054102 IDXG:FacilitiesAndInfrastructureMember 2021-12-31 0001054102 IDXG:LegalMember 2021-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2019-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2020-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2019-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2020-01-01 2020-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2020-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2019-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2020-01-01 2020-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2020-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0001054102 us-gaap:AllowanceForCreditLossMember 2021-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2021-01-01 2021-12-31 0001054102 IDXG:AllowanceForDoubtfulNotesMember 2021-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2021-01-01 2021-12-31 0001054102 us-gaap:ValuationAllowanceOtherTaxCarryforwardMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure IDXG:Integer 0001054102 false FY P7Y P2Y P3Y P3Y P3Y 10-K true 2021-12-31 --12-31 2021 false 000-24249 Interpace Biosciences, Inc. DE 22-2919486 Morris Corporate Center 1 Building C 300 Interpace Parkway Parsippany NJ 07054 (855) 776-6419 No No Yes Yes Non-accelerated Filer true false false false 42186849 4226422 Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant’s definitive proxy statement for the 2021 annual meeting of stockholders, or Proxy Statement, or will be included in an amendment hereto, to be filed within 120 days of the end of the fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part hereof 243 BDO USA, LLP Woodbridge, New Jersey 3064000 2772000 250000 600000 72000 275000 6158000 8028000 2694000 2722000 12166000 14122000 6349000 7349000 7287000 11351000 8433000 8433000 4032000 4384000 160000 42000 38427000 45681000 2694000 4511000 3024000 3161000 9198000 9795000 766000 766000 15682000 18233000 1383000 1818000 3154000 3540000 1500000 7942000 4648000 4637000 34309000 28228000 0.01 0.01 5000000 5000000 47000 47000 47000 47000 46536000 46536000 0.01 0.01 100000000 100000000 4228169 4075257 4195412 4055593 403000 402000 186106000 184404000 -227059000 -212116000 32757 19664 1868000 1773000 -42418000 -29083000 -8109000 -855000 38427000 45681000 41314000 32398000 4064000 4461000 23369000 21673000 17945000 10725000 10067000 9254000 1882000 2795000 13669000 18192000 2585000 2578000 -13000 4064000 4461000 -338000 -489000 31942000 36791000 -13997000 -26066000 496000 549000 424000 -496000 467000 -15413000 -26148000 -667000 53000 -14746000 -26201000 -197000 -250000 -14943000 -26451000 3033000 -14943000 -29484000 -3.57 -7.26 -0.04 -0.06 -3.61 -7.32 4135000 4029000 4135000 4029000 4075 402000 3932 393000 9 37 1000 12 6 80 8000 36 4132000 402000 4055 402000 10 4142 402000 4055 402000 13 5 39 1000 4194 403000 4060 402000 34 15 4228 403000 4075 402000 20 -1773000 12 -1721000 20 -1773000 12 -1721000 7 49000 20 -1773000 19 -1770000 20 -1773000 19 -1770000 13 95000 1 3000 33 -1868000 20 -1773000 184404000 182514000 108000 -828000 2205000 -2205000 476000 286000 418000 184798000 182580000 551000 400000 185349000 182980000 226000 477000 563000 186052000 183543000 54000 861000 186106000 184404000 -212116000 -185665000 -4207000 -6494000 -216323000 -192159000 -3446000 -5580000 -219769000 -197739000 -3561000 -6234000 -223330000 -203973000 -3729000 -8143000 -227059000 -212116000 -42418000 -29083000 -14943000 -26451000 5374000 5501000 496000 549000 -140000 585000 1156000 50000 -61000 122000 -120000 -312000 1255000 2187000 113000 55000 58000 -38000 -37000 -13000 -338000 -489000 37000 2000 -2148000 -1725000 -28000 -241000 118000 -1817000 -198000 137000 -1976000 -1086000 1395000 149000 -88000 -8719000 -13979000 354000 1575000 39000 -315000 -1575000 335000 434000 19223000 7500000 8000000 312000 7924000 123000 1500000 -3000000 52000 8976000 16605000 -58000 1051000 3372000 2321000 3314000 3372000 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zeQE1TVRJ6Bl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"/>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_z55fS1kNXmZ3">Nature of Business and Significant Accounting Policies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--NatureOfBusinessPolicyTextBlock_z6sXskdZKkq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z1C7iG5VSBe4">Nature of Business</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zew0v1IBPdw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zfxXqQJ2dxt9">Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has one reporting segment: the Company’s clinical and pharma services business. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zzVqPAxMYHs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zrzE40KS9kig">Accounting Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zpJVFbOE61W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z6KJ6oP1DqPc">Reverse stock split</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 15, 2020, <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20200113__20200115_zWIsRn2b9YBa" title="Reverse stock split description">the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share</span>. The Company’s issued and outstanding stock decreased from <span title="Common stock shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20191230_z9TUtwchSsMe" title="Shares issued">39,323,701</span></span> to <span title="Common stock shares outstanding"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20191231_z4eF6cOy17cd" title="Shares issued">3,932,370</span></span> and <span title="Common stock shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20191230_zbYpICaewtO" title="Shares outstanding">39,205,895</span></span> to <span title="Common stock shares outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20191231_zXf3BPZzPL0h" title="Shares outstanding">3,920,589</span></span> at December 31, 2019. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the reverse stock split for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zupC2qp77NI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zAw0RcnRrXwb">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyZC0dboBtl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zsqgEqN1mmf1">Accounts Receivable, Net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--OtherCurrentAssetsPolicyTextBlock_zZ7kJ4LWfxf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zQfOaBOo1Z46">Other current assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zFvs9E1Xem69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zydV0XHpp7e2" style="display: none">Schedule of Current Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zzRR2HWhFq4k" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20201231_zTJjxf1FR8xa" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryNet_iI_pn3n3_maOACzWve_zkQQN52Tufaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Lab supply inventory</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzWve_zv3HNkUt3Yf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">625</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OtherItems_iI_pn3n3_maOACzWve_zHIuY8gyHxga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzWve_zooowyIKgPe9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,694</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,722</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zCrMETHHbOJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zieLXF1Wtl0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zisprH9dDqr9">Property and Equipment, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_z2DZMpv5mEAh" title="Property, plant and equipment, useful life::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0750">seven</span></span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zjdDlFbrE454" title="Property, plant and equipment, useful life">twelve years</span> for furniture and fixtures; <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zVZ9cMihcZoa" title="Property, plant and equipment, useful life::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0754">two</span></span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zaQbOLKeh0ia" title="Property, plant and equipment, useful life">five years</span> for office and computer equipment; <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember__srt--RangeAxis__srt--MinimumMember_zXHr7VSkQEd5" title="Property, plant and equipment, useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0758">three</span></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember__srt--RangeAxis__srt--MaximumMember_zhaT276DiaPf" title="Property, plant and equipment, useful life">twelve years</span> for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zfNTDXCUoLdd" title="Property, plant and equipment, useful life::XDX::P3Y">three</span> to <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zx1p1LxZ18pk" title="Finite-lived intangible asset, useful life">ten years</span>. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z3wewhbpB2Ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zVdTiR4fE0b7">Software Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareForInternalUseMember__srt--RangeAxis__srt--MinimumMember_zPq0q62V2bP5" title="Property, plant and equipment, useful life::XDX::P3Y"> <span style="-sec-ix-hidden: xdx2ixbrl0768">three </span></span>to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareForInternalUseMember__srt--RangeAxis__srt--MaximumMember_z6Z1xiJrhx7c" title="Property, plant and equipment, useful life">seven years</span>. Software costs that do not meet capitalization criteria are expensed immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareForExternalUseMember_zJ0ryVVwjJig" title="Property, plant and equipment, useful life">three years</span>. Software costs that do not meet capitalization criteria are expensed immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Property and Equipment</i>, for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zawj4CtaDVk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zMQIlHMWI8Se">Long-Lived Assets, including Finite-Lived Intangible Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition related amortization expense in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_z2E7sj9nXZ86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zVS70Ts3mB5b">Contingencies</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zky35cAtn9y3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zD8tnEDh7x5j">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--DeferredRevenuePolicyTextBlock_zRgDDMgdcfR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b><i><span id="xdx_869_zXYqRTnHRiAi">Deferred Revenue</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_847_ecustom--CostOfRevenuePolicyTextBlock_zbYMzDrN43v3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zLrPwxWRZl1i">Cost of revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zdp4Rl0KfLqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z7bdkNLw0Ywl">Stock-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 15, <i>Stock-Based Compensation,</i> for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--TreasuryStockPolicyTextBlock_z11LvbQxe1Xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zi8Y0TQ9OmK1">Treasury Stock</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zEONWZ3mAnc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zS5X8AjNDqM5">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, <i>Leases</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zANLijLjTEMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zgdD4tI9joh2">Income taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20210101__20211231_zyxLyRzM9rZc" title="Income tax examination, likelihood of unfavorable settlement">Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement</span>. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zsASgcTab0i7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zJw5YjsFjxib">Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2021 and 2020, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.</span></p> <p id="xdx_85F_zpGUeI85PYEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--NatureOfBusinessPolicyTextBlock_z6sXskdZKkq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z1C7iG5VSBe4">Nature of Business</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zew0v1IBPdw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zfxXqQJ2dxt9">Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has one reporting segment: the Company’s clinical and pharma services business. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zzVqPAxMYHs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zrzE40KS9kig">Accounting Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zpJVFbOE61W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z6KJ6oP1DqPc">Reverse stock split</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 15, 2020, <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20200113__20200115_zWIsRn2b9YBa" title="Reverse stock split description">the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share</span>. The Company’s issued and outstanding stock decreased from <span title="Common stock shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20191230_z9TUtwchSsMe" title="Shares issued">39,323,701</span></span> to <span title="Common stock shares outstanding"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20191231_z4eF6cOy17cd" title="Shares issued">3,932,370</span></span> and <span title="Common stock shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20191230_zbYpICaewtO" title="Shares outstanding">39,205,895</span></span> to <span title="Common stock shares outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20191231_zXf3BPZzPL0h" title="Shares outstanding">3,920,589</span></span> at December 31, 2019. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the reverse stock split for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share 39323701 3932370 39205895 3920589 <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zupC2qp77NI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zAw0RcnRrXwb">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyZC0dboBtl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zsqgEqN1mmf1">Accounts Receivable, Net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--OtherCurrentAssetsPolicyTextBlock_zZ7kJ4LWfxf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zQfOaBOo1Z46">Other current assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zFvs9E1Xem69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zydV0XHpp7e2" style="display: none">Schedule of Current Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zzRR2HWhFq4k" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20201231_zTJjxf1FR8xa" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryNet_iI_pn3n3_maOACzWve_zkQQN52Tufaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Lab supply inventory</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzWve_zv3HNkUt3Yf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">625</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OtherItems_iI_pn3n3_maOACzWve_zHIuY8gyHxga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzWve_zooowyIKgPe9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,694</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,722</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zCrMETHHbOJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zFvs9E1Xem69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zydV0XHpp7e2" style="display: none">Schedule of Current Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zzRR2HWhFq4k" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20201231_zTJjxf1FR8xa" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryNet_iI_pn3n3_maOACzWve_zkQQN52Tufaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Lab supply inventory</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzWve_zv3HNkUt3Yf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">625</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OtherItems_iI_pn3n3_maOACzWve_zHIuY8gyHxga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzWve_zooowyIKgPe9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,694</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,722</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1786000 2052000 800000 625000 108000 45000 2694000 2722000 <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zieLXF1Wtl0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zisprH9dDqr9">Property and Equipment, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_z2DZMpv5mEAh" title="Property, plant and equipment, useful life::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0750">seven</span></span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zjdDlFbrE454" title="Property, plant and equipment, useful life">twelve years</span> for furniture and fixtures; <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zVZ9cMihcZoa" title="Property, plant and equipment, useful life::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0754">two</span></span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zaQbOLKeh0ia" title="Property, plant and equipment, useful life">five years</span> for office and computer equipment; <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember__srt--RangeAxis__srt--MinimumMember_zXHr7VSkQEd5" title="Property, plant and equipment, useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0758">three</span></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember__srt--RangeAxis__srt--MaximumMember_zhaT276DiaPf" title="Property, plant and equipment, useful life">twelve years</span> for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zfNTDXCUoLdd" title="Property, plant and equipment, useful life::XDX::P3Y">three</span> to <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zx1p1LxZ18pk" title="Finite-lived intangible asset, useful life">ten years</span>. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P12Y P5Y P12Y P10Y <p id="xdx_84C_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z3wewhbpB2Ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zVdTiR4fE0b7">Software Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareForInternalUseMember__srt--RangeAxis__srt--MinimumMember_zPq0q62V2bP5" title="Property, plant and equipment, useful life::XDX::P3Y"> <span style="-sec-ix-hidden: xdx2ixbrl0768">three </span></span>to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareForInternalUseMember__srt--RangeAxis__srt--MaximumMember_z6Z1xiJrhx7c" title="Property, plant and equipment, useful life">seven years</span>. Software costs that do not meet capitalization criteria are expensed immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SoftwareForExternalUseMember_zJ0ryVVwjJig" title="Property, plant and equipment, useful life">three years</span>. Software costs that do not meet capitalization criteria are expensed immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Property and Equipment</i>, for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P7Y P3Y <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zawj4CtaDVk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zMQIlHMWI8Se">Long-Lived Assets, including Finite-Lived Intangible Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition related amortization expense in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_z2E7sj9nXZ86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zVS70Ts3mB5b">Contingencies</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zky35cAtn9y3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zD8tnEDh7x5j">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--DeferredRevenuePolicyTextBlock_zRgDDMgdcfR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b><i><span id="xdx_869_zXYqRTnHRiAi">Deferred Revenue</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_847_ecustom--CostOfRevenuePolicyTextBlock_zbYMzDrN43v3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zLrPwxWRZl1i">Cost of revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zdp4Rl0KfLqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z7bdkNLw0Ywl">Stock-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 15, <i>Stock-Based Compensation,</i> for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--TreasuryStockPolicyTextBlock_z11LvbQxe1Xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zi8Y0TQ9OmK1">Treasury Stock</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zEONWZ3mAnc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zS5X8AjNDqM5">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, <i>Leases</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zANLijLjTEMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zgdD4tI9joh2">Income taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20210101__20211231_zyxLyRzM9rZc" title="Income tax examination, likelihood of unfavorable settlement">Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement</span>. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zsASgcTab0i7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zJw5YjsFjxib">Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2021 and 2020, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.</span></p> <p id="xdx_806_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zF1OUlCOI355" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zSvfPkG30zwe">Recent Accounting Standards</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recently Adopted Accounting Guidance</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment was effective for annual periods beginning after December 15, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted this pronouncement on January 1, 2021 and the impact was not material to the Company’s Consolidated Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration: underline">Accounting <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pronouncements Pending Adoption </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company does not expect this will have any impact on its unaudited consolidated financial statements.</span></p> <p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zuHTV4142fFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_82E_zurG7vf2TG2d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the fiscal year ended December 31, 2021, we had an operating loss of $<span id="xdx_909_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20210101__20211231_zWc0vCi2kuId">14.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> million. As of December 31, 2021, we had cash, cash equivalents and restricted cash of $<span id="xdx_900_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20211231_zqPNzGvpfwK4">3.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, total current assets of $<span id="xdx_90D_eus-gaap--AssetsCurrent_iI_pn5n6_c20211231_zRXMLAU8SFD3">12.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and current liabilities of $<span id="xdx_907_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20211231_z8sUo05oIpQk">15.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. As of March 18, 2022, we had approximately $<span id="xdx_90D_eus-gaap--Cash_iI_pn5n6_c20211231_zmLS5eHXbpM8">2.7</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of cash on hand, excluding restricted cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, the Company announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT<sup>®</sup> and ThyraMIR<sup>®</sup> tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT<sup>®</sup> (0245U) and ThyraMIR<sup>®</sup> (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be insufficient to meet its anticipated cash requirements through the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 7, 2021, the Company entered into secured promissory notes in the amount of $<span id="xdx_908_eus-gaap--SecuredDebt_iI_pn6n6_c20210107__us-gaap--DebtInstrumentAxis__custom--AmpersandNotesMember_zYLDtYBUcq0c">3</span> million and $<span id="xdx_905_eus-gaap--SecuredDebt_iI_pn6n6_c20210107__us-gaap--DebtInstrumentAxis__custom--OneThousandThreeFifteenCapitalNoteMember_z81jfJPfapta">2 </span>million with Ampersand (“Ampersand Note”) and 1315 Capital (“1315 Capital Note”), respectively. See Note 13, <i>Notes Payable, </i>of the notes to the financial statements. On May 10, 2021, the Company amended the Ampersand Note to increase the principal amount to $<span id="xdx_90A_eus-gaap--SecuredDebt_iI_pn5n6_c20210510__us-gaap--DebtInstrumentAxis__custom--AmpersandNotesMember_zmwdz1AbQjDd">4.5</span> million and amended the 1315 Capital Note to increase the principal amount to $<span id="xdx_904_eus-gaap--SecuredDebt_iI_pn5n6_c20210510__us-gaap--DebtInstrumentAxis__custom--OneThousandThreeFifteenCapitalNoteMember_zHxCgMdkfsA2">3.0</span> million. The maturity dates of the Notes were the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the Company entered into a $<span id="xdx_901_eus-gaap--LineOfCredit_iI_pn5n6_c20211031__us-gaap--LineOfCreditFacilityAxis__custom--ComericaBankMember_zSADquyHz0d8">7.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million revolving credit facility with Comerica. See Note 19, <i>Revolving Line of Credit</i>, for more details. In addition, also in October 2021, the Company entered into the $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20211031__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--BroadOakMember_zw78q0K8F8Ce">8.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million BroadOak Term Loan, the proceeds of which were used to repay in full at their maturity the notes extended by Ampersand and 1315 Capital discussed above. See Note 13, <i>Notes Payable,</i> for more details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the Company is targeting to achieve adjusted EBITDA and cash flow breakeven during Fiscal 2022, we may not generate positive cash flows from operations for the year ending December 31, 2022. We intend to meet our ongoing capital needs by using our available cash and availability under the Comerica Loan Agreement, as well as through revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options. However, if we are unable to meet the financial covenants under the Comerica Loan Agreement, the revolving line of credit and notes payable will become due and payable immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity and expand the business through acquisitions or other strategic transactions. With the Company’s delisting from Nasdaq in February 2021, its ability to raise additional capital on terms acceptable to the Company may be adversely impacted. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to the Company. In January 2022, the Company’s registration statement for a rights offering become effective. The rights offering was subsequently terminated in January 2022. </span></p> -14000000.0 3300000 12200000 15700000 2700000 3000000 2000000 4500000 3000000.0 7500000 8000000.0 <p id="xdx_802_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_z7oJV8hyF2A1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zYK95rQPhpZh">Discontinued Operations</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zlLABr4HxDik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2021 and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B2_zyjUvaKWTe11" style="display: none">Schedule of Discontinued Operations</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: lowercase"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zj1sfOMEPrW2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20201231_znCzHzrWy0j5" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIzvxg_zpX5o4dsaFt4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">   766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">   766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzvxg_maLODGIz5Ji_zemQevIyXJ4j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities from discontinued operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iTI_pn3n3_mtLODGIz5Ji_zSpCncU1ViKc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zLkZNySuIYii" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20200101__20201231_zhg32E0Vc5u4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="6" style="text-align: center">Years Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_pn3n3_maILFDOzktr_zK1eNSiFfDTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income from discontinued operations, before tax</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0824">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0825">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_pn3n3_msILFDOzktr_zaIA8nEV4UZa" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">197</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">250</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_mtILFDOzktr_z0okTalfqyHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from discontinued operations, net of tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(197</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(250</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zZUdgTDVBlAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zlLABr4HxDik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2021 and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B2_zyjUvaKWTe11" style="display: none">Schedule of Discontinued Operations</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: lowercase"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zj1sfOMEPrW2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20201231_znCzHzrWy0j5" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIzvxg_zpX5o4dsaFt4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">   766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">   766</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzvxg_maLODGIz5Ji_zemQevIyXJ4j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities from discontinued operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iTI_pn3n3_mtLODGIz5Ji_zSpCncU1ViKc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zLkZNySuIYii" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20200101__20201231_zhg32E0Vc5u4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="6" style="text-align: center">Years Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_pn3n3_maILFDOzktr_zK1eNSiFfDTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income from discontinued operations, before tax</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0824">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0825">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_pn3n3_msILFDOzktr_zaIA8nEV4UZa" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">197</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right">250</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_mtILFDOzktr_z0okTalfqyHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from discontinued operations, net of tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(197</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(250</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 766000 766000 766000 766000 766000 766000 197000 250000 -197000 -250000 <p id="xdx_801_eus-gaap--FairValueDisclosuresTextBlock_zW26WFUcapk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zTVoREPhS2x">Fair Value Measurements</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the consolidated financial statements include contingent consideration, notes payable, and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations for assets and liabilities include certain unobservable inputs in the assumptions and projections used in determining the fair value assigned to such assets or liabilities.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.</span></p> <p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zwTzbxydMjIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8BA_ztTNBLY18FYj" style="display: none">Schedule of Financial Instrument Measured on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: lowercase"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: lowercase"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center">Fair Value Measurements</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Carrying</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Fair</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asuragen</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--AsuragenMember_zFbLk1488W45" style="width: 9%; text-align: right" title="Contingent consideration">1,871</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember__dei--LegalEntityAxis__custom--AsuragenMember_zXgMsNiwfBO6" style="width: 9%; text-align: right" title="Contingent consideration">1,871</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__dei--LegalEntityAxis__custom--AsuragenMember_zShJvZdsJ4Nk" style="width: 9%; text-align: right" title="Contingent consideration">    <span style="-sec-ix-hidden: xdx2ixbrl0841"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__dei--LegalEntityAxis__custom--AsuragenMember_zMsAJOBrac4h" style="width: 9%; text-align: right" title="Contingent consideration">   <span style="-sec-ix-hidden: xdx2ixbrl0843"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--AsuragenMember_zuwes26EF5Ji" style="width: 9%; text-align: right" title="Contingent consideration">1,871</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--WarrantLiability_iI_pn3n3_c20211231_zsKPfu1Hw87" style="text-align: right" title="Warrant liability">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zsdA8WENznP7" style="text-align: right" title="Warrant liability">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zR0kl3aOP1c9" style="text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJXj5sqjb1Ad" style="text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPcY6NughNgc" style="text-align: right" title="Warrant liability">71</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">BroadOak loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zzt1RUVHCQQk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable">7,942</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember__dei--LegalEntityAxis__custom--BroadOakLoanMember_zwBNaA6inwQh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable">7,942</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__dei--LegalEntityAxis__custom--BroadOakLoanMember_zLXnQjFpW41c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__dei--LegalEntityAxis__custom--BroadOakLoanMember_zocdFM23Uk7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--BroadOakLoanMember_zr7oo8FAWfs7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable">7,942</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231_zytg2v2fggp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">9,884</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zY25UvrwcJX3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">9,884</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkDrLX7N2qXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi3odO8FDje1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkg29MkAQ0pj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">9,884</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center">Fair Value Measurements</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Carrying</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Fair</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asuragen</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--AsuragenMember_z6JZFbS6fct" style="width: 9%; text-align: right" title="Contingent consideration">2,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember__dei--LegalEntityAxis__custom--AsuragenMember_zhNwIc0IAiPa" style="width: 9%; text-align: right" title="Contingent consideration">2,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__dei--LegalEntityAxis__custom--AsuragenMember_z8NHndtPSLv3" style="width: 9%; text-align: right" title="Contingent consideration">   <span style="-sec-ix-hidden: xdx2ixbrl0881"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__dei--LegalEntityAxis__custom--AsuragenMember_z29oJOcQk9Xf" style="width: 9%; text-align: right" title="Contingent consideration">   <span style="-sec-ix-hidden: xdx2ixbrl0883"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--AsuragenMember_zRY29Wd9Rv5f" style="width: 9%; text-align: right" title="Contingent consideration">2,216</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other long-term liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--WarrantLiability_iI_pn3n3_c20201231_z5cYxWxenjek" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zxpTBrucLOEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zULQTiMuKrs2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDOotuNzA4ml" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNBPIyV6A7e9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231_z3pg8PJWuIZc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">2,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zwyVVIM5Nkd5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">2,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTxUjSeYuse9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDhy5ABZuUy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoVUUzA5nIe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">2,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"/> <p id="xdx_8A3_zNewhDckZzYk" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In connection with the BroadOak loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted approach regarding the loan’s change in control feature. See Note 13, <i>Notes Payable,</i> for more details. The fair value measurement is based on the estimated probability of a change in control and thus represents a Level 3 measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zgwGslSAUGHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B9_zi3SaDzfmHC" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accretion/</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to Fair Value/</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Received</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark to</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asuragen</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zOim4cDM86n" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,216</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--LoanProceeds_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zDoVg4oHzARg" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Loan proceeds"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0911"> </span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zHkhBIQF6Vdk" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(503</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zLwzTHW4M1mh" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">496</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zzSJvkSus5kl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(338</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_ztJNFrZdxxW3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,871</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters Warrants</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_znN0fJ1H7oX" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_ecustom--LoanProceeds_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zBbnvFjMaRk9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0923"> </span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zl3TwjywVEkc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_z4YfaBNVZkLk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zWyF8Ig3trKf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zUkzU8DgLuJl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BroadOak Loan</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_z5saH22xG6A9" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_ecustom--LoanProceeds_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zkg315UMcKKa" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zvtlhzdauC7e" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zcfC9CtKbPW7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zl176P9Vxt34" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(58</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_z2oD4gMrybGe" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,942</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231_zjETLA70qDe8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,237</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_ecustom--LoanProceeds_pn3n3_c20210101__20211231_zjSMxyqhgksh" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231_zv87WxZxLSta" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5</span>03</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231_zJolFHs3DEOd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">496</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231_zcMND2tewRP6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(346</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231_zyZR2QLKKQmk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,884</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zbdjbKPoxjMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of the Company’s non-financial assets, such as other intangible assets are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.</span></p> <p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zwTzbxydMjIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8BA_ztTNBLY18FYj" style="display: none">Schedule of Financial Instrument Measured on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: lowercase"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: lowercase"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center">Fair Value Measurements</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Carrying</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Fair</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asuragen</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--AsuragenMember_zFbLk1488W45" style="width: 9%; text-align: right" title="Contingent consideration">1,871</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember__dei--LegalEntityAxis__custom--AsuragenMember_zXgMsNiwfBO6" style="width: 9%; text-align: right" title="Contingent consideration">1,871</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__dei--LegalEntityAxis__custom--AsuragenMember_zShJvZdsJ4Nk" style="width: 9%; text-align: right" title="Contingent consideration">    <span style="-sec-ix-hidden: xdx2ixbrl0841"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__dei--LegalEntityAxis__custom--AsuragenMember_zMsAJOBrac4h" style="width: 9%; text-align: right" title="Contingent consideration">   <span style="-sec-ix-hidden: xdx2ixbrl0843"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--AsuragenMember_zuwes26EF5Ji" style="width: 9%; text-align: right" title="Contingent consideration">1,871</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--WarrantLiability_iI_pn3n3_c20211231_zsKPfu1Hw87" style="text-align: right" title="Warrant liability">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zsdA8WENznP7" style="text-align: right" title="Warrant liability">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zR0kl3aOP1c9" style="text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJXj5sqjb1Ad" style="text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WarrantLiability_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPcY6NughNgc" style="text-align: right" title="Warrant liability">71</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">BroadOak loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zzt1RUVHCQQk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable">7,942</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember__dei--LegalEntityAxis__custom--BroadOakLoanMember_zwBNaA6inwQh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable">7,942</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__dei--LegalEntityAxis__custom--BroadOakLoanMember_zLXnQjFpW41c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__dei--LegalEntityAxis__custom--BroadOakLoanMember_zocdFM23Uk7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LongTermNotesPayable_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--BroadOakLoanMember_zr7oo8FAWfs7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes Payable">7,942</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231_zytg2v2fggp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">9,884</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zY25UvrwcJX3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">9,884</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkDrLX7N2qXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi3odO8FDje1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkg29MkAQ0pj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">9,884</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center">Fair Value Measurements</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Carrying</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">Fair</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asuragen</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--AsuragenMember_z6JZFbS6fct" style="width: 9%; text-align: right" title="Contingent consideration">2,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember__dei--LegalEntityAxis__custom--AsuragenMember_zhNwIc0IAiPa" style="width: 9%; text-align: right" title="Contingent consideration">2,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__dei--LegalEntityAxis__custom--AsuragenMember_z8NHndtPSLv3" style="width: 9%; text-align: right" title="Contingent consideration">   <span style="-sec-ix-hidden: xdx2ixbrl0881"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__dei--LegalEntityAxis__custom--AsuragenMember_z29oJOcQk9Xf" style="width: 9%; text-align: right" title="Contingent consideration">   <span style="-sec-ix-hidden: xdx2ixbrl0883"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--AsuragenMember_zRY29Wd9Rv5f" style="width: 9%; text-align: right" title="Contingent consideration">2,216</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other long-term liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--WarrantLiability_iI_pn3n3_c20201231_z5cYxWxenjek" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zxpTBrucLOEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zULQTiMuKrs2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDOotuNzA4ml" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--WarrantLiability_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNBPIyV6A7e9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liability">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231_z3pg8PJWuIZc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">2,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueMeasuredAtNetAssetValuePerShareMember_zwyVVIM5Nkd5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">2,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTxUjSeYuse9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDhy5ABZuUy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoVUUzA5nIe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">2,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"/> 1871000 1871000 1871000 71000 71000 71000 7942000 7942000 7942000 9884000 9884000 9884000 2216000 2216000 2216000 21000 21000 21000 2237000 2237000 2237000 <p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zgwGslSAUGHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B9_zi3SaDzfmHC" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accretion/</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to Fair Value/</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Received</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark to</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asuragen</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zOim4cDM86n" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,216</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--LoanProceeds_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zDoVg4oHzARg" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Loan proceeds"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0911"> </span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zHkhBIQF6Vdk" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(503</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zLwzTHW4M1mh" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">496</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_zzSJvkSus5kl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(338</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--AsuragenMember_ztJNFrZdxxW3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,871</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters Warrants</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_znN0fJ1H7oX" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_ecustom--LoanProceeds_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zBbnvFjMaRk9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0923"> </span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zl3TwjywVEkc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_z4YfaBNVZkLk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zWyF8Ig3trKf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zUkzU8DgLuJl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BroadOak Loan</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_z5saH22xG6A9" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_ecustom--LoanProceeds_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zkg315UMcKKa" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zvtlhzdauC7e" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zcfC9CtKbPW7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_zl176P9Vxt34" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(58</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--BroadOakLoanMember_z2oD4gMrybGe" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,942</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231_zjETLA70qDe8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,237</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_ecustom--LoanProceeds_pn3n3_c20210101__20211231_zjSMxyqhgksh" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Loan proceeds"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_iN_pn3n3_di_c20210101__20211231_zv87WxZxLSta" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5</span>03</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion_pn3n3_c20210101__20211231_zJolFHs3DEOd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion/Interest Accrued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">496</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20210101__20211231_zcMND2tewRP6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Adjustment to Fair Value/Mark to Market"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(346</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231_zyZR2QLKKQmk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,884</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2216000 503000 496000 -338000 1871000 21000 50000 71000 8000000 -58000 7942000 2237000 8000000 5000 496000 -346000 9884000 <p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zF4HGbnVZX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zrEItUt1FJsh">Property and Equipment</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwt0X7rpPbCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8BE_zofXuzXO712l" style="display: none">Schedule of Property and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zPJPKydY9uth" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20201231_zkgLt1jP96e5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGz6wf_zfaCMnOX0nUb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">339</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">339</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FixturesAndEquipmentGross_iI_pn3n3_maPPAEGz6wf_zbRiWN56Kbhh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab and office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,837</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,536</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3n3_maPPAEGz6wf_zlkdnkIYt4l4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">339</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGz6wf_zX4dpjeM9hw6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Internal-use software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,572</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGz6wf_z5OnXE2S8aLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">506</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">505</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzUyr_mtPPAEGz6wf_zPLMt1fyw7Jg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzUyr_zoAbm0v78big" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,942</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzUyr_zVDQ48UNDDYc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,349</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,349</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zv7BPSDgLLs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense from continuing operations was approximately $<span id="xdx_90A_eus-gaap--DepreciationAndAmortization_pn5n6_c20210101__20211231_znh0IZ8gFBM5" title="Depreciation and amortization expense">1.2</span> million and $<span id="xdx_908_eus-gaap--DepreciationAndAmortization_pn5n6_c20200101__20201231_zsv9Tfki7Fja" title="Depreciation and amortization expense">0.8</span> million for the years ended December 31, 2021 and 2020, respectively. There was internal-use software amortization expense included in depreciation and amortization expense in 2021 of approximately $<span id="xdx_901_eus-gaap--AdjustmentForAmortization_pn5n6_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zzXAXE9KlK69" title="Amortization expense">0.3</span> million. As of December 31, 2021, capitalized external-use software was fully amortized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwt0X7rpPbCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8BE_zofXuzXO712l" style="display: none">Schedule of Property and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zPJPKydY9uth" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20201231_zkgLt1jP96e5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGz6wf_zfaCMnOX0nUb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">339</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">339</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FixturesAndEquipmentGross_iI_pn3n3_maPPAEGz6wf_zbRiWN56Kbhh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab and office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,837</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,536</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3n3_maPPAEGz6wf_zlkdnkIYt4l4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">339</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGz6wf_zX4dpjeM9hw6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Internal-use software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,572</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGz6wf_z5OnXE2S8aLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">506</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">505</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_maPPAENzUyr_mtPPAEGz6wf_zPLMt1fyw7Jg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzUyr_zoAbm0v78big" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,942</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzUyr_zVDQ48UNDDYc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,349</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,349</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 339000 339000 7837000 7536000 331000 339000 1572000 1572000 506000 505000 10585000 10291000 4236000 2942000 6349000 7349000 1200000 800000 300000 <p id="xdx_802_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zGBqFkKz49N4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_z0kzcGvo9qP4">Goodwill and Other Intangible Assets</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $<span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn5n6_c20190701__20190731__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember_zOmo7RM1lwvl">15.6</span> million, with goodwill of approximately $<span id="xdx_908_eus-gaap--Goodwill_iI_pn5n6_c20190731__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember_zVdYvFegLqV4">8.3</span> million and identifiable intangible assets of approximately $<span id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn5n6_c20190731__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember_zoqJm6jsmIfh">7.3</span> million. The goodwill balance at December 31, 2021 was $<span id="xdx_90F_eus-gaap--Goodwill_iI_pn5n6_c20211231_zuoxRzDVvHZj">8.4</span> million. The net carrying value of the identifiable intangible assets as of December 31, 2021 and December 31, 2020 is as follows:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zVUoNwKe5qJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B1_zNr8EtBYRORa" style="display: none">Schedule of Identifiable Intangible Assets Carrying Value</span><span/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center">Life</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asuragen acquisition:</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 33%">Thyroid</td><td style="width: 2%"> </td> <td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--AsuragenAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThyroidMember_z2EXVtRQsnpb" style="width: 12%; text-align: center" title="Finite-Lived Intangible Asset, Useful Life">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AsuragenAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThyroidMember_zl4v8b4NuFV1" style="width: 22%; text-align: right" title="Finite-lived Intangible Assets, Gross">8,519</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--AsuragenAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThyroidMember_zgeiF4au3Tyf" style="width: 22%; text-align: right" title="Finite-lived Intangible Assets, Gross">8,519</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RedPath acquisition:</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Pancreas test</td><td> </td> <td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PancreasTestMember_znUB2ZDho9a8" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PancreasTestMember_zGrLaXhKx9Tf" style="text-align: right" title="Finite-lived Intangible Assets, Gross">16,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PancreasTestMember_z5viSggvd2W3" style="text-align: right" title="Finite-lived Intangible Assets, Gross">16,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Barrett’s test</td><td> </td> <td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BarrettsTestMember_zQqvUqDQ2tRk" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BarrettsTestMember_zIg8uwQGu0kc" style="text-align: right" title="Finite-lived Intangible Assets, Gross">6,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BarrettsTestMember_zk9Dz8ZW0Sl9" style="text-align: right" title="Finite-lived Intangible Assets, Gross">6,682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioPharma acquisition:</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Trademarks</td><td> </td> <td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDToPBcamHBi" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z5Mbk6XgaZ49" style="text-align: right" title="Finite-lived Intangible Assets, Gross">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_znYP0xn5H4Bd" style="text-align: right" title="Finite-lived Intangible Assets, Gross">1,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Customer relationships</td><td> </td> <td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1qdDPw994ab" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ze8uRShytUX6" style="text-align: right" title="Finite-lived Intangible Assets, Gross">5,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE9y8AGe9kCb" style="text-align: right" title="Finite-lived Intangible Assets, Gross">5,700</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CLIA Lab</td><td> </td> <td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALabMember_zFouGK04z826" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">2.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALabMember_zZ3KGxP4Lbgb" style="text-align: right" title="Finite-lived Intangible Assets, Gross">609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALabMember_zKvLp3PQC23k" style="text-align: right" title="Finite-lived Intangible Assets, Gross">609</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231_zYgE10XlOxG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-lived Intangible Assets, Gross">39,251</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231_zIRjJVdZTUO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-lived Intangible Assets, Gross">39,251</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Amortization</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20211231_z8NhMS1HN8o9" style="text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(31,964</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zCVWDrAtt8xj" style="text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(27,900</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net Carrying Value</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20211231_zAeBRZQWRN2f" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Net">7,287</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20201231_zJ8p78Q4uNi2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Net">11,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zIud8gJ7f5b7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zRrRAAvWLVg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table displays a roll forward of the carrying amount of goodwill from January 1, 2020 to December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span><span id="xdx_8BC_zs2HY7OaH1Gf" style="display: none">Schedule of Goodwill Carrying Value</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; padding-bottom: 2.5pt">Balance as of January 1, 2020</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zRMJYsVANbYh" style="border-bottom: Black 2.5pt double; width: 20%; text-align: right" title="Goodwill, Beginning Balance">8,433</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Adjustments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--GoodwillPurchaseAccountingAdjustments_pn3n3_c20200101__20201231_z4OVjaPnzKhg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iS_pn3n3_c20210101__20211231_z0J34J4qXnUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Beginning Balance">8,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Adjustments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--GoodwillPurchaseAccountingAdjustments_pn3n3_c20210101__20211231_z8fMCuHPiWIc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--Goodwill_iE_pn3n3_c20210101__20211231_z634WeJPHL2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Ending Balance">8,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zfYNSUXYT6tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense was approximately $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20210101__20211231_zCwA8JdR5ymb" title="Amortization expense">4.1</span> million and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20200101__20201231_zD6tvXGUNkLa" title="Amortization expense">4.5</span> million for the years ended December 31, 2021 and 2020, respectively. Estimated amortization expense for the next five years is as follows:</span></p> <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBb92czqYaB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B8_zMKLgDOXiaAh" style="display: none">Schedule of Future Estimated Amortization Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2025</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2026</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20211231_zqiroBzihGe7" style="text-align: right" title="2022">2,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_c20211231_zdaBui7Nr7kl" style="text-align: right" title="2023">1,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_c20211231_zhMddlvPQt4g" style="text-align: right" title="2024">873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_c20211231_zSFkep9bk1fh" style="text-align: right" title="2025">873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_c20211231_zhj6LFN1lsWa" style="text-align: right" title="2026">873</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zLyyXolmZNa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 15600000 8300000 7300000 8400000 <p id="xdx_89D_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zVUoNwKe5qJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B1_zNr8EtBYRORa" style="display: none">Schedule of Identifiable Intangible Assets Carrying Value</span><span/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center">Life</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asuragen acquisition:</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 33%">Thyroid</td><td style="width: 2%"> </td> <td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--AsuragenAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThyroidMember_z2EXVtRQsnpb" style="width: 12%; text-align: center" title="Finite-Lived Intangible Asset, Useful Life">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AsuragenAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThyroidMember_zl4v8b4NuFV1" style="width: 22%; text-align: right" title="Finite-lived Intangible Assets, Gross">8,519</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--AsuragenAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThyroidMember_zgeiF4au3Tyf" style="width: 22%; text-align: right" title="Finite-lived Intangible Assets, Gross">8,519</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RedPath acquisition:</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Pancreas test</td><td> </td> <td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PancreasTestMember_znUB2ZDho9a8" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PancreasTestMember_zGrLaXhKx9Tf" style="text-align: right" title="Finite-lived Intangible Assets, Gross">16,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PancreasTestMember_z5viSggvd2W3" style="text-align: right" title="Finite-lived Intangible Assets, Gross">16,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Barrett’s test</td><td> </td> <td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BarrettsTestMember_zQqvUqDQ2tRk" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BarrettsTestMember_zIg8uwQGu0kc" style="text-align: right" title="Finite-lived Intangible Assets, Gross">6,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--RedPathAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BarrettsTestMember_zk9Dz8ZW0Sl9" style="text-align: right" title="Finite-lived Intangible Assets, Gross">6,682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioPharma acquisition:</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Trademarks</td><td> </td> <td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDToPBcamHBi" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z5Mbk6XgaZ49" style="text-align: right" title="Finite-lived Intangible Assets, Gross">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_znYP0xn5H4Bd" style="text-align: right" title="Finite-lived Intangible Assets, Gross">1,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Customer relationships</td><td> </td> <td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1qdDPw994ab" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ze8uRShytUX6" style="text-align: right" title="Finite-lived Intangible Assets, Gross">5,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--BioPharmaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE9y8AGe9kCb" style="text-align: right" title="Finite-lived Intangible Assets, Gross">5,700</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CLIA Lab</td><td> </td> <td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALabMember_zFouGK04z826" style="text-align: center" title="Finite-Lived Intangible Asset, Useful Life">2.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALabMember_zZ3KGxP4Lbgb" style="text-align: right" title="Finite-lived Intangible Assets, Gross">609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALabMember_zKvLp3PQC23k" style="text-align: right" title="Finite-lived Intangible Assets, Gross">609</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20211231_zYgE10XlOxG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-lived Intangible Assets, Gross">39,251</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231_zIRjJVdZTUO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-lived Intangible Assets, Gross">39,251</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Amortization</td><td> </td> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20211231_z8NhMS1HN8o9" style="text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(31,964</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zCVWDrAtt8xj" style="text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(27,900</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net Carrying Value</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20211231_zAeBRZQWRN2f" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Net">7,287</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20201231_zJ8p78Q4uNi2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Net">11,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P9Y 8519000 8519000 P7Y 16141000 16141000 P9Y 6682000 6682000 P10Y 1600000 1600000 P8Y 5700000 5700000 P2Y3M18D 609000 609000 39251000 39251000 31964000 27900000 7287000 11351000 <p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zRrRAAvWLVg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table displays a roll forward of the carrying amount of goodwill from January 1, 2020 to December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span><span id="xdx_8BC_zs2HY7OaH1Gf" style="display: none">Schedule of Goodwill Carrying Value</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; padding-bottom: 2.5pt">Balance as of January 1, 2020</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zRMJYsVANbYh" style="border-bottom: Black 2.5pt double; width: 20%; text-align: right" title="Goodwill, Beginning Balance">8,433</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Adjustments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--GoodwillPurchaseAccountingAdjustments_pn3n3_c20200101__20201231_z4OVjaPnzKhg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iS_pn3n3_c20210101__20211231_z0J34J4qXnUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Beginning Balance">8,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Adjustments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--GoodwillPurchaseAccountingAdjustments_pn3n3_c20210101__20211231_z8fMCuHPiWIc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--Goodwill_iE_pn3n3_c20210101__20211231_z634WeJPHL2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Ending Balance">8,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 8433000 8433000 8433000 4100000 4500000 <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBb92czqYaB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B8_zMKLgDOXiaAh" style="display: none">Schedule of Future Estimated Amortization Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2025</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2026</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20211231_zqiroBzihGe7" style="text-align: right" title="2022">2,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_c20211231_zdaBui7Nr7kl" style="text-align: right" title="2023">1,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_c20211231_zhMddlvPQt4g" style="text-align: right" title="2024">873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_c20211231_zSFkep9bk1fh" style="text-align: right" title="2025">873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_c20211231_zhj6LFN1lsWa" style="text-align: right" title="2026">873</td><td style="text-align: left"> </td></tr> </table> 2143000 1734000 873000 873000 873000 <p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zw6rWblJb4Wi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zbDcowjA9Yq1">Leases</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance lease assets are included in fixed assets, net of accumulated depreciation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_ecustom--ScheduleOfFinancingAndOperatingLeasesTableTextBlock_zbEUhObLrnLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span id="xdx_8B2_zxs86SzNEeu9" style="display: none">Schedule of Financing and Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: right; border-collapse: collapse; width: 97%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Classification on the Balance Sheet</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">Financing lease assets</td><td style="width: 2%"> </td> <td style="width: 40%; text-align: left">Property and equipment, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--FinanceLeaseRightOfUseAssetsClassifiedUnderPropertyAndEquipmentNet_iI_pn3n3_c20211231_zgidb0iVrv5c" style="width: 18%; text-align: right" title="Finance lease assets">636</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease right of use assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zkVRNRz7DUNd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease assets">4,032</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--TotalLeaseAssets_iI_pn3n3_c20211231_zelWXAN0qcgc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets">4,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Financing lease liabilities</td><td> </td> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_c20211231_z6Eab6QyJcZi" style="text-align: right" title="Finance Lease, Liability, Current">79</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--OperatingLeaseLiabilitiesCurrent_iI_pn3n3_c20211231_zGDfO0ai9Fz6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Lease, Liability, Current">1,041</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total current lease liabilities</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LongTermDebtAndCapitalLeaseObligationsCurrent_iI_pn3n3_c20211231_zTVNeLJBIA56" style="text-align: right" title="Total current lease liabilities">1,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Noncurrent</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Financing lease liabilities</td><td> </td> <td style="text-align: left">Other long-term liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FinanceLeaseLiabilitiesNoncurrent_iI_pn3n3_c20211231_zwunKztlkSK7" style="text-align: right" title="Finance Lease, Liability, Noncurrent">59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_zk7pQ6AsFB8i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Lease, Liability, Noncurrent">3,154</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total long-term lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iI_pn3n3_c20211231_z7kSnHzFaFf7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total long-term lease liabilities">3,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--TotalLeaseLiabilities_iI_pn3n3_c20211231_zdGNuTNNfLP6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">4,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><p id="xdx_8A8_zTJ1lcTruyek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining lease term for the Company’s operating leases was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zuKIyyZNksV7" title="Operating lease, weighted average remaining lease term">6.4</span> years as of December 31, 2021 and <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zgPXdoKdZpne" title="Operating Lease, Weighted Average Remaining Lease Term">7.1</span> years as of December 31, 2020 and the weighted average discount rate for those leases was <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zV7osvfu4YRi" title="Operating lease, weighted average discount rate, percent">6.5</span>% and <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20201231_zGaaHhyEgPJ2" title="Operating lease, weighted average discount rate, percent">6.0</span>% as of December 31, 2021 and December 31, 2020, respectively. The Company’s operating lease expenses are recorded within “Cost of revenue” and “General and administrative expenses.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabiltiesTableTextBlock_zuCQAUU97hNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdNxbaPqyWW6" style="display: none">Schedule of Maturities of Operating and Financing Lease Liabilities</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financing Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zkJ8QTcCCWGk" style="width: 18%; text-align: right" title="Operating Leases 2022">1,295</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zwCiuuBGE5Ng" style="width: 18%; text-align: right" title="Finance Lease 2022">86</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zbTrPO9iaMZ7" style="text-align: right" title="Operating Leases 2023">897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zjx5d8PuzZkd" style="text-align: right" title="Finance Lease 2023">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_znytejeQEb2b" style="text-align: right" title="Operating Leases 2024">567</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zyT3MNYVVotf" style="text-align: right" title="Finance Lease 2024"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zYoDqhnv0uXc" style="text-align: right" title="Operating Leases 2025">402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zuBTtrTSz3hk" style="text-align: right" title="Finance Lease 2025"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2026-2030</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zpnWeoLXa366" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases 2026-2030">1,924</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zaYnfsiCmZee" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases 2026-2030"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zuEv5arrs3pg" style="text-align: right" title="Operating Leases,Total minimum lease payments">5,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zyeE9jwxj725" style="text-align: right" title="Financing Leases,Total minimum lease payments">146</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount of lease payments representing effects of discounting</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zVUAFCTRmXec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing effects of discounting">890</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zv98IDMhK5Df" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Less: amount of lease payments representing effects of discounting">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zo4GFtudyh3b" style="text-align: right" title="Operating Leases, Present value of future minimum lease payments">4,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zx5R30EGPIBh" style="text-align: right" title="Finance Leases, Present value of future minimum lease payments">138</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current obligations under leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--OperatingLeaseLiabilitiesCurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_ztG903ed0gU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: current obligations under leases">1,041</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_z5aI8qD28DYh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Less: current obligations under leases">79</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term lease obligations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zk5IPxD2ZiU4" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Long-term lease obligations">3,154</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--FinanceLeaseLiabilitiesNoncurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zClFpfCR8Qt2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Long-term lease obligations">59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zRCwHv21L9Xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_ecustom--ScheduleOfFinancingAndOperatingLeasesTableTextBlock_zbEUhObLrnLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span id="xdx_8B2_zxs86SzNEeu9" style="display: none">Schedule of Financing and Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: right; border-collapse: collapse; width: 97%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Classification on the Balance Sheet</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">Financing lease assets</td><td style="width: 2%"> </td> <td style="width: 40%; text-align: left">Property and equipment, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--FinanceLeaseRightOfUseAssetsClassifiedUnderPropertyAndEquipmentNet_iI_pn3n3_c20211231_zgidb0iVrv5c" style="width: 18%; text-align: right" title="Finance lease assets">636</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease right of use assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zkVRNRz7DUNd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease assets">4,032</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--TotalLeaseAssets_iI_pn3n3_c20211231_zelWXAN0qcgc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease assets">4,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Financing lease liabilities</td><td> </td> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_c20211231_z6Eab6QyJcZi" style="text-align: right" title="Finance Lease, Liability, Current">79</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--OperatingLeaseLiabilitiesCurrent_iI_pn3n3_c20211231_zGDfO0ai9Fz6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Lease, Liability, Current">1,041</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total current lease liabilities</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LongTermDebtAndCapitalLeaseObligationsCurrent_iI_pn3n3_c20211231_zTVNeLJBIA56" style="text-align: right" title="Total current lease liabilities">1,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Noncurrent</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Financing lease liabilities</td><td> </td> <td style="text-align: left">Other long-term liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FinanceLeaseLiabilitiesNoncurrent_iI_pn3n3_c20211231_zwunKztlkSK7" style="text-align: right" title="Finance Lease, Liability, Noncurrent">59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_zk7pQ6AsFB8i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Lease, Liability, Noncurrent">3,154</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total long-term lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iI_pn3n3_c20211231_z7kSnHzFaFf7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total long-term lease liabilities">3,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--TotalLeaseLiabilities_iI_pn3n3_c20211231_zdGNuTNNfLP6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">4,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 636000 4032000 4668000 79000 1041000 1120000 59000 3154000 3213000 4333000 P6Y4M24D P7Y1M6D 0.065 0.060 <p id="xdx_896_ecustom--ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabiltiesTableTextBlock_zuCQAUU97hNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdNxbaPqyWW6" style="display: none">Schedule of Maturities of Operating and Financing Lease Liabilities</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financing Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zkJ8QTcCCWGk" style="width: 18%; text-align: right" title="Operating Leases 2022">1,295</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zwCiuuBGE5Ng" style="width: 18%; text-align: right" title="Finance Lease 2022">86</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zbTrPO9iaMZ7" style="text-align: right" title="Operating Leases 2023">897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zjx5d8PuzZkd" style="text-align: right" title="Finance Lease 2023">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_znytejeQEb2b" style="text-align: right" title="Operating Leases 2024">567</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zyT3MNYVVotf" style="text-align: right" title="Finance Lease 2024"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zYoDqhnv0uXc" style="text-align: right" title="Operating Leases 2025">402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zuBTtrTSz3hk" style="text-align: right" title="Finance Lease 2025"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2026-2030</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zpnWeoLXa366" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases 2026-2030">1,924</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zaYnfsiCmZee" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases 2026-2030"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zuEv5arrs3pg" style="text-align: right" title="Operating Leases,Total minimum lease payments">5,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zyeE9jwxj725" style="text-align: right" title="Financing Leases,Total minimum lease payments">146</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount of lease payments representing effects of discounting</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zVUAFCTRmXec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing effects of discounting">890</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zv98IDMhK5Df" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Less: amount of lease payments representing effects of discounting">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zo4GFtudyh3b" style="text-align: right" title="Operating Leases, Present value of future minimum lease payments">4,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zx5R30EGPIBh" style="text-align: right" title="Finance Leases, Present value of future minimum lease payments">138</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current obligations under leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--OperatingLeaseLiabilitiesCurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_ztG903ed0gU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: current obligations under leases">1,041</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_z5aI8qD28DYh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Less: current obligations under leases">79</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term lease obligations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--OpearatingLeaseMember_zk5IPxD2ZiU4" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Long-term lease obligations">3,154</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--FinanceLeaseLiabilitiesNoncurrent_iI_pn3n3_c20211231__us-gaap--LeaseContractualTermAxis__custom--FinancingLeaseMember_zClFpfCR8Qt2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Long-term lease obligations">59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1295000 86000 897000 60000 567000 402000 1924000 5085000 146000 890000 8000 4195000 138000 1041000 79000 3154000 59000 <p id="xdx_809_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z3uGfPkXMDM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zMdqWpywOxOf">Retirement Plans</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers an employee 401(k) saving plan. Under the Interpace Biosciences, Inc. 401(k) Plan, employees may contribute up to <span id="xdx_90C_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_uPure_c20210101__20211231_zwQZnydtEVrf" title="Defined contribution plan, maximum annual contributions per employee, percent">50%</span> of their pre- or post-tax base compensation. The Company currently offers a safe harbor matching contribution equal to <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20210101__20211231_zYsQdIHX0zw9" title="Defined contribution plan, employer matching contribution, percent">100%</span> of the first <span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zoim11l8VYI5" title="Defined contribution plan, employer matching contribution, percent">3%</span> of the participant’s contributed base salary plus <span id="xdx_90D_ecustom--DefinedContributionPlanEmployerMatchingContributionAtFiftyPercent_pid_uPure_c20210101__20211231_zQ8TgdXC2fGc" title="Defined contribution plan employer matching contribution at fifty percent">50%</span> of the participant’s base salary contributed exceeding <span id="xdx_908_ecustom--DefinedContributionPlanEmployerMatchingContributionAtFiftyPercent_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zTyXj1XNCw98" title="Defined contribution plan employer matching contribution at fifty percent">3%</span> but not more than <span id="xdx_909_ecustom--DefinedContributionPlanEmployerMatchingContributionAtFiftyPercent_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zqcomq7gdD15" title="Defined contribution plan employer matching contribution at fifty percent">5%</span>. Participants are not allowed to invest any of their 401(k) funds in the Company’s common stock. The Company’s total contribution expense from continuing operations related to the 401(k) plan for the years ended December 31, 2021 and December 31, 2020 was approximately $<span id="xdx_905_eus-gaap--PensionAndOtherPostretirementBenefitExpense_pn5n6_c20210101__20211231_z7QIpjwRVOG8" title="Contribution expense">0.3</span> million and $<span id="xdx_90F_eus-gaap--PensionAndOtherPostretirementBenefitExpense_pn5n6_c20200101__20201231_zw8bpI3s4Oqj" title="Contribution expense">0.4</span> million, respectively.</span></p> 0.50 1 0.03 0.50 0.03 0.05 300000 400000 <p id="xdx_807_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_zVTVSWQfqhr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zI12GlAx4kb6">Accrued Expenses and Other Long-Term Liabilities</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zz3971OxRlgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued expenses consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B0_z8pn1FhjD0Yf" style="display: none">Schedule of Other Accrued Expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20211231_zNNumLjRuLZh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20201231_zNu0N24hHbk7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedRoyaltiesCurrent_iI_pn3n3_maOALCzm77_z9YPV8ufz1r4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Accrued royalties</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,710</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iI_pn3n3_maOALCzm77_zEPnzAdcWpke" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">398</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--UpfrontMedicarePaymentAdvance_iI_pn3n3_maOALCzm77_z8YkMDinQF4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Upfront Medicare payment</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1177"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,066</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OperatingLeaseLiabilitiesCurrent_iI_pn3n3_maOALCzm77_zKVkvaAekIGj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,041</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_maOALCzm77_zfXFPitFKjr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financing lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maOALCzm77_zELaZjPuNe4f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pn3n3_maOALCzm77_zYqWV21lY3ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">120</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1190"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityCurrent_iI_pn3n3_maOALCzm77_z5l78IXGxqb3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1193"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedMarketingCostsCurrent_iI_pn3n3_maOALCzm77_znZe4gaRcCd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued sales and marketing - diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedLabCosts_iI_pn3n3_maOALCzm77_zvWvZQFIx4X1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued lab costs - diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOALCzm77_zp7h3RLQA5Uh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--TaxesPayableCurrent_iI_pn3n3_maOALCzm77_z1o3VfqeoEYk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Taxes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">334</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--UnclaimedPropertyCurrent_iI_pn3n3_maOALCzm77_zsY5HhDIaacl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unclaimed property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--OthersAccruedExpensesCurrent_iI_pn3n3_maOALCzm77_zk4qJtnLNQK2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">All others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,452</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,398</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtOALCzm77_z047H5MjwSoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,198</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,795</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zdVI7ekptpn2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfLongTermLiabilitiesTableTextBlock_z1AYG757xxGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other long-term liabilities consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zHoRXIGXrXV1" style="display: none">Schedule of Long Term Liabilities</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_z7GBqGyfNHwf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20201231_zHfXQUY0uL0e" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_ecustom--WarrantLiabilityNoncurrent_iI_pn3n3_maOLNzYOW_zn86PlwJRmNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Warrant liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">21</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilityForUncertainTaxPositionsNoncurrent_iI_pn3n3_maOLNzYOW_zvgggqJRNin9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,577</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredRevenueNoncurrent_iI_pn3n3_maOLNzYOW_zA5BMrpq2rkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OtherAccruedExpensesAndLongTermLiabilities_iI_pn3n3_maOLNzYOW_zOnxtf7D0qL3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherLiabilitiesNoncurrent_iTI_pn3n3_mtOLNzYOW_z10yhHkWvf28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other long-term liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,648</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,637</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zvlJ41aEr67d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zz3971OxRlgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued expenses consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B0_z8pn1FhjD0Yf" style="display: none">Schedule of Other Accrued Expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20211231_zNNumLjRuLZh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20201231_zNu0N24hHbk7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedRoyaltiesCurrent_iI_pn3n3_maOALCzm77_z9YPV8ufz1r4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Accrued royalties</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,710</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iI_pn3n3_maOALCzm77_zEPnzAdcWpke" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">398</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--UpfrontMedicarePaymentAdvance_iI_pn3n3_maOALCzm77_z8YkMDinQF4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Upfront Medicare payment</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1177"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,066</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OperatingLeaseLiabilitiesCurrent_iI_pn3n3_maOALCzm77_zKVkvaAekIGj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,041</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_maOALCzm77_zfXFPitFKjr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financing lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maOALCzm77_zELaZjPuNe4f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestPayableCurrent_iI_pn3n3_maOALCzm77_zYqWV21lY3ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">120</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1190"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityCurrent_iI_pn3n3_maOALCzm77_z5l78IXGxqb3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1193"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedMarketingCostsCurrent_iI_pn3n3_maOALCzm77_znZe4gaRcCd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued sales and marketing - diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedLabCosts_iI_pn3n3_maOALCzm77_zvWvZQFIx4X1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued lab costs - diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOALCzm77_zp7h3RLQA5Uh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--TaxesPayableCurrent_iI_pn3n3_maOALCzm77_z1o3VfqeoEYk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Taxes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">334</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--UnclaimedPropertyCurrent_iI_pn3n3_maOALCzm77_zsY5HhDIaacl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unclaimed property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--OthersAccruedExpensesCurrent_iI_pn3n3_maOALCzm77_zk4qJtnLNQK2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">All others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,452</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,398</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtOALCzm77_z047H5MjwSoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,198</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,795</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3890000 2710000 488000 398000 2066000 1041000 1027000 79000 177000 40000 54000 120000 71000 47000 51000 228000 161000 932000 854000 245000 334000 565000 565000 1452000 1398000 9198000 9795000 <p id="xdx_893_ecustom--ScheduleOfLongTermLiabilitiesTableTextBlock_z1AYG757xxGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other long-term liabilities consisted of the following as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zHoRXIGXrXV1" style="display: none">Schedule of Long Term Liabilities</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_z7GBqGyfNHwf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20201231_zHfXQUY0uL0e" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_ecustom--WarrantLiabilityNoncurrent_iI_pn3n3_maOLNzYOW_zn86PlwJRmNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Warrant liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">21</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilityForUncertainTaxPositionsNoncurrent_iI_pn3n3_maOLNzYOW_zvgggqJRNin9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,577</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredRevenueNoncurrent_iI_pn3n3_maOLNzYOW_zA5BMrpq2rkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OtherAccruedExpensesAndLongTermLiabilities_iI_pn3n3_maOLNzYOW_zOnxtf7D0qL3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherLiabilitiesNoncurrent_iTI_pn3n3_mtOLNzYOW_z10yhHkWvf28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other long-term liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,648</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,637</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 21000 4577000 4342000 13000 136000 58000 138000 4648000 4637000 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMgc7k6isW6g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zt8pSYsCQyS5">Commitments and Contingencies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases facilities and certain equipment under agreements classified as operating leases, which <span id="xdx_90E_ecustom--OperatingLeaseExpireDateDescription_c20210101__20211231_zNAf8gfUkDo6" title="Operating lease expire date description">expire at various dates through May 2030</span>. Substantially all of the property leases provide for increases based upon use of utilities and landlord’s operating expenses as well as pre-defined rent escalations. Total expense from continuing operations under these agreements for the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20211231_z9XvaT03d8h6" title="Expense">1.2</span> million and $<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pn5n6_c20200101__20201231_zeAD7qPN8PGa" title="Expense">2.1</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock_zEwCl30wYBLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, contractual obligations with terms exceeding <span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20211231_zZOvWNCJuUtf" title="Contractual obligations terms">one</span> year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span id="xdx_8B9_zyQgIPkwJGK1" style="display: none">Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Less than</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">1 to 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">3 to 5</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">After</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">5 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zQBCHJIrT30l" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, Total">5,085</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_z8N7HGhUXtvd" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, Less than 1 Year">1,295</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears_iI_pn3n3_c20211231_zj5yiDzVivkk" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, 1 to 3 Years">1,464</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueThreeToFiveYears_iI_pn3n3_c20211231_zmSQ2rI4F602" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, 3 to 5 Years">816</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_zPdPwyCHv3Nf" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, After 5 Years">1,510</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zzqGn2JK5BZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, Total">5,085</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_zR93106lXRmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, Less than 1 Year">1,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears_iI_pn3n3_c20211231_zjQrMbPAp0U3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, 1 to 3 Years">1,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueThreeToFiveYears_iI_pn3n3_c20211231_ze34k1GcmfX3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, 3 to 5 Years">816</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_zn3nudz6UcL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, After 5 Years">1,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><p id="xdx_8A8_zwXWPYv9uZ93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.</span></p> expire at various dates through May 2030 1200000 2100000 <p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock_zEwCl30wYBLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, contractual obligations with terms exceeding <span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20211231_zZOvWNCJuUtf" title="Contractual obligations terms">one</span> year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span id="xdx_8B9_zyQgIPkwJGK1" style="display: none">Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Less than</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">1 to 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">3 to 5</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">After</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">5 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zQBCHJIrT30l" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, Total">5,085</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_z8N7HGhUXtvd" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, Less than 1 Year">1,295</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears_iI_pn3n3_c20211231_zj5yiDzVivkk" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, 1 to 3 Years">1,464</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueThreeToFiveYears_iI_pn3n3_c20211231_zmSQ2rI4F602" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, 3 to 5 Years">816</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_zPdPwyCHv3Nf" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right" title="Operating lease obligations, After 5 Years">1,510</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zzqGn2JK5BZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, Total">5,085</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_zR93106lXRmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, Less than 1 Year">1,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears_iI_pn3n3_c20211231_zjQrMbPAp0U3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, 1 to 3 Years">1,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueThreeToFiveYears_iI_pn3n3_c20211231_ze34k1GcmfX3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, 3 to 5 Years">816</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_zn3nudz6UcL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligations, After 5 Years">1,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5085000 1295000 1464000 816000 1510000 5085000 1295000 1464000 816000 1510000 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3pNU2WuVjSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zvv9RcQUyn5e">Equity</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock Issuance: Securities Purchase and Exchange Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20200109__20200110__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAndExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zp5Nf3ZfLrlg" title="Preferred stock aggregate value">20.0</span> million in Series B Preferred Stock of the Company, at an issuance price per share of $<span id="xdx_903_ecustom--IssuancePricesOfPreferredStock_pid_c20200109__20200110__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAndExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzSHEBmjqVUi" title="Issuance price of preferred stock">1,000</span>. Pursuant to the Securities Purchase and Exchange Agreement, 1315 Capital agreed to purchase <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200109__20200110__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAndExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__dei--LegalEntityAxis__custom--OneThreeOneFiveCapitalMember_ztZUVVzP9VZd" title="Aggregate of shares issued">19,000</span> shares of Series B Preferred Stock at an aggregate purchase price of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20200109__20200110__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAndExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__dei--LegalEntityAxis__custom--OneThreeOneFiveCapitalMember_zaW2tZPrtEke" title="Preferred stock aggregate value">19.0</span> million and Ampersand agreed to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200109__20200110__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAndExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__dei--LegalEntityAxis__custom--AmpersandLimitedPartnershiMember_zYr6vZpLQfP4" title="Aggregate of shares issued">1,000</span> shares of Series B Preferred Stock at an aggregate purchase price of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20200109__20200110__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAndExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__dei--LegalEntityAxis__custom--AmpersandLimitedPartnershiMember_zDk6GMb3j38d" title="Preferred stock aggregate value">1.0</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company agreed to exchange $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHWBrZR1ZkL2" title="Value of preferred stock exchanged">27.0</span> million of the Company’s existing Series A convertible preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuIM9pWWdWXj" title="Preferred stock par/stated value">0.01</span> per share, held by Ampersand (the “Series A Preferred Stock”), represented by <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrIja9DRvQab" title="Aggregate of shares issued">270</span> shares of Series A Preferred Stock with a stated value of $<span id="xdx_909_ecustom--PreferredSharesStatedValue_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znp661HkW7C7" title="Preferred shares stated value">100,000</span> per share, which represents all of the Company’s issued and outstanding Series A Preferred Stock, for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGkxCKlm4am" title="Aggregate of shares issued">27,000</span> newly issued shares of Series B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”). Following the Exchange, no shares of Series A Preferred Stock remained designated, authorized, issued or outstanding. The Series B Preferred Stock has a conversion price of $<span id="xdx_90D_ecustom--PreferredStockAdjustedConversion_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zh7vzTj698k1" title="Preferred stock adjusted conversion">6.00</span> as compared to a conversion price of $<span id="xdx_904_ecustom--PreferredStockAdjustedConversion_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztkSpn5TXnR6" title="Preferred stock adjusted conversion">8.00</span> on the Series A Preferred Stock, but did not include certain rights applicable to the Series A Preferred Stock, including a six-percent (<span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20211231_zBR2P0eHEJji" title="Preferred stock dividend percentage">6</span>%) dividend and a conversion price adjustment for any failure by the Company to achieve a revenue target of $<span id="xdx_907_ecustom--CompanyAchieveRevenueTarget_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_zqOmuREuxYC5" title="Company achieve revenue target">34.0</span> million in 2020 related to its clinical services or a weighted-average anti-dilution adjustment. Under the terms of the Securities Purchase and Exchange Agreement, Ampersand also agreed to waive all dividends and weighted-average anti-dilution adjustments accrued to date on the Series A Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $<span id="xdx_906_ecustom--IntrinsicValueOfBeneficialConversionFeature_pn5n6_c20200608__20200610__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_zqxt9b9m3Y27" title="Intrinsic value of beneficial conversion feature">2.2</span> million, which the Company recorded as a reduction to additional paid-in capital upon the sale of the Series B Preferred stock. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the Common Stock on January 15, 2020 of $<span id="xdx_90E_ecustom--IntrinsicValueOfEffectiveConversionPricePerShare_pid_c20200114__20200115__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_znpSIe1576Zi" title="Intrinsic value of effective conversion price per share">6.79</span> per share and the effective conversion price per share of $<span id="xdx_905_ecustom--PreferredStockAdjustedConversion_pid_c20200114__20200115__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_zb4IjrHqvrR9" title="Preferred stock adjusted conversion">6.00</span> multiplied by the number of shares of common stock issuable upon conversion. The Company fully amortized the beneficial conversion feature during the three months ended March 31, 2020 in accordance with GAAP. The beneficial conversion feature resulted in an increase in the loss attributable to common shareholders for the three months ended March 31, 2020 in the Condensed Consolidated Statement of Operations, as it represented a deemed dividend to the preferred shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect. During October 2021, Ampersand and 1315 Capital provided consent to the Company to enter into the Comerica Loan Agreement and the BroadOak Term Loan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, there were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmXcNs2ndZa9" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zriqIi03sfhb" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEDeMtU3ySE5" title="Preferred Stock, Shares Issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBdILuDqExLk" title="Preferred Stock, Shares Outstanding">47,000</span></span></span></span> Series B issued and outstanding shares of preferred stock, respectively.</span></p> 20000000.0 1000 19000 19000000.0 1000 1000000.0 27000000.0 0.01 270 100000 27000 6.00 8.00 0.06 34000000.0 2200000 6.79 6.00 47000 47000 47000 47000 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zzN8GeZUhk68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zkEhZTsiIkUf">Notes Payable</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BroadOak Loan and Repayment of Promissory Notes </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 29, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “BroadOak Loan Agreement”) with BroadOak, providing for a term loan in the aggregate principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211029__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--BroadOakMember_zwGsKRM1d1nj" title="Debt instrument, face amount">8,000,000</span> (the “Term Loan”). Funding of the Term Loan took place on November 1, 2021. The Term Loan matures upon the earlier of (i) <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20211028__20211029__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--AmpersandTwoThousandEighteenMember_zLu3gShgNxsf" title="Debt instrument, maturity date">October 31, 2024</span> or (ii) the occurrence of a change in control, and bears interest at the rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211029__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--AmpersandTwoThousandEighteenMember_zGZOgL8kaY3e" title="Debt interest percentage">9</span>% per annum. The Term Loan is secured by a security interest in substantially all of the Company’s and its subsidiaries’ assets and is subordinate to the Company’s recently established $<span id="xdx_902_eus-gaap--LineOfCredit_iI_c20211029__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--ComericaBankMember_zFOzobB39iHa" title="Long-term Line of Credit">7,500,000</span> revolving credit facility with Comerica Bank. <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateTerms_c20211028__20211029__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--ComericaBankMember_zKLRkwiUi1Fg" title="Debt instrument interest, description">The Term Loan has an origination fee of <span id="xdx_900_ecustom--DebtInstrumentOriginationFeePercentage_iI_dp_uPure_c20211029__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--AmpersandTwoThousandEighteenMember_zc2sQPiNBAu3" title="Percentage of debt origination fee">3</span>% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BroadOak Loan Agreement contains affirmative and negative restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the BroadOak Loan Agreement, the Company and its subsidiaries entered into that certain First Amendment to Loan and Security Agreement and Consent with Comerica, dated as of November 1, 2021 (the “Comerica Amendment”), pursuant to which Comerica consented to the Company’s and its subsidiaries’ entry into the BroadOak Loan Agreement, and amended that certain Loan and Security Agreement among Comerica, the Company and its subsidiaries (the “Comerica Loan Agreement”) to, among other things, permit the indebtedness, liens and encumbrances contemplated by the BroadOak Loan Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a condition for BroadOak to extend the Term Loan to the Company and its subsidiaries, the Company’s existing creditor, Comerica, and BroadOak entered into that certain Subordination and Intercreditor Agreement, dated as of November 1, 2021, pursuant to which BroadOak agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to BroadOak to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Intercreditor Agreement”). BroadOak further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Intercreditor Agreement provides that it is solely for the benefit of BroadOak and Comerica and is not for the benefit of the Company or any of its subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company concluded that the Note met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5 that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to shareholders’ equity. Accordingly, the Company elected the fair value option for the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Secured Promissory Notes – Related Parties </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $<span id="xdx_909_eus-gaap--SecuredDebt_iI_pn6n6_c20210107__us-gaap--DebtInstrumentAxis__custom--AmpersandNotesMember_zy9E6G47fzG6" title="Promissory note">3</span> million, and 1315 Capital, in the amount of $<span id="xdx_906_eus-gaap--SecuredDebt_iI_pn6n6_c20210107__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneThousandThreeFifteenCapitalNoteMember_zd5UqY59u959" title="Promissory note">2</span> million, respectively (together, the “Notes”) and a related security agreement (the “Security Agreement”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampersand holds <span id="xdx_905_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20210107__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--AmpersandMember_zHQ92AacPFf6">28,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210106__20210107__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zqzhiff2z5Hb">4,666,666 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Common Stock, and 1315 Capital holds <span id="xdx_90E_ecustom--NumberOfHoldsShares_pid_c20210106__20210107__dei--LegalEntityAxis__custom--OneThreeOneFiveCapitalMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zaiVYjmmNRTg">19,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210106__20210107__dei--LegalEntityAxis__custom--OneThreeOneFiveCapitalMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zC5hum3Uwsy8">3,166,668 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Common Stock. On an as-converted basis, such shares would represent approximately <span id="xdx_90A_ecustom--FullyDilutedPercentageOfCommonStock_pid_dp_uPure_c20210106__20210107__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNotesMember_znX9bvhgeIAe">38.7</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_ecustom--FullyDilutedPercentageOfCommonStock_pid_dp_uPure_c20210106__20210107__dei--LegalEntityAxis__custom--OneThreeOneFiveCapitalMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zgOotRGKwH38">26.3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of our fully-diluted shares of Common Stock, respectively. In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 12, <i>Equity</i>). As a result, the Company considers the Notes and Security Agreement to be a related party transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The rate of interest on the Notes was equal to eight percent (<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20210106__20210107__us-gaap--DebtInstrumentAxis__custom--PromissoryNotesMember_z2mR3HW0RfS">8.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%) per annum and their maturity date was the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. No interest payments were due on the Notes until their maturity date. All payments on the Notes were pari passu.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2021, (i) the Company and Ampersand amended the Ampersand Note to increase its principal amount to $<span id="xdx_909_eus-gaap--SecuredDebt_iI_pn5n6_c20210510__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--AmpersandNoteMember_zBOJyM7yGMN3" title="Promissory note">4.5</span> million, (ii) the Company and 1315 Capital amended the 1315 Capital Note to increase its principal amount to $<span id="xdx_901_eus-gaap--SecuredDebt_iI_pn5n6_c20210510__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--OneThousandThreeFifteenCapitalNoteMember_zum89o4aigC2" title="Promissory note">3.0</span> million and (iii) the Company and Ampersand amended the Security Agreement to include the new total principal amount of the Notes of $<span id="xdx_907_eus-gaap--SecuredDebt_iI_pn5n6_c20210510__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zzH8aGXqcSR3" title="Promissory note">7.5</span> million. The maturity date of the Notes remained the earlier of <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210501__20210510__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zYYHuxaB71Jb" title="Maturity date">June 30, 2021</span> and the date on which all amounts become due upon the occurrence of any event of default and the interest rate remained <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20210501__20210510__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zFWbw83UvwB9" style="font: 10pt Times New Roman, Times, Serif" title="Interest rate">8</span>%, and except with respect to their respective principal amounts, the terms of the Notes and the Security Agreement were otherwise unchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 24, 2021, August 31, 2021, and September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021, September 30, 2021, and October 31, 2021, respectively and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, August 31, 2021, and September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remained in full force and effect, and was not amended in connection with the amendments to the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of the amendments, the Company reviewed the changes in accordance with ASC 470 and determined they should be treated as modifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span id="xdx_909_ecustom--DescriptionOfFundedDebtAmount_c20210106__20210107_zyJQZEMEQ0u7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Notes contained certain negative covenants which prevented the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company used the proceeds of the BroadOak Term Loan discussed above to repay in full at their maturity all outstanding indebtedness under the promissory notes with Ampersand, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $<span id="xdx_908_eus-gaap--RepaymentsOfLongTermDebt_pn5n6_c20210928__20210929__dei--LegalEntityAxis__custom--AmpersandMember__us-gaap--DebtInstrumentAxis__custom--TermLoanMember_zMS5Zb0AWYza" title="Repayment of notes">4.5</span> million, and 1315 Capital, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $<span id="xdx_905_eus-gaap--RepaymentsOfLongTermDebt_pn6n6_c20210928__20210929__dei--LegalEntityAxis__custom--OneThousandThreeFifteenCapitalMember__us-gaap--DebtInstrumentAxis__custom--TermLoanMember_z9PI99Xxdq85" title="Repayment of notes">3</span> million, respectively. The Company, Ampersand, and 1315 Capital also terminated a related security agreement.</span></p> 8000000 2024-10-31 0.09 7500000 The Term Loan has an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date 0.03 3000000 2000000 28000 4666666 19000 3166668 0.387 0.263 0.080 4500000 3000000.0 7500000 2021-06-30 0.08 The Notes contained certain negative covenants which prevented the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year 4500000 3000000 <p id="xdx_80A_ecustom--WarrantsTextBlock_z8HyuoL1f2wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zs3OqqLfFXLf">Warrants</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zyPCpoyC4tC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding and warrant activity for the year ended December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zJSRvoFR5ws9" style="display: none">Schedule of Warrants Outstanding and Warrants Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Classification</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Expiration<br/> Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants<br/> Issued</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balance </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants<br/> Cancelled/ <br/> Expired</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balance </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 39%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z3QAncY6s7xe" title="Description">Private Placement Warrants, issued January 25, 2017</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zip2ia1ljiK2" title="Classification">Equity</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zLMj9ZxnTEgl" title="Exercise Price">46.90</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zTBdidzmziT5" title="Expiration Date">June 2022</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zslo5NMDm8ei" title="Warrants Issued">85,500</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zhpH0Xl4SGdf" title="Warrants">85,500</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zSb1tgNeBrM4" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z8fYWR9RGkGg" title="Warrants">85,500</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zJx0jar6SDji" title="Description">RedPath Warrants, issued March 22, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_908_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_z7WBBFUBwz56" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zsqCLUf7kFJ5" title="Exercise Price">46.90</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zwTVlSR6pNs9" title="Expiration Date">September 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zqxOLky3H0Pj" title="Warrants Issued">10,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zKVgAjkHEcnl" title="Warrants">10,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zTmFxDdZmrFi" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zVDieoqnjtr9" title="Warrants">10,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zAKu0RGfc9Vd" title="Description">Underwriters Warrants, issued June 21, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_905_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zeuicsonSI53" title="Classification">Liability</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zjdZPQJj41w1" title="Exercise Price">13.20</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zhlNvjKF5VVa" title="Expiration Date">December 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zoU6vbvQfyWl" title="Warrants Issued">57,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zchsvK4Womj4" title="Warrants">53,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_z0FNJEe2cCA1" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1397">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_ziqwVeJn7Pe7" title="Warrants">53,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zj2ZqDggmlpb" title="Description">Base &amp; Overallotment Warrants, issued June 21, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_z8YGVTIyS9o5" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_ztFyTzf1sdQi" title="Exercise Price">12.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zPlG9xoHJxrb" title="Expiration Date">June 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zrAMvrOF8kBa" title="Warrants Issued">1,437,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zo57qfGylAPc" title="Warrants">870,214</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zcp27GMIJZLd" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_z8wFjm6Ycmk6" title="Warrants">870,214</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zFvA5o0mlko8" title="Description">Warrants issued October 12, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zUlfId2rRD3b" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zWwMAymw67Bc" title="Exercise Price">18.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zPrU7aan1c93" title="Expiration Date">April 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zc6SeXQ4kiHd" title="Warrants Issued">320,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zvt1ILUV8YG3" title="Warrants">320,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zrlexDzKLlRe" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zQIw37SztyN5" title="Warrants">320,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zuQNx07NFPMl" title="Description">Underwriters Warrants, issued January 25, 2019</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zyfYeD6pMM3j" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zdgyl2cOABc" title="Exercise Price">9.40</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zEm3heeSewcd" title="Expiration Date">January 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zkiY2y48var8" title="Warrants Issued">65,434</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zxIrbBT8XYrf" title="Warrants">65,434</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zaUmSG1NUAG6" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1445">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zPMT9Qz145X4" title="Warrants">65,434</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zXy23HYJimna" title="Warrants Issued">1,975,934</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231_z47fyuvWZZSl" title="Warrants">1,404,648</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_zcmZUYWuAjpb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">     <span style="-sec-ix-hidden: xdx2ixbrl1453"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231_zqHLsiGGL0Li" title="Warrants">1,404,648</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> </table> <p id="xdx_8A0_zgv3P08IjNml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise price of the warrants is $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzT6Mbv4a8Jh" title="Weighted average exercise price">15.97</span> and the weighted average remaining contractual life is approximately <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ILwT9TFGOd" title="Weighted average remaining contractual life">0.4</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zyPCpoyC4tC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding and warrant activity for the year ended December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zJSRvoFR5ws9" style="display: none">Schedule of Warrants Outstanding and Warrants Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Classification</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Expiration<br/> Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants<br/> Issued</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balance </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants<br/> Cancelled/ <br/> Expired</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balance </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 39%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z3QAncY6s7xe" title="Description">Private Placement Warrants, issued January 25, 2017</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zip2ia1ljiK2" title="Classification">Equity</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zLMj9ZxnTEgl" title="Exercise Price">46.90</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zTBdidzmziT5" title="Expiration Date">June 2022</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zslo5NMDm8ei" title="Warrants Issued">85,500</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zhpH0Xl4SGdf" title="Warrants">85,500</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zSb1tgNeBrM4" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z8fYWR9RGkGg" title="Warrants">85,500</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zJx0jar6SDji" title="Description">RedPath Warrants, issued March 22, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_908_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_z7WBBFUBwz56" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zsqCLUf7kFJ5" title="Exercise Price">46.90</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zwTVlSR6pNs9" title="Expiration Date">September 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zqxOLky3H0Pj" title="Warrants Issued">10,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zKVgAjkHEcnl" title="Warrants">10,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zTmFxDdZmrFi" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--RedPathWarrantsMember_zVDieoqnjtr9" title="Warrants">10,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zAKu0RGfc9Vd" title="Description">Underwriters Warrants, issued June 21, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_905_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zeuicsonSI53" title="Classification">Liability</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zjdZPQJj41w1" title="Exercise Price">13.20</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zhlNvjKF5VVa" title="Expiration Date">December 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zoU6vbvQfyWl" title="Warrants Issued">57,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_zchsvK4Womj4" title="Warrants">53,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_z0FNJEe2cCA1" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1397">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantsMember_ziqwVeJn7Pe7" title="Warrants">53,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zj2ZqDggmlpb" title="Description">Base &amp; Overallotment Warrants, issued June 21, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_z8YGVTIyS9o5" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_ztFyTzf1sdQi" title="Exercise Price">12.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zPlG9xoHJxrb" title="Expiration Date">June 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zrAMvrOF8kBa" title="Warrants Issued">1,437,500</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zo57qfGylAPc" title="Warrants">870,214</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_zcp27GMIJZLd" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--BaseandOverallotmentWarrantsMember_z8wFjm6Ycmk6" title="Warrants">870,214</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zFvA5o0mlko8" title="Description">Warrants issued October 12, 2017</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zUlfId2rRD3b" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zWwMAymw67Bc" title="Exercise Price">18.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zPrU7aan1c93" title="Expiration Date">April 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zc6SeXQ4kiHd" title="Warrants Issued">320,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zvt1ILUV8YG3" title="Warrants">320,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zrlexDzKLlRe" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedMember_zQIw37SztyN5" title="Warrants">320,000</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zuQNx07NFPMl" title="Description">Underwriters Warrants, issued January 25, 2019</span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90E_ecustom--WarrantsClassification_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zyfYeD6pMM3j" title="Classification">Equity</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zdgyl2cOABc" title="Exercise Price">9.40</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_903_ecustom--ExpirationDateDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zEm3heeSewcd" title="Expiration Date">January 2022</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zkiY2y48var8" title="Warrants Issued">65,434</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zxIrbBT8XYrf" title="Warrants">65,434</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zaUmSG1NUAG6" title="Warrants Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1445">-</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--UnderwritersWarrantsTwoMember_zPMT9Qz145X4" title="Warrants">65,434</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zXy23HYJimna" title="Warrants Issued">1,975,934</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231_z47fyuvWZZSl" title="Warrants">1,404,648</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_zcmZUYWuAjpb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Cancelled/Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">     <span style="-sec-ix-hidden: xdx2ixbrl1453"> </span>-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211231_zqHLsiGGL0Li" title="Warrants">1,404,648</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> </table> Private Placement Warrants, issued January 25, 2017 Equity 46.90 June 2022 85500 85500 85500 RedPath Warrants, issued March 22, 2017 Equity 46.90 September 2022 10000 10000 10000 Underwriters Warrants, issued June 21, 2017 Liability 13.20 December 2022 57500 53500 53500 Base & Overallotment Warrants, issued June 21, 2017 Equity 12.50 June 2022 1437500 870214 870214 Warrants issued October 12, 2017 Equity 18.00 April 2022 320000 320000 320000 Underwriters Warrants, issued January 25, 2019 Equity 9.40 January 2022 65434 65434 65434 1975934 1404648 1404648 15.97 P0Y4M24D <p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zxruqWtSgkGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zMymBBk3ji4c">Stock-Based Compensation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stock-incentive program is a long-term retention program that is intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. Currently, the Company is able to grant options, stock appreciation rights (“SARs”) and restricted shares from the Interpace Biosciences, Inc. 2019 Equity Incentive Plan. No new grants may be made under the Company’s prior stock incentive plan, the Interpace Diagnostics Group, Inc. (now known as Interpace Biosciences, Inc.) Amended and Restated 2004 Stock Award and Incentive Plan (the “2004 Plan”). Unless earlier terminated by action of the Company’s board of directors, the 2004 Plan will remain in effect until such time as no stock remains available for delivery and the Company has no further rights or obligations under the 2004 Plan with respect to outstanding awards thereunder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockIncentivePlanMember_zktulkaIaWJ8" title="Share-based compensation arrangement by share-based payment award, description">stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the Company’s expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility is based on historical volatility. As there is no trading volume for the Company’s options, implied volatility is not representative of the Company’s current volatility so the historical volatility of the Company’s common stock is determined to be more indicative of the Company’s expected future stock performance. The expected life is determined using the safe-harbor method. The Company expects to use this simplified method for valuing employee options until more detailed information about exercise behavior becomes available over time. The Company bases the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option valuation model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest. The Company recognizes compensation cost, net of estimated forfeitures, arising from the issuance of stock options on a straight-line basis over the vesting period of the grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company began an employee stock purchase plan in 2020 and recognized approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z9J139Ws8CH2" title="Share-based compensation expense">0.1</span> million and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pn4n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDGIFz2G8whj" title="Share-based compensation expense">0.04</span> million in expense related to that plan for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated compensation cost associated with the granting of restricted stock and restricted stock units is based on the fair value of the Company’s common stock on the date of grant. The Company recognizes the compensation cost, net of estimated forfeitures, arising from the issuance of restricted stock and restricted stock units on a straight-line basis over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2021 and December 31, 2020.</span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zL0lrleTwAWh" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zBtJcm48ONik" style="display: none">Schedule of Stock Options, Valuation Assumptions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center"/><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zTr2Qm4ja5Ii" title="Risk-free interest rate">0.79</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zqN5oXph8Uy8">0.75</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z35uR1I9Ws2j" title="Expected life">6</span>.0 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zK9w5cr3lcgb">6.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zHD6qHEw5vm2" title="Expected volatility">134.73</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zhrdFyLwAbc1">123.71</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zhcODwg5Yet4" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1480">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zsTU9Fjg7MPh"><span style="-sec-ix-hidden: xdx2ixbrl1481">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_8A9_zqxna8tsHZRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average fair value of stock options granted during the year ended December 31, 2021 was estimated to be $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_znghuhOe4n6g" title="Weighted-average fair value of stock options granted">4.64</span>. The weighted-average fair value of stock options granted during the year ended December 31, 2020 was estimated to be $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231_zRBNY2Q1yvcj" title="Weighted-average fair value of stock options granted">5.36</span>. There were <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20211231_zPZeGkVNCtua" title="Options exercised">13,042</span> options exercised in 2021. There were <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20200101__20201231_zMoQOL7oXLNa" title="Options exercised">no</span> options exercised in 2020. Historically, shares issued upon the exercise of options have been new shares and have not come from treasury shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zKg6qKVv9IOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation for the years ended December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zA9jknU5reT4" style="display: none">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">RSUs and restricted stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RSUsandRestrictedStockMember_zxhOm1rSeuL5" style="width: 18%; text-align: right" title="Total stock-based compensation expense">433</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__custom--RSUsandRestrictedStockMember_zEtQKhp0Zc56" style="width: 18%; text-align: right" title="Total stock-based compensation expense">176</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Performance-based awards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9Bou0EFze7" style="text-align: right" title="Total stock-based compensation expense">107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjATz8GaQUp3" style="text-align: right" title="Total stock-based compensation expense">265</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock awards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_z0LOEJnYXUsf" style="text-align: right" title="Total stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1501">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zaCNFl6fHrO9" style="text-align: right" title="Total stock-based compensation expense">116</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKMu7zsjmO5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBIIHlKZofW4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,630</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zJzdiP13LN28" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,255</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231_zKyPKjI8cD09" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">2,187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zbvQ9dfJtd8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrOcOXVCFXp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of stock option activity for the year ended December 31, 2021, and changes during such year, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zLBH9zEgKLdk" style="display: none">Schedule of Stock Option Activity </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-Average</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2021</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zxLXIi1TI4P5" style="width: 11%; text-align: right" title="Shares outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">848,819</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zW9k65N0ExIf" style="width: 11%; text-align: right" title="Weighted average grant price outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.76</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYpTAIVn4WAc" title="Weighted average remaining contractual period outstanding beginning balance">8.59</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20210101__20211231_z5E3GxTuVkx3" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1521">-</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_z9SWqlmKBRVa" style="text-align: right" title="Shares granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,500</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z09tqxeTOHRd" style="text-align: right" title="Weighted average grant price granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--WeightedAverageRemainingContractualPeriodGranted_dtY_c20210101__20211231_zCoB1MIa24xb" title="Weighted average remaining contractual period granted">9.21</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_pn3n3_c20210101__20211231_zoCut8AF4Vna" style="text-align: right" title="Aggregate intrinsic value granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231_zvq4H0R93dj3" style="text-align: right" title="Shares exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,042</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z7NzdmwYfTsh" style="text-align: right" title="Weighted average grant price exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.45</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited or expired</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zYd3H6HSliL3" style="border-bottom: black 1.5pt solid; text-align: right" title="Shares forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(550,766</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zp9p9RmnPvK9" style="text-align: right" title="Weighted average grant price forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_ecustom--StockBasedCompensationAggregateInstrinsicValueForfeitedOrExpired_pn3n3_c20210101__20211231_z4E3ANduX9u8" style="text-align: right" title="Aggregate intrinsic value forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1539">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z0BZ6axyw03h" style="border-bottom: black 2.25pt double; text-align: right" title="Shares outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">632,511</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zDfCPJUKk8rf" style="text-align: right" title="Weighted average grant price outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.89</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zXOx43Lg79df" title="Weighted average remaining contractual period outstanding ending balance">8.40</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20210101__20211231_zsX2l5IquO47" style="text-align: right" title="Aggregate intrinsic value outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2021</span></td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20210101__20211231_ztoBdKKOU0wi" style="text-align: right" title="Shares exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206,732</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20210101__20211231_zjZc2iXOiBPg" style="text-align: right" title="Weighted average grant price exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zC5aftlzNzFl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.53</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20210101__20211231_z0Z4pJ4B4qxj" style="text-align: right" title="Aggregate intrinsic value exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1554"> </span>-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested and expected to vest</span></td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20210101__20211231_z6sCG0DI76Ba" style="text-align: right" title="Shares vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">537,520</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_z8p1VUzT8ZLa" style="text-align: right" title="Weighted average grant price vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.15</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--WeightedAverageRemainingContractualPeriodVestedAndExpectedToVest_dtY_c20210101__20211231_z70NphNC1nM" title="Weighted average remaining contractual period vested and expected to vest">8.36</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20210101__20211231_zMjNJBXsMLSb" style="text-align: right" title="Aggregate intrinsic value vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1562">-</span></span></td> <td> </td></tr> </table> <p id="xdx_8A3_zmM3Ep7aL8S5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_z2QS4mwpdeL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the status of the Company’s non-vested options for the year ended December 31, 2021, and changes during such year, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zZYcN7lPinm2" style="display: none">Schedule of Non Vested Option Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br/> Average <br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Nonvested at January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20210101__20211231_zW1KtFN008L7" style="width: 18%; text-align: right" title="Non-vested Shares outstanding beginning balance">487,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231_z628sjHQFuP2" style="width: 18%; text-align: right" title="Non-vested weighted average grant date fair value outstanding beginning balance">5.81</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zSDHt1RP6KQ5" style="text-align: right" title="Non-vested Shares granted">347,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zgKlNdifhFH9" style="text-align: right" title="Non-vested weighted average grant date fair value granted">4.64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20210101__20211231_zARR3zjjkBoc" style="text-align: right" title="Non-vested Shares vested">(127,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zd1abpRCgIj2" style="text-align: right" title="Non-vested weighted average grant date fair value vested">6.54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20210101__20211231_zqpVe6MWJK7h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-vested Shares forfeited">(284,646</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zcQrnKYJ5Azg" style="text-align: right" title="Non-vested weighted average grant date fair value forfeited">5.72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20210101__20211231_z7yfVq1cGyZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested Shares outstanding ending balance">422,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231_zMBKobvgD8lg" style="text-align: right" title="Non-vested weighted average grant date fair value outstanding ending balance">4.78</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zry7d68XQZpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate fair value of options vested during the years ended December 31, 2021 and 2020 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn5n6_c20210101__20211231_zxfBJmgLYlF9" title="Share-based compensation aggregate fair value of option">0.8</span> million and $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn5n6_c20200101__20201231_zVT8pTr64lrh" title="Share-based compensation aggregate fair value of option">1.5</span> million, respectively. The weighted-average grant date fair value of options vested during the year ended December 31, 2020 was $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20200101__20201231_zulzus7bVDFg" title="Weighted-average grant date fair value of options vested">7.34</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zb4NlvtGmCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2021, and changes during such year, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zcv4PDdvUwfc" style="display: none">Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; border-collapse: collapse; width: 96%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Date</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested at January 1, 2021</span></td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOf87UhJkd28" style="width: 11%; text-align: right" title="Non-vested Shares beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">239,457</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSumiT8UawP3" style="width: 11%; text-align: right" title="Non-vested Weighted Average Grant Date Fair Value beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NonVestedAverageRemainingVestingPeriodBeginning_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zibHdj80dNHj" title="Non-vested Average Remaining Vesting Period Beginning balance">1.75</span></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding_iS_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6R3N2BH2mQa" style="width: 11%; text-align: right" title="Non-vested Aggregate Intrinsic Value Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,348,781</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHck6etRSkd" style="text-align: right" title="Non-vested Shares granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">207,438</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zX6A0b2HvaO2" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.46</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSW2KsWklCD7" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1606">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeFyjGUxAR0a" style="text-align: right" title="Non-vested Shares Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65,577</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziydulfN1Im6" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.65</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA8XJqQT9iU2" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbX7Gzb6p8m2" style="border-bottom: black 1.5pt solid; text-align: right" title="Non-vested Shares Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(52,379</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwDSQY6okblg" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXu9lIB0ARa3" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1618">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1TmS2Bz9tCj" style="border-bottom: black 2.25pt double; text-align: right" title="Non-vested Shares ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">328,939</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJoq7ES2Y8ba" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.67</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--NonVestedAverageRemainingVestingPeriodEnding_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z50JBXglTJ9i" title="Non-vested Average Remaining Vesting Period Ending balance">1.34</span></span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding_iE_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzQir7TLnli4" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,467,043</span></td> <td> </td></tr> </table> <p id="xdx_8AE_z3bMhOc6Drm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate fair value of restricted stock units vested during each of the years ended December 31, 2021 and 2020 was $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn5n6_c20210101__20211231_zxPr2Qqgslnd" title="Aggregate fair value of restricted stock units">0.3</span> million and $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn5n6_c20200101__20201231_zFlF6gg9UUoj" title="Aggregate fair value of restricted stock units">0.4</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, there was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_z3rvOvvt6jS6" title="Total unrecognized compensation cost related to unvested stock options and restricted stock units">2.0</span> million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock units.</span></p> stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances 100000 40000.00 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zL0lrleTwAWh" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zBtJcm48ONik" style="display: none">Schedule of Stock Options, Valuation Assumptions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center"/><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zTr2Qm4ja5Ii" title="Risk-free interest rate">0.79</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zqN5oXph8Uy8">0.75</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z35uR1I9Ws2j" title="Expected life">6</span>.0 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zK9w5cr3lcgb">6.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zHD6qHEw5vm2" title="Expected volatility">134.73</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zhrdFyLwAbc1">123.71</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zhcODwg5Yet4" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1480">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zsTU9Fjg7MPh"><span style="-sec-ix-hidden: xdx2ixbrl1481">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 0.0079 0.0075 P6Y P6Y6M 1.3473 1.2371 4.64 5.36 13042 0 <p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zKg6qKVv9IOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation for the years ended December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zA9jknU5reT4" style="display: none">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">RSUs and restricted stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RSUsandRestrictedStockMember_zxhOm1rSeuL5" style="width: 18%; text-align: right" title="Total stock-based compensation expense">433</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__custom--RSUsandRestrictedStockMember_zEtQKhp0Zc56" style="width: 18%; text-align: right" title="Total stock-based compensation expense">176</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Performance-based awards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9Bou0EFze7" style="text-align: right" title="Total stock-based compensation expense">107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjATz8GaQUp3" style="text-align: right" title="Total stock-based compensation expense">265</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock awards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_z0LOEJnYXUsf" style="text-align: right" title="Total stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1501">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zaCNFl6fHrO9" style="text-align: right" title="Total stock-based compensation expense">116</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKMu7zsjmO5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBIIHlKZofW4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,630</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zJzdiP13LN28" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,255</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20201231_zKyPKjI8cD09" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">2,187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 433000 176000 107000 265000 116000 715000 1630000 1255000 2187000 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrOcOXVCFXp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of stock option activity for the year ended December 31, 2021, and changes during such year, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zLBH9zEgKLdk" style="display: none">Schedule of Stock Option Activity </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-Average</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2021</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zxLXIi1TI4P5" style="width: 11%; text-align: right" title="Shares outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">848,819</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zW9k65N0ExIf" style="width: 11%; text-align: right" title="Weighted average grant price outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.76</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zYpTAIVn4WAc" title="Weighted average remaining contractual period outstanding beginning balance">8.59</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pn3n3_c20210101__20211231_z5E3GxTuVkx3" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1521">-</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_z9SWqlmKBRVa" style="text-align: right" title="Shares granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,500</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z09tqxeTOHRd" style="text-align: right" title="Weighted average grant price granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--WeightedAverageRemainingContractualPeriodGranted_dtY_c20210101__20211231_zCoB1MIa24xb" title="Weighted average remaining contractual period granted">9.21</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_pn3n3_c20210101__20211231_zoCut8AF4Vna" style="text-align: right" title="Aggregate intrinsic value granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231_zvq4H0R93dj3" style="text-align: right" title="Shares exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,042</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z7NzdmwYfTsh" style="text-align: right" title="Weighted average grant price exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.45</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited or expired</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zYd3H6HSliL3" style="border-bottom: black 1.5pt solid; text-align: right" title="Shares forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(550,766</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zp9p9RmnPvK9" style="text-align: right" title="Weighted average grant price forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_ecustom--StockBasedCompensationAggregateInstrinsicValueForfeitedOrExpired_pn3n3_c20210101__20211231_z4E3ANduX9u8" style="text-align: right" title="Aggregate intrinsic value forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1539">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z0BZ6axyw03h" style="border-bottom: black 2.25pt double; text-align: right" title="Shares outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">632,511</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zDfCPJUKk8rf" style="text-align: right" title="Weighted average grant price outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.89</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zXOx43Lg79df" title="Weighted average remaining contractual period outstanding ending balance">8.40</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pn3n3_c20210101__20211231_zsX2l5IquO47" style="text-align: right" title="Aggregate intrinsic value outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2021</span></td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20210101__20211231_ztoBdKKOU0wi" style="text-align: right" title="Shares exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206,732</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20210101__20211231_zjZc2iXOiBPg" style="text-align: right" title="Weighted average grant price exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zC5aftlzNzFl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.53</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20210101__20211231_z0Z4pJ4B4qxj" style="text-align: right" title="Aggregate intrinsic value exercisable ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span style="-sec-ix-hidden: xdx2ixbrl1554"> </span>-</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested and expected to vest</span></td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20210101__20211231_z6sCG0DI76Ba" style="text-align: right" title="Shares vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">537,520</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_z8p1VUzT8ZLa" style="text-align: right" title="Weighted average grant price vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.15</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--WeightedAverageRemainingContractualPeriodVestedAndExpectedToVest_dtY_c20210101__20211231_z70NphNC1nM" title="Weighted average remaining contractual period vested and expected to vest">8.36</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20210101__20211231_zMjNJBXsMLSb" style="text-align: right" title="Aggregate intrinsic value vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1562">-</span></span></td> <td> </td></tr> </table> 848819 8.76 P8Y7M2D 347500 6.00 P9Y2M15D 13042 9.45 550766 9.15 632511 6.89 P8Y4M24D 206732 9.14 P7Y6M10D 537520 7.15 P8Y4M9D <p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_z2QS4mwpdeL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the status of the Company’s non-vested options for the year ended December 31, 2021, and changes during such year, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zZYcN7lPinm2" style="display: none">Schedule of Non Vested Option Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br/> Average <br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Nonvested at January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20210101__20211231_zW1KtFN008L7" style="width: 18%; text-align: right" title="Non-vested Shares outstanding beginning balance">487,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231_z628sjHQFuP2" style="width: 18%; text-align: right" title="Non-vested weighted average grant date fair value outstanding beginning balance">5.81</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zSDHt1RP6KQ5" style="text-align: right" title="Non-vested Shares granted">347,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zgKlNdifhFH9" style="text-align: right" title="Non-vested weighted average grant date fair value granted">4.64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20210101__20211231_zARR3zjjkBoc" style="text-align: right" title="Non-vested Shares vested">(127,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zd1abpRCgIj2" style="text-align: right" title="Non-vested weighted average grant date fair value vested">6.54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20210101__20211231_zqpVe6MWJK7h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-vested Shares forfeited">(284,646</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zcQrnKYJ5Azg" style="text-align: right" title="Non-vested weighted average grant date fair value forfeited">5.72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20210101__20211231_z7yfVq1cGyZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested Shares outstanding ending balance">422,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231_zMBKobvgD8lg" style="text-align: right" title="Non-vested weighted average grant date fair value outstanding ending balance">4.78</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 487318 5.81 347500 4.64 127696 6.54 284646 5.72 422476 4.78 800000 1500000 7.34 <p id="xdx_89A_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zb4NlvtGmCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2021, and changes during such year, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zcv4PDdvUwfc" style="display: none">Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; border-collapse: collapse; width: 96%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Date</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period</span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested at January 1, 2021</span></td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOf87UhJkd28" style="width: 11%; text-align: right" title="Non-vested Shares beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">239,457</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSumiT8UawP3" style="width: 11%; text-align: right" title="Non-vested Weighted Average Grant Date Fair Value beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NonVestedAverageRemainingVestingPeriodBeginning_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zibHdj80dNHj" title="Non-vested Average Remaining Vesting Period Beginning balance">1.75</span></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding_iS_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6R3N2BH2mQa" style="width: 11%; text-align: right" title="Non-vested Aggregate Intrinsic Value Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,348,781</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHck6etRSkd" style="text-align: right" title="Non-vested Shares granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">207,438</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zX6A0b2HvaO2" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.46</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSW2KsWklCD7" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1606">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeFyjGUxAR0a" style="text-align: right" title="Non-vested Shares Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65,577</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziydulfN1Im6" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.65</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA8XJqQT9iU2" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbX7Gzb6p8m2" style="border-bottom: black 1.5pt solid; text-align: right" title="Non-vested Shares Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(52,379</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwDSQY6okblg" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXu9lIB0ARa3" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1618">-</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1TmS2Bz9tCj" style="border-bottom: black 2.25pt double; text-align: right" title="Non-vested Shares ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">328,939</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJoq7ES2Y8ba" style="text-align: right" title="Non-vested Weighted Average Grant Date Fair Value Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.67</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--NonVestedAverageRemainingVestingPeriodEnding_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z50JBXglTJ9i" title="Non-vested Average Remaining Vesting Period Ending balance">1.34</span></span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding_iE_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzQir7TLnli4" style="text-align: right" title="Non-vested Aggregate Intrinsic Value Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,467,043</span></td> <td> </td></tr> </table> 239457 10.00 P1Y9M 1348781000 207438 5.46 65577 4.65 52379 5.23 328939 3.67 P1Y4M2D 2467043000 300000 400000 2000000.0 <p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zRzZZqit641a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zXcuDRsLO303">Revenue Sources </span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s clinical services customers consist primarily of physicians, hospitals and clinics. Its revenue channels include Medicare, Medicare Advantage, Medicaid, Client Billings (hospitals, etc.), and commercial payers. The following sets forth the net revenue generated by revenue channel accounted for more than 10% of the Company’s revenue from continuing operations during the years ended December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and December 31, 2020, revenue from Medicare was approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--MedicareMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHj6LWijKJG3" title="Revenue from continuing operations">54</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--MedicareMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQ2yWYvBCM14" title="Revenue from continuing operations">50</span>% of total revenue, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_ztNZxiVhszK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zhuEJedgD657" style="display: none">Schedule of Revenue by Major Customers </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="6" style="text-align: center">Years Ended December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Customer</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Medicare</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--MedicareCustomerMember_zf1ya6b8dU58" style="width: 18%; text-align: right" title="Revenue">17,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--MedicareCustomerMember_zD8uqsFWSdz4" style="width: 18%; text-align: right" title="Revenue">10,186</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medicare Advantage</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--MedicareAdvantageCustomerMember_zvCEcExI00E7" style="text-align: right" title="Revenue">5,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--MedicareAdvantageCustomerMember_zzTHth1kRmH5" style="text-align: right" title="Revenue">3,566</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Commercial Payors</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CommercialPayersCustomerMember_zvUQw7C3Yymd" style="text-align: right" title="Revenue">5,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--CommercialPayersCustomerMember_zsf5Vaca3c89" style="text-align: right" title="Revenue">4,136</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Client Billings</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--ClientBillingsCustomerMember_zQCjAaA6q6Xf" style="text-align: right" title="Revenue">3,752</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--ClientBillingsCustomerMember_zrxBc4MG6kEk" style="text-align: right" title="Revenue">2,582</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zPG1Nx82J5Vj" style="margin-top: 0; margin-bottom: 0"> </p> 0.54 0.50 <p id="xdx_89F_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_ztNZxiVhszK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zhuEJedgD657" style="display: none">Schedule of Revenue by Major Customers </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="6" style="text-align: center">Years Ended December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Customer</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Medicare</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--MedicareCustomerMember_zf1ya6b8dU58" style="width: 18%; text-align: right" title="Revenue">17,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--MedicareCustomerMember_zD8uqsFWSdz4" style="width: 18%; text-align: right" title="Revenue">10,186</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medicare Advantage</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--MedicareAdvantageCustomerMember_zvCEcExI00E7" style="text-align: right" title="Revenue">5,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--MedicareAdvantageCustomerMember_zzTHth1kRmH5" style="text-align: right" title="Revenue">3,566</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Commercial Payors</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CommercialPayersCustomerMember_zvUQw7C3Yymd" style="text-align: right" title="Revenue">5,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--CommercialPayersCustomerMember_zsf5Vaca3c89" style="text-align: right" title="Revenue">4,136</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Client Billings</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--ClientBillingsCustomerMember_zQCjAaA6q6Xf" style="text-align: right" title="Revenue">3,752</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--MajorCustomersAxis__custom--ClientBillingsCustomerMember_zrxBc4MG6kEk" style="text-align: right" title="Revenue">2,582</td><td style="text-align: left"> </td></tr> </table> 17778000 10186000 5859000 3566000 5555000 4136000 3752000 2582000 <p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zvpU4yRLTeaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zM0GGLPgMs18">Income Taxes</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zqrf7wGV3LHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The benefit from income taxes on continuing operations for the years ended December 31, 2021 and 2020 is comprised of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zgKHHs6Qfo7l" style="display: none">Schedule of Components of Income Tax Expense (Benefit)</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_z89SwFyM1na3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200101__20201231_zmdeVlqZo3Rh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzSih_z95oVrQ1s4q4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzSih_zLMHJb9u609i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(705</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">16</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzSih_maITEBzegO_z2S7ENMJVzqh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzDCd_ze3HloA0okCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzDCd_z6D43g3xB8a8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzDCd_maITEBzegO_zHmjpnJA9xN1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzegO_zetmQZYso37" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">(Benefit) provision from income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zJagUHjurlQk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company performs an analysis each year to determine whether the expected future income will more likely than not be sufficient to realize the deferred tax assets. The Company’s recent operating results and projections of future income weighed heavily in the Company’s overall assessment. As a result of this analysis, the Company continues to maintain a full valuation allowance against its federal and state net deferred tax assets at December 31, 2021 as the Company believes that it is more likely than not that these assets will not be realized. In the current year, the company maintains a full valuation allowance in consolidation and no separate company deferred tax liability recorded will be recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zB5285juHZvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2021 and 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zAyCr4Z2DFch" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_z7PEAKfPYOu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20201231_zcothWnbz6Hf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzp5q_maDTANzWmY_zB82zJ0lDFTk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Federal net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">24,923</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">17,015</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn3n3_maDTANzp5q_maDTANzWmY_zYodJlzEjUL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">State net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,953</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANzp5q_maDTANzWmY_zlJfsCwSxbb2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,844</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,492</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pn3n3_maDTANzp5q_maDTANzWmY_zlgXurEhqOA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Allowances and reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">585</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">436</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTANzp5q_maDTANzWmY_z9zrJYq4PYbf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">571</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTANzp5q_maDTANzWmY_z2dFTjYuxENh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">State taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTANzp5q_maDTANzWmY_z7rMklgQYgKk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Credit carryforward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxCreditInterest_iI_pn3n3_maDTANzp5q_maDTANzWmY_zRt7hPTNSlS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">163(j) interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">745</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxCreditLeases_iI_pn3n3_maDTANzp5q_maDTANzWmY_zDBhZx8HFFWj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTANzp5q_maDTANzWmY_zlRcT3wTKnpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzp5q_msDTANzWmY_z5mxFQiY2up7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,170</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzWmY_zKcDK1YrgLF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross deferred tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">527</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Deferred tax liability:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_z4ahjWBjoyY5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_zlTyECPhtw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Deferred tax liability-net valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A2_z6pnuj0flPH1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s deferred tax asset and deferred tax liabilities are included within <i>Other long-term liabilities</i>, respectively, within the consolidated balance sheet as of December 31, 2021 and 2020. Federal tax attribute carryforwards at December 31, 2021, consist primarily of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zc4aq8UDSEn6">118.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of federal net operating losses. In addition, the Company has approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zcRqZOlqsygg">56.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of state net operating losses carryforwards post 382 ownership change. The utilization of the federal carryforwards as an available offset to future taxable income is subject to limitations under federal income tax laws. <span id="xdx_904_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20210101__20211231_zRklQCKYsQg5">Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL, and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as similar state tax provisions. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carry forwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. During 2021, the Company completed a 382 assessment of the available NOLs under Section 382 and determined that the Company underwent an ownership change on March 30, 2017 and July 15, 2019 and as a result, NOLs attributable to the pre-ownership change are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code due to the multiple ownership changes. The Company has adjusted their NOL carryforwards to address the impact of the 382 ownership change. Federal Net Operating Losses of $<span id="xdx_90F_ecustom--ReductionInOperatingLossCarryforwards_pn5n6_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zTw1FhB5YWK8">71.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million are subject to annual limitation as of the ownership changes for ownership changes. The remaining $<span id="xdx_909_ecustom--RemainingReductionInOperatingLossCarryforwards_pn5n6_c20190707__20190715__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zoOLj0ZRJSed">47.4M </span>of NOLs incurred post July 15, 2019 are not subject to any annual limitation and can be carried forward indefinitely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zckOzetj9gPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8BD_zjSQCc6wAsMh" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="display: none"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20210101__20211231_zRuOBvtxIUe4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20200101__20201231_zvUWiNgwFDa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zJACWUIZWfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal statutory rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_z2IbpCS7CFA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income tax rate, net of Federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_zRaLQDK1G1c1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meals and entertainment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zvuhySVss0Tb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNakedCredit_pid_dp_uPure_zXd7jRV4kIel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naked credit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> <tr id="xdx_40D_ecustom--CreditSale_pid_dp_uPure_zdVqGVAb6Avj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ NOL credit sale</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z6t7ZvahV9Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective tax rate</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">4.3</td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> </table> <p id="xdx_8A2_zL99huHPb4Hg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrHfuIknpps9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxJjubppDmg7" style="display: none">Schedule of Unrecognized Tax Benefits Roll Forward</span> <span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Unrecognized</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Tax Benefits</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Balance of unrecognized benefits as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20200101__20201231_zndRTXoMTVI5" style="width: 20%; text-align: right" title="Unrecognized tax benefits beginning balance">877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions for tax positions of prior years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_c20200101__20201231_z4fVIbh61EZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions for tax positions of prior years">          <span style="-sec-ix-hidden: xdx2ixbrl1759"> </span>-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of January 1, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_z0qX18DV9Abe" style="text-align: right" title="Unrecognized tax benefits beginning balance">877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions for tax positions of prior years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_c20210101__20211231_zTIKSwAn4Zc8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions for tax positions of prior years"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20210101__20211231_zBkZ0JeXCdv6" style="text-align: right" title="Unrecognized tax benefits ending balance">877</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zhS9O3Awqk44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, the total amount of gross unrecognized tax benefits was $<span id="xdx_907_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20211231_zjuhcxlY3ov1" title="Unrecognized tax benefits">0.9</span> million and $<span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20201231_zY0QUs8GxCx8" title="Unrecognized tax benefits">0.9</span> million, respectively. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of December 31, 2021 and 2020 was $<span id="xdx_907_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20211231_zxb7AEOKhDyg" title="Unrecognized tax benefits would affect the effective tax rate">0.9</span> million and $<span id="xdx_906_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20201231_zIvxTIR2gVB5" title="Unrecognized tax benefits would affect the effective tax rate">0.9</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized interest and penalties of $<span id="xdx_90F_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pn5n6_c20210101__20211231_zry10g9M5tZ3" title="Income tax examination penalties and interest expense">0.2</span> million and $<span id="xdx_909_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pn5n6_c20200101__20201231_zQIt79ymV9G9" title="Income tax examination penalties and interest expense">0.3</span> million, respectively, related to uncertain tax positions in income tax expense during each of the years ended December 31, 2021 and 2020. At December 31, 2021 and 2020, accrued interest and penalties, net were $<span id="xdx_909_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_pn5n6_c20211231_z2S85nw4onak" title="Income tax examination penalties and interest accrued">3.6</span> million and $<span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_pn5n6_c20201231_zjYrHZweH44j" title="Income tax examination penalties and interest accrued">3.4</span> million, respectively, and included in the <i>Other long-term liabilities </i>in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_ecustom--ScheduleOfTaxYearsSubjectToExaminationTableTextBlock_zI3kwY7qSpog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z6t6WGTLbZpl" style="display: none">Schedule of Tax Years Subject to Examination</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify">Jurisdiction</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center">Tax Years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Federal</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__us-gaap--EarliestTaxYearMember_z3FMc3NJVTHd">2017</span> – <span id="xdx_90A_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__us-gaap--LatestTaxYearMember_zsA7dZ44b6Lf">2021</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State and Local</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__us-gaap--EarliestTaxYearMember_zU0tP55nEjt8">2016</span> – <span id="xdx_908_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__us-gaap--LatestTaxYearMember_zanRVtSiWv28">2021</span></td></tr> </table> <p id="xdx_8AB_zb7NPTSKX5V2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent there was a failure to file a tax return in a previous year; the statute of limitation will not begin until the return is filed. There were no examinations in process by the Internal Revenue Service as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zqrf7wGV3LHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The benefit from income taxes on continuing operations for the years ended December 31, 2021 and 2020 is comprised of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zgKHHs6Qfo7l" style="display: none">Schedule of Components of Income Tax Expense (Benefit)</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_z89SwFyM1na3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200101__20201231_zmdeVlqZo3Rh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzSih_z95oVrQ1s4q4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzSih_zLMHJb9u609i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(705</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">16</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzSih_maITEBzegO_z2S7ENMJVzqh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzDCd_ze3HloA0okCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzDCd_z6D43g3xB8a8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzDCd_maITEBzegO_zHmjpnJA9xN1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzegO_zetmQZYso37" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">(Benefit) provision from income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -705000 16000 -705000 16000 24000 23000 14000 14000 38000 37000 -667000 53000 <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zB5285juHZvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2021 and 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zAyCr4Z2DFch" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_z7PEAKfPYOu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20201231_zcothWnbz6Hf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzp5q_maDTANzWmY_zB82zJ0lDFTk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Federal net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">24,923</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">17,015</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn3n3_maDTANzp5q_maDTANzWmY_zYodJlzEjUL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">State net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,953</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANzp5q_maDTANzWmY_zlJfsCwSxbb2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,844</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,492</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pn3n3_maDTANzp5q_maDTANzWmY_zlgXurEhqOA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Allowances and reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">585</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">436</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTANzp5q_maDTANzWmY_z9zrJYq4PYbf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">571</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTANzp5q_maDTANzWmY_z2dFTjYuxENh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">State taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTANzp5q_maDTANzWmY_z7rMklgQYgKk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Credit carryforward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxCreditInterest_iI_pn3n3_maDTANzp5q_maDTANzWmY_zRt7hPTNSlS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">163(j) interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">745</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxCreditLeases_iI_pn3n3_maDTANzp5q_maDTANzWmY_zDBhZx8HFFWj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTANzp5q_maDTANzWmY_zlRcT3wTKnpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzp5q_msDTANzWmY_z5mxFQiY2up7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,170</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzWmY_zKcDK1YrgLF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross deferred tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">527</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Deferred tax liability:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_z4ahjWBjoyY5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_zlTyECPhtw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Deferred tax liability-net valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 24923000 17015000 3498000 2953000 1844000 1492000 585000 436000 571000 292000 942000 900000 2000 229000 1047000 745000 41000 54000 95000 95000 33170000 23684000 378000 527000 471000 582000 93000 55000 118600000 56300000 Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year 71200000 47400000 <p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zckOzetj9gPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8BD_zjSQCc6wAsMh" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="display: none"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20210101__20211231_zRuOBvtxIUe4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20200101__20201231_zvUWiNgwFDa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zJACWUIZWfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal statutory rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_z2IbpCS7CFA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income tax rate, net of Federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_zRaLQDK1G1c1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meals and entertainment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zvuhySVss0Tb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNakedCredit_pid_dp_uPure_zXd7jRV4kIel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naked credit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> <tr id="xdx_40D_ecustom--CreditSale_pid_dp_uPure_zdVqGVAb6Avj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ NOL credit sale</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z6t7ZvahV9Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective tax rate</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">4.3</td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%)</span></td></tr> </table> 0.210 0.210 0.042 0.040 -0.001 -0.001 -0.253 -0.250 -0.002 -0.001 0.047 0.000 0.043 -0.002 <p id="xdx_89C_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrHfuIknpps9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxJjubppDmg7" style="display: none">Schedule of Unrecognized Tax Benefits Roll Forward</span> <span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Unrecognized</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Tax Benefits</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Balance of unrecognized benefits as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20200101__20201231_zndRTXoMTVI5" style="width: 20%; text-align: right" title="Unrecognized tax benefits beginning balance">877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions for tax positions of prior years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_c20200101__20201231_z4fVIbh61EZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions for tax positions of prior years">          <span style="-sec-ix-hidden: xdx2ixbrl1759"> </span>-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of January 1, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20210101__20211231_z0qX18DV9Abe" style="text-align: right" title="Unrecognized tax benefits beginning balance">877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions for tax positions of prior years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_c20210101__20211231_zTIKSwAn4Zc8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions for tax positions of prior years"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20210101__20211231_zBkZ0JeXCdv6" style="text-align: right" title="Unrecognized tax benefits ending balance">877</td><td style="text-align: left"> </td></tr> </table> 877000 877000 877000 900000 900000 900000 900000 200000 300000 3600000 3400000 <p id="xdx_895_ecustom--ScheduleOfTaxYearsSubjectToExaminationTableTextBlock_zI3kwY7qSpog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z6t6WGTLbZpl" style="display: none">Schedule of Tax Years Subject to Examination</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify">Jurisdiction</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center">Tax Years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Federal</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__us-gaap--EarliestTaxYearMember_z3FMc3NJVTHd">2017</span> – <span id="xdx_90A_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__us-gaap--LatestTaxYearMember_zsA7dZ44b6Lf">2021</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State and Local</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__us-gaap--EarliestTaxYearMember_zU0tP55nEjt8">2016</span> – <span id="xdx_908_eus-gaap--OpenTaxYear_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__us-gaap--LatestTaxYearMember_zanRVtSiWv28">2021</span></td></tr> </table> 2017 2021 2016 2021 <p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zqOTMY1TduXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_829_zuNsWhDQpeJi"> Basic and Diluted Net Loss per Share</span></span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6ICOwscx3ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2021 and 2020 are as follows (rounded to thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zE7u65l9PGSk" style="display: none">Schedule of Weighted Average Number of Shares</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Basic weighted average number of common shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20210101__20211231_ziQrNTyVB3C8" style="width: 18%; text-align: right" title="Basic weighted average number of common shares">4,135</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20200101__20201231_z8m21tUfhoV9" style="width: 18%; text-align: right" title="Basic weighted average number of common shares">4,029</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Potential dilutive effect of stock-based awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20210101__20211231_zG1R575MKlRj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Potential dilutive effect of stock-based awards"><span style="-sec-ix-hidden: xdx2ixbrl1797">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20200101__20201231_zFyVwGR47tdf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Potential dilutive effect of stock-based awards"><span style="-sec-ix-hidden: xdx2ixbrl1799">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Diluted weighted average number of common shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20210101__20211231_zStpH0vo7FA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted weighted average number of common shares">4,135</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20200101__20201231_zMBg0ZDQihLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted weighted average number of common shares">4,029</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zPCYmVftxKm" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Series B Preferred Stock, on an as converted basis of <span id="xdx_905_ecustom--NumberPreferredStocksOnConvertedBasis_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zm7Vtwyu0E1i" title="Number preferred stocks on converted basis">7,833,334</span> shares and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8Lhvy6YZl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zVsPV085YVb8" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zRD4AfCtbPye" style="width: 18%; text-align: right" title="Antidilutive securities excluded from earning per share">632</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNMuDAC4azpc" style="width: 18%; text-align: right" title="Antidilutive securities excluded from earning per share">849</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units (RSUs)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zr2G9eC9Xxq" style="text-align: right" title="Antidilutive securities excluded from earning per share">329</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zptFkiJFYzrg" style="text-align: right" title="Antidilutive securities excluded from earning per share">238</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z09yjKjS6rbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive securities excluded from earning per share">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zmfGmCW3QChd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive securities excluded from earning per share">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231_zELgbjn9wgnh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from earning per share">2,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231_znSL1HWLf5C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from earning per share">2,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zjd2zKefSyc3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6ICOwscx3ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2021 and 2020 are as follows (rounded to thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zE7u65l9PGSk" style="display: none">Schedule of Weighted Average Number of Shares</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Basic weighted average number of common shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20210101__20211231_ziQrNTyVB3C8" style="width: 18%; text-align: right" title="Basic weighted average number of common shares">4,135</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20200101__20201231_z8m21tUfhoV9" style="width: 18%; text-align: right" title="Basic weighted average number of common shares">4,029</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Potential dilutive effect of stock-based awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20210101__20211231_zG1R575MKlRj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Potential dilutive effect of stock-based awards"><span style="-sec-ix-hidden: xdx2ixbrl1797">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20200101__20201231_zFyVwGR47tdf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Potential dilutive effect of stock-based awards"><span style="-sec-ix-hidden: xdx2ixbrl1799">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Diluted weighted average number of common shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20210101__20211231_zStpH0vo7FA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted weighted average number of common shares">4,135</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20200101__20201231_zMBg0ZDQihLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted weighted average number of common shares">4,029</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4135000 4029000 4135000 4029000 7833334 <p id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8Lhvy6YZl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zVsPV085YVb8" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zRD4AfCtbPye" style="width: 18%; text-align: right" title="Antidilutive securities excluded from earning per share">632</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNMuDAC4azpc" style="width: 18%; text-align: right" title="Antidilutive securities excluded from earning per share">849</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units (RSUs)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zr2G9eC9Xxq" style="text-align: right" title="Antidilutive securities excluded from earning per share">329</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zptFkiJFYzrg" style="text-align: right" title="Antidilutive securities excluded from earning per share">238</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z09yjKjS6rbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive securities excluded from earning per share">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zmfGmCW3QChd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive securities excluded from earning per share">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231_zELgbjn9wgnh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from earning per share">2,366</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231_znSL1HWLf5C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from earning per share">2,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 632000 849000 329000 238000 1405000 1405000 2366000 2492000 <p id="xdx_800_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zECc838YjIfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zW4HHqNexe7c">Revolving Line of Credit</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “Comerica Loan Agreement”) with Comerica Bank (“Comerica”), providing for a revolving credit facility of up to $<span id="xdx_90F_eus-gaap--LineOfCredit_iI_c20211013__us-gaap--TypeOfArrangementAxis__custom--ComericaLoanAgreementMember__srt--ProductOrServiceAxis__custom--ComericaBankMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_z6sytbYYNbM4" title="Line of credit, principal">7,500,000</span> (the “Credit Facility”). The Company may use the proceeds of the Credit Facility for working capital and other general corporate purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount that may be borrowed under the Credit Facility is the lower of (i) the revolving limit of $<span id="xdx_905_eus-gaap--LineOfCredit_iI_c20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zlQTEWGk9c2j" title="Line of credit">7,500,000</span> (the “Revolving Line”) and (ii) <span id="xdx_906_ecustom--PercentageOfAccountsReceivable_dp_uPure_c20211012__20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_z5DNDSgfpLBf" title="Percentage of accounts receivable">80</span>% of the Company’s eligible accounts receivable plus an applicable non-formula amount consisting of $<span id="xdx_909_eus-gaap--LineOfCredit_iI_c20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zi5CTwtAX9kk" title="Line of credit">2,000,000</span> of additional availability at close not based upon the Company’s eligible accounts receivable, with such additional availability reducing by $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220630__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zlzik1xvxqFf" title="Line of credit reductions">250,000</span> per quarter beginning with the quarter ending June 30, 2022. Borrowings on the Credit Facility are limited to $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_z1E9CVoqk4sa" title="Line of credit facility, maximum capacity">5,000,000</span> until <span id="xdx_90C_ecustom--PercentageOfAccountsReceivable_dp_uPure_c20211012__20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zY2LiWziLTs7" title="Percentage of accounts receivable">80</span>% of the Company’s and its subsidiaries’ customers are paying into a collection account or segregated governmental account with Comerica. The Revolving Line can also include, at the Company’s option, credit card services with a sublimit of $<span id="xdx_90F_ecustom--RevolvingLineOptionCreditCardServicesBorrowingLimit_iI_c20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zJNsajLr3msj" title="Revolving Line option credit card services borrowing limit">300,000</span>. Borrowings on the Revolving Line are subject to an interest rate equal to prime plus <span id="xdx_90C_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_uPure_c20211012__20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zeo4n5tMGlAh" title="Percentage of line of credit interest">0.50</span>%, with prime being the greater of (x) Comerica’s stated prime rate or (y) the sum of (A) the daily adjusting LIBOR rate plus (B) <span id="xdx_90A_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_uPure_c20211012__20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_zaocg5fOm6la" title="InterestRate">2.5</span>% per annum. The Company is also required to pay an unused facility fee quarterly in arrears in an amount equal to <span id="xdx_90C_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_dp_uPure_c20211012__20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zSvbIfEjTHvh" title="Percentage of line of credit unused facility fee">0.25</span>% per annum on the average unused but available portion of the Revolving Line for such quarter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Credit Facility matures on <span id="xdx_90D_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20211012__20211013__us-gaap--CreditFacilityAxis__custom--LoanAndSecurityAgreementMember_zoUhIpmUia1h" title="Line of credit, maturity date">September 30, 2023</span>, and is secured by a first priority lien on substantially all of the assets of the Company and its subsidiaries. As of December 31, 2021, the balance of the revolving line was $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20211231__srt--TitleOfIndividualAxis__custom--RevolverMember_zzzViLKrVW6l">1.5</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Comerica Loan Agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica Loan Agreement. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The Comerica Loan Agreement also contains financial covenants requiring specified minimum liquidity and minimum revenue thresholds and also contains customary events of default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a condition for Comerica to extend the Credit Facility to the Company and its subsidiaries, the Company’s existing creditors, Ampersand and 1315 Capital (the “Existing Creditors”), entered into that certain Subordination Agreement, dated as of October 13, 2021, pursuant to which each Existing Creditor agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to such Existing Creditor to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Subordination Agreement”). Each Existing Creditor further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Subordination Agreement provides that it is solely for the benefit of Comerica and each of the Existing Creditors and is not for the benefit of the Company or any of its subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revolving Line of Credit – Silicon Valley Bank</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 13, 2018 the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”), which provided for up to $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20181113__us-gaap--TypeOfArrangementAxis__custom--SVBLoanAgreementMember__srt--ProductOrServiceAxis__custom--SiliconValleyBankMember_zuh0thvtvYcd" title="Line of credit">4.0</span> million of debt financing consisting of a term loan of up to $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20181113__us-gaap--TypeOfArrangementAxis__custom--SVBLoanAgreementMember__srt--ProductOrServiceAxis__custom--SiliconValleyBankMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember_zBRc0UpCFhAf" title="Line of credit">850,000</span> and a revolving line of credit based on its outstanding accounts receivable (the “Revolving Line”) of up to $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_pn4n6_c20181113__us-gaap--TypeOfArrangementAxis__custom--SVBLoanAgreementMember__srt--ProductOrServiceAxis__custom--SiliconValleyBankMember_zFoJtdeKAsP1" title="Line of credit outstanding accounts receivable">3.75</span> million. As of December 31, 2020, the balance of the Revolving Line with SVB was <span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_dc_c20201231__srt--TitleOfIndividualAxis__custom--RevolverMember_zrX84BK5s9l9" title="Line of credit">zero</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2021, the Company terminated the SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company.</span></p> 7500000 7500000 0.80 2000000 250000 5000000 0.80 300000 0.0050 0.025 0.0025 2023-09-30 1500000 4000000.0 850000 3750000 0 <p id="xdx_807_ecustom--TransitionExpensesTextBlock_zi3oHiSVTuYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_824_zAVPTV9DY7Th">Transition Expenses</span></span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfTransitionExpensesTableTextBlock_zwoE3Bre8Vo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain legal expenses. The following is a roll forward of the transition expenses liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B1_z97gcmwOr26j" style="display: none">Schedule of Transition Expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: right; border-collapse: collapse; width: 97%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" id="xdx_4BE_us-gaap--BalanceSheetLocationAxis_custom--PersonnelMember_zitu9qJam5if" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" id="xdx_4BE_us-gaap--BalanceSheetLocationAxis_custom--FacilitiesAndInfrastructureMember_zKnExrqxpyI7" style="text-align: center">Facilities/</td><td> </td><td> </td> <td colspan="2" id="xdx_4B8_us-gaap--BalanceSheetLocationAxis_custom--LegalMember_zlnfBTqSfH7" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" id="xdx_4BC_zEq9SRNAJFse" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Personnel</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Infrastructure</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Legal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="14" style="text-align: center"/><td> </td></tr> <tr id="xdx_433_c20210101__20211231_ecustom--TransitionExpensesLiabilities_iS_pn3n3_zcQ12xqtXNod" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">885</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,154</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--TransitionExpense_pn3n3_zf3Y86QO3Mo" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Transition expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--PaymentTransitionExpenses_pn3n3_zv42Og39wOda" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,929</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,305</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(505</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,739</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_433_c20210101__20211231_ecustom--TransitionExpensesLiabilities_iE_zmYQJGknzFah" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1879">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1880">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1882">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_8A3_zXSd2LlpSa8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfTransitionExpensesTableTextBlock_zwoE3Bre8Vo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain legal expenses. The following is a roll forward of the transition expenses liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_8B1_z97gcmwOr26j" style="display: none">Schedule of Transition Expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: right; border-collapse: collapse; width: 97%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" id="xdx_4BE_us-gaap--BalanceSheetLocationAxis_custom--PersonnelMember_zitu9qJam5if" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" id="xdx_4BE_us-gaap--BalanceSheetLocationAxis_custom--FacilitiesAndInfrastructureMember_zKnExrqxpyI7" style="text-align: center">Facilities/</td><td> </td><td> </td> <td colspan="2" id="xdx_4B8_us-gaap--BalanceSheetLocationAxis_custom--LegalMember_zlnfBTqSfH7" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" id="xdx_4BC_zEq9SRNAJFse" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Personnel</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Infrastructure</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Legal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="14" style="text-align: center"/><td> </td></tr> <tr id="xdx_433_c20210101__20211231_ecustom--TransitionExpensesLiabilities_iS_pn3n3_zcQ12xqtXNod" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">885</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,154</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--TransitionExpense_pn3n3_zf3Y86QO3Mo" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Transition expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--PaymentTransitionExpenses_pn3n3_zv42Og39wOda" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,929</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,305</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(505</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,739</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_433_c20210101__20211231_ecustom--TransitionExpensesLiabilities_iE_zmYQJGknzFah" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1879">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1880">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1882">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 885000 269000 1154000 1044000 1036000 505000 2585000 -1929000 -1305000 -505000 -3739000 <p id="xdx_80A_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zjvpKaT5zZq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zmmLvFe9BN3c">Supplemental Cash Flow Information</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zEiU41RCOZF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplemental Disclosure of Other Cash Flow Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zcp62dogD3Af" style="display: none">Supplemental Cash Flow Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Cash paid for taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_90D_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20210101__20211231_z7a3yRxTi0rj" title="Cash paid for taxes">369</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_906_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20200101__20201231_ziaX0Hie6YI4" title="Cash paid for taxes">218</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for interest</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--InterestPaidNet_pn3n3_c20210101__20211231_zCcVIG2JxVhi" style="text-align: right" title="Cash paid for interest">424</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--InterestPaidNet_pn3n3_c20200101__20201231_zI41ZU4I8PFa" style="text-align: right" title="Cash paid for interest">60</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplemental Disclosures of Non Cash Activities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Taxes accrued for repurchase of restricted shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--TaxesAccruedForRepurchaseOfRestrictedShares_pn3n3_c20210101__20211231_zj5Rv5ibUDsd" style="width: 16%; text-align: right" title="Taxes accrued for repurchase of restricted shares">95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--TaxesAccruedForRepurchaseOfRestrictedShares_pn3n3_c20200101__20201231_zgWNqJ40dBP8" style="width: 16%; text-align: right" title="Taxes accrued for repurchase of restricted shares"><span style="-sec-ix-hidden: xdx2ixbrl1898">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Investing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Preferred Stock Deemed Dividend</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--PreferredStockDeemedDividend_pn3n3_c20210101__20211231_zOPyrAjW0J9h" style="text-align: right" title="Preferred Stock Deemed Dividend"><span style="-sec-ix-hidden: xdx2ixbrl1900">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--PreferredStockDeemedDividend_pn3n3_c20200101__20201231_zcr7Dz2Oi2qg" style="text-align: right" title="Preferred Stock Deemed Dividend">3,033</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investment in DiamiR</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--InvestmentInDiamir_pn3n3_c20210101__20211231_zlpFg87Z5E18" style="text-align: right" title="Investment in DiamiR">248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--InvestmentInDiamir_pn3n3_c20200101__20201231_zoBdRx6AfM1" style="text-align: right" title="Investment in DiamiR"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Financing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued financing costs</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--AccruedFinancingCosts_pn3n3_c20210101__20211231_zHXeoGkC5D7g" style="text-align: right" title="Accrued financing costs"><span style="-sec-ix-hidden: xdx2ixbrl1908">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--AccruedFinancingCosts_pn3n3_c20200101__20201231_zQNFvGCVjLe9" style="text-align: right" title="Accrued financing costs">31</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_z7JQck7JkQIl" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zEiU41RCOZF" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplemental Disclosure of Other Cash Flow Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zcp62dogD3Af" style="display: none">Supplemental Cash Flow Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Cash paid for taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_90D_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20210101__20211231_z7a3yRxTi0rj" title="Cash paid for taxes">369</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_906_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20200101__20201231_ziaX0Hie6YI4" title="Cash paid for taxes">218</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for interest</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--InterestPaidNet_pn3n3_c20210101__20211231_zCcVIG2JxVhi" style="text-align: right" title="Cash paid for interest">424</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--InterestPaidNet_pn3n3_c20200101__20201231_zI41ZU4I8PFa" style="text-align: right" title="Cash paid for interest">60</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplemental Disclosures of Non Cash Activities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Taxes accrued for repurchase of restricted shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--TaxesAccruedForRepurchaseOfRestrictedShares_pn3n3_c20210101__20211231_zj5Rv5ibUDsd" style="width: 16%; text-align: right" title="Taxes accrued for repurchase of restricted shares">95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--TaxesAccruedForRepurchaseOfRestrictedShares_pn3n3_c20200101__20201231_zgWNqJ40dBP8" style="width: 16%; text-align: right" title="Taxes accrued for repurchase of restricted shares"><span style="-sec-ix-hidden: xdx2ixbrl1898">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Investing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Preferred Stock Deemed Dividend</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--PreferredStockDeemedDividend_pn3n3_c20210101__20211231_zOPyrAjW0J9h" style="text-align: right" title="Preferred Stock Deemed Dividend"><span style="-sec-ix-hidden: xdx2ixbrl1900">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--PreferredStockDeemedDividend_pn3n3_c20200101__20201231_zcr7Dz2Oi2qg" style="text-align: right" title="Preferred Stock Deemed Dividend">3,033</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investment in DiamiR</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--InvestmentInDiamir_pn3n3_c20210101__20211231_zlpFg87Z5E18" style="text-align: right" title="Investment in DiamiR">248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--InvestmentInDiamir_pn3n3_c20200101__20201231_zoBdRx6AfM1" style="text-align: right" title="Investment in DiamiR"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Financing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued financing costs</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--AccruedFinancingCosts_pn3n3_c20210101__20211231_zHXeoGkC5D7g" style="text-align: right" title="Accrued financing costs"><span style="-sec-ix-hidden: xdx2ixbrl1908">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--AccruedFinancingCosts_pn3n3_c20200101__20201231_zQNFvGCVjLe9" style="text-align: right" title="Accrued financing costs">31</td><td style="text-align: left"> </td></tr> </table> 369000 218000 424000 60000 95000 3033000 248000 31000 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zcYUpvZfee0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zrDMwZAQhAik">Subsequent Events</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b>Centers for Medicare &amp; Medicaid Services (CMS) Billing Policy Notice &amp; Rights Offering</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On January 28, 2022, the Company announced that the Centers for Medicare &amp; Medicaid Services (CMS) issued a new billing policy whereby CMS would no longer reimburse for the use of the Company’s ThyGeNEXT<sup>®</sup> and ThyraMIR<sup>®</sup> tests when billed together by the same provider/supplier for the same beneficiary on the same date of service and that the Company was terminating its previously announced rights offering and the mutual termination of the standby purchase agreement with 3K Limited Partnership. The CMS billing policy decision was subsequently reversed in February 2022, however the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="f_006"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTERPACE BIOSCIENCES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VALUATION AND QUALIFYING ACCOUNTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>YEARS ENDED DECEMBER 31, 2021 AND 2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($ in thousands)</span></p> <p id="xdx_89D_eus-gaap--SummaryOfValuationAllowanceTextBlock_zxVA3cn0LKAc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zBIOqc0zmGHk" style="display: none">Schedule II - Valuation and Qualifying Accounts</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Additions</td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center">Balance at</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Reductions)</td><td> </td><td> </td> <td colspan="2" id="xdx_F50_z5w8FOFeNRid" style="text-align: center">(1)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Balance at</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center">Beginning</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Charged to</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Deductions</td><td> </td><td> </td> <td colspan="2" style="text-align: center">end</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Description</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Period</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operations</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Other</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Period</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Allowance for doubtful accounts</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zPVkmuUXh9Ei" style="width: 11%; text-align: right" title="Balance at Beginning of Period">25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_z1oz2wZbteha" style="width: 11%; text-align: right" title="Additions (Reductions) Charged to Operations">     <span style="-sec-ix-hidden: xdx2ixbrl1918"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_fKDEp_z6ntu1Dg1sHf" style="width: 11%; text-align: right" title="Deductions Other">250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zdp4ILMdR2a5" style="width: 11%; text-align: right" title="Balance at end of Period">275</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Allowance for doubtful notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zoRKmDAglkE5" style="text-align: right" title="Balance at Beginning of Period">869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zOoWCSVwVZ2l" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1926">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_fKDEp_zEhltEq5fWyd" style="text-align: right" title="Deductions Other"><span style="-sec-ix-hidden: xdx2ixbrl1928">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zjQPhgq0M3L7" style="text-align: right" title="Balance at end of Period">869</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax valuation allowance</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDIp_zXPJNhg4WIOk" style="text-align: right" title="Balance at Beginning of Period">17,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDIp_zkCCJHDTh1L6" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1934">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDEpKDIp_zFf2ndfTXfud" style="text-align: right" title="Deductions Other">6,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDIp_zKtHi1dq4uE1" style="text-align: right" title="Balance at end of Period">23,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Allowance for doubtful accounts</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zT9JhkaiVjJ2" style="text-align: right" title="Balance at Beginning of Period">275</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zLgOYMXlnNce" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1942">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_fKDEp_zusJoJ5vF3A" style="text-align: right" title="Deductions Other">(203</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_ziSGgifg2Ghk" style="text-align: right" title="Balance at end of Period">72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allowance for doubtful notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zkIItAZgp3qj" style="text-align: right" title="Balance at Beginning of Period">869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zTY3b1CnzQIi" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1950">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_fKDEp_zZ4cNOacn0Ik" style="text-align: right" title="Deductions Other"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zYfJzrdSiuP3" style="text-align: right" title="Balance at end of Period">869</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax valuation allowance</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_zr3qkNsCTxZ6" style="text-align: right" title="Balance at Beginning of Period">23,684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_zlMpLMql3vue" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1958">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDEp_zIfl83k32n2e" style="text-align: right" title="Deductions Other">9,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_zyEZLctmwxSe" style="text-align: right" title="Balance at end of Period">33,170</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zSL7J8x8TLy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F10_zRrj259VX2Vc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes payments and actual write offs, as well as changes in estimates in the reserves.</span></td></tr> </table> <p id="xdx_8AD_zYLOtHicyGZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89D_eus-gaap--SummaryOfValuationAllowanceTextBlock_zxVA3cn0LKAc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zBIOqc0zmGHk" style="display: none">Schedule II - Valuation and Qualifying Accounts</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Additions</td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center">Balance at</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Reductions)</td><td> </td><td> </td> <td colspan="2" id="xdx_F50_z5w8FOFeNRid" style="text-align: center">(1)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Balance at</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: center">Beginning</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Charged to</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Deductions</td><td> </td><td> </td> <td colspan="2" style="text-align: center">end</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Description</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Period</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operations</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Other</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Period</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Allowance for doubtful accounts</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zPVkmuUXh9Ei" style="width: 11%; text-align: right" title="Balance at Beginning of Period">25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_z1oz2wZbteha" style="width: 11%; text-align: right" title="Additions (Reductions) Charged to Operations">     <span style="-sec-ix-hidden: xdx2ixbrl1918"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_fKDEp_z6ntu1Dg1sHf" style="width: 11%; text-align: right" title="Deductions Other">250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zdp4ILMdR2a5" style="width: 11%; text-align: right" title="Balance at end of Period">275</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Allowance for doubtful notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zoRKmDAglkE5" style="text-align: right" title="Balance at Beginning of Period">869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zOoWCSVwVZ2l" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1926">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_fKDEp_zEhltEq5fWyd" style="text-align: right" title="Deductions Other"><span style="-sec-ix-hidden: xdx2ixbrl1928">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zjQPhgq0M3L7" style="text-align: right" title="Balance at end of Period">869</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax valuation allowance</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDIp_zXPJNhg4WIOk" style="text-align: right" title="Balance at Beginning of Period">17,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDIp_zkCCJHDTh1L6" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1934">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDEpKDIp_zFf2ndfTXfud" style="text-align: right" title="Deductions Other">6,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20200101__20201231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDIp_zKtHi1dq4uE1" style="text-align: right" title="Balance at end of Period">23,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Allowance for doubtful accounts</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zT9JhkaiVjJ2" style="text-align: right" title="Balance at Beginning of Period">275</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_zLgOYMXlnNce" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1942">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_fKDEp_zusJoJ5vF3A" style="text-align: right" title="Deductions Other">(203</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--AllowanceForCreditLossMember_ziSGgifg2Ghk" style="text-align: right" title="Balance at end of Period">72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allowance for doubtful notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zkIItAZgp3qj" style="text-align: right" title="Balance at Beginning of Period">869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zTY3b1CnzQIi" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1950">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_fKDEp_zZ4cNOacn0Ik" style="text-align: right" title="Deductions Other"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--AllowanceForDoubtfulNotesMember_zYfJzrdSiuP3" style="text-align: right" title="Balance at end of Period">869</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax valuation allowance</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ValuationAllowancesAndReservesBalance_iS_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_zr3qkNsCTxZ6" style="text-align: right" title="Balance at Beginning of Period">23,684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ValuationAllowancesAndReservesChargedToCostAndExpense_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_zlMpLMql3vue" style="text-align: right" title="Additions (Reductions) Charged to Operations"><span style="-sec-ix-hidden: xdx2ixbrl1958">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ValuationAllowancesAndReservesDeductions_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_fKDEp_zIfl83k32n2e" style="text-align: right" title="Deductions Other">9,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ValuationAllowancesAndReservesBalance_iE_pn3n3_c20210101__20211231__us-gaap--ValuationAllowancesAndReservesTypeAxis__us-gaap--ValuationAllowanceOtherTaxCarryforwardMember_zyEZLctmwxSe" style="text-align: right" title="Balance at end of Period">33,170</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zSL7J8x8TLy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F10_zRrj259VX2Vc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes payments and actual write offs, as well as changes in estimates in the reserves.</span></td></tr> </table> 25000 250000 275000 869000 869000 17027000 6657000 23684000 275000 -203000 72000 869000 869000 23684000 9486000 33170000 Includes payments and actual write offs, as well as changes in estimates in the reserves. EXCEL 104 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ς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end XML 105 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 106 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 107 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 266 464 1 true 94 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://interpace.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://interpace.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://interpace.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://interpace.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Operations (Parenthetical) Sheet http://interpace.com/role/StatementsOfOperationsParenthetical Consolidated Statements of Operations (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders' Deficit Sheet http://interpace.com/role/StatementsOfStockholdersDeficit Consolidated Statements of Stockholders' Deficit Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://interpace.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Recent Accounting Standards Sheet http://interpace.com/role/RecentAccountingStandards Recent Accounting Standards Notes 9 false false R10.htm 00000010 - Disclosure - Going Concern Sheet http://interpace.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 00000011 - Disclosure - Discontinued Operations Sheet http://interpace.com/role/DiscontinuedOperations Discontinued Operations Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://interpace.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Property and Equipment Sheet http://interpace.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 00000014 - Disclosure - Goodwill and Other Intangible Assets Sheet http://interpace.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://interpace.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Retirement Plans Sheet http://interpace.com/role/RetirementPlans Retirement Plans Notes 16 false false R17.htm 00000017 - Disclosure - Accrued Expenses and Other Long-Term Liabilities Sheet http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilities Accrued Expenses and Other Long-Term Liabilities Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://interpace.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Equity Sheet http://interpace.com/role/Equity Equity Notes 19 false false R20.htm 00000020 - Disclosure - Notes Payable Notes http://interpace.com/role/NotesPayable Notes Payable Notes 20 false false R21.htm 00000021 - Disclosure - Warrants Sheet http://interpace.com/role/Warrants Warrants Notes 21 false false R22.htm 00000022 - Disclosure - Stock-Based Compensation Sheet http://interpace.com/role/Stock-basedCompensation Stock-Based Compensation Notes 22 false false R23.htm 00000023 - Disclosure - Revenue Sources Sheet http://interpace.com/role/RevenueSources Revenue Sources Notes 23 false false R24.htm 00000024 - Disclosure - Income Taxes Sheet http://interpace.com/role/IncomeTaxes Income Taxes Notes 24 false false R25.htm 00000025 - Disclosure - Basic and Diluted Net Loss per Share Sheet http://interpace.com/role/BasicAndDilutedNetLossPerShare Basic and Diluted Net Loss per Share Notes 25 false false R26.htm 00000026 - Disclosure - Revolving Line of Credit Sheet http://interpace.com/role/RevolvingLineOfCredit Revolving Line of Credit Notes 26 false false R27.htm 00000027 - Disclosure - Transition Expenses Sheet http://interpace.com/role/TransitionExpenses Transition Expenses Notes 27 false false R28.htm 00000028 - Disclosure - Supplemental Cash Flow Information Sheet http://interpace.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 28 false false R29.htm 00000029 - Disclosure - Subsequent Events Sheet http://interpace.com/role/SubsequentEvents Subsequent Events Notes 29 false false R30.htm 00000030 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) Policies http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPolicies 30 false false R31.htm 00000031 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) Sheet http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables Nature of Business and Significant Accounting Policies (Tables) Tables http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPolicies 31 false false R32.htm 00000032 - Disclosure - Discontinued Operations (Tables) Sheet http://interpace.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://interpace.com/role/DiscontinuedOperations 32 false false R33.htm 00000033 - Disclosure - Fair Value Measurements (Tables) Sheet http://interpace.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://interpace.com/role/FairValueMeasurements 33 false false R34.htm 00000034 - Disclosure - Property and Equipment (Tables) Sheet http://interpace.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://interpace.com/role/PropertyAndEquipment 34 false false R35.htm 00000035 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://interpace.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://interpace.com/role/GoodwillAndOtherIntangibleAssets 35 false false R36.htm 00000036 - Disclosure - Leases (Tables) Sheet http://interpace.com/role/LeasesTables Leases (Tables) Tables http://interpace.com/role/Leases 36 false false R37.htm 00000037 - Disclosure - Accrued Expenses and Other Long-Term Liabilities (Tables) Sheet http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilitiesTables Accrued Expenses and Other Long-Term Liabilities (Tables) Tables http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilities 37 false false R38.htm 00000038 - Disclosure - Commitments and Contingencies (Tables) Sheet http://interpace.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://interpace.com/role/CommitmentsAndContingencies 38 false false R39.htm 00000039 - Disclosure - Warrants (Tables) Sheet http://interpace.com/role/WarrantsTables Warrants (Tables) Tables http://interpace.com/role/Warrants 39 false false R40.htm 00000040 - Disclosure - Stock-Based Compensation (Tables) Sheet http://interpace.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://interpace.com/role/Stock-basedCompensation 40 false false R41.htm 00000041 - Disclosure - Revenue Sources (Tables) Sheet http://interpace.com/role/RevenueSourcesTables Revenue Sources (Tables) Tables http://interpace.com/role/RevenueSources 41 false false R42.htm 00000042 - Disclosure - Income Taxes (Tables) Sheet http://interpace.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://interpace.com/role/IncomeTaxes 42 false false R43.htm 00000043 - Disclosure - Basic and Diluted Net Loss per Share (Tables) Sheet http://interpace.com/role/BasicAndDilutedNetLossPerShareTables Basic and Diluted Net Loss per Share (Tables) Tables http://interpace.com/role/BasicAndDilutedNetLossPerShare 43 false false R44.htm 00000044 - Disclosure - Transition Expenses (Tables) Sheet http://interpace.com/role/TransitionExpensesTables Transition Expenses (Tables) Tables http://interpace.com/role/TransitionExpenses 44 false false R45.htm 00000045 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://interpace.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://interpace.com/role/SupplementalCashFlowInformation 45 false false R46.htm 00000046 - Disclosure - Subsequent Events (Tables) Sheet http://interpace.com/role/SubsequentEventsTables Subsequent Events (Tables) Tables http://interpace.com/role/SubsequentEvents 46 false false R47.htm 00000047 - Disclosure - Schedule of Current Assets (Details) Sheet http://interpace.com/role/ScheduleOfCurrentAssetsDetails Schedule of Current Assets (Details) Details 47 false false R48.htm 00000048 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) Sheet http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative Nature of Business and Significant Accounting Policies (Details Narrative) Details http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables 48 false false R49.htm 00000049 - Disclosure - Going Concern (Details Narrative) Sheet http://interpace.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://interpace.com/role/GoingConcern 49 false false R50.htm 00000050 - Disclosure - Schedule of Discontinued Operations (Details) Sheet http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails Schedule of Discontinued Operations (Details) Details 50 false false R51.htm 00000051 - Disclosure - Schedule of Financial Instrument Measured on Recurring Basis (Details) Sheet http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails Schedule of Financial Instrument Measured on Recurring Basis (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Sheet http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Details 52 false false R53.htm 00000053 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 53 false false R54.htm 00000054 - Disclosure - Property and Equipment (Details Narrative) Sheet http://interpace.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://interpace.com/role/PropertyAndEquipmentTables 54 false false R55.htm 00000055 - Disclosure - Schedule of Identifiable Intangible Assets Carrying Value (Details) Sheet http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails Schedule of Identifiable Intangible Assets Carrying Value (Details) Details 55 false false R56.htm 00000056 - Disclosure - Schedule of Goodwill Carrying Value (Details) Sheet http://interpace.com/role/ScheduleOfGoodwillCarryingValueDetails Schedule of Goodwill Carrying Value (Details) Details 56 false false R57.htm 00000057 - Disclosure - Schedule of Future Estimated Amortization Expense (Details) Sheet http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails Schedule of Future Estimated Amortization Expense (Details) Details 57 false false R58.htm 00000058 - Disclosure - Goodwill and Other Intangible Assets (Details Narrative) Sheet http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative Goodwill and Other Intangible Assets (Details Narrative) Details http://interpace.com/role/GoodwillAndOtherIntangibleAssetsTables 58 false false R59.htm 00000059 - Disclosure - Schedule of Financing and Operating Leases (Details) Sheet http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails Schedule of Financing and Operating Leases (Details) Details 59 false false R60.htm 00000060 - Disclosure - Schedule of Maturities of Operating and Financing Lease Liabilities (Details) Sheet http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails Schedule of Maturities of Operating and Financing Lease Liabilities (Details) Details 60 false false R61.htm 00000061 - Disclosure - Leases (Details Narrative) Sheet http://interpace.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://interpace.com/role/LeasesTables 61 false false R62.htm 00000062 - Disclosure - Retirement Plans (Details Narrative) Sheet http://interpace.com/role/RetirementPlansDetailsNarrative Retirement Plans (Details Narrative) Details http://interpace.com/role/RetirementPlans 62 false false R63.htm 00000063 - Disclosure - Schedule of Other Accrued Expenses (Details) Sheet http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails Schedule of Other Accrued Expenses (Details) Details 63 false false R64.htm 00000064 - Disclosure - Schedule of Long Term Liabilities (Details) Sheet http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails Schedule of Long Term Liabilities (Details) Details 64 false false R65.htm 00000065 - Disclosure - Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases (Details) Sheet http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases (Details) Details 65 false false R66.htm 00000066 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://interpace.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://interpace.com/role/CommitmentsAndContingenciesTables 66 false false R67.htm 00000067 - Disclosure - Equity (Details Narrative) Sheet http://interpace.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://interpace.com/role/Equity 67 false false R68.htm 00000068 - Disclosure - Notes Payable (Details Narrative) Notes http://interpace.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://interpace.com/role/NotesPayable 68 false false R69.htm 00000069 - Disclosure - Schedule of Warrants Outstanding and Warrants Activity (Details) Sheet http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails Schedule of Warrants Outstanding and Warrants Activity (Details) Details 69 false false R70.htm 00000070 - Disclosure - Warrants (Details Narrative) Sheet http://interpace.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://interpace.com/role/WarrantsTables 70 false false R71.htm 00000071 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) Sheet http://interpace.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails Schedule of Stock Options, Valuation Assumptions (Details) Details 71 false false R72.htm 00000072 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Sheet http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Details 72 false false R73.htm 00000073 - Disclosure - Schedule of Stock Option Activity (Details) Sheet http://interpace.com/role/ScheduleOfStockOptionActivityDetails Schedule of Stock Option Activity (Details) Details 73 false false R74.htm 00000074 - Disclosure - Schedule of Non Vested Option Activity (Details) Sheet http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails Schedule of Non Vested Option Activity (Details) Details 74 false false R75.htm 00000075 - Disclosure - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) Details 75 false false R76.htm 00000076 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://interpace.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://interpace.com/role/Stock-basedCompensationTables 76 false false R77.htm 00000077 - Disclosure - Schedule of Revenue by Major Customers (Details) Sheet http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails Schedule of Revenue by Major Customers (Details) Details 77 false false R78.htm 00000078 - Disclosure - Revenue Sources (Details Narrative) Sheet http://interpace.com/role/RevenueSourcesDetailsNarrative Revenue Sources (Details Narrative) Details http://interpace.com/role/RevenueSourcesTables 78 false false R79.htm 00000079 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details) Sheet http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails Schedule of Components of Income Tax Expense (Benefit) (Details) Details 79 false false R80.htm 00000080 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 80 false false R81.htm 00000081 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 81 false false R82.htm 00000082 - Disclosure - Schedule of Unrecognized Tax Benefits Roll Forward (Details) Sheet http://interpace.com/role/ScheduleOfUnrecognizedTaxBenefitsRollForwardDetails Schedule of Unrecognized Tax Benefits Roll Forward (Details) Details 82 false false R83.htm 00000083 - Disclosure - Schedule of Tax Years Subject to Examination (Details) Sheet http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails Schedule of Tax Years Subject to Examination (Details) Details 83 false false R84.htm 00000084 - Disclosure - Income Taxes (Details Narrative) Sheet http://interpace.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://interpace.com/role/IncomeTaxesTables 84 false false R85.htm 00000085 - Disclosure - Schedule of Weighted Average Number of Shares (Details) Sheet http://interpace.com/role/ScheduleOfWeightedAverageNumberOfSharesDetails Schedule of Weighted Average Number of Shares (Details) Details 85 false false R86.htm 00000086 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 86 false false R87.htm 00000087 - Disclosure - Basic and Diluted Net Loss per Share (Details Narrative) Sheet http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative Basic and Diluted Net Loss per Share (Details Narrative) Details http://interpace.com/role/BasicAndDilutedNetLossPerShareTables 87 false false R88.htm 00000088 - Disclosure - Revolving Line of Credit (Details Narrative) Sheet http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative Revolving Line of Credit (Details Narrative) Details http://interpace.com/role/RevolvingLineOfCredit 88 false false R89.htm 00000089 - Disclosure - Schedule of Transition Expenses (Details) Sheet http://interpace.com/role/ScheduleOfTransitionExpensesDetails Schedule of Transition Expenses (Details) Details 89 false false R90.htm 00000090 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://interpace.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://interpace.com/role/SupplementalCashFlowInformationTables 90 false false R91.htm 00000091 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Details 91 false false All Reports Book All Reports form10-k.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm idxg-20211231.xsd idxg-20211231_cal.xml idxg-20211231_def.xml idxg-20211231_lab.xml idxg-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 110 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 28, "contextCount": 266, "dts": { "calculationLink": { "local": [ "idxg-20211231_cal.xml" ] }, "definitionLink": { "local": [ "idxg-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "idxg-20211231_lab.xml" ] }, "presentationLink": { "local": [ "idxg-20211231_pre.xml" ] }, "schema": { "local": [ "idxg-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 704, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 97, "http://interpace.com/20211231": 43, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 143 }, "keyCustom": 96, "keyStandard": 368, "memberCustom": 54, "memberStandard": 34, "nsprefix": "IDXG", "nsuri": "http://interpace.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://interpace.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Going Concern", "role": "http://interpace.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Discontinued Operations", "role": "http://interpace.com/role/DiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Fair Value Measurements", "role": "http://interpace.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Property and Equipment", "role": "http://interpace.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://interpace.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Leases", "role": "http://interpace.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Retirement Plans", "role": "http://interpace.com/role/RetirementPlans", "shortName": "Retirement Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Accrued Expenses and Other Long-Term Liabilities", "role": "http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilities", "shortName": "Accrued Expenses and Other Long-Term Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Commitments and Contingencies", "role": "http://interpace.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Equity", "role": "http://interpace.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://interpace.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Notes Payable", "role": "http://interpace.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Warrants", "role": "http://interpace.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Stock-Based Compensation", "role": "http://interpace.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Revenue Sources", "role": "http://interpace.com/role/RevenueSources", "shortName": "Revenue Sources", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Income Taxes", "role": "http://interpace.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Basic and Diluted Net Loss per Share", "role": "http://interpace.com/role/BasicAndDilutedNetLossPerShare", "shortName": "Basic and Diluted Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Revolving Line of Credit", "role": "http://interpace.com/role/RevolvingLineOfCredit", "shortName": "Revolving Line of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:TransitionExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Transition Expenses", "role": "http://interpace.com/role/TransitionExpenses", "shortName": "Transition Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:TransitionExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Supplemental Cash Flow Information", "role": "http://interpace.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Subsequent Events", "role": "http://interpace.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://interpace.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:NatureOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Nature of Business and Significant Accounting Policies (Policies)", "role": "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies", "shortName": "Nature of Business and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:NatureOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "IDXG:OtherCurrentAssetsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Nature of Business and Significant Accounting Policies (Tables)", "role": "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables", "shortName": "Nature of Business and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "IDXG:OtherCurrentAssetsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Discontinued Operations (Tables)", "role": "http://interpace.com/role/DiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Fair Value Measurements (Tables)", "role": "http://interpace.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Property and Equipment (Tables)", "role": "http://interpace.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:ScheduleOfFinancingAndOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Leases (Tables)", "role": "http://interpace.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:ScheduleOfFinancingAndOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Accrued Expenses and Other Long-Term Liabilities (Tables)", "role": "http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilitiesTables", "shortName": "Accrued Expenses and Other Long-Term Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://interpace.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "IDXG:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Warrants (Tables)", "role": "http://interpace.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "IDXG:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "role": "http://interpace.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://interpace.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Revenue Sources (Tables)", "role": "http://interpace.com/role/RevenueSourcesTables", "shortName": "Revenue Sources (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Income Taxes (Tables)", "role": "http://interpace.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Basic and Diluted Net Loss per Share (Tables)", "role": "http://interpace.com/role/BasicAndDilutedNetLossPerShareTables", "shortName": "Basic and Diluted Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "IDXG:TransitionExpensesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:ScheduleOfTransitionExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Transition Expenses (Tables)", "role": "http://interpace.com/role/TransitionExpensesTables", "shortName": "Transition Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "IDXG:TransitionExpensesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:ScheduleOfTransitionExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Supplemental Cash Flow Information (Tables)", "role": "http://interpace.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfValuationAllowanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Subsequent Events (Tables)", "role": "http://interpace.com/role/SubsequentEventsTables", "shortName": "Subsequent Events (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfValuationAllowanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "IDXG:OtherCurrentAssetsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Schedule of Current Assets (Details)", "role": "http://interpace.com/role/ScheduleOfCurrentAssetsDetails", "shortName": "Schedule of Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "IDXG:OtherCurrentAssetsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "IDXG:ReverseStockSplitPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-132020-01-15", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative)", "role": "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "shortName": "Nature of Business and Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "IDXG:ReverseStockSplitPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-132020-01-15", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Going Concern (Details Narrative)", "role": "http://interpace.com/role/GoingConcernDetailsNarrative", "shortName": "Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Operations (Parenthetical)", "role": "http://interpace.com/role/StatementsOfOperationsParenthetical", "shortName": "Consolidated Statements of Operations (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Schedule of Discontinued Operations (Details)", "role": "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails", "shortName": "Schedule of Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:WarrantLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Financial Instrument Measured on Recurring Basis (Details)", "role": "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails", "shortName": "Schedule of Financial Instrument Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:WarrantLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)", "role": "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "shortName": "Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Schedule of Property and Equipment (Details)", "role": "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Schedule of Identifiable Intangible Assets Carrying Value (Details)", "role": "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails", "shortName": "Schedule of Identifiable Intangible Assets Carrying Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Schedule of Goodwill Carrying Value (Details)", "role": "http://interpace.com/role/ScheduleOfGoodwillCarryingValueDetails", "shortName": "Schedule of Goodwill Carrying Value (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Schedule of Future Estimated Amortization Expense (Details)", "role": "http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails", "shortName": "Schedule of Future Estimated Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Goodwill and Other Intangible Assets (Details Narrative)", "role": "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "shortName": "Goodwill and Other Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfFinancingAndOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:FinanceLeaseRightOfUseAssetsClassifiedUnderPropertyAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Schedule of Financing and Operating Leases (Details)", "role": "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails", "shortName": "Schedule of Financing and Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfFinancingAndOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:FinanceLeaseRightOfUseAssetsClassifiedUnderPropertyAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Deficit", "role": "http://interpace.com/role/StatementsOfStockholdersDeficit", "shortName": "Consolidated Statements of Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-03-31_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Schedule of Maturities of Operating and Financing Lease Liabilities (Details)", "role": "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails", "shortName": "Schedule of Maturities of Operating and Financing Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabiltiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_OpearatingLeaseMember", "decimals": "-3", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Leases (Details Narrative)", "role": "http://interpace.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Retirement Plans (Details Narrative)", "role": "http://interpace.com/role/RetirementPlansDetailsNarrative", "shortName": "Retirement Plans (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Schedule of Other Accrued Expenses (Details)", "role": "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails", "shortName": "Schedule of Other Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfLongTermLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:WarrantLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Schedule of Long Term Liabilities (Details)", "role": "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails", "shortName": "Schedule of Long Term Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfLongTermLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:WarrantLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases (Details)", "role": "http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "shortName": "Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "lang": null, "name": "IDXG:LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:OperatingLeaseExpireDateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://interpace.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "IDXG:OperatingLeaseExpireDateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockDividendRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - Equity (Details Narrative)", "role": "http://interpace.com/role/EquityDetailsNarrative", "shortName": "Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockDividendRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - Notes Payable (Details Narrative)", "role": "http://interpace.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-062021-01-07", "decimals": null, "lang": "en-US", "name": "IDXG:DescriptionOfFundedDebtAmount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "IDXG:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000069 - Disclosure - Schedule of Warrants Outstanding and Warrants Activity (Details)", "role": "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails", "shortName": "Schedule of Warrants Outstanding and Warrants Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "IDXG:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "role": "http://interpace.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "p", "IDXG:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000070 - Disclosure - Warrants (Details Narrative)", "role": "http://interpace.com/role/WarrantsDetailsNarrative", "shortName": "Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "IDXG:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000071 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details)", "role": "http://interpace.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "shortName": "Schedule of Stock Options, Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000072 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details)", "role": "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "shortName": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000073 - Disclosure - Schedule of Stock Option Activity (Details)", "role": "http://interpace.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000074 - Disclosure - Schedule of Non Vested Option Activity (Details)", "role": "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails", "shortName": "Schedule of Non Vested Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000075 - Disclosure - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details)", "role": "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails", "shortName": "Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": null, "lang": "en-US", "name": "IDXG:NonVestedAverageRemainingVestingPeriodBeginning", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000076 - Disclosure - Stock-Based Compensation (Details Narrative)", "role": "http://interpace.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000077 - Disclosure - Schedule of Revenue by Major Customers (Details)", "role": "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails", "shortName": "Schedule of Revenue by Major Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_MedicareCustomerMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_SalesRevenueNetMember_custom_MedicareMember_us-gaap_CustomerConcentrationRiskMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000078 - Disclosure - Revenue Sources (Details Narrative)", "role": "http://interpace.com/role/RevenueSourcesDetailsNarrative", "shortName": "Revenue Sources (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_SalesRevenueNetMember_custom_MedicareMember_us-gaap_CustomerConcentrationRiskMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000079 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details)", "role": "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "shortName": "Schedule of Components of Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Nature of Business and Significant Accounting Policies", "role": "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPolicies", "shortName": "Nature of Business and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000080 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000081 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000082 - Disclosure - Schedule of Unrecognized Tax Benefits Roll Forward (Details)", "role": "http://interpace.com/role/ScheduleOfUnrecognizedTaxBenefitsRollForwardDetails", "shortName": "Schedule of Unrecognized Tax Benefits Roll Forward (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "IDXG:ScheduleOfTaxYearsSubjectToExaminationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_DomesticCountryMember_us-gaap_EarliestTaxYearMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OpenTaxYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000083 - Disclosure - Schedule of Tax Years Subject to Examination (Details)", "role": "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails", "shortName": "Schedule of Tax Years Subject to Examination (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "IDXG:ScheduleOfTaxYearsSubjectToExaminationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_DomesticCountryMember_us-gaap_EarliestTaxYearMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OpenTaxYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000084 - Disclosure - Income Taxes (Details Narrative)", "role": "http://interpace.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000085 - Disclosure - Schedule of Weighted Average Number of Shares (Details)", "role": "http://interpace.com/role/ScheduleOfWeightedAverageNumberOfSharesDetails", "shortName": "Schedule of Weighted Average Number of Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R86": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000086 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "role": "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "IDXG:NumberPreferredStocksOnConvertedBasis", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000087 - Disclosure - Basic and Diluted Net Loss per Share (Details Narrative)", "role": "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative", "shortName": "Basic and Diluted Net Loss per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "IDXG:NumberPreferredStocksOnConvertedBasis", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000088 - Disclosure - Revolving Line of Credit (Details Narrative)", "role": "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative", "shortName": "Revolving Line of Credit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_RevolverMember", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfTransitionExpensesTableTextBlock", "IDXG:TransitionExpensesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:TransitionExpensesLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000089 - Disclosure - Schedule of Transition Expenses (Details)", "role": "http://interpace.com/role/ScheduleOfTransitionExpensesDetails", "shortName": "Schedule of Transition Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "IDXG:ScheduleOfTransitionExpensesTableTextBlock", "IDXG:TransitionExpensesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "IDXG:TransitionExpensesLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Recent Accounting Standards", "role": "http://interpace.com/role/RecentAccountingStandards", "shortName": "Recent Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000090 - Disclosure - Supplemental Cash Flow Information (Details)", "role": "http://interpace.com/role/SupplementalCashFlowInformationDetails", "shortName": "Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_AllowanceForCreditLossMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000091 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)", "role": "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails", "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_AllowanceForCreditLossMember", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } } }, "segmentCount": 94, "tag": { "IDXG_AccruedFinancingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued financing costs.", "label": "Accrued financing costs" } } }, "localname": "AccruedFinancingCosts", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_AccruedInterestNotesPayable": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Interest Notes Payable.", "label": "AccruedInterestNotesPayable", "negatedLabel": "Accrued interest - note payable" } } }, "localname": "AccruedInterestNotesPayable", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_AccruedLabCosts": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 10.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued lab costs.", "label": "Accrued lab costs - diagnostics" } } }, "localname": "AccruedLabCosts", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_AdjustmentsToAdditionalPaidInCapitalAmortizationOfBeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital amortization of beneficial conversion feature.", "label": "Amortization of beneficial conversion feature" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAmortizationOfBeneficialConversionFeature", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "IDXG_AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfSeriesShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital extinguishment of series shares.", "label": "Extinguishment of series A shares" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfSeriesShares", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "IDXG_AllowanceForDoubtfulNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allowance for Doubtful Notes [Member]", "label": "Allowance for Doubtful Notes [Member]" } } }, "localname": "AllowanceForDoubtfulNotesMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "IDXG_AmpersandLimitedPartnershiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ampersand 2018 Limited Partnership [Member]", "label": "Ampersand 2018 Limited Partnership [Member]" } } }, "localname": "AmpersandLimitedPartnershiMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_AmpersandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ampersand [Member]", "label": "Ampersand [Member]" } } }, "localname": "AmpersandMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_AmpersandNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ampersand Note [Member]", "label": "Ampersand Note [Member]" } } }, "localname": "AmpersandNoteMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_AmpersandNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ampersand Notes [Member]", "label": "Ampersand Notes [Member]" } } }, "localname": "AmpersandNotesMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_AmpersandTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ampersand Two Thousand Eighteen [Member]", "label": "Ampersand 2018 [Member]" } } }, "localname": "AmpersandTwoThousandEighteenMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_AsuragenAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asuragen Acquisition [Member]", "label": "Asuragen Acquisition [Member]" } } }, "localname": "AsuragenAcquisitionMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_AsuragenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asuragen [Member]", "label": "Asuragen [Member]" } } }, "localname": "AsuragenMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "IDXG_BarrettsTestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Barrett's Test [Member]", "label": "Barrett's Test [Member]" } } }, "localname": "BarrettsTestMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_BaseandOverallotmentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base & Overallotment Warrants [Member]", "label": "Base & Overallotment Warrants [Member]" } } }, "localname": "BaseandOverallotmentWarrantsMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "IDXG_BioPharmaAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioPharma Acquisition [Member]", "label": "BioPharma Acquisition [Member]" } } }, "localname": "BioPharmaAcquisitionMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_BroadOakLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BroadOak Loan [Member]", "label": "BroadOak Loan [Member]" } } }, "localname": "BroadOakLoanMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "IDXG_BroadOakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broad Oak [Member]", "label": "Broad Oak [Member]" } } }, "localname": "BroadOakMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_CLIALabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CLIA Lab [Member]", "label": "CLIA Lab [Member]" } } }, "localname": "CLIALabMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_ChangeInFairValueOfNotePayable": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change In Fair Value Of Note Payable.", "label": "ChangeInFairValueOfNotePayable", "negatedLabel": "Change in fair value of note payable" } } }, "localname": "ChangeInFairValueOfNotePayable", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrent description.", "label": "Description" } } }, "localname": "ClassOfWarrantOrRightTitleOfSecurityWarrantOrRightsOutstanding", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "IDXG_ClientBillingsCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Client Billings Customer [Member]", "label": "Client Billings Customer [Member]" } } }, "localname": "ClientBillingsCustomerMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "IDXG_ComericaBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Comerica Bank [Member]", "label": "Comerica Bank [Member]" } } }, "localname": "ComericaBankMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_ComericaLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Comerica Loan Agreement [Member]", "label": "Comerica Loan Agreement [Member]" } } }, "localname": "ComericaLoanAgreementMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_CommercialPayersCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Payers Customer [Member]", "label": "Commercial Payers Customer [Member]" } } }, "localname": "CommercialPayersCustomerMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "IDXG_CommonStockIssuedThroughMarketSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued through market sales.", "label": "Common stock issued through market sales" } } }, "localname": "CommonStockIssuedThroughMarketSales", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "IDXG_CommonStockIssuedThroughMarketSalesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued through market sales, shares.", "label": "Common stock issued through market sales, shares" } } }, "localname": "CommonStockIssuedThroughMarketSalesShares", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "IDXG_CompanyAchieveRevenueTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Company achieve revenue target.", "label": "Company achieve revenue target" } } }, "localname": "CompanyAchieveRevenueTarget", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "IDXG_CostOfRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of revenue [Policy Text Block]", "label": "Cost of revenue" } } }, "localname": "CostOfRevenuePolicyTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "IDXG_CreditSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit sale.", "label": "NJ NOL credit sale" } } }, "localname": "CreditSale", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "IDXG_DebtInstrumentOriginationFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of debt origination fee.", "label": "Percentage of debt origination fee" } } }, "localname": "DebtInstrumentOriginationFeePercentage", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "IDXG_DeferredIncomeTaxes": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes.", "label": "DeferredIncomeTaxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxes", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_DeferredRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Revenue [Policy Text Block]", "label": "Deferred Revenue" } } }, "localname": "DeferredRevenuePolicyTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "IDXG_DeferredTaxAssetsTaxCreditInterest": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets attributable to interest.", "label": "163(j) interest" } } }, "localname": "DeferredTaxAssetsTaxCreditInterest", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_DeferredTaxAssetsTaxCreditLeases": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets attributable to leases.", "label": "DeferredTaxAssetsTaxCreditLeases", "verboseLabel": "Leases" } } }, "localname": "DeferredTaxAssetsTaxCreditLeases", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_DefinedContributionPlanEmployerMatchingContributionAtFiftyPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution of fifty percent to a defined contribution plan.", "label": "Defined contribution plan employer matching contribution at fifty percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionAtFiftyPercent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "IDXG_DescriptionOfFundedDebtAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of funded debt amount.", "label": "[custom:DescriptionOfFundedDebtAmount]" } } }, "localname": "DescriptionOfFundedDebtAmount", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "IDXG_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Financing And Operating Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://interpace.com/20211231", "xbrltype": "stringItemType" }, "IDXG_DisclosureTransitionExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transition Expenses" } } }, "localname": "DisclosureTransitionExpensesAbstract", "nsuri": "http://interpace.com/20211231", "xbrltype": "stringItemType" }, "IDXG_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://interpace.com/20211231", "xbrltype": "stringItemType" }, "IDXG_EffectiveIncomeTaxRateReconciliationNakedCredit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Naked Credit.", "label": "Naked credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNakedCredit", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "IDXG_EmployeeStockPurchasePlanExpense": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan Expense.", "label": "ESPP expense" } } }, "localname": "EmployeeStockPurchasePlanExpense", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_ExpirationDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date, description.", "label": "Expiration Date" } } }, "localname": "ExpirationDateDescription", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "IDXG_FacilitiesAndInfrastructureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities And Infrastructure [Member]", "label": "Facilities And Infrastructure [Member]" } } }, "localname": "FacilitiesAndInfrastructureMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "domainItemType" }, "IDXG_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion.", "label": "Accretion/Interest Accrued" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretion", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_FinanceLeaseLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance lease liabilities current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Financing lease liability", "verboseLabel": "Finance Leases, Less: current obligations under leases" } } }, "localname": "FinanceLeaseLiabilitiesCurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails", "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails", "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_FinanceLeaseLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance lease liabilities noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "verboseLabel": "Finance Leases, Long-term lease obligations" } } }, "localname": "FinanceLeaseLiabilitiesNoncurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails", "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease Liability Payments Due Year Four And Thereafter.", "label": "FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter", "verboseLabel": "Operating Leases 2026-2030" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_FinanceLeaseRightOfUseAssetsClassifiedUnderPropertyAndEquipmentNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance lease right of use assets classified under property and equipment net.", "label": "Finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAssetsClassifiedUnderPropertyAndEquipmentNet", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_FinancingFeesRelatedParty": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Fees Related Party.", "label": "FinancingFeesRelatedParty", "negatedLabel": "Financing fees - related party" } } }, "localname": "FinancingFeesRelatedParty", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_FinancingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing Leases [Member]", "label": "Financing Leases [Member]" } } }, "localname": "FinancingLeaseMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "IDXG_FullyDilutedPercentageOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fully diluted percentage of common stock.", "label": "[custom:FullyDilutedPercentageOfCommonStock]" } } }, "localname": "FullyDilutedPercentageOfCommonStock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "IDXG_IncreaseDecreaseInAccruedSalariesAndBonus": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Accrued Salaries And Bonus", "label": "IncreaseDecreaseInAccruedSalariesAndBonus", "negatedLabel": "(Decrease) increase in accrued salaries and bonus" } } }, "localname": "IncreaseDecreaseInAccruedSalariesAndBonus", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_IncreaseDecreaseInLongtermLiabilities": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "increase decrease in longterm liabilities.", "label": "IncreaseDecreaseInLongtermLiabilities", "negatedLabel": "(Decrease) increase in long-term liabilities" } } }, "localname": "IncreaseDecreaseInLongtermLiabilities", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_IntrinsicValueOfBeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of beneficial conversion feature.", "label": "Intrinsic value of beneficial conversion feature" } } }, "localname": "IntrinsicValueOfBeneficialConversionFeature", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "IDXG_IntrinsicValueOfEffectiveConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic value of effective conversion price per share.", "label": "Intrinsic value of effective conversion price per share" } } }, "localname": "IntrinsicValueOfEffectiveConversionPricePerShare", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "IDXG_InvestmentInDiamir": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment In Diamir.", "label": "Investment in DiamiR" } } }, "localname": "InvestmentInDiamir", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_IssuancePricesOfPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance prices of preferred stock.", "label": "Issuance price of preferred stock" } } }, "localname": "IssuancePricesOfPreferredStock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "IDXG_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab Equipment [Member].", "label": "Lab Equipment [Member]" } } }, "localname": "LabEquipmentMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_LegalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal [Member]", "label": "Legal [Member]" } } }, "localname": "LegalMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "domainItemType" }, "IDXG_LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due one to three years", "label": "Operating lease obligations, 1 to 3 Years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueOneToThreeYears", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_LesseeOperatingLeaseLiabilityPaymentsDueThreeToFiveYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due three to five years", "label": "Operating lease obligations, 3 to 5 Years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThreeToFiveYears", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Operating Lease Liability Payments Due Year Four And Thereafter", "label": "Operating Leases 2026-2030" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_LiabilitiesAndStockholderEquity": { "auth_ref": [], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities and stockholder equity.", "label": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholderEquity", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "IDXG_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan And Security Agreement [Member]", "label": "Loan And Security Agreement [Member]" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_LoanExpenses": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loan Expenses.", "label": "LoanExpenses", "negatedLabel": "Loan expenses - BroadOak" } } }, "localname": "LoanExpenses", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_LoanProceeds": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan Proceeds.", "label": "Loan proceeds - BroadOak", "verboseLabel": "Loan proceeds" } } }, "localname": "LoanProceeds", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_LossOnTransaction": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss on transaction.", "label": "LossOnTransaction", "negatedLabel": "Loss on DiamiR transaction" } } }, "localname": "LossOnTransaction", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "IDXG_MedicareAdvantageCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare Advantage Customer [Member]", "label": "Medicare Advantage Customer [Member]" } } }, "localname": "MedicareAdvantageCustomerMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "IDXG_MedicareCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare Customer [Member]", "label": "Medicare Customer [Member]" } } }, "localname": "MedicareCustomerMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "IDXG_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]" } } }, "localname": "MedicareMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_NatureOfBusinessPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature Of Business [Policy Text Block]", "label": "Nature of Business" } } }, "localname": "NatureOfBusinessPolicyTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "IDXG_NewAccountingPronouncementAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "New Accounting Pronouncement Adoption.", "label": "Adoption of Asc" } } }, "localname": "NewAccountingPronouncementAdoption", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "IDXG_NewAccountingPronouncementAdoptionOfASC842": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "New accounting pronouncement.", "label": "Adoption of Asc 842" } } }, "localname": "NewAccountingPronouncementAdoptionOfASC842", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "IDXG_NonVestedAverageRemainingVestingPeriodBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non vested Average Remaining Vesting Period Beginning balance.", "label": "Non-vested Average Remaining Vesting Period Beginning balance" } } }, "localname": "NonVestedAverageRemainingVestingPeriodBeginning", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "durationItemType" }, "IDXG_NonVestedAverageRemainingVestingPeriodEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non vested Average Remaining Vesting Period.", "label": "Non-vested Average Remaining Vesting Period Ending balance" } } }, "localname": "NonVestedAverageRemainingVestingPeriodEnding", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "durationItemType" }, "IDXG_NotePayableFees": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Note Payable Fees.", "label": "NotePayableFees", "negatedLabel": "Note payable fees" } } }, "localname": "NotePayableFees", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_NumberOfHoldsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of holds shares .", "label": "[custom:NumberOfHoldsShares]" } } }, "localname": "NumberOfHoldsShares", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "IDXG_NumberPreferredStocksOnConvertedBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number preferred stocks on converted basis.", "label": "Number preferred stocks on converted basis" } } }, "localname": "NumberPreferredStocksOnConvertedBasis", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "IDXG_OfficeAndComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and Computer Equipment [Member].", "label": "Office and Computer Equipment [Member]" } } }, "localname": "OfficeAndComputerEquipmentMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_OneThousandThreeFifteenCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1315 Capital [Member]", "label": "1315 Capital [Member] [Default Label]", "verboseLabel": "1315 Capital [Member]" } } }, "localname": "OneThousandThreeFifteenCapitalMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_OneThousandThreeFifteenCapitalNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1315 Capital Note [Member]", "label": "1315 Capital Note [Member]" } } }, "localname": "OneThousandThreeFifteenCapitalNoteMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_OneThreeOneFiveCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1315 Capital [Member]", "label": "1315 Capital [Member]" } } }, "localname": "OneThreeOneFiveCapitalMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_OpearatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Leases [Member]", "label": "Operating Leases [Member]" } } }, "localname": "OpearatingLeaseMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "IDXG_OperatingLeaseExpireDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease expire date description.", "label": "Operating lease expire date description" } } }, "localname": "OperatingLeaseExpireDateDescription", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "IDXG_OperatingLeaseLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease liabilities current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability", "verboseLabel": "Operating Leases, Less: current obligations under leases" } } }, "localname": "OperatingLeaseLiabilitiesCurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails", "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails", "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_OtherAccruedExpensesAndLongTermLiabilities": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other accrued expenses and long term liabilities.", "label": "OtherAccruedExpensesAndLongTermLiabilities", "verboseLabel": "Other" } } }, "localname": "OtherAccruedExpensesAndLongTermLiabilities", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_OtherCurrentAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other current assets [Policy Text Block]", "label": "OtherCurrentAssetsPolicyTextBlock", "verboseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsPolicyTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "IDXG_OtherItems": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other.", "label": "Other" } } }, "localname": "OtherItems", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_OthersAccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 14.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Others accrued expenses current.", "label": "All others" } } }, "localname": "OthersAccruedExpensesCurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_PancreasTestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pancreas Test [Member]", "label": "Pancreas Test [Member]" } } }, "localname": "PancreasTestMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_PaymentTransitionExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment transition expenses.", "label": "Payments" } } }, "localname": "PaymentTransitionExpenses", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_PercentageOfAccountsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Accounts Receivable.", "label": "Percentage of accounts receivable" } } }, "localname": "PercentageOfAccountsReceivable", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "percentItemType" }, "IDXG_PersonnelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personnel [Member]", "label": "Personnel [Member]" } } }, "localname": "PersonnelMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "domainItemType" }, "IDXG_PreferredSharesStatedValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares stated value.", "label": "Preferred shares stated value" } } }, "localname": "PreferredSharesStatedValue", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "IDXG_PreferredStockAdjustedConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock adjusted conversion.", "label": "Preferred stock adjusted conversion" } } }, "localname": "PreferredStockAdjustedConversion", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "IDXG_PreferredStockDeemedDividend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock deemed dividend.", "label": "Preferred Stock Deemed Dividend" } } }, "localname": "PreferredStockDeemedDividend", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrants[Member]", "label": "Private Placement Warrants[Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "IDXG_ProceedsFromLoan": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Loan.", "label": "Loan proceeds - related parties" } } }, "localname": "ProceedsFromLoan", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_PromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Notes [Member]", "label": "Promissory Notes [Member]" } } }, "localname": "PromissoryNotesMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_RSUsandRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RSUs and Restricted Stock [Member]", "label": "RSUs and Restricted Stock [Member]" } } }, "localname": "RSUsandRestrictedStockMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "xbrltype": "domainItemType" }, "IDXG_RedPathAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RedPath Acquisition [Member]", "label": "RedPath Acquisition [Member]" } } }, "localname": "RedPathAcquisitionMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_RedPathWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RedPath Warrants [Member]", "label": "RedPath Warrants [Member]" } } }, "localname": "RedPathWarrantsMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "IDXG_ReductionInOperatingLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction in operating loss carryforwards.", "label": "[custom:ReductionInOperatingLossCarryforwards]" } } }, "localname": "ReductionInOperatingLossCarryforwards", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "IDXG_RemainingReductionInOperatingLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remaining Reduction In Operating Loss Carryforwards", "label": "[custom:RemainingReductionInOperatingLossCarryforwards]" } } }, "localname": "RemainingReductionInOperatingLossCarryforwards", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "IDXG_ReversalOfBonusAccrual": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reversal Of Bonus Accrual.", "label": "ReversalOfBonusAccrual", "negatedLabel": "Reversal of 2019 bonus accrual" } } }, "localname": "ReversalOfBonusAccrual", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IDXG_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reverse Stock Split [Policy Text Block]", "label": "Reverse stock split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "IDXG_RevolverMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolver [Member]", "label": "Revolver [Member]" } } }, "localname": "RevolverMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_RevolvingLineOptionCreditCardServicesBorrowingLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revolving line option credit card services borrowing limit.", "label": "Revolving Line option credit card services borrowing limit" } } }, "localname": "RevolvingLineOptionCreditCardServicesBorrowingLimit", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "IDXG_SVBLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SVB Loan Agreement [Member]", "label": "SVB Loan Agreement [Member]" } } }, "localname": "SVBLoanAgreementMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_ScheduleOfFinancingAndOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Financing And Operating Leases [Table Text Block]", "label": "Schedule of Financing and Operating Leases" } } }, "localname": "ScheduleOfFinancingAndOperatingLeasesTableTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "IDXG_ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum lease payment under noncancelable leases [Table Text Block]", "label": "Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableLeasesTableTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "IDXG_ScheduleOfLongTermLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long term liabilities [Table Text Block]", "label": "Schedule of Long Term Liabilities" } } }, "localname": "ScheduleOfLongTermLiabilitiesTableTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "IDXG_ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabiltiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Maturities Of Operating And Financing Lease Liabilties [Table Text Block]", "label": "Schedule of Maturities of Operating and Financing Lease Liabilities" } } }, "localname": "ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabiltiesTableTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "IDXG_ScheduleOfTaxYearsSubjectToExaminationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Tax Years Subject To Examination [Table Text Block]", "label": "Schedule of Tax Years Subject to Examination" } } }, "localname": "ScheduleOfTaxYearsSubjectToExaminationTableTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "IDXG_ScheduleOfTransitionExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Transition Expenses [Table Text Block]", "label": "Schedule of Transition Expenses" } } }, "localname": "ScheduleOfTransitionExpensesTableTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/TransitionExpensesTables" ], "xbrltype": "textBlockItemType" }, "IDXG_SecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security Agreement [Member]", "label": "Security Agreement [Member]" } } }, "localname": "SecurityAgreementMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_SecurityPurchaseAndExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security Purchase and Exchange Agreement [Member]", "label": "Security Purchase and Exchange Agreement [Member]" } } }, "localname": "SecurityPurchaseAndExchangeAgreementMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_SeriesBPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Preferred Stock [Member]", "label": "Series B Preferred Stock [Member] [Default Label]", "verboseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStocksMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation on weighted average remaining contractual terms.", "label": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "durationItemType" }, "IDXG_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate intrinsic value granted.", "label": "Aggregate intrinsic value granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding", "periodEndLabel": "Non-vested Aggregate Intrinsic Value Ending balance", "periodStartLabel": "Non-vested Aggregate Intrinsic Value Beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueOutstanding", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of forfeited award under share-based payment arrangement. Excludes share and unit options.", "label": "Non-vested Aggregate Intrinsic Value Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options.", "label": "Non-vested Aggregate Intrinsic Value Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual period outstanding ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "IDXG_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon Valley Bank [Member]", "label": "Silicon Valley Bank [Member]" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_SoftwareForExternalUseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software for External Use [Member].", "label": "Software for External Use [Member]" } } }, "localname": "SoftwareForExternalUseMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_SoftwareForInternalUseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software for Internal Use [Member].", "label": "Software for Internal Use [Member]" } } }, "localname": "SoftwareForInternalUseMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_StockBasedCompensationAggregateInstrinsicValueForfeitedOrExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate instrinsic value forfeited or expired.", "label": "Aggregate intrinsic value forfeited or expired" } } }, "localname": "StockBasedCompensationAggregateInstrinsicValueForfeitedOrExpired", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Incentive Plan [Member]", "label": "Stock Incentive Plan [Member]" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_TaxesAccruedForRepurchaseOfRestrictedShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Taxes Accrued For Repurchase Of Restricted Shares.", "label": "Taxes accrued for repurchase of restricted shares" } } }, "localname": "TaxesAccruedForRepurchaseOfRestrictedShares", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "IDXG_ThyroidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thyroid [Member]", "label": "Thyroid [Member]" } } }, "localname": "ThyroidMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "IDXG_TotalLeaseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total lease assets.", "label": "Total lease assets" } } }, "localname": "TotalLeaseAssets", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_TotalLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total lease liabilities.", "label": "Total lease liabilities" } } }, "localname": "TotalLeaseLiabilities", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_TransitionExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition expense.", "label": "Transition expenses" } } }, "localname": "TransitionExpense", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_TransitionExpensesLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Expenses Liabilities.", "label": "TransitionExpensesLiabilities", "periodEndLabel": "Balance at December 31, 2021", "periodStartLabel": "Balance at December 31, 2020" } } }, "localname": "TransitionExpensesLiabilities", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_TransitionExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Expenses [Text Block]", "label": "TransitionExpensesTextBlock", "verboseLabel": "Transition Expenses" } } }, "localname": "TransitionExpensesTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/TransitionExpenses" ], "xbrltype": "textBlockItemType" }, "IDXG_TreasuryStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury stock [Policy Text Block]", "label": "Treasury Stock" } } }, "localname": "TreasuryStockPolicyTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "IDXG_UnclaimedPropertyCurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 13.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unclaimed property current.", "label": "Unclaimed property" } } }, "localname": "UnclaimedPropertyCurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_UnderwriterWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriter Warrants [Member]", "label": "Underwriter Warrants [Member]" } } }, "localname": "UnderwriterWarrantsMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "IDXG_UnderwritersWarrantsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters Warrants [Member]", "label": "Underwriters Warrants [Member]" } } }, "localname": "UnderwritersWarrantsTwoMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "IDXG_UpfrontMedicarePaymentAdvance": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront Medicare payment advance.", "label": "Upfront Medicare payment" } } }, "localname": "UpfrontMedicarePaymentAdvance", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_WarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Liability.", "label": "Warrant liability" } } }, "localname": "WarrantLiability", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_WarrantLiabilityCurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 8.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability current.", "label": "WarrantLiabilityCurrent", "verboseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityCurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_WarrantLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability noncurrent.", "label": "WarrantLiabilityNoncurrent", "verboseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityNoncurrent", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "IDXG_WarrantsClassification": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant classification.", "label": "Classification" } } }, "localname": "WarrantsClassification", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "IDXG_WarrantsIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Issued [Member]", "label": "Warrants Issued [Member]" } } }, "localname": "WarrantsIssuedMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "IDXG_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "IDXG_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Text Block]", "label": "Warrants [Text Block]", "verboseLabel": "Warrants" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "IDXG_WeightedAverageRemainingContractualPeriodGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual period granted.", "label": "Weighted average remaining contractual period granted" } } }, "localname": "WeightedAverageRemainingContractualPeriodGranted", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "IDXG_WeightedAverageRemainingContractualPeriodVestedAndExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual period vested and expected to vest.", "label": "Weighted average remaining contractual period vested and expected to vest" } } }, "localname": "WeightedAverageRemainingContractualPeriodVestedAndExpectedToVest", "nsuri": "http://interpace.com/20211231", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r634", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r634", "r636", "r637" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r634", "r636", "r637" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r634", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevenueSourcesDetailsNarrative", "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r634", "r636", "r637" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevenueSourcesDetailsNarrative", "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r203", "r353", "r355", "r601" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r279", "r315", "r385", "r388", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r599", "r602", "r620", "r621" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r279", "r315", "r385", "r388", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r599", "r602", "r620", "r621" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r203", "r353", "r355", "r601" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r201", "r353", "r354", "r570", "r598", "r600" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r201", "r353", "r354", "r570", "r598", "r600" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r279", "r315", "r361", "r385", "r388", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r599", "r602", "r620", "r621" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r279", "r315", "r361", "r385", "r388", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r599", "r602", "r620", "r621" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r144", "r386" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r144", "r148", "r386" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r144", "r148", "r262", "r386", "r557" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r204", "r552" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r125", "r126", "r127", "r129", "r130" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.", "label": "Accrued Expenses and Other Long-Term Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r62", "r555" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r28", "r48", "r205", "r206" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $72 and $275, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpenseIncludingAssetRetirementObligations": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion expense, which includes, but is not limited to, accretion expense from asset retirement obligations, environmental remediation obligations, and other contingencies.", "label": "Interest accretion expense" } } }, "localname": "AccretionExpenseIncludingAssetRetirementObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 9.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued sales and marketing - diagnostics" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r34", "r35", "r67" ], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 11.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r34", "r35", "r67" ], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r59", "r245" ], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r49" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r132", "r133", "r134", "r425", "r426", "r427", "r508" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r107", "r235" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Acquisition related amortization expense", "terseLabel": "Amortization expense", "verboseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative", "http://interpace.com/role/StatementsOfOperations", "http://interpace.com/role/StatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r330", "r338", "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Beneficial Conversion Feature in connection with Series B Issuance" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r390", "r392", "r432", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r392", "r422", "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r125", "r126", "r127", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r54", "r211", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r91", "r107", "r299", "r538" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r107", "r229", "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from earning per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r107", "r241" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset impairment" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r120", "r190", "r193", "r199", "r217", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r499", "r502", "r525", "r553", "r555", "r578", "r588" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r30", "r32", "r80", "r120", "r217", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r499", "r502", "r525", "r553", "r555" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r393", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTransitionExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r384", "r387" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r384", "r387", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r485" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Transition expense" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r106", "r496" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://interpace.com/role/StatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r492", "r493", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r492", "r494" ], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r492", "r494" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r488", "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r622" ], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Internal-use software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r56", "r555", "r612", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r26", "r56", "r109" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r38", "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r103", "r109", "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r103", "r109", "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash \u2013 ending", "periodStartLabel": "Cash, cash equivalents and restricted cash \u2013 beginning" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r103", "r529" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r117", "r120", "r154", "r155", "r156", "r159", "r161", "r170", "r171", "r172", "r217", "r265", "r269", "r270", "r271", "r274", "r275", "r313", "r314", "r318", "r322", "r525", "r639" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative", "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise Price", "verboseLabel": "Weighted average exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails", "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r73", "r261", "r582", "r593" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r258", "r259", "r260", "r263", "r615" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r264", "r616" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r132", "r133", "r508" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r47", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r47", "r555" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value; 100,000,000 shares authorized; 4,228,169 and 4,075,257 shares issued, respectively; 4,195,412 and 4,055,593 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r179", "r180", "r203", "r522", "r523", "r614" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r179", "r180", "r203", "r522", "r523", "r611", "r614" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r179", "r180", "r203", "r522", "r523", "r611", "r614" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Revenue Sources" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSources" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r179", "r180", "r203", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Revenue from continuing operations" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r177", "r179", "r180", "r181", "r522", "r524", "r614" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r179", "r180", "r203", "r522", "r523", "r614" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r114", "r501" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r45", "r46", "r325", "r331", "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r94", "r120", "r217", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r525" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue (excluding amortization of $4,064 and $4,461, respectively)" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r121", "r461", "r473" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r461", "r473", "r475" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r121", "r461", "r473" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r178", "r203" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r116", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r293", "r300", "r301", "r302", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r41", "r42", "r43", "r119", "r124", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r303", "r304", "r305", "r306", "r539", "r579", "r580", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r276", "r303", "r304", "r537", "r539", "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r69", "r296", "r537" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r69", "r277" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt interest percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt instrument interest, description" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r70", "r279", "r514" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r71", "r119", "r124", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r303", "r304", "r305", "r306", "r539" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r289", "r536", "r540" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Line of credit reductions" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r462", "r473" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r121", "r462", "r473", "r474", "r475" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r462", "r473" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r454" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsStateTaxes": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.", "label": "State taxes" } } }, "localname": "DeferredTaxAssetsStateTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r457", "r459", "r460" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Credit carryforward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.", "label": "Allowances and reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r453" ], "calculation": { "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r440", "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedLabel": "Deferred tax liability-net valuation allowance" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r459", "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined contribution plan, employer matching contribution, percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined contribution plan, maximum annual contributions per employee, percent" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r107", "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r107", "r188" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Fair value of liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r393", "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r15", "r88", "r594" ], "calculation": { "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income from discontinued operations, before tax" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r7", "r8", "r15", "r19", "r441", "r472", "r479" ], "calculation": { "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Income tax expense" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r2", "r3", "r16", "r242", "r247" ], "calculation": { "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r23", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarliestTaxYearMember": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Earliest identified tax year.", "label": "Earliest Tax Year [Member]" } } }, "localname": "EarliestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per basic and diluted share of common stock" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share of common stock:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r162", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r162", "r164", "r165", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Basic and Diluted Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BasicAndDilutedNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r122", "r442", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r442", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": { "auth_ref": [ "r442", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.", "label": "Meals and entertainment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r442", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income tax rate, net of Federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r67" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued salary and bonus" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Total unrecognized compensation cost related to unvested stock options and restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r84", "r85", "r86", "r132", "r133", "r134", "r138", "r145", "r147", "r169", "r218", "r330", "r338", "r425", "r426", "r427", "r466", "r467", "r508", "r530", "r531", "r532", "r533", "r534", "r535", "r603", "r604", "r605", "r644" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails", "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r107", "r308" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Mark to market on warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r511", "r512", "r513", "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r515", "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r291", "r303", "r304", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r380", "r512", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r291", "r362", "r364", "r369", "r380", "r512", "r559" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r291", "r303", "r304", "r362", "r364", "r369", "r380", "r512", "r560" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r291", "r303", "r304", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r380", "r512", "r561" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r364", "r510", "r520" ], "lang": { "en-us": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Adjustment to Fair Value/Mark to Market" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r291", "r303", "r304", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r380", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r542", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Leases, Present value of future minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Financing Leases,Total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease 2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Leases, Less: amount of lease payments representing effects of discounting" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-lived intangible asset, useful life", "verboseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r230", "r232", "r234", "r237", "r571", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r234", "r575" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r234", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Lab and office equipment" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r244" ], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r107" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on DiamiR transaction" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r224", "r225", "r555", "r577" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://interpace.com/role/ScheduleOfGoodwillCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r226", "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfGoodwillCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r92", "r120", "r190", "r192", "r195", "r198", "r200", "r217", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r525" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Long-Lived Assets, including Finite-Lived Intangible Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r93", "r108", "r141", "r142", "r143", "r144", "r157", "r161", "r498" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r87", "r190", "r192", "r195", "r198", "r200", "r576", "r583", "r585", "r596" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "From continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r19", "r22", "r480", "r594" ], "calculation": { "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Loss from discontinued operations, net of tax", "totalLabel": "Loss from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.", "label": "From discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r122", "r443", "r451", "r456", "r471", "r477", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r436", "r445" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income tax examination, likelihood of unfavorable settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income tax examination penalties and interest accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income tax examination penalties and interest expense" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r146", "r147", "r189", "r441", "r472", "r478", "r597" ], "calculation": { "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "(Benefit) provision for income taxes", "totalLabel": "(Benefit) provision from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r83", "r438", "r439", "r451", "r452", "r455", "r463" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r106" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Decrease in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r106" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r106" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "(Decrease) increase in accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r106" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Decrease in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r106" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Increase in other long-term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest accretion expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "negatedLabel": "Related party interest" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r102", "r104", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r35", "r36", "r67" ], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r27", "r78", "r555" ], "calculation": { "http://interpace.com/role/ScheduleOfCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Lab supply inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LatestTaxYearMember": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Latest identified tax year.", "label": "Latest Tax Year [Member]" } } }, "localname": "LatestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r33", "r244" ], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Operating Leases,Total minimum lease payments", "verboseLabel": "Operating lease obligations, Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating lease obligations, After 5 Years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases 2022", "verboseLabel": "Operating lease obligations, Less than 1 Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Operating Leases, Less: amount of lease payments representing effects of discounting" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r66", "r120", "r194", "r217", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r500", "r502", "r503", "r525", "r553", "r554" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "IDXG_LiabilitiesAndStockholderEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r53", "r120", "r217", "r525", "r555", "r581", "r591" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, preferred stock and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r68", "r120", "r217", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r500", "r502", "r503", "r525", "r553", "r554", "r555" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r2", "r3", "r16", "r18", "r22", "r247" ], "calculation": { "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r2", "r3", "r16", "r18", "r22", "r242", "r247" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Current liabilities from discontinued operations", "totalLabel": "Current liabilities from discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r72" ], "calculation": { "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Uncertain tax positions" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r43", "r580", "r587" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of credit", "verboseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r63", "r119" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Line of credit, maturity date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "InterestRate" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r63", "r119" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Line of credit" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of credit outstanding accounts receivable" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r63", "r119" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Percentage of line of credit unused facility fee" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Total long-term lease liabilities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Total current lease liabilities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r71" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable at fair value", "verboseLabel": "Notes Payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r103" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r103" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activity" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r103", "r105", "r108" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r22", "r81", "r82", "r86", "r89", "r108", "r120", "r137", "r141", "r142", "r143", "r144", "r146", "r147", "r157", "r190", "r192", "r195", "r198", "r200", "r217", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r509", "r525", "r584", "r595" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss) attributable to parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows", "http://interpace.com/role/StatementsOfOperations", "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r141", "r142", "r143", "r144", "r151", "r152", "r158", "r161", "r190", "r192", "r195", "r198", "r200" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r135", "r136", "r139", "r140", "r148", "r149", "r150", "r215", "r216", "r219", "r220", "r356", "r357", "r358", "r359", "r428", "r468", "r469", "r470", "r507", "r526", "r527", "r528", "r551", "r572", "r573", "r574", "r606", "r607", "r608", "r609", "r610", "r645" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RecentAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r190", "r192", "r195", "r198", "r200" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedLabel": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Leases, Present value of future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r542" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion", "terseLabel": "Operating Leases, Long-term lease obligations", "verboseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails", "http://interpace.com/role/ScheduleOfMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r541" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right of use assets", "verboseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfFinancingAndOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r547", "r549" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease, weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r546", "r549" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards, Limitations on Use" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r25", "r131", "r185", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Nature of Business and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r34", "r35", "r36", "r67" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses", "totalLabel": "Total other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r79", "r555" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://interpace.com/role/ScheduleOfCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets", "totalLabel": "Total other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other intangible assets, net" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r72" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other gains and expenses, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r29", "r31", "r223" ], "calculation": { "http://interpace.com/role/ScheduleOfCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfOtherEquity": { "auth_ref": [ "r100" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to reacquire equity classified as other.", "label": "Payments for Repurchase of Other Equity", "negatedLabel": "Cash paid for repurchase of restricted shares" } } }, "localname": "PaymentsForRepurchaseOfOtherEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r98" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.", "label": "Contribution expense" } } }, "localname": "PensionAndOtherPostretirementBenefitExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r361", "r363", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r380", "r381", "r382", "r383", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RetirementPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r393", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConversionsInducements": { "auth_ref": [ "r167" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.", "label": "Preferred Stock Conversions, Inducements", "negatedLabel": "Less adjustment for preferred stock deemed dividend" } } }, "localname": "PreferredStockConversionsInducements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred stock dividend percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r46", "r313" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock par/stated value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r46", "r313" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r99" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Issuance of common stock, net of expenses" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r99" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Issuance of Series B preferred stock, net of expenses" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Borrowings (payments) on Line of Credit" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r59", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r250", "r617", "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r58", "r244" ], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r39", "r40", "r246", "r555", "r586", "r592" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r246" ], "calculation": { "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Computer equipment" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r57", "r246", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r39", "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r39", "r244" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r90", "r222" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt (recovery) expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayment of notes" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r101" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Payment of related party note and related interest" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r435", "r569", "r622" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r60", "r238", "r239", "r622" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Software Costs" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r26", "r38", "r112" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r50", "r338", "r429", "r555", "r590", "r606", "r610" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r132", "r133", "r134", "r138", "r145", "r147", "r218", "r425", "r426", "r427", "r466", "r467", "r508", "r603", "r605" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r186", "r187", "r191", "r196", "r197", "r201", "r202", "r203", "r352", "r353", "r570" ], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue, net", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r115", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r179", "r203" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Other Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/AccruedExpensesAndOtherLong-termLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Identifiable Intangible Assets Carrying Value" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BasicAndDilutedNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "verboseLabel": "Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r376", "r377", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RetirementPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r3", "r9", "r10", "r11", "r12", "r13", "r14", "r17", "r20", "r21", "r22", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Schedule of Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r154", "r155", "r159", "r161", "r166" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Financial Instrument Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r230", "r233", "r571" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill Carrying Value" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Revolving Line of Credit" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r59", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r251", "r252", "r253", "r254", "r255", "r256", "r257" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevenueSourcesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r393", "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r398", "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r74", "r117", "r170", "r171", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r322", "r328", "r331", "r332", "r333", "r335", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r342", "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrants Outstanding and Warrants Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r450", "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BasicAndDilutedNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Future Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r43", "r580", "r589" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "verboseLabel": "Promissory note" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://interpace.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative", "http://interpace.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r106" ], "calculation": { "http://interpace.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfCashFlows", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r391", "r394" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-based compensation arrangement by share-based payment award, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Non-vested Shares Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Non-vested Weighted Average Grant Date Fair Value Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Non-vested Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Non-vested Weighted Average Grant Date Fair Value Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Non-vested Shares ending balance", "periodStartLabel": "Non-vested Shares beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Non-vested Weighted Average Grant Date Fair Value Ending balance", "periodStartLabel": "Non-vested Weighted Average Grant Date Fair Value beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Non-vested Shares Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Non-vested Weighted Average Grant Date Fair Value Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Warrants Cancelled/Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Shares forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted average grant price forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares granted", "verboseLabel": "Non-vested Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails", "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Non-vested weighted average grant date fair value granted", "verboseLabel": "Weighted-average fair value of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r400", "r424" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares outstanding ending balance", "periodStartLabel": "Shares outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average grant price outstanding ending balance", "periodStartLabel": "Weighted average grant price outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value exercisable ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Shares vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average grant price vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r391", "r395" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average grant price exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average grant price granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r393", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Schedule of Non Vested Option Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "periodEndLabel": "Shares exercisable ending balance" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Aggregate intrinsic value outstanding ending balance", "periodStartLabel": "Aggregate intrinsic value outstanding beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Non-vested Aggregate Intrinsic Value Vested", "verboseLabel": "Share-based compensation aggregate fair value of option" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r417", "r430" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Non-vested Shares outstanding ending balance", "periodStartLabel": "Non-vested Shares outstanding beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Non-vested Shares forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Non-vested weighted average grant date fair value forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Non-vested weighted average grant date fair value outstanding ending balance", "periodStartLabel": "Non-vested weighted average grant date fair value outstanding beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual period outstanding beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Aggregate fair value of restricted stock units" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Non-vested Shares vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Non-vested weighted average grant date fair value vested", "verboseLabel": "Weighted-average grant date fair value of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfNonVestedOptionActivityDetails", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average grant price exercisable ending balance" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance,shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r45", "r46", "r47", "r117", "r120", "r154", "r155", "r156", "r159", "r161", "r170", "r171", "r172", "r217", "r265", "r269", "r270", "r271", "r274", "r275", "r313", "r314", "r318", "r322", "r330", "r525", "r639" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/BasicAndDilutedNetLossPerShareDetailsNarrative", "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r77", "r84", "r85", "r86", "r132", "r133", "r134", "r138", "r145", "r147", "r169", "r218", "r330", "r338", "r425", "r426", "r427", "r466", "r467", "r508", "r530", "r531", "r532", "r533", "r534", "r535", "r603", "r604", "r605", "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails", "http://interpace.com/role/StatementsOfStockholdersDeficit", "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails", "http://interpace.com/role/ScheduleOfTransitionExpensesDetails", "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails", "http://interpace.com/role/StatementsOfStockholdersDeficit", "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r132", "r133", "r134", "r169", "r570" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical", "http://interpace.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "http://interpace.com/role/ScheduleOfRevenueByMajorCustomersDetails", "http://interpace.com/role/ScheduleOfTransitionExpensesDetails", "http://interpace.com/role/ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails", "http://interpace.com/role/StatementsOfStockholdersDeficit", "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r76", "r294", "r330", "r331", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r46", "r47", "r330", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Common stock issued through ESPP, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r46", "r47", "r330", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued, shares", "verboseLabel": "Aggregate of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r46", "r47", "r330", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Restricted stock issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r46", "r47", "r330", "r338", "r403" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Options exercised", "negatedLabel": "Shares exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfStockOptionActivityDetails", "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r46", "r47", "r330", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Common stock issued through ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r46", "r47", "r330", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued", "verboseLabel": "Value of preferred stock exchanged" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r330", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Restricted stock issued" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r47", "r51", "r52", "r120", "r213", "r217", "r525", "r555" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "IDXG_LiabilitiesAndStockholderEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Balance, value", "periodEndLabel": "Balance,value", "periodStartLabel": "Balance,value", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets", "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r118", "r314", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r338", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r556", "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/SubsequentEventsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfTaxYearsSubjectToExaminationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 12.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r265", "r269", "r270", "r271", "r274", "r275" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r37", "r310" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary equity, par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r207", "r208", "r209", "r210", "r212", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable, Net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r75", "r340" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r75", "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r47", "r330", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury stock purchased, shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r75", "r340", "r341" ], "calculation": { "http://interpace.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost (32,757 and 19,664 shares, respectively)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r330", "r338", "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Treasury stock purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/EquityDetailsNarrative", "http://interpace.com/role/NotesPayableDetailsNarrative", "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r437", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax benefits", "periodEndLabel": "Unrecognized tax benefits ending balance", "periodStartLabel": "Unrecognized tax benefits beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative", "http://interpace.com/role/ScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Additions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized tax benefits would affect the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r173", "r174", "r175", "r176", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Accounting Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceOtherTaxCarryforwardMember": { "auth_ref": [ "r125", "r126", "r127", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to carryforward, classified as other.", "label": "SEC Schedule, 12-09, Valuation Allowance, Other Tax Carryforward [Member]" } } }, "localname": "ValuationAllowanceOtherTaxCarryforwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r125", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at end of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "Additions (Reductions) Charged to Operations" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r129" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "Deductions Other" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r125", "r126", "r127", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves." } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r125", "r126", "r127", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleIi-ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/RevolvingLineOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Potential dilutive effect of stock-based awards" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWeightedAverageNumberOfSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r153", "r161" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted", "verboseLabel": "Diluted weighted average number of common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWeightedAverageNumberOfSharesDetails", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares and common share equivalents outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r151", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic", "verboseLabel": "Basic weighted average number of common shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://interpace.com/role/ScheduleOfWeightedAverageNumberOfSharesDetails", "http://interpace.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=122038299&loc=d3e42851-122695" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r23": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r24": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r25": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r434": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r558": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r623": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r624": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r625": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r626": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r627": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r628": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r629": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r633": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r634": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r635": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r636": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r637": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r638": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r639": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r641": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r642": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r643": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 111 0001493152-22-008501-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-008501-xbrl.zip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

//Z]DL(]&3$Q[QD3\V3$Q(R8F-^C^^%<4Y<7 M?\#_4Q2K10TF_SF?MXS]N<*4IK]<5,&M#"%?E7C93'58K/>Z;C?;7B58E>RR MQJ-K^"H[[6//%JQ\Y%HL3P-%5,[:8KUPS\(][YV&D*!8+25P%$>#?A+<"\:Q M/D)S.7"P:-4$/+PFJE?=XV,OQA1&6\UHLT<)TQ-2^VM.H"=B!W*9)?* UL: 2*GKM3G!>)@SQ7J%TH;&WIRTCQF"N5+;,3NU_NP/==^SY;M7O%)-D M:;V#Q%G-BD[TVN)-&)A@CV6Q0[L0"-"@J;H]IYS!J=:IB0KL.X]]R!I1?6 M'=D95$]G6>3A1^+IMMH53K 5X 'YHA,%A-W7C18XCV.0?%)+_Y5Q#B;VJ>I' M>;JL:'./O%F:7';"+1Y\^0X-U4P];BW1"F61: 4O+[C)MID388,6'PS@W3.+ M<:^EU8I^5EQ4#;@():S!4-R!DDO7QXN:'&Z^\6Z5A@01%PF^7 M9FVLQKC$F3&TM+3\''.I3[__[A68,O'?>BO\I;<"65;)"-#9VAE_GX,?%:3U M$$(K%=<8\B'( _"7' RT&/HI2^-P!,J9C2?6*5L46J MVL:42"F3F=+X0F'8/N*,_3DK6^2A'P>>SC^W93[YY)&?P8E@'?"*'VM5G9 H;\#D7"B"C MZ[42H%&Z 27(-2B[\BL\XV21K[,@1!YJK1. "L+U>;TOKR=/?WBE.A1T;?2] MJB)DA_38<*<65#"S]OASKB%>9CPW3NG(0S3OFM@?=[=A9>5@/ M2)+\W+@&JK(QCQOBI#:$V&$?%D;](5_A1GC\GQ6"':CJ.?W/]2'?VY#\^NX[0 DZU%:4.>HY2H!2UL3BZ55$_K63B:D3OJU=+Q,4,A_ MM.K@XI&:M&8?8%?0ZI41K!'$^59P#$\(637#FV;QU6W>93^KKUE9/XM/2#*Z MJ1:^8_D\E+W=3N8_RSM6^3Z+B^IJ[;.EI>*D4E\<32WW:O>+7*F:%S'T4HA< MUQ>8>3.7=VF([Y4'FGC=Y8[ #'!&#[[$HJ[77=#:@^(!1]'O1P1./EP3\I;Z M]R=C_?L]U[\_&>O?8_W[=^@7:/-&T!>YO&#^K(3^"YT@8("1*W3?P0.:I6';\R<7O<64KZS]Q#:@[]2._#[BI66:Y3+ZZB M2.:VHL8]U7%8G.]8SLFD_I)(FT;C%)GY$<^.Z.X=7 M>=YC'9?5R8[UG,Q9 &2Z)0O(;+ VNH!)Q%G$%&R",$2&=(BMD1T,.;IOD5T'.Y-8OO\IYF]FV?P-L_LO+D]W?E+OB MR@\7 A%;,6L?Q20I,J-WV1J9T8'#!?WV8IO7^P H7K9HOW$&:9XQ_'\[@OAO MFG5T206SGIXXTZ-'"("Z/VOWBF+T*, $U-]3$:C9'IA*')A'R&(%HK;)ZZTX0@0@4RV_$[=8 M*T-0+4>M'"99J.8GD$7KV1RW^CGLGO,>Z[BL3G:LYWR"!.91,8OKY56PO>OL M?DJNL:HD20/^K*T;4=4L;3MIRG1M#[I$;+-F]9UW),LHDJR;';KYU AYE]-.7('\:C::_33 M>,\IN+'_],QPX@EEL/$SZ/U;5?Y*=']X&QGM8I*C];*N2FA#2&S29',7*0-Q M,6*2A+!!^[,_P8CX? EGQ9_T#'B6:(J]=F+V?8AV8M-;,?$Q"HD]7L MZKR\E0MKHQ*[M19VT\&)4$5><##T%/B,?3R/2/4X&F46KJ?SOY=HD6<.5 71NG.YO1#M_ C%S,0"\'[:US,S5)1\EY7OH, MYG@TYR<_V!B*O'[*4@C)< RHK+9!>VKR.M@G;:17>V:F(>@\+M2S-N:P'57S MQ$I5*O/5[/(M/VBRI?R ;(HX 2B!B"X*C"25;R33L]Y>;HF>V0T(EY$V@_$W MJ Y4*>+W])#Q0Z%&+RZUU_2X*>IP.^W2=TD,)KWP91T%NX3J.EFP^4,OQ*ENS@_% )[N#(_F[^0'>Y")>5K<%>O)#ZX+\2+H0B"YTD^> MB).TJ9#9MJPY)%^5822J/];J?EIE.,W1:\&UB]@)W >'Z>W)3#PSB#YB7)X3 MH25B!8$M]LV*'8WX;W#O%M" ?)-K^YD8J[5V(>.7R<7(;/K%UPUR3TI*9F-9 MLE*,C4*U-9?_@8(NO&E\,]<\/SM="GW$D I*,_K(!Z5DH=G1QPQ)ELR&$=,F M1DEY;I[F[]4,G/-8QV5ULF,]Y]/ENVS=@+6-HD+PMM^2IM?XNXDJIA,2G.S= M\(..61/9**,.'T>AO.RHF[S1! (2^EEK6M.SW#^!@FN&/'9#2TVUM7:MDK<@ MEEX2-*2@)\O@''98CYOI'-;G>8]U7%8G.]9SM-%NQ.BNB]M+;?5.YC.1RE,% MBEC+M'*>\W0^5+)]4&8/ TFRQ8&EV;,9FT3!3^5"ZQ9&7M5,Y1^S@M)BB$S$D*%D!5OVIJYZ1<6I$2FY4 C M+'\"M6Z:UF')5&DRINH*J)X M*V;:BX9?P8,6*[LR5_>@L5Y:5[IJ+\=*2B'*DH_Y>;>F1T MZPYX9'3[H/RDD -(G!951,L:((*UP7,9*UCJ89B'T-'U\T ]5*WH"N6D?32, MP<,7#>@#.!0:#].A&,.# M2K91@"35;3N4:;,$(D1-(1Y1ENC7@+AID\!;FXB@5=DEY8E.AC"=5)N"ZJM: M-I/_D ^T7,:$YI@3/(N5>=YC'9?5R8[U'*VS2ANJICE,M/-#+9F$"V*/*M_2 MSW8-]_9UX7&=KL(@BAZ@8N@SM+I*5K/;L-UZ/\@\"-;LT&O!&A8:(:K264OJ M:AGTL)-/ %GK#7["L#*V)!Z.24<1!L84:;M%HL\5B?,:M2N]1OI4]ZMJLJAD M&L'C;KV8S8H": :2F^?>D1E:#WVB.P/QNW]M#9GE8MSZ9[";SGNLX[(ZV;&> MT8EB:O(8'J4OB#$(AX!9?77-(?%H9K%)00!N$KT7X\!$6N.?*:WR#G+=O=IV M.7@R\J#(25 X(L%J/?/JRA$&0$E0-DW.,,<)<'#9!@6G9E+=JX6WVI)])_ F MJL1G9":KXE8A> YBOKVX'Y%?7'V8MZ!QU9: T M#V(=\294Q)*2>3?>'VD(F,GSY9*+F-* WHHI>W->M[)$72)]2%B/TA#\V=.J MO*VI482O?I,CS^=9P3_C:;F*#S\S\ T;1UMY)CP+BY+=P?D8GI5LMY7]\T?M M[0SR-]W+?I,O\[+)J6O3B)M2+0I_P&R]OKR0"+C%([:S;24!NJ:';K?$;M1)O<9;&6H0>-K+^WQ60G M9@6VM$6CFSWY9.BY+R\B*.VPQ-^'&YMX2DT/6==.C6;;0#\A)/:,WJ*YP]ZD$<0XI]/6: M\JTRY&V=[^+/$OO@K?,4HM5M-Y=1NZ]@_:$1",IVIVUNO5[HJ\V5W"#<)C,Q ML;_X@\(T7EXNA89Q?O?-S?3((6.>378KAKC( M-<=ID?$ZOX5)B8^M#]H5ATUU\VC%I\&$3Y/(7\RJ/2RDK7UT5(?>!2O7-@F# M@;YWGH$'+[ZCTRO#@BPM^N+NH0G'=+/2Z"UPK"W"]8O=U'3_U.!IJEEG$V4Y M$AK(].B#J\2@KMO+BT6!F(?+5!90IF=+P,1F.VZ1JHQZW$$MKK_!KB?/ECT] M.:X57??:C]%?_2P(ALD86OQ35SV>=73Q!@[6D/$6ISC;R)/HM988W%0U[S!% MLP")6F@V?-E&]G U]3@7N%/:](>RTV SFJ8PYJ-UVX29"4#CZ$M'5^)@X1^V M".I8_5Z7%WSSO:'.:;GZBGTWT3,#4.6VTJ!!WK"B8AH;OCH],I6R256NF3+$ MKAR-]S&L0WQY<3)"Q..9=U2?]$;LZX$8*#W$0Q]J\) YE"OUCJ@8WH[BHN>[ M3" NBK-97EO'_,2V9S)*O$$&8BOK #HQ>89H(F&4(R'%6@]X&G-CU<@8CC7] M(V$J3RU> >Z9R5FYUFHD0T"-*\H=[L_3$1GSG Z8XU$]:DN#GBF[OWEN)'^V M)$5ID!2L?CGB0KB6]0PN@R2QQI<7T04,>.!&'@#^ \Z<75WC^A0'S9'A:O%)G62+J M[@ VLK)QB#$>KG&6L'TH4*=8K!S?E?V ILQ7A#;*^%J0PVO3!(:6IMH$KT U MD[/UOBED@*^RI1RS63VK:D:(F,[.2U,C:,]?YO"M9"W+^.32>,Y=)8=P #SY M)2(II?O&R(*@5A)?8'Q_"4,\WU9V6\O'-,K#]G6 2@R;-G(Q-C([NWNX]KA MJF,2$B #2UW>3;+YO. E#_; 2HOV> ^F<#!YY"SD9L3 @)-HB#0I$U6* 1:9_2\ZK06Q]I?J/=]1"+IO2; Z9Y4 MRX_5-X@=R,C5]>^H,$'X)_C_X!F@W#<9\,:^=4:\@:RF96O@2ZY5D$&S-1MG MH$K8/64H@,A4DW]__&CZZ-$C?IU$G/=U5=XNVS62:M>3[S3_.1WP2+MNG4N0 M\]D*6<69Y=9L5,6&Y-66"DW=U*<6@./7( J-93\6!Y)([?0]-ZC^I MCV-O81J*OG!77N@%)S>->*:[M+,<3FVONZZ9(EWKKSXZSO8I'SMQ*^TW?#C? M85,=I(E5:/]BP/ _5$KR)T\2MWQ!27(NX4D)Z>\#=R[).%KR+4G-)0$2BBKM M%A>;&G'L8$I-\Y2^9QR1]<\EM08=P^-^)#6HEFLQ'Q^P\WBNYPS4S;3,S'*V M++$YH1?RAW=22.,&@3@:J]R$4 3+R\")EPG*AEDQL5Q< )&?J//>L!:S3X]WANGI//]-WEUB3\E,@5I1,^T'9+K (?DU-R MGS6L,!TDXD#OUQEPG;[%,&A=:6NY M5HM?R3SY:Y(;9PO$R76!:HG6_Y"GL8-1R7!#84Y6#6OA;KQIL"?Q5'[R MB,?RU/[[\2-#D*#&7LN-2[Y#Z.'!RB[Q3 MNW=8TF-!5R)9&:18R+INMS"QGC1R@_W=TQ:.7[@4Y$4??\]5/?B:#Q ;VA$ =X^..FDX:D8>E&.#)WGO->V\ MSW[UT_7_7$_^8'>\01CRV@=FD@+K?6+5$G&[&LU5_.V('0QKAAH\5K#!E M'83#N2]07IXQ3F#LP'_%\GYX>/$7JMC8MFUG$@DDN#6Y'=P295;)\ZT<#]4; M3Q7+"ULX9]=\WF+:[?!#E FTBAQ^:ZX#'*.)S(5[9W*%;66>3*;( E"%&75Z M+#C)_Q:6S&_V#27ZEA&](S?'6K"BEC@#:WG"YTFPP$-ZE6=W!8L63@4?TOY( MN@&K4JWOY)G3H(?W,"B(!E8Z0S[S"(B\[K3>)VLN? $C]5=[>9%4?>14M>P* M?DJHVR8V58?5/4TJ 3UH(/L[T.;%=9O-N M\#J?%HDL##=R4U;,K&2:>CRW6NGT\FAEM1JF8LV5;$RRLE*YF JV-9/ELP;# M&U KJ#>E* 6YZ)PUS#4)J:UY&>P2^IA ?H]64OPL]8DE%PU_]D4;6)R(,5[ M]?,&_3)1/V=@>8+HK#JN*L%0Z7KA'@G5J^[$T3JL*P8JB^J^# \"SBX,SKT MAZA1S8S<@(VY,C\$1\E84!'TC-_0L854APV3Q$YA[R'%E <(+?%-B>*- WZF MCAOL<%.I@5-T\0&^"E ?9I:B_VXS::7O@\OA]U[11473Y+S;.K)4P=B7S/IM M*L)P[3FL.HNK>WH%R#,BJWB%.M^VCA+F.,56+Z8I1M( QA0$8EXG7\IFVB'' MU1T8<&8$ N@ZT1>2; @@J3IY'!F](@ZFGL=1LBXD=Z8.^^JG=,8 X:3\00T0 MGC+7H/Y8/"\(R B675=AF0,2>@=W07885DL'WINB#IF1-J0OO@36M1&7=)K+ M@)#M[NE)RM==4"3C^SSL.J&-JCMQ0Z9'U2(GT$+LYY$5=3UYE?AK\V0)ZIF5 M'E6*/*![EBZW_@G&3 2X%XI0)0J>6H=&\# IG7R1"Y7^1&LY%D=>X2?:MYP6 M;0QC,9?YJ*@3Y"4)^O+OO&.N)[8-)[U="&\\Q6B7"S6UVAKFCC-?$(L.67C$ M0&886#(ZIXY.GP426EW)+6F;'WL(>4'Q*9@G2MUA?XT>3N*D6_OL/BMD2&?C\B0]XP,^7Q$AHS(D-_V MF'\/PQ;?[F71O)&C[&5N;56O*Z97GLD[7"._TXK)?4%0ZFX_)F9_>T?\F82I M]\0C3UJ%YR*KH717(:@+;VYK;\XJ[3R?IUWWXM[;;>#;Y8LQ _^;OVAM 5CO MS3]35*[RF2&7*J\L1Y:H0=IUD0/P,]5_0KI7PO*DI6EX,9@P97K1!.;?]CQA MS9LE*PS7030."*<-R;KA@;.7>IWK/MPB M=:?"1#OFJG@]#P4BR3A9XVRN/&VC"DB*_@H-=#Y_AU=&+76#]%>F*X)7MD1O M>FFV<>QDC>'W6;.R_DQ-9#(A]]9;L5E[G=_A3G]KZZ)9%-Y 269WCPR:/'^C MF7UDUF4L-7%F&NRH\PZ<6@O5$+MXWAVM3*8.1KMADP9*#$([*!4ML$?H("_# MHH=%'I*.BE^W24*[B&X:RZ/ZN,O)G[.RQ:)]_/ETHK 4F8A[I'U53CJW)@W9 MQ\^W(49<90MKTV6WO-_TVQ>^.?^O)U]\\>2SSQYA>O-;9PE1;*-]I<"4WHD9 M67 @W^6SFB-Y\AE'\I4F1;]ML<(HS\)?&9E",I9O"B.P-T:$3&9HKG^I\[OJ M31"$T0N@6'_+5Y*TJQA'O3\W\8^RJ)QBBJ-4ID*.]4;V^CH9Z+W3!F23'ZN= MD3W< 6R#B_(A^$/='GQ]B>RK8R#[3XK=LX'QHX0O;KVIN*!%W).>9K55TO* M@!\62NQNV"EV<"@?T)96/0A*9[6_+,YOK*RQ-6UECC,))_6;=4ES5[N;H M?T'Q12&*RK6W2JX,46^7U#-H091NL@02VB[]V>:20X:,B6AXA- MVTD+LR68]0F\=_GR0G'&2HPSW*GV@83[Y^B5_%"5!7J8RELP?WB1/.^(6 O M56"+RV*8^HZVYBW"N>]7N>&579'[WJIZ6%NE^@V$[^F>2Z[-KFV<72B9S0AA ML[JQ>QZT:,GRSTPV4&UZQT# IA=K-MK#SV)MR:K&@*\IB(ZYO,2O0LUH%_UE M;="716U',/:"*H$'?8]=LO_#[]I2'A'G*3R=!#+MEJ0*IRL>59D$BG*)F<\? M\/!UA\NTZ%D\28YB<\72DW>OTN+B4%5;JZ-6]V6T9G=YUZ-CGNKZ\>/; 6".=HB\LA8W0BVVC[4S>D[,>=6ZYD25>+:P.FDZH&W@_A>#L M]CKGJ(#IK[\3IOER2J'1/8J!UXK(H6+,0[$@JXO,HP?D10P%%%[J#0-.!Z%. M@7R2G)7K7/VG9#]4C>G-36X!<@0]4]&\\6JT'9.!@"(=G3AM!Z_!P! 1'T+7 MVL"@Z>0.O(GCLS]Y:/)E*Z>SS_O!W(03_0^546D>^IA*+I.\*O]O&2TY.YB1 MUY^)7=NR_<$.]:[Q4(,2[,M8$#VI@_"P($IHESMWV;TMH$7!0H4N%Y41##Z@ M5G 4G#;5$'"FU9\BQ(Y)W3V-I3>5;!FV-$6V68DU\K%T>JH+YD9!:HR]4.K6 MSG*#@CD:+^(C+$L12?M81U-7')89W?0D=0RG*#,#PRF6%"IT>8%$P,P;OVEC M:,RC8<)!_? 7:,T&EF"C94\C?CBV4/5+W#3:'WS_XVF$ @(, MCWWC_L'>]7P6I;8(AOT;$)@9KX>&1EPK=W MU15M?>B'>=5N@7*ZO'@*,J^IK0MOXW>&K_!U)VYT"K"?Q"G/K=6_\;R!]K58 M;M!B[FGXQ:L7KY]K/&<-).J,HVA<+Q02IN_:#9#'F?3(O7S;:>SRXF^H7Y>] M0/@[AM3:#3'%Q\_GNVHF#_K)(^05'EF'$.<@YA-D,)X"\ EY6M3SMM@-Y#^T MST9]+^/IQH[1,]:22R$#U99KEKM!KH&,PZYPQV5#6=?<<@!8*NC94398E^@- M))/CR7Q2AI88E717V8):JRN:T]VS'%]8-V**Q,C\H5@W;XK)W?7D?S)D8F!N MV'"X2%E_O57(%LE555]U%T3H'"+]>Z%^+*- 2#+SCR2YS]%XI%;6_(9<9JI( M.&QEIW;%I*"'#I&[A$'?)VPFT\FS.#4E!_K*T%(_ M(#U6HU/25\?DQMAS,)87]NQ&7?2,%@L/_SW;@)>3'SG8:4<)X+:5:5JS@ZRW M&#UU'A*AR_3LCGW48:41L5/F46& Z\CWELV1?/Y8)^F3J6VWFZ:IYH6^;XSA MA^ KR!&V8H+B\D+6W0_[NL@69 ^&CQ%76G>145';TCQ\/9K60>,"W>EO?KR9 M-/GMQE+Q62#8#:^3:XU!9[H=4>39Y*S%^0*1LV<%FG 4!(JF8K>!;MCND!;% MPG()B]J.FLG!Y.)4+>1PNM,=IZ>7)^B+\#*Y=<0 %EN'6J)%PF[.,$)3];K' M/YV:LM$_L1X_?>=E>'D1UN'SI:^_E_+BZ<,^K_MK\;FOQ?_\45^0W$E/3,(& =$'37]]A&H*U*>5$ MR7_.M/?8 _?PS Y4W.@S)X;9>A<^^8R&[NGU!"?G%U_+Z?-8^1-,1D]L1DU@ MCB_&F""2;\6_^?-_(%GMMX#8OAA!;.\9Q/;%"&(;06R_PSC@>7EYH6['$YZ% MGTW?,88TYZ0NQ&.$VZM;IF+R09SM=0P&,C^LW8-2[+EZJ'5I'8/B+"$\O[PH MV_DZ%Q=*5OH"A_#%<:/+3=D'(>.DNQ>7%H4\Q[9SM=M%VJ\Y_',E;S_=? M=IY?7KSE0)_\TO.\/Z?B%)M7]OG@C*Z+I3AXS;R@>89GPJMPH?&UIG0:,])) MD,MI7I5_:\ND@[4[1^QCJ\H')B"A\B 19IA8KT#82*R$JX5:9;!6W,<:%)ON M,M.C"MH2ZB&7S:YN?04NQ8I78$3)-UT8S.V "GTE%UCIAG#*D(UBT:9LYXI(@.;K;U[AB/GDC_FRC MF!X/7Q)0%V7NCOJOP+1E.Y:@9 ^S--4+>#4-*(N)W<^,I,H[I0Y+9:YC9S.R4UEP4=2Y#EUO5-%!YFZ(E"-BWWA"T&S6 MR17L@" 58'X?>\,=KZGUCSA@"?3G8(.0Q_ F_?!872D1M1#=3%ZLB@9RYF[) M0MO8'#"8'LX=(V"E@$,X-":@7\COET^M=SP%\"G\E>WFI)$> @\V3NLDK\; M0?9V%IXHZ[;D&15(DD-T-KZB[,NNO&VR^%SHNQLN(Q-%%S*91W >QP @YEAT MK*F=/(3CVEXQF)*2;4J0MU"U'ML5Z2[,<*YC5J(,C!)FECULKJZ!E$Q19W&L MHYR225:$PU^9=-P; @V>*'YWH"J3[R2(^7GE 328"Y7=&8;9=-96"TU[,FA MK1SIB 9H!(@O'R01&*$0I[>R?$VYJEM9[9RBT,P*K7[--Q^)E +^<6,=!>(R MB^UD'TKF^E/R-^_<2-GR$V18Z%I14*)Y\UJ/KR*8N3&XMIV+.BZ,&D(;^&;< M JFYS.2LWN3!N-)K )@5318$1@/H/3<*%Y=W,*TKYTX*'00//*#"O#F^:$C[ M.-5TO@9_D!Z&H8^HH04W847%DSIL((7#)S9]FOQX MAMKNDG:*UCI!\$LH;>R2*)(A9U$WN\!9I82"1O-I/3?:P$"RR:Y+-X#5BYU# M[#<_+DP5QR(O'>HGNT) M050>EL&NEF?+7A?5K([B>'29\P5YFP9Z91+1K$,1,NV83[^.A8$>&:W5H7]&QOH2@RM?;FEQU52A-&D9E+M9_&E"@FJ-(UZ6! M+@^N919!INN;3C]1THBAXTAYE0Z;-1"W!E#FQ#'?$0"4D&XE31_=&_6*J'PY MVAUTB!LR#)0O4) E9'=5[0URV#'/M)X)/[$34;,WK?-3_Y7YPDZ@1,,7@RTW M7J[< J=^CLA>?TY5E]!*UHME5 !/CF40-,%*(I!@62XLPMX:>+ [<6@%^,N> MZEHP!R*"@M4L#.+0TWD_ND"F$;=K(PZNRZRMY4SDT= !YW;4_[P#PTEV)NY+=-(T%#IATR"&E;% /^>(YY^- MAY*(.3D?D&0(ML7$*)/C26F((P&:W(M?$H]_W>^9[7>&]BR8T=;YO3J6"OBK M&MQMLBW=5OVU=]8=[*HDFM&'W >Y29YA\5;>+C3T?$G$(VY,9/9),A-QH_F& MZAI29B] C920_KM/VJ$1F@;MBL3W<@I'_=W]JMKP,%A4L9?$K;N>RJ92JNYV MOBD!+#/_P7R*7:>QA*#)6<[S+0T,.PM,O>8>4ZN\EOVVX^TOC$%2_,"9V''O MY * +2S&RF;C^%A3_T?+(L["K9R*Y;XSN,L+']T[^S]ER#O^+U4ZHVTU;^%# MENE\"R#DRQ$0\IX!(5^.@) 1$/)[8#5ZKFD5DAM-7L:#'5;Y#V:51Y*;WS[' M3++YI%+3&A-HF>^2N&-=@-6F<+KOKC!\9&BPL&J7_1Q5 MC2Q^'I/$I[@TD"1VIF\4)1=<#E@$9'#'B45,D;_T$BT&$[1DR#]4T:W1@E]= M+8M=4/*]"=STRZ)!,P\T4B8*K/E&@O$-&Y(> XORY#&<0PQCH4T-AWIFATO4 MPIL?GW^/?RPG3.#^7&RTD_S?'S_^\OKSB4S)VB/K?__L\^M/PE^,IISAPO7E MQ:NNSL*2A-N[^TIB)110+&O.HK?XON(A9]N5YB\.QRI#ZNT?JVD#?H:DS,_; M@C"))8.M=B-3*CM57G'B"[2+:O]^RIH[*5J?]#TZP D^=_Q)N(BPJ/*-U08 M)SX7I&_J_OM__(5;&#P0H$#V3(P[Y%T4>*>8GW9G$"'5^ NE:Z;[NP-I@KF2 M!_[RT7_@:PYVDI%9Q12/\H'X_^=H?%Y7EDWQ8/>P5*Y]V[L\O#3?_+;"S5(I M8 G[(2R>@X7>?>V:KRA!,!9KK[YF+$D(JB;+^F&_,>$LJWJ.6OVNM_W"X&5N MV+O2R3/&P71'P1V>&CT-5-62)%MMV]8@?("*=V[EJT^^?,(1??+E)QC@,U?Q M>(G<5(O6&.4+>?S5EY^'RA+^:&*(2L>D13SNF>[C 9;(W9J)"=BP%P;:5-K% MRL!?)4<(II%X?%5LM5V9R!>9A,^PZ8!\U>R($J6MZCR_XE& .D=EW3R1)]FL MF//2M%XW5)(83RYY9?HY=NTL7CUMK?+ MK$X@W]@B2[XSVV+O.@OV3A])92_]#,S*LB5)GC^GK[YI #R%Y#OYP"(>,D6A MJ&@"4RR;C8S2:5,*S=_+I,=WH6_J>O)-ZT4JF_)&3:Z\"F)1(Q;4KQUK4(M M+1+>:$H,'F]&?$W$9$WMM>QV=2%&V\\=S??G5_U!'E*6IPG#@[DS9*5MA,L+ M; 2;9Z[Y11ONUK]3X^V>^J1H+LL6,'9!X.3P7,6 DKXR[[HV643+?F/C82.@U+JNF1@^Z'!41VT3 YRXL@.3O)K MBDDR'[(;> ZBQ92GR1.YNZZ-@#B*FE7Z%\SHQJ2\DUQQE=Q699_6EH MHW07U:2WIKS@)K",Y#*ZQVN[[,,X0%>RO+#H6.V]L[(?1HXC^[ M'V[K%TR3OZ7S?3WR3:I3TPJH4*>QS<8JD<5*QJ+65WP"FY?I]!I(&DB' M[G9^^/7&6H9ZC_%56[<3\#$)^9UC6>/ AK6H9GD$TJ+1:%,ME+@5+AAK8>G( M#"7!\/3R@K8X2H*D-3#J[T:-"AF$E12#A%&AJ06Y;5UE^I_D2)VFA,R)@#9' M";Z'2,9LJB&*8VZ"#+FX6?DF]/8L(-N.=ZTZB97)HAO_GGN[O2BM55$492[2H&5O0%W'E!]LB8"]6.Q%A0OUC"DOMMK>9-/6RNB M_;F:J8BR_(Z^GJTO0HKVW=S&%&5! /ZJ3R M-N^*6M[Q#23)7Z*K9ZF%ZV_%Y%2;8H[CM:VUH7V>L)7.\GB];MQD5T_XC;/ M4/R+W$X6?MYEXA[+\#71$GI@:&6!]>\E0IC](,W% MWM:$;^/D( !K\?P2;YU>5&K1-V.OII8L'\$G/IPZBNNFP7EJG.- M78#[\^HZ-WC5(R[46\##\.LO35X6K@U0. FPZB#/$JJSPX792$AT )\?&F6$ MSW2$J?3UZAEG-_R 79*WE&V_&LNV[[EL^]58MAW+MK_;.,,43ZP'N6.7:\TK MJMV.H#(A7>[T'=&/$9\C/E/4+@S>:"*ZR8S3 :?L6&0\R;7U M6CF5_F8H^\[R$"\EN!7D4I-7"DS9^LHQ@NH#.W>_:Z JWW#9Q-S3+"_S)=._ MLFAO ^ =]+]50TMJ"+Z&S,-]-]MQFYEVT5O6W@0;#A9TQ-I99Z/XU6*3#; L MX0[[R@T)R7*&N)9,QF@G*#LF[$G9^A#!U\[;;M@\W6-:)K1,;A'E#AW%-X.[ M?9?[CW3W(J1R)F9T5R17RKM#T HL?'&V?-3J^6'SF0MY7]5O""9/88-1%,D+ MPF8D)K=U=;];]9QY=(^Y"@JSKD&(M#?QG)"=BE%86TYN8LN]5^)&Z9=;F,G; M#0Q8[PR=+LGL[GF&7P=*'&]A1MHZL+:1@-1L]LX,?0!-[!JBE)6 MP#8980[5NM5]=,#4[\%0O=%(?T!]>5'(KW7+-;MJ_@;T-GDD4@_)Z&GWR%WD M,\:\RH:GV9-#]&P,DL:S[_16* BI@9?V8X\YBOQV'WH!MFW=B,7DV@VB-,M) MLYK$]7J*-XC=N*6:6RYG /N>2:WC_%N3#=L8])KKB9)X-[^6@NG07X MVSKD5;+2S=$B5%:K5 H0Z24^'4B\01CN6=*D[R_V&L6&1BH AUIT!/:P_F>- M(PFU39_ ("&*3EH^G,N5M3+EXPZK@;PYWC2;ZIW)0$ODDYF[Q3%^%:3C/%^; M2*$E\G&XHZ:Y=8-:)M@E54-1%ENK$K/12';QD0&:,6[Y=>PK:-9MT[1 MW"2AA^X$?%)UCR'?@5FT,'V/@;WI9YHU+\>#BG1;N!B)I5S#!;0AQ4#;6VP, MK3,LH"0!OZ1D6>RP9<9=VUH<)+!M9VLEI95'NI/W='EA>Z"\[2I.Z\72YP@+ ME(=GO4GRZ[T6RV2Y^!0VN5V172H8^2(,BDTN*+DP-2FSI#0<\@:9QL!EN?D; M33JS4L!7F,B'I:^M8V:T;NZ?V"N$C9=9^0-$LBV?^0H7, @EL[?L U6=O[JZ MTV7JTP=QX#:!C]XCS ;=N2XP<.@Z)K X1QW]](("UF-U*LUG] M;-2(K)L9^\8 ?73\1U^-]OXO=XIR& M_M7G7WSUKQK[KSQ8Q-,8VZ!)%X.DV"U$&AMSO!*W(H*,>L;!FMWZ6DF=.6&: M]616]SDMYW&L#XQU7%8G.]8S,HO0I\784J.FS40I1$23')[^T("W$A_J-DF_ MMD!KU+>:<0UXV"0>G)K#/\^VQ8XT>_"\$V2?O'#>.6^P<5NUYCW5<5B<[UC.RW,52QW:?#YA$#=*9@8%A3K(+ M#QCQ8>;0D%A@2@)U)_S;C3B(3S *XQ>RMAA7@539IG'QG\-Z.N^QCLOJ9,=Z M1C95K%MC>0)V6*&41PAI MSN%Q-"!:';@^^]247M6?^BW&6E\K!KD6AP M)LY[K..R.MFQGI-=3)*GLQ1G]+:JH8(3M72>&RE>ITC84PYP*E"KL;!UQ_L$ MK#R,<42TUZ* )$>[-OXS*_FBBM.WS[GU^[C"\YM\G^*M@ DHR2L7*.:BFXSO M*HA?QKPJMCX.0I@X4JVA^3T##YUGFS7_D =6CO4^L"!WIB-68T./X(9UJY2* M,CF,CNQUP_2>;2WJ812^?']$X;]7%/[GCT84_HC"'PO,OYH7U"O=GI-3]*L. M_4Q])(=5#[5E=/P()6E-2&W)+ ^2#HE$K;/#6&Y'M_X<5L%YCW5<5B<[UC.R MA&1&PN!B).5QC=*44X1\$V3O#^0.@6L$Y#<+;34:.;) <1C7C4OX'%;%>8]U M7%8G.]8SLHQ#/F+ Z(N+.*\H-HE,4>2N@;Y4KHV92XF,(__(: K/=LV>\UC' M976R8SUS4SBO-C-T7!NQ4FC0"$II_"M%VA^P@=X.Q[\^75;1" #-(0;+]4>#59YMHB M(2PS*$QUT-B9_YS7\T(%6;L [:438NRR';*8>W;>944#R:^NK*IZOOS-MJWG MJXS-CG,0 U(&5HO-J/"R)JR#"8D G0--I8Z;\!S6]7F/=5Q6)SO6#\BV=V7X M D-"$&,,(JJ#%+1FT]>%7'SA_=>&U [TW'E/RM7=RJ^"V85[HDPZ2&V:IK1PV7H@SL9RY5 M(1%ZW6603>EC,)QP?VW]6.<969W301BU!NQ2$0ENQT/V'%;?>8]U7%8G.]:S MLL Q"([XWR:*IQ1=RBGERXD,07#;%D53M]L!/0@"?S+SXS:1D?4D/1A10:ZA 66^,D(D#V+BX1!W4$SE MPVR#.$^JT,@^=WFAS3':_'B,C3$<@YJVSD<^M0?O?G9P]Y%/[4,TYUJ6"=F( M@KH\69>2>6]24*4R[.SJ:IU2@=+MAX!F^?Q;L][K..R.MFQ MGI%]:\N$X,'2GXEJ:"2E5P+(&.]UA8/&E7D.+_N\QSHNJY,=ZQD9/!,2*]R? MJU+%,2:Q!K#GXO35^::"/E8UMZ^Z?FN/W"9J7HE[6" 7RI$660V56HCH1A5H MX"CS\JZHJY)5]J]#_6E<]V>PE,Y[K..R.MFQGI$Y+?-[0PJ9;'J*4U>IEN:- M46*5>[&&B[Q>[]4V[O+U.I_O6E1]:AC-W1ZPI6I>T+$DB08%*?W:H>&<0C"S M/(?^>/[WEBH/81@[!=$[$]?A%2"#")"3:VBK^F&^@X*/@MEIQ5&=;\8:U-"P M?T,50FCGHF(XG)I6::+-IBT+/Z@FY7)I2XCN=N^/_9^]=E]O&DJS1_XS@.R#JJ_K"CJ TNEK6U,Q$J&2Y M6MVVY9;DKNXX<>($2((DVB# @BI.$]_">\8:6),Y+" *5W)#%!MY') LS32098@GQW'8CZ3)9M_VJY40 M@ODKVNN, "CE" *F;4,//&MMC\VZWC;+0\_,BI+_DG(.B=\V"21*FJ?"$MG84YWWFLIR1X97V,W!*X6LW99)&MK=;/QR' MPXB;"U84&8/-TG!:YF"*UU4ID+/+HPZZQ>49W=+TXNDT['VF#Z))W(_&<:\ M@68J__1F=7KQC_,W6[O''1HFPM\9.DC*;S%:[%4Y11L]\FQ*9>@S>R22$Q>\ MXQ%H%I+;$+V.X[28TAY#[M) N4<#$-GCL+@=P#_X>/QF!= T?;9&#+]9;0>C MNLT/@UN<%P:_B V"B='ZHZ?>=KOU6\2.Y$TDOJ..3MHV1ND(J!<1WMZLB\N! M>^K-O,R"WP80VH&_NS +SD;,<>U 7KB5"TRE!34%X8J=UN"GFP:7Z'^:]KVO MF+J^?O N[&:Y.++GGIR_=TC'*Y5S6HIWY^^OM-DC5"43"H4EZ2,AET4O2X@" MPR0A9]X=RJ>$7L/DL%A^/H"JS/PCYK4T+-R;[2)T(4A,=>L:)M(HBA)9'A@# M9L5!6MF3_C/2@YM^F-(V]K@[ OA;28)CTU1QTF=-"5J/K$\WDFTSR5V#JTT< MO&ZCZ-#=SZ$Y><3M%NTS/1+2;Y289VS4Z=D_96M\"WB<>SAE=QM.V2?FE-UM M.&4;3MFU1$A^95_T$N'>=NM2TV#7&=N+I])_F!O6!A_1F?C)_+EUWY9G#!JP M!R=]HCELGX=LR-YD"=JGU[6.5IJ"43PKW:]WK.W^;FQ ,G[9A2C8 M;H33%:>VK(YAV^45UBK1CDOX*E?K/6VSM]M9W$!(&,QFPP0JPKD0%6J\ZA8LV6 M4**Q(/-CLC[K1TE<,(JHSC_AF/Z'L.B'O[,9:+\KRO#B^O3O_VQD=1.V?[/' MVHC5VHYU@U2@IB=D@.2$1F%.+B83:$@*BB,EFO)HY&\3MG2SQ]J(U=J.=8/4 MFI?V57:WFHC5[V683P&*]'#CC:;;*)'QX:+*F*__M_7N_M'OT,CE\MM08P,,5CTZQD1*C^?@L=%_C'KBZ[T9P;(36; M/=9&K-9VK!ND.47=:8TSZJH+X19GYD!?W8$S=QH-T3G6*;IYY9G$GZ,D'F59 M7W A\32X-<@L4R[2MU7:TWB,'PX4D4\?TB,;&=\$L=GLL39BM;9CW2#5.EU*S".O0C_-(,'_>N[F&![50-S&ZDC7';!,D=[/'VHC5VHYU@[0W=_U6NJ$! MMY:8AJS-@4(NT^D2-:P-%2=1WHNDDE<)+5;ZO4%H%UG2[\QW=+1Y0M*@6L7]MU4=$W**87,U-^ F M[/AFC[41J[4=Z[>D]9!I1L-4[6K0J+:-V-;-'FLC5FL[U@U2;39XIOD2C921 M'U=*4*QJLW6$YY#)AUP_0WPQC^A1@!TV"G"#)'63Q]J(U=J.=8,48)SVZ:'Y MS')B_PZR-6*WM6#=( M_5984;4TT+D"=N ;+7M !I6H#\R4.]B3T! MO%X3?J6=QP.QO.B.0P?I+!B44^F(IH!%UVVB3S8QU_QQ99TKY6B:03S[QC_Y MEJ/;'>LJ?(**RLA[9;MEZ488$^:*-DU)4#B5#@E>PT$T+(&S5) R!XI,^N)R MO25J+S$)C'>21S?<%<*.ECOEF7Z*M 3\/2T';;?X^;=H0)DD_&;MF%:0 K9+ MLUA=:I9&_F[>)1TPYDOU#J9NK._R> MKC7T,.P8-Y8D&(199D4A;O!C;>SP-LSS$+5@]'W3H*\CS>_LP,@6Y/N)=@$= M$66QHC_$7^>]H=NTE-[X2@9\$V<#_K=+\%'6T#,C9!>=I2'(2OLD#MV MP-RG8V$-L4G1'U'>0^?$CAFY= PQ(Z:_^XMF.^YI;U_3GT>.499^(RWO-E%# M>E?CPWC-4>S(!N34-GB@[S*]^7_1*<(*'1U@A>C?=,:*FDZ'BR_A+DR5;HJ# M."7=C8I*ZRXUS9C74I(NTG;K;=3-2W1KWSOL+&N:A#ZL(FHD 2Q5T%LJ6:=R M00;OQ5]^ 0JNO9V?Y5/^C]V?7]HFOQ&3TGCB9QGV/1&DU60A_(5N"O-<4F2Y MH?.G[^N?B^#7/"LG:/.\';S 9_IZ?J1Y.U2FU] Y^+W,)%%DB1 T7,G7F/?T M=LL]OA'==1+=:Y$@W+PJI-A4Z4AL18H[XP[HJD?79WJF:3TG5RC=>WG80VO7 M_Y6-)T=QL1&6$54Q\CI!O]18.JQ-KY=6NX4;DQML)_%TJEVD,VD7SB -&!FY M):ASC68[KO^L5UHZR;,"P73M+JX]=H47CXY!MYSAEI:.UTF"?^?1! R@Y/1" M(W.GZ\+O[2.V4X(NX2#%,P$NL>8&6@91Z;EHS,$RS;4SHXWL\Y)$.?<*IB-= ML;',\L..9V,XU"TRMD:GTCD09?S.5KES&\<9&G6;!H+&(EWR)-57&2FY^0$P MX9518)HH@>S]*\L_Z]S/]*NR_#(.3V]P/V0VDI1#A1:V*#P>0QZU\Z 19; X*G(7^V^LT\Y&,0].KJ.J5)$VQC1=U!)E&G(G@.< MSHA=.'I?G!M_@0X>#2^-PES_GI&[$\,)]FJ27!="[:;._[T=O!5C76YR9R/. MVX/F/D;"D9L>UEW+8@BB&S=Z!69 8X@&9%5GR9/B\20Q'>5]=KDP-59D$+$- M:1ZN0Z_AZH!.[Y'3B9:&-POM%ZNT'DQ>ETGE_2#J(WH/SS,:"\<'% )2JA6U M$-X".J)>K=U"?H$A5%*G'SXWW?_#D4_M(="2&WYJF/ 4M#+6O82NB8B>SHZV M)%NW^E'(6IHW81Q^YL4Q.AAS4[_M%@&((HKX"W"_.2FXG"27)M736M&/+T@&],_4VOY36\T5'8L1=M*_D,KR;*.UK M/=Z$Q,M<>([;JMV2++0)"^3C*C\#NR.R NX^;;3Q.FECSYO-T04:@:^,O$=< MW6P[3:(T5<*=H)?0I\R-SL=;MEU\4P^>X)E)^".9-#38F;6\YMW7H$KF(P\E M)[8/&LR*BE]0TXU?NY8R=3Z YE[<>1>+JYBY9*7#2AV3NA.RZ:K1SSV"#[=W M=J!/V0*UH<_.O0)&&DK#M479_;>"8]1']21;/=4@+Q,H3KC;)($1PJ76$@U. MZ->7](5@/SS!;)WS*W@KFTM@K0ZL])3W%+U( MT-JU(,4DT-^(>^S'*FHW)?X%@[JRKZ W:A"V#Q2S@G !OY!NWAVRT# M-.:@ &XD;K!-U@N,B'[6*\'XX*^\$\!C)?RNF67Z9%0563"FG;&^)WYLS"@1?6,"=F/A;>8LC'-D M"EL[XKU3M!D3(="2XFOB%2P.@._&0DZXF(->YV!',LUN ^WU",=4L-R!@SB2 M"LUNJ_3]P0W0)6Q2A[U1=3U&4=(W;S%SM2I7GZZKM63.';L3B]/QI^*O@+^W M'5[T=HMTUI#$Q3+$VI7/1",QG#*XA2:2.T234VRGF G[8+2 MX$2/C2TMK =;V3KL;UC7W0-7VF_@2D\,5]IOX$H-7.D[-&#.$616U$AG_EZ= MLV;4=OBS%@SC4?C)/R_>:60^X#X!XA_1]TG$^5A<(0BCA(\*='W)< MX'=D5?,ADB@/6S[6;E!;/]=*U5[$X!K_$W,;D0^D+PZ'B,U%0FD^=PORW5U$ MOKFE*R;6@DVO,(!#8XED0$7]LF?[6!BSRCAP>/2-1 _%)2R Y>TCWZD6AYG/ M@Z($/!@3(F"7\-XX08.6>(IA_U?W?RYA4;=;EUJ^@OWX)9)HZT>)X.I6-SB_ MYX_[_19I@,3/+,0I>2^!2P)HL($[6-.C^P5R"/0/NNI8ER!!H3E4B3 C%\'P M03:0$?!7)<4Q$8ED3SA?H1 Z">TC]@?)X !^;6!YH:ML$P!<2^$Z*9#SU82- M;.JL Z2?0"_A'#-*,+:=-NGJ& +EZ948E>B6RP-<4 M9\=9^&;J@TL*I=VJW&/J45^%>3=,HV+KXH\DFG%LCS[9V]G9$QS+XN6%0][XW6;_?;KVE^_9S\!O2,E=3NHNGP26LZ#%/]I0.1@EO\V.>334N2._M MX(#=XDJC_Z\!RKG3Y)!E-!2D OG=@JJ82I#22PK*34P&!1V_N!C)&>8,(Q)< MJ0'^JK]\4S$)%@!FTSQ+"H/G,)62O2R?9%R4.$3B2QYI0Y\,LY521475SJN, M*5LBE66LTU*LGU@QL/0L#,X^U&DP?@R;944&=+#8)]P$ANV(*0DV7D,;8600 M/TYF%=EC23#%EI@ QN!K1"NZ$M)(R2I:F$ :B03U$?JBWTRY+0Z"/FQ?6H"* M3DR>9U-K8WP_+R1Z=I--HTHO!9Z&V'A%-'<0*^O:6$;/IB3?9N0F1'^$.*XX MG1[Z[X3.Z923)+#;62#)RI8><"@5CD@?8E0F_3L,K?="^C/ONY-TI7ID=^?$ M:*)*/@/ :;EW$YQ^21&K&I,\KQ7H+@FP.Q/V;!E!E#^SCHGZSJDA51<-54VA M,-J&$-TK;Z,<> PGOXR@DEBA/(4^!P8RS8+HQB6ON0U4HD??(K5<2SPSX>HB M]<(21DU9:/J#LS0TJ$&<&.SWWTMM8P\SEA09@R;>0DWO[FS]W;HLVNT^P%[T M@[^6:13L[PB(\QN.^6WB48.9RU%[^,E\29)+GDY9T:/_%MNAGOYF]5F3H(-P M "B(71.KFF=12(MR2+_!O)B[5#\(3**C)CD,YZF*/(0 2M\"?N;E;!9%-+) M$OEZ0T,?=TG<]G0^5^:Z;P/%.!*AV*IA'2G3^/_E8.O5J0E5F#0&&W$+V&>1[]& MB" 5123FEEH\D@ ^!^3L^,3@9195@MLP;R4PB=U&#ZR5'C# /!'^&A= 32.D MJL89;H.II,:E?LK4*UFD@C.1&1J6.I,X@-WKG<*3>!AA_U& ^O)(^S[%KMSC8*7-R!A=Y78 UXSMJ57L>*U)^ M;,<7-L#ZYQ9IN]VZ4&Y\WSTR1MV=*\4+[,(L'2O;:OI(E*?2@,W-Q.A*AOOA MWW1O^=ZZ)QH;;Z@"<67P M@:L_=0,4\[!RR0T&"CJ9T'&8Y+ BYQT?KYY.SD=OE")AY,_\6#]M_5M/81M^^KR0J:H9P3"E'X&8+% M4$POC5\!]RITCR-I_:A'5FYD5MY6YWK@J((&80LQ*Z9SX8437*VH1V,>EF0/ M* +70$.EC[5%DKC-=-.5V(,5*!)1&G;OJ:+VZY@X/V@2YT^<.#]H$N=-XOP[ MM(@E#03 KL:VI2Y&2NP,'A=Y5A-4OL/F+>XP]ASM %*W;+!YE0@:$Z)+M,S# MWDQN=PWD5"PG>6+%R:Z _Q1?5G<-UA4!F?(9K\*ZR2BMI9S>F5'R\S%6:A_F MD3GO!H9BC8$%&07D0ZN O =OKV:/V_22M<.-.ZEN6Z0I5L&&1/>[#]9WO'MJ M!J0:5HTLX\K5&:09I.^9H%L8.L!+B#[TC/V%#!O6J0H MSZ$D,JX"()&@D\EOEQ1(F=<'MO0XFU$A<#N."_Y"GQV3BHM146Q1.F+'2C,E MXDE'-IRMKCEB6DP#7W5::LS::A:(\5>Y>*4Y(>&S#R**K[Q]!0N%D%7S$D++$(45,@@ MN([< (_HBZ54,2 .3>42HA':R(EV<20*,:4SF6-JLOLP$S-T7P^E.(%TV\8 MX,J5-AH5J^QBCIJCP2X^O].*I*X>JHL0P-LQN MBC(6CA=ACC-UZY8*48%*3OL9*C8NTK*!5D4H*XXY,)0!'8_,"[E*+9A6#CUZ MP%V4%:RH^9TNGBMZU].Q#77F[.SN='?G?HA"ZW3VL^=*" M>#IQAGP:P21'@K_NXP,XI[[;$7>M'QP?=HZ.=CNO]W?O&L-!Y_AP_[XQ5([( MLB&T6X)1L$.XB9AD);^A!QV_VNT<'.[<1^$MFN:L. F'G+ $F'@JK1=91:\.7M^U9EDYY=)9Y1953E1ZR)"M&H84 M_GB\?; #G?'CP:OMXQVNH]ZES<, ME(E6:%F='\.H0I%8$KI?JLP!V.$'E5I9;-9/"HDO%C1 M(8/>688[.JN(?R%65GP3)Q&0X464:M6=TN=6S!Y_/M]PZG<3+1OFA["%%Y#B M)2;WG6S+E1Y&YHQ(E$V0[N9\Z,\7>)3Y%E7LEOLK8NNLIAT^!?D<$KV%](Y& M+"*H>"B>6@K&BAPRI%BO=4NH)P<<%FJ"<&)R4/8:#R@UG[W@.;4\,1'IF MKK ^\TD6, ^JU&USV2T:QR(762$JH/8=MP;UP1'@"A>,9:D6?G)6)[>CZ![* M.&@N)73C@HZT1K5^(\&->X ;APUPXXF!&X<-<*,!;GR'5_)\#(QNXJTIV?\< M%^^3"8:"2=]7Z4=).!/V3.0:IYS?];A,)1O P>LYVOF[E7\3>'IV6;A@IPVZ M@*D9>9OBU!1A"A44F0!CKKSH:&6$E&%((85DRH/NC&NU8\U(,7"@$.8FMB;" M0L$$G %E RY'=1I8(2.)=_3)=^T)>ZCDBV#0L%]:R]201^-,4=;VE_-X4$-^ M^T"Q;+#,JV( M)B%G/MBZE9\(F)H<4'6EK43X6;8J'PBK&09W."Y;IW0$NFT,:JNO&,.@58E2 M=H7$6H<,?N4-K'YWX9M,E\)#E5H"N]0<'X'/S/$1#^4,0=?B8\_D+F(Z@&&N MT]E&@4]@*S1-BG)O9]\$K'X5%D2;-L+'[\);"P*:JJ2]H46Y#84%=Q1WP=U6 M*H%OE [#H6'2#UU]+^U1US#$"*X]MBX!O C7=297Y@M F)\C 3S)_#A+A#SX-- MQ;4SN'PO[%6R@'<$2#&0$)"FLVEO_#,O-#X9.4B.(8?QA3@F>.>MUJN"7V(> M#NW5'-MTT, \OB1*QC%1=Z12UVG@)9%0%&G9@/% M''^"XI#N2/R+&@52$XZMK@<7^,Z6#\@ZDK;$ VZG$4G=6QP M&I<#.+CX/).JG7OIC/.J60)6",#T\%0$-1LP\%J*MA/J"!8!][^[7YS9%E!Q M=H5J<)QZ\82KQ=AP6>5@+$IXN^4I4@_6RL/TDE&#$L]DS@*\W&8/]9*RK[6& MB[$83.22\0%OZAMUG+53&\[5'&-IE@G3>'*6[PT M6*$V)FWSPFRWK-(IAR9O0/7?V\%1F)P8C,L*&N M=/K>%U1(C;2)9)5%1Q*RE7XK1MZB:0Q_J'+KJ;++OO+RR&;I1O6SVW2(AE:+R3E6/P,3 MJ:FJ'W&+RW00WF1"2B,]HJ:X01'X8,(SE0*AOO-535F8:G5G#I_SB)FN_.XA MR[.7[H2M%F=8.:) 7=L7RBVVB?KACV5NPD06NVC,DQKP8J/=UD>[.==10P8^ M/8#?X,\P ]AM+Y0Y(KZ)O(2",MQ5:W=<[P!#?-?<=6LI#7S7U1)++#1CKS;X M-%TUPF(:6&97N>'8+7)T'/.-YNJT-]\T%3N.']*-HG2)?$I<3)F]G;!:S%PW MTLAR/HPT?DD"/)U-I&--[//J>2$M#WN"3CKV6R%<@X*U\%TH.(]-=[5C(7[? M'/TCRH:B/"ULDD%>B0B@D)$M-&-K=.Q:G2JO[QK>,4Y=6S4-P$XLM#6K)LC@ MP]*7%]KQL5#7"YUP^,207V9Q*5U/2=1XT>-)_$B:PUMPSA=6EO'OFO=VJB]N M%/=:BM@#T\+*#NAE^0HDBT!!"E-36*,8,B)8OGFQM6Z&0'R<=ZX1&( MG4D;+3PV(V/7\ _-Z]6R\-FDE\D[5UG><(J4^=8*5O9%A"[18^W3V0_'L'H5 MKF_$OYJ3=A-0:B-[C;AR3I 2EA/32\%;24VTT\!#='N56\ BM]TAM(G!+B8E MO/EZ+.VP%M/E5B' "058J3>*"GMKD@N')@UP(OJE^F9\^$'JQ1G/Q-<#RF28 M*'=Z(30Y'BBD0LBD)T-%?4'X_*)..YO%< M[XUNE$:#>&I4U_S+OY%,TSWXPE<-OO")\86O&GQA@R_\L\:#VSA_H^8W\L%3 MJ^SCTOW^@5?5V]757U"S_S^8/7)[_N ![VP?D:ESYU[$_?_^(?S_=G8.?K!& MY= MO']_]N'Z:GXJ?,1X^_68/9Y1WJ6;!KR>:1\RF.7_"2MI>EOD>R^L33/%# M]G31T&?;L48=?JDZ/'QL=;BW6=KPX^7%Q[/+Z_.S1O-MNN:3:(7E7QE%85][ M!PBR,LEZ#%(GM_]CF!?Q1/)2>,%?D?R;H5 -C4+ G(54%N->_HA! 43N[2MA M-L CR;F-3&=G^6I>,>>>-=#!&$ MQP/27A*S+BKCBZ?3HEOFPU&'NZ87L^0F3./P[A'NH7UQ]?X@OOLSR/ MBQOT7Z%-R/+I*#@-= YKML)[X%U$WL?SH"\?K+.*LVA_BJTG3WM MT9$ _'*+*$X21S<>VYEIE#XGBF&?/&WH 8NJT.\Q[[L'NW(PL,!V#+)]4WV* M [(T!!/.#<0=\BX>,#'D4S'C-6;7!II=KQ[;[-K?++/KW=FO)^]DA&2!G9Z= MO3G_\&MC@FVZMN8V67DTCY!FU)I4Z?C@HUA:$^/_= MJ)=Q2ZV;++D1"V/AYZ3WXT(R0(+?XIL#20OD)80_X:F3V1LJ5^LWG^;N^=*[ MY^BQ[YZ#S;I[WI]_.-/0Y\G;L^M_!6_.KT[?75Q]NFR" !M_ ]'^?LBF= O9 MOE7;CX\KD3S5C81LK\XNMS./'MC(/-\S*/+G\V]FU#/'MQ65P\>F2D^P7'X*SOW\ZO_Y7 M)[@\>W=R??8FN+J^./W;7R[>O3F[#-Z?7%^?75X%)Q_>!.=75Y_H3Q\_79[^ MY>3J["JX>*N_10/%3Y?G3=IJT^8#P>"R!) +V;9C3XA\WM ]6]W+^)HS.3.] M4=JMMU$WYS+TO4-#:+U8JHF^WU$2%[;6'FFI#V'1#W\/3K6H7+9?Z%*B(1B7 MM A4BSHOKD___L_@%W0 UJ\*]3=#CXO9N)LEAD'J_,T_?]TVW%&+O_N]S*:: MV,BC 9=/,E//5C\*T=!8&;X-C!\QNS0">C;,:;50&2@%]4#8HHD7#30M%&W[ M5&!9(TN; LE%8Y"(2TG;+6$TN"(_=-JPVZUGM. B;;?F^26X4C4R)$LABE^W M2%-O32.4\DMI?X%-M9V%A+9(,.6.T.@N?\M-Q(KR9$/V31,9DH)QM%SE 2ED6-"EX=(2R?_*5568,,*PIP]ED-- M:O3R>8)U 0]4AKJ@\4(W6?X"3WDK[$,R,!QIW4=?G-^E)GZ_MO,A'?@7CR_P M,D(&OS%Q-DPU"D52/]@]/JK6Z#"' K8T$'X>9QF]YJ.YMQU\R*;&Y'!\;A[' M^Y+'Y89;L*#I9%JOT]-VG-EMNDP!CJ*$WY)F:'O*Y K%-(_(!$K#\;&-HJ!H%L9$*8@5BP*]. AC,

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½&$ M@[]\2:)BK\YIXD=Z[+9F>7F*#FW2Y\%IG_,[.2:Y/$*[Q]0])9UIX?[(G@ZW ME=?5DYI=FG5E-I*6W^(MW9"3K._PFB70EFUYO&$_+7;?%R%NEV.M FQ]>[JB M:F--B3\R1&/&46L=7'NA(2!-J)?7J[;(1;T^?((3O(H*RX8RPJ*?%C+:=7'3 ML#8'L$V,]4%YWK^UR;;!5R4KB-EF%P+ZMK;\';C&T51?)&A%IS(M&X:E-4]G M\L>X+#E7;V,*8&,8@U]YOKVIY4G)7Q_[H"D6Y$UDYZL5IJD>;J/!;5#@P<%' MNV8PQJ2?MC#>>7&#L+<'L%6,=D+5-%JCW?Z!VH5YS'7W-KXD657&^6\L3M0] M67Z;QO%%FK&)?[O686_03]L8Z[BX9=A: ]@N1KJ@:A5=DZQ%-$81M8IJL[-O MI"-/_D\<9/E=^? 7TDKOT_.78!,E^MB_AQT/F^/LW11L@S,WXIW"^R)7,9>2 ME5E#M3E4I*AC$%P<_PW3S4DX7#SA+%CCS^7F 6?U#)UMGF]ERT_T'N&N.'!; M&/).^"G0*W>KU=90;0Y5]MI)5WC9_2(IHC"*2YIYW=&:(VP06P$4C\1W4Q5156?5V5!DD>=0\=6!Q#TVCYR*$.71)F31M4[JOU:K>-.B9(Z'X\A(==S:YTWGY_U,&<;1BI7*:B^:!4/0R>2+M*,U>/^-" M\D[Z(F[O?>#!]>]ZV/T.AD("4-R-(,$#RFD0>T51(PV$#^QT]TV&MT$4UIE$ M765=XJY*P257],"[S)%+@^&1%B)_O3N317C>(_D,UV6!-[DHJ^W^ZFS4P$-J M1P6[G[Q_6#&>X5=D JI/-W<;JI:3=6VG)_7G]TY?;I&2Q$^5;BH0_M?21@/JQ72D>(J?4+ MY*(_,=7_ D)6J8-748)%?8:-(HBBS9PC1D6;6RTPI#2&:DE'JHZ8/A1.\K4$ MZ)[:+,?LA[MM',E26R--IV'3W)5>Q-2K@>&E.5;19>A$#N7L;$%.)5&(\V46 M;7530C-^LM-TLZG/'%8K=Y=Y7N)0])DDHHZ3*X/9/!U0;F:$":&(24'Y#ITZ M($8?HR-_ %]$A%;R6=*=*)"(+>V;ON1X5<97T4J6[1II@L@C>%>,$HF=&IB( M;8Y5GDILVU0"-]I'J&3Z*"8&@!!37OY9RTPS5:>W_%@XT[NZQT /##DMP [9 M6:D>QU071;M;%MCL $1V=D[9M+OCKJ*O.(X>TS2DVTI7P5.:T?'B'2Z*:@5- M.HD]RI:72Z''N"N\,=K&$!B&[X->?M MB4ZS@I8*/<,/AE-D(A5?A^1EX&6'W(?R8 AJ %)]R)PH'1>TY"M5 S;AU7-) M-\DE$W9; T4%N%_/1"0)AU8J>/Q09T BPVFJ.==:FFKP5="E]ZX+%UMX,5?# MSY^KCY#@-;V%1+G>H@#)K6^U5?![5\X#:<]T-Q']?W00\Q3$]*CQKFP%_:%7 M0V,@*1N<[V?39728Q/W>-,H^!L'$FBF\&+8#*G54[5[K"/=*I[ ?!Y53A@J> MHI=VD=CG^K#J4YJM"E=2Y/-4(C@ND:;*NQCILE$/KYC %((V.?OS+A"0T M)9TVN@B6]-+$4CH3*1=W6O1: [I7O5HB"Z:A:@ .^<1&S#OY(T0U4*4"A5-1 MODWS(/Z8I>66C"OCDBYGTG,E:4+&FB5N+CA,$_X&+/7^YFE,.R[0/MG+&%1E MW]LNG#8PG3/;Z-5*/?8&X9#QY>]<#[LIK!I*0&A MR E>I=FN:)F\AYG&NNO+729\)<-+728P#2F#F- ?R5*\JL\X0@_,%%VOA]RB MZ-X$5I2/Q1+CSF.D+>^MQ=1=;=O0&8+=$@S1*[>@L'.,GG)G@Y:RI5F@]7$SSBT)L:]GJF;V16X76!S>*5J;N):ZZAY M$DH358MDCX-X1O*DS FF/#]--P_UKM]3UF.O<5*0?^516/?:C=>OD@\RRI++ MAK:'J]WF-,(,M,7$\2YPLYVM&EIV]6:J0%)?V2VCHD3&6342&;RV)LE0P'LT M5:$:?NM:K)W.4Q8NFG/6-DW6=/LOO1@^OPE>9>FE2 [@PKX*Y? 3,"%42P'I M0R*VA"O.@)RI/!^WP MIO-;=^ILC&Y6^"TJ'K\DZ4..LR?:6BZ3;4DW[W9O LEO!^E@'=B8+5W>.>VS MO(PXYGA=PI''E ]RVIRVI'6DX5T19(4JB,_IZ+ QGN!UE"35H"*FY2D==\,L M9;A*@^0F2Y<8AWSEM>Z/<#I<.31^_C)(T+:6.O 0)R'8[D"H=D9EA@<>0K S M?W%31#S]TZ"=_)K=4ZYF1/"ZT9U[V6-H.;$_="L8%JQQSOPL9T/=N5]7VYG, M]2#O6;D+[T0;%-GOWU\F!2:>%*C>L_@VN[F/0930U$FJJF> M?\"=H/ZUSM@GRA_NO4G[\IAKYN%?RKQ@91F+%.U6,;[_%&1?Z9_H_V)?!W$. M?/CI=D!3#4#/DUER,3-'A^PZ9Q7C3$:?+CN.DK2(@OB^2,*+Z(7^*_^8=4HK M#%^97-YI8-;![O%9)@PG\&D0 T8E+9D& M&*(9P>37O^D%@#@#Q[/38!L504QO?6XPWJ6KXCG(L"J&Z=7<%CPP.J7 MTBL:-I%M:*MD$_O%1^T\1\'N&2CL/(2UK*!CW=-\G]0IR8XJE3RT\U)&6+E= M?+B@VPO@AK\N50<,E6XM4VBXW<2GA=[?O2<5!Y/+Z3'R=7L44<#SZ\WW6*W? ;+$=A=KJ8QZAR@*Z@G/[CH*XZN5"G1J0$*-8/%3K'$)H M4:Y.=^^!XL+*$6*Z\$G8F8,P&,F-,02$J!I'#:DKL0)M9FFT!W:=YQ'J6$,+ MP]DD&,27'SW4*0$AM&2"3*UQ"%%7<=10P\;/WK8M?DS3\#F*8]$7:7[SLCE0 M>SJ-0S=\Z8W $;(Z7.:PE3<(;\@K>@QR3((2+4)-ZWJT,R^R1,M0UV6;MW)' M1#2E(I@(8(-6OH?95PUEHP;O=A[2:#W&%NY55D-IW\X[R:,_V,7XK[ M9QP_X4]I4CR.&&T9&062$5B\ --T5V\13#R9Q(UA:R L?'^0S/]/'&3WS^DD M[ZJU!9?G W?'T[LV=*"L[J,7D/G#X9*9/-_^%G6-->"$[KJ\)Z6IJ4,F=0>_ M@-8_'BRM+\B+G>PM5<9@D[KK\'Z O<5L(OLTS4UWL!A8\+.%Q=@U M\1X6K3H8EMIC5NUBZ=FH[UBN%C>8&6#;6'IH*<#JOFF2Z0/N4KTQ11G^)18)K9O/YQ)4'KIZ'.X]@%(?4#4?>)P_;*76E0 M/_9(MN$7RI:G[A#E>C6,9I(/HU-R>J#.R('>>0BE!ACV&\'<]T#$#!^&E>2C MEU[%*2VCQ,Y$YXL'DI4%R]Y.'*4@G/VX9C"EHZ5KMN<_2)8T'26A"=5W@)'_ MJDS-58J3/;2">QNM'XOKU9>\)L]I'.0YB60X_)*$.&O.WTF.%7;?PQ16W977 MG.P5[ II[FW2>WR9U@]!?DL-HYA:1@$SZ&GK2=O01%Z*.@:E IR 9 =W^(%V MX,)^0R#@+$#)X;7,?"L!HO!)4DGNCY__*W6#2R8'K2]QU MX4>DX:6+D$,7AG]>' 8[C##*PC;3.FI',J]'J-:;B3K]&&9&'KV.,_J8PF\) MI%. 02%#E/*N938:355CJ[XOZ@P_T*GENHH80WW]$$?KJK"KF(,C;3BMQ#7& M/=&M7T8&O'-V']3B3G-9R=2=YX1W-=GUH)_)I[;N1+M*OOM1W@%=5[K3\$XK M*YCF'>I.%<2XJ$4F_E;&2M#'1RK(-AV9V><#UY?M%3(A]E[CNRWO@6447,GH MCI@X+H@-9UW5;O#9"8?J46I/T,/@7@!4,,+O2'EGB!:::JP/[VI)6F$/5WWH M&KVHK%?=.*G.,H@J)F':#56_8T0*VTTOLVI5F MDY=6RS_A.!?TI+L"MZO+#*<-^:[ ;>:JT$I2S^;VO;/2],3E>'/N.3O>:9[, M]K: L7RT YJQ2(Y@';7D!L$K:U #,Z*H\&6)L"P=QQNDP@,Z'RPLGUJC[>;:4.*M^HC[":J8/AIAU<; M5*&0TJK9*8ZKC[ #-K#*CJA;&P%#WK'(3<(KH'/J^@:J+KA@J@\NQ"J**I@I M@V&J+6)MH(5"3YLFJ"B@8&\&:IB5%4VPM0&&NB.!F\180)43M*U37?W#4!U: MA%54^##2!4-22\#:\+HW,R5+E[:-:9&$]X\XP\&JX&Z5G<*@LZ7021QOETSW MLN:=M).Y8!)C?T]8^.$'AYO&1M%XI"&OF\OL:3O*"I0]37M[X(ZMCG/;/1,G MF+GL/CFL]P@[$K".H4?5'I=-E$2;LMGOM*W- "&MKH6.3*!@Y:YC2OX,I'$(XX!EH["T MX3V&VS0"*P-@R#\&M7(ZXBU17A(3)*]2*NV2QAK(!@=4P%!3C4\?>6\JEJ&G M("Y9#<956909AIV""-NC3=L%$#6-HR,8JJG0Z:+==#2;:S9H^C/78$ZNV<$U MS=::PZSI[DP1*FEEE^IC>OF(T]9=@/4!#<&:Y1W /M[,9TB!74AO#MB@+0Y. MZG4^** &N->![8-HA@;'?[F6..[3>4OM?\.T%A0.%^05!6M\BS=!E#0_T@.G MLG+"]F;\#0;,G92'(+T-,#G=2.#:D^V-)52;0JVM>CV>6CL$EI_5X^W;H, W MF+QYZ;2-O1DP+%U"QO9F<0D2._;RMS0'B^ MNZOA#*^B!(]TIJJLYH6VHZY+%5NYTV6ND"(:U-FB';!4QM$-0B,>W M:\BG:5)DT4-)_%DE2!G'WQYQT1.>;;9R^8DW6,8EE#P2?XE4( MZ+^/66B-8P)?9$UGV=%&6R)RA#:5=10P\SV)G"8R"-=/@);62-Y6_4*R3T&Q M?&37_71^'].DC P":$D6CALT( -KT-N-N0L6S:5N#1EI-Y75GM!D;42R1W>$ MIXOB(EH5KV+J3V74V=[=R5[ [L:(?2UZ;P:3NF'<%#0M 04%6E'SP'J-&YSD MU/<7:3YD6&BRC#= &RSBSKNS4ET<;*@LM^881KW8[ 0MT[Y<=C'O*[ MVR!,;KAQ>9?2[\VS=%QS-9ZA-2AKF)-Y M(@J@E3;M_W?J,V7 7[;D.R?%)QQ&RR##]5;[1?A$EUA%B9%&P5GF:@2\S4J5 MTMYCI#'$(5EJ'=0H-3N_WL;&+R#;3>S ZBYT:LK_O@+:5C)R7Q>D[V,(57YP MR.+KN)V4P\2#\!8_X:3$ZEQ")NQX,DT!>#!1)I#T'HN-X E&]4P8994T$/9< M)J31X+P@?0E=:E2S1R;LDCUJP%WVB"7!L$<);\B>1ICVWE1ZIE3OMR#+@J30 M#$S4HL[2.PW8MHN2R$$9)AA@'+*AE@;7%=5#\D]!]A47;.HS+\SF4"0J'B92 ME. %LRE">3!!Q@"D;%XE#V*6F_=K3AIB;+%WAG$Y$!_$%-IRHE2IY M"#,:!P2!1J+AG6)6,&6DVW:TT J#FG# MFQQ,.:-JIN'XE%[!+K%31&U#M.(+[]B704&=!M2[ >8:6@Q'V>K;>572WB8Y M%,<[Y:*@ISJT%_%"G>UH/;A(,](-D;XGB!*2F-RD><3V\DKI-T;?2 L'6P6*'EID+>XV*1FG=282@!T!3HW(M' MJAQWD%PMDK"YY;C3N4MS,T-MM_FOE4O];-A(%0J]QL'FMB-0 SYS96TU"[TT MR!S9KH9%-S_N7!*^L^'I$SFI@ RF$,EHY+I-/IT2)$>(?6O@WW/6JU\/]GM+ M/;'Z_O1IJ'@,$O0.T1KPGJ_/N$[P?! MS03@K3C\#A4I^L#H.]?\C:DWS)'[]")ZVI_ O"UP#):Y:TWAH:'#XK $O16) M/U 2_S0-B1U?H[&@=X6P"T3("]BS5QO8 E,$7N?NF%RD9\@[XZ= ;\5X9F J MRLOF%7IND$%IE.&SH,!G.%]FT98B$8YD3=3 M3^,@-RS;)M#P4Z1-"EU$=,"5EN-8:K]NM+44I/( MNB27$FZ75D)!,(12H>-.W3+6M#PR+7TV9PNG0"[SO,3A69F1\'J#LR@-?Z6% M_S_C9_:+\*,8*<*;D[.#/?Q^OS;W(6RS9C4M9U\2ORP?B2 .9\I^*2YZ\/ F MBY:8L.VF>3[S1Y2-Z32T[$)^88Y4T(1LP8D#^C3\2;(KK.[@N"MHAQQ MEGDJ>3FFRDY+)%DYU*N.9*3I/:J,@CODY2V.Y*+>B>-&3X%2ZK0Y90BE)B+\"]E7K"B=R18YY*).[V. M![JHX0M((U: 1ATE2EV8"6I%6D>HU@39#YY%3U&(D[!S<4"P-NL%9:K^^D"U M,_(>4*SGG8\CP.IH&=;*32%+HCE3=#M--]L@>5TL'R/\A.OMF/=!ML;"(P%* M<6+5G_?+VJ*ETN M(U8>O Z=%SB@-RT*1YTVZNZ&]_9.[<;ZYKHPB&8/6%"$I;*PNUOSH372Z4+1 MJC+CB(KG[,KBZ GO_&"3&Y+!XD@;WDAIZIZ4F3H#,.EIB-J H[BQU*5H-9%% M+QM@0PF065\U+*HF>XR2CKZ"OPQ/!%R>UW6EO7/1&*(\AV,:1ZC209=P9]?$F1XL:%W<(H^D$P6WI*B M%BE_&O>A0%&K<8161 <%3 E(..C[](D.1PF'Z(Y.HY?05W![WEL'7$ZRKC28 M$*"%.&17(\*VT(*D4U.,EL[M5HM6VCEY&P/^Z&;BF)Q^*FV@=#2 + E^33GB MR2;H9V:IY]R(B@WSY9.B7+;O,2;P7 M9B]+3G?SCW>UM]??WHSWL+$_=L'M7(TEI)X41R6QATZA;;U1;K'=H;U>=3QE MS5Q4&6HJHTY/3DWR HQW6VLM@FDDD[C!'=%B6W[J%E&9197=IKD<==H(FQGK MM+"=^9D2P,_EY@%GUZM_2^,PK_"(,@^AF+/43@&RS>,$,MZ)I0$VI,J?EF5> MI)M?!!I[S\-+/O]%&<>O9U%<]L;&E.&;39I(3_ 8J3FCAX43NXO=]#HPZ&,. M5$8G PM0EGGD ^AN0+8>??>584QVB!PRF_/H:GKGZ"BXTNN_L@GFA*4S'>U< MRO7JHDS":M367^'I#[:5"@[G-0R =Z8S%-+>V6(,41;+E+I0HM@MKB^AS:]7 M35W2[NS&H.G(Q5U&*AWH;FR2R7KGER' (;M:<9I^TSF:N;+M^D!^7?+].KN- MUH_%?52PF@]5JO_:_U&Q?VL2B^YV]4_B^F[C_U[FO!-U.A_XU82YUPQJ2#F# M'ZVB92"K<"63='V]A 3J\&J)@1@,DBBQ"8MXM$) ND,AS<]?R$@DRJLZ!>V/ M>>NH+:,G2'OI)T"/5\TJU)#3&^FL,:JPK%V8U"[3R'L M++AI ;?Q32KIG2U&\ 0UU&IY= 9G$Q&;J#L)4.+O#&$"\KP-:;)YS:A.1"CTX&VB<(0KXQU0.@V0ZN[2+,5CNA9 M6WK%S:[;DZY".X5PX'V$]N7.W&M(G^^F>?Y<-<^$E0L+E7N>#VP>WG!O>Y,17 (0K(H^F&1=P, +#7[!O8##T!HK3^UCE M %Z.-BIEC0%:>:*Q@.)H=?!3$A=!E+%"'0LRH-M4+_8VRK]>9!AWU_:GSAC, MGWL0R:?M:YPDXS1]J/<0X-I3;M67B!ZOB.SNO-<4^T^F;+L/^K?R8/)6Z*T3 M2Q*Z:'B3+:W,^4#GK776%\!JM]SNFBZ(X4*O-FN]+&P5_3F)BAY0]< M=::R)Q]L=ZI^E;-UJ.+'PFJR3GR5MMVG5OHMM^!N'5B7WZ+_W(-OO:+7.'O; M[3[T;;=<@:?_IZK-I7HODHK3] MC,-I4A-[I+R$C6H?LTP8=9^!N@^AE[1U!>L'(?8D8(771L>C*TUUMBD,'T2_ MQ[V(23JV*W#%X"9SA6M?!FU*TZ2NS&K+.6Q7BYA9KR]'X5Z;^NI64V67[)QDEACY*C=">.'O Z2MA:WD,0TTTF M;Z\-#I8_>[LSYO\@ZJ:4SM6+5H]]XVS9P7;MVOZ9;D9K[3@\E#HQ9 MA-&^/MDVB/=3+P?M@^0@%A#W?]63K"R.AP$FQ_;G^\A-/U40?-N1A-MT=5T\ MXNS^,6BV7K6W#P\N^]$>N? +Z2!BRX0O?Y(@,P$>L%F*W_<,LODFF$-;5N89Z1[NY(]E@:\LWH?U/L-2N:%2>N< M-"]PIGDL@^>":O%3O<8IYSFU#P77,3MR6-*/KRIUTK+3C&YDU%7G>4O-V,/6 MJCTQO:GF[WH;UEZ #B<=<5]K;I;MYI(O=W$TE[&O3>:*;TPGRJQY;Q@(.XIUWN;O>T53/NY\FL>9K< M28-][KC>+J+?)'(87(*Z _MM\\[(]=%[L,TYZF/=:O06TTG7&O9 7_U:N]7 MO/\"UF@(0#(57WY/MW\:3D_UW_MUJ_VI4/LTW^]CW([=:7NY66?*JCQR41:/ M:1;]#8=?DA!GG:6^&^)"WDL";NG[;^XQKG^A92WJEVN5H!XG_R.+D54]Y?GD$#.]C;_^^3UX\ZPC5 MF(Y0!]41:L-1#0RUR% '&J+8((6@/>8_?\4Y_0YLJ;.J89W2/W7>BF3,.--\ M[!YX_(]_'+[V*:?_1X,!FN)X?!7FLR:'D=Q,_RI=U4\S?_P;B!M.UJ%-G_UW M$Q4L*[,],2N(*+"2B*R@?)&R/__=-'D/>PKW!?6VPH/KK07[(?I[#"53;S"< M,>SL>\Q;\C+V.F0LM0GO&+C&??MCX1*#WF<0IO1BO[7X_^Z#DS6( ;T)GK?5 M\_H?T.O!_#WVMU,-Z \DM.PQ@?LY32HGF\7C:F STW2Q]&F'M.R@>653+BU( M'O6F"A(:N3ILLD3ZN&Z<@KWCH&L,3O&.!GD7*]!Q1@)8>[?6W!_) ,!!-FGC M%SM+*]<^_4TW?%/O%;'@63QH#FG?OB)F]JU'"CA9]5A4T^UV6_)E'](;(5SQ?LX;5#\UY-'R MR+U/!8\ ]"9"@=^I8FLT;R97V/L5[)\^& 670^"TOQ7,MU2BP=!5NS7,PZXJ M3[NR]K9.P&CKL R:_]03UO;//X@ED+&O=9+%#]N'@UU^=^B\ MOA<#O?MFWC?E?'ET4FAO+&"X74B=$-??:9B98/S&G?5G1A"U@J@9Q.Q,'Z$D MAV8(LGJO\N!\!/UK>R'128-&=,+"VH2S(S$CG6M/P%CJ>Y^_V .T@K%\48K: M$JI,H1-'7!T]W- U>XR?/S;R*#%+]5-EMQ_MO=.WY/#?S>;C"U?#[SQ]=O< MF#S79_$10V -MR$$&7<#[8_31"G70Q:_5[M;8CG\P8K'R]ZM@'@/%!"\'S4P MF2@.@,]6JKDA;\.1X>/?1JXA?JEN4HG^LT%NNG3GMWY4\BNX?=4.W@Z\08DU MOK<8*( -2BS!><\UH+Z1_0'3O'*OMZ154& % M%V_^CQK*P(L>LP3G=E>]M\&, ,';2%.DK]9-(L(]_N]G5"-S73^PN8!XG&S. M=U02K^$-;.S O:EP8?5!G$82(V2P4@XHKV/_P&73JO#YUAG.0];^/FQS6X5YTV.9=NN;?3!W;.Y%R\J=U&&4;*,0+Q/L=+S)EY<.GN@9V! M !2%P;R+4>GOM,'6]X3=&W-1]9<_T04R6"5[&)-E4QZ[W7F &9U1W M;2\[QE&PLT[OVLX[XAH%)Z ME5F;:%>3&.S'^MTTEW>*EVVMK3@FC[+'&0]^^.%KP>9&],.KE/=V]OK #$X> M7X1Y-M0.,?IA*_6>]HQY>X=3U?SM,':DX]IN5%)\;]7VI6^JP'E_HW#[NM[- M^K5$CSN(7:J&+VWZALT_"TYF,Z^#\@ME^ZV3N$7Z)7:+;)7ZEDE4Y$!:Z?EF M&Z>O&-_A["E:8O$0HET]86\GOT^+(.[^?IKFQ>>T^$]-I2K+A8%G\%A6/IR6!ML'9^%&F(&7ONWCQ) OM2T@,?N4$H%Z1%EX&^5?[X.'6+8M5R;L,EJJ 7>9 M)Y8$$Z>4\(:DZ0DC*HW^Q.3_"RJ/KJ($7Q9X([LU2*7@E4\<<"6G6FFXO!I" M-.$6U4%,"2S!2"9-_T &L[)AG%K%*\D$X)4TZ\C#)1H/4M+W(?IV2&*4%%%2 MTI7V=(LK,U"&,J=EEA%7+G!(@,6D.S^O5L1.<()742%[(SHMIYPSVF;DCX)Q:$1KSC-!RJP14"1;[ M+A,R5,66M),J>>";Q@$!T20:3AE6T"D#U7C3"*MX(F)9J0+AV1E>88(GK&.O M'=],E5WRSLZA+O_,-*'-?%BAAMWC-J[T@O]V(1$Q RA(GC!4.8A&J(1[^C:0I%?5S,ER?HJS?/3(,M>5VG& MUK T5#6RX"-&6+@FBA<&ZF!&C_:8)1D52G#13)HE:Q03;;3LJA\>?7N=]_[O M;V .*+&%3H]D><_6(5)>Y( P3SM8]I-_-'^K^ZK>9J(DK'LFXUAN8=!K"[!V M7-D&C*W!;06V+O!K=COIPV'[+=QVKQ33ALK^CVD:/D=Q3+R[3 KB2/00X^HGTU>F M-.&5WP;.*0FMT(?+8#WH(65W8BA@SKN-7T970VO5.2A*YFW$X=+ M- ZC. L&/4]!_G%*_CLJ1LU1R+1]=^H*EW0=N$ 5+@.5>+E2 MXR21%M/=TP,'C;6)75#V=7T5*"RS M@SOD62-$1IV0#F]PSM SA=4,4C-8-GT-(DVOS).[HF0?KP;M<@)SR$,6MH(H M:"2A$O$SUNU3Z(MZI5H'K));1 [6RK<"X9 ['S.Z2M+L/:!C1[!3$E=1\!#% M41'A_":CRSS%ZPWQI5@DK'['EAZMUK\0,RN>>&?CHH22)B8 ASX+^$,J-_)L M&A@WPJ!Y;/4^(+#2G'R'P3%=7D?C85R+OQ[3]>4GL)WM^6J%ET7TA-N-3[?D MI=!SZLF2X*]2B>9P#)TJ+ F2UYZPY-U-8MEIZ83I7D6O2,+^9KU/R4SOBVPO M4MXHH0S.)EH3M\7[A:71>C^3T)J%SGG;]B"S=U -0>.$>!UFMVV4-8"C:GO2 M"C7M@_[P4&WG.*#&\3E-0AR61.PAQO6*_2<V_9D_("#:F"V7@U;').M$O^N] &UJ]-'6C'L,AD_=S?Y4Z"UK1&OR+9U M63SBH-J7O5\.)ADE"W)&\2+XBL-J(4BT;&1MPMERW4CGVM4[2WWO)-T#-'=% M!Y5 2R8R$_6JY]\%7*4K[E=GA.$AM5S8_03C,W-XN"_XO]'GZZOZ$Z*<"(+N MH$_;0C37;1T:JQ@L-N"_6U4YIN\Q1=K>"3@:\I"CK8%VX :$HU\ZE22)6YHC M(5)IE^S30.Y232+JX>8J,GC/"M5,LAKJD$]=Z>Z0/R?_6$=) N]"*8E_I$%E M;%O-+<[+F)ZPHF4O;\@KRZKBQ43V)LTC59BQDW#,LR&T 9^:GR'Q9H!)P(\$ M$1%$9>!PP*Z0#)2Z,79E8@Z@*HQU$1A5N '/KJMH$Q75S,QU\B6WS\%X S#8 M)W/,M#OL:Q\ .R60;=AZA#I&4)J@+^I+9_>8\K^MEIW3Y#(Q#GTVBLX6"JP< M:=<0C+2\D\X:ZI!L?UJR*UE^,;*Q=SHFI=HFB.B$WQZ/]XI@B-I[B I%82?^X?@^*WM(S#R\TV6!;M\I9Z MQ_=88P"FY@T=-B"KQA)T)IO!-Y_)?::V4,#,H.(1(PQUJ;13^3781 E+(V]P M$L3TR$=5IH=5%*@W&DI>J[45E^0?Z:*DC*^)"3!T'X>;K\'4[L[&.SMHVQAB MFTF;TA-$A-DZ,'ZS\FG2:U*MK4#D]\#%,?RN31P<':]8E>TYM=ED1_UIL"$ MNOWP9#12:+\!F?L):EVJTS]$)&O]$-J\NH]!N^>@ MYD'5#2J=1U&EYF&(/ VQQP';H+/GR[O2[.*9SKS+1CGU2^DVQZEL@VF($SO$ M;8N=JME=@=N$M.>;6VS24CH^F,CV ;6Z_NN8L,E5AM]*>^MYHVQL^:ZQX5YC MPY5)M"6-BV6;0-K3+B48.LTF#$Y>3UF&?!H'N7+W\P@[?E)&2S?%6:&A$3#\ M'XMG0) MFT[)Z9%.(P=ZQSB5&F H_'_;N[;FQFUD_5?P=))4:;8RR:9JM\Z3KUE7S8Q\ M;,UL;>4A15.0Q1.*5$A*MO/K#QH7WG A2%E">^8\[":QNIL?T V@ 32ZO6!J MSS5?R49?T0^R1/^(0X[;HBY*F\=_E//L(L_VM*CH$E ;@WX\&4\6ZS.J(76( MCQ=7<%L<#55[XBX.GK:*69P[\AC&6/&3!Q!P)#-CXR"F614]PAE '(-;4][1 MF"9[P]KNQ7$RP_*#7EN4FQR'*7EAU,ZQ:R98A2/)1HJ:#\E2>DD?JINLK(H= M',I_SJ)-7E00-W*9E+%C%^;!=]I,IY[-Z"8]'6 *;G]CD6HU%&!%A -TD:VC M4(&)6 [1 =]\)7*.7$5X4^1-;Z"^B+?NE>K%TS3@1I[3) M*8UKF^<8?FR70Q.PNVWW:.'<^SS=0WPN -[R-%NJ.-+RGA;[)*9EC9@_:##' M$4\0<\+ [LF-;$5WCY81?/8\$'C?(&M)1)@FEZ6FUIA)(Z441QZ4/)*"0,2S MK0I$@FC2RUW!((NT#B/&M5U$Z-EVJ'%#LZV-/[AE'P#:4,>R)D=LIY^S74F7 M:LF ,X&$AY%<4]JXVB-ZR5->: L>U>PA<_82AMJVQ[3 O2-+NY[QC@LF*_D= MLJ*8!\/5\S81&= NV:A]/Z(#-<[0!FYIRI I]]A0&ZT9J]O=G9%-5,$=U0M9 MXIZ8ZU=OAVS87$)"6^AP X>,U2X!M=T.PAXX;+T??9QDA4D4MF-/Q(_N?W,\)4_N.I M;,>K+2%M9-@N@D\Q3EA]I3=TZKG6T>Y8HA?P''7+-%X!V(E/=[,R!+BY5+%1 MXK"%(7B:XR[H3QWK_^J3,J(4D2/0CIB6WR-Q4UO%?6ZC9&FO5VHB#/) 4@-J M? -94P4?QX/0^E9S$95KLF4D*@4LFG<W-$M:_ Z*MG^YXY]M4CB^OF2<=8+52GE(#+EO^S MB])D]0*O[>6I*T2)I7FY,S\VGL!_"K.:W"RPMM',P8UP*F+M\K6O,'RY./B3*P6;76O+&670MX4];= M1WT$"_^ [L6L7L,3TD2Q[0PMF+,A#]TLFVQ/WE,>68QJ3OL@PXL1T_W6%.". M,]7SNJ 8VX:*P*TW8:$7;)O\2)>+'/PF*/CL3,LX418>"QYHKK]%6P0%G[!? M [V]#MCW=8KD\@A%MDRI*+2/.18Q+11Y(^PIZ__/[7X@D##IR MSC9L#2C9D.;OK>CREFVN,O:7=6)1RQ #+M5XHM7\8\5&?OKQ_3^(9"8-]]9+ M:0=<-\"B2_NC7,W]/>L/^B2(W=<0?=)<2EN$*?]&EJ$*3 U 0O9 T]@K8#! MB'3/="G2KI2M9EO" W0&K!IRHG7HB8^C2#+*?#+ &41;D$\ORE[.XG5"]_2. M_2_;T04":PA,^?34:P8M+ M>>.!&QZ;"PEBA0(7XZ$6TIH,R4J("3+T^LVLBVXUK>3;8I7C;E#!0P)P:]D3 MO8>JFUIC+4WSLX(FX6J@R5:<-OD>Q[V)L[>1!VTXCM14%8E_Y>FRM,0K&VAP M:< .T))ID(V--= J+SZDQR$S)"8/*>VNTF[?8X -EX)&8;;Z(RUV5+Y)ZQ77 M628:!-9%BZL_=[U7ZS[TN%3G!U9_F5YS\8N$LN$CE#,&&7+7NS1]D?5OVEDF M1/3)!KCA0'C+B MK"2JF-/]L*L@@!?B:=13NB CQ-ZR#S0RO5L?8G@KBNN@G:*VE L(HK1_1T41 M995:,'5OH4^ 2RD6='TE2#)2TSG[^H +M5^C))MG_*5]%-M &XA.=CUF!5@K M7*/ I7$;O+[*@0XRN%<-91#G/"]+=W]K%+CZVP9/<[D97:^_@TQH=:3I32:C M2[-'P';!IH"755[P,J*:$KRX<"EF#&0]M:WDA0>-N>(F*>@P;O,' (-*51+@H(F2% MNC56.W<(^6,N\+K(=X_KCU'Q!ZWNHY3:CFZ].7$I>"QLP_UR?5A!$BZ!5$($ MV7 9I 0A,WD C%6K4_3YYC1YH Z#Z.Z8Y9Q0Z6\,Y.EEG4+NO&TQ'MV?<6G% MB,VRYRZ#'BB>%WFTG$>VRZSNS[@ZV8A->_<"1(11X0CO7CSEBW6^@W^]2A[7 M%;6?EP^RX-*&-UY[D#<4,%2L1/$&U=O]E_,/>90-AD$8R7#IQXE1N]+]PY)^XE*31Y(A][S+$7ZSZ7D"G-^![70YRNYS9X7W. 62972^4JMUMT?RWE3 MH44_VCM('"X-OTI;3.<9X/8LFPN90*,RV4<5O4VCF/MA ^=(;G)<>O/"JH]- MSD1J+J+80CJH=_ *O%H/*,=(A4LG+HB&:V6@)2B._@[)4(M* RZ(GIEJ@TQ4 MYU%)V8PZ9WXPV]WGE<=D->/5\1@!L=[SJ=+A,Q W2.&JY0<0=\C /1'B.!UZY M;)&KU)=1"I5P;C*9A.GJ&>+L=DFYYF=Y*_&VS!(\%PNE**EWT!8W#J7(?7>7&9[QZJU2[]E%?4YA\-T"/3 MN!=83:&*BY?I47R$,X;=3W@8\-DF+ZKDKTB< HY)$O&JTI'9P1&:-GT:B%I? MPIF/HEL_O!7_JQF-E1*7 0S!U")C:WI>#'T6_,CM/,EOV2*QB<[B/]D"PDW+ MMH.UDN+2R2!.;<>J&$B+(^R$+%^L#BO%2HE+)T,PK4]VL6ADL7XI\L1V8-#Y M%5?/FZ!I-00%3= .E@>LPQ9O(\35[0,H;UTEP];H5GWY,S F_0]#M%Q]NSCY$#Y8>[_R* MJ[--T+3''HR&,**PN;#HDRQ>!?EZBSQC_RIN-#N!)?_X^T]:]_NSXM+-:-S: M&P_Z!&5]I02R;8L(LE7@#Z7YTB1KXY2M7$2Z2^2BQJ4J'ZB:RU3S$,5$6EPX M%#2L%.2*&.Y\*@C#A*M$+] UL$6 MS&[:W9]Q=;,1FW96!'O$X.;<>H\S\);/2HFK[X=@.AXDX7BL=Y%O:)'$D4\F M+P ZOZR@I>"W#CVR[LBM$ M)H&D6G_.\@?8S,/1S4VVW?$CH%:BY3O(# %5KGE2T;I4!!RW4F/X_;$^A,L" MCMQ*;;?)/D=$0?+6!PE\D;0_2<0W^\FRZZ\2_MFFX@>I/WRLVY7Z*$DX^M=1 MW*FH8CR_ZI.>[$9E *Q^5-BEPV6B;I#V(S^Y(U/T0=, VX,P- I6-[DC>'%I:3QP;?\!$HBZ M?&0R2",$+D@:,>0^W(O:FVQ/Q4/ F^PRB3:)[G+I)+A49<6GEUQ6A'"$)TC# ME)*-UW2Y@^Q:AC@L6*SMDYL_*RXEC<:M13M) 3!TS+%HW,L)/%=>TE62T>5% MGHF*=0PBA&5=;;9I_D*+CU$5KWE*HN;WL^HZ654O\O944_C!$G'9P6LUQYVX ME0IQM/R./!9P0+^-7OC[^*=U$J])M::*I(!7S.)34/N6;"2 YL_RW?,*,*@B MJ_S--%F*MG1)MPQ6&,>(\A3IRS/(C_1(ZXL+WI517.VBE'52DB]_!;>"ZADI MQPK 95@3T6M>EQ1#(B&'%/4%4-Q( CM@HIAQ<5EA%A%P&AZ8,\$&TP8F0=XU M9^ T/O(]X/E+0R*#JL_@@DK<_[7'&6>ESQ&9..F-4[__S MR\?W/U]^Q[ZV9?TKDDFLX>/;G!>+6;'OPMR99Y2\T*A@$B!0><,@K MK9."UW581B^!ZLKX3AQ?F//(R+(E^!S@MR_R+Z8*RX<*Q&7CK]2:P^;9/9?- M#89*Z; $[T.5;FZ\60AF7'2#&;T]^$%>7)8P'KC5AV=S H1QDGX<)Q(OGK^L M.-?F]75!1*V XGYN2O;VJ]HPDQR7O!,+ ;7ZE"!R SA=5JC78LK M 6P-4A+(GI]LKY0,PE<@+B7TSCUZ_@];TLK[W2D)1#)],#6NS+/,IK:DEAT?\>E.C,XPW9:4 6^ MF8SEPL#>+QEX%+4] :XEITF8!L&DQX] MCV+1N:.0:S%*YZOS/-N)JZDHU51L)L.E12=&P^TS)P9%<7(BZ?P VY(<8X@!EV8\T6H)*"4;$4_2%:-XD7X5,)F&_OA0WL?>1VE4B&67 M&Y7ATM.3$Y<"Q\+6KTCE0TLE &Y*U1VVDL&G22XE3#V?/*9T65ZS/T'LHNY^ M]PAP:OJ2'RIO<[+@V8P6G)RG(H4R7("-"%J1NWAMN3XU*#%U8M<)DSP;K0"CUESEE;6T$4=2EK#K(U+-]0'GYEBJ;HT^!2B1U@ M7P^*D@A2PFD#'XI^A"SP_%QBOJKW4%=<&HZY*#A.,2\6OW"K7SK;Y M /Q7L[,%!Z[W3)DTGT&RX_U RY+2[N:^#D^7M^GEY8["B?$U4Q-KU&+-EN=H M51D/GPZ0ALN 7J,I^@$7R.P??K2> RBYA GFA_0$1'-+:H0'33 'D(K(9 > MFV^EQ*7>(9CV? / 0"0'X2Q!U@/8K:C]BSX.6S_BZG<#,FV4P%LY11.L;ZT9 M0=L_XNO;@;R?O&^O0F;ZO+O_#*^R6_']<)QEJQC@(,;5]QY(M4-7QL*C;=J/ M%/C97M"$W[S&T'QUOBN3C*U7MWF:Q"]V]W& 'I>6_,!J6V3.Q<_&)1_Y37"& M]M[$N;TX2;[?,A=B2%M##+C4Y8G6?)NA#LHY(Q:%"3>"'NAF3Y*"2[6'-,'L MF]%IWG28<\7!$@/Z/#O(@DO!WGA-U1,:3M)A)8HWB-8^;]E_0,:'91)'!56Q MYLL]6)^F,"HIC@]0]742380MZD?(@>>#UZV^V)^AV7%LS@ M;+^"+75&87M;9"'%U_0!*/=V.)(?:+IR> MQ((A3/[-BJUFZAVUVMS9%.(BQJ44#Z1:4D[. L5W^!A1)2V":D>F&*C=DD^, MWJ(;.RDNS0SBM*19J%\AO)"L9@DW9'JFQ?Q"PYL+\P#R8L6EM-&XC8-+'UMP M@F%\9Q).L7*2$!4FAK;$@QP(U>@!UZP].>9D30TLN^+N+8MXP#)49MJ#!YGB MO ';4TV+HASB;0XO0QV\"C4WJYN*;BP3)?\)F2+ZN(Q#)? E__6.OT](LF2S MVW"+4:<9/-*?(!OQ#3DT3M=NL@430WD4Q)Z?M1DK[1PB[61)XPYOLF5- M&2,*UY@XN!U#*U#^D":/_//EC/P,K\1_$6\* T5I9O)=?._Y//P53A_Y^_9S M^IAD\%?]:'4^,MXWHDE=^06ZR@3J6!:C^?;;^=;"6)T MKRD<%EQV%[XC]%L'#^F6>M/^W_-%=76=/"6_[ M-91OW/K[_>!A_TW^FC<_ M2ENB4LLOLS+DLQ8NMKKPX:"%L(HZP@T?2>9CLZ M=$O@(L:E ^D>IF,DJ<0+ 03EFL!9247N[*"0AX#HZ%+ADLI3HS6T:&H@PZ3 M^6J5Q'!(!#/_KJ(%3.E;:*VMT.< R[->*+53L0X&U\M%".I.6M]A7F]$#T, MJ4@GP:44*S[M/4/T@*7;[_-5Q?P.\%RNGIDY9%'ZV5J+U46,2Q4>2+4;$\G" M4]DJ)L*XT"B(IQCP59!&C%9!-J1.!2FF\ IB$RE;[.(D2MD.@A;EP+KO)L>E M)"^LANIEDHD(+AP.@7)/>'PP% /P],\L]+@4Y0?6ZK'5;#A4=9$FL#=/4O;# MX^!X'"H9U'P8G(O(A/8P [418Q+/1Y(M3I.DH64X@$D MC@WH+?O7I"SSXH6G(K)EHC51X=*("Z(A*9:DE0F8?$;( 2$K=:'F#\DFD:_P M,_:7=;+M=GB[01Y,)PM \6Z 7E[;QH'+>GSAVDMPIX*1;!O.8YN5>JK+G*@' MF=FZ'[9N:JL7V\E,:T0C:N/RX,%E7OZ ^P96/\>.&U;RU']K<"P#RXLB?P)G M0H54S;,/#,Y\)2IX&ILZR',ZT_*$W]C5 ,RH_)#JUE4S:8NBTK";(J)YU=, M,>?%G*=IGM%%SL/ZS"&.$^7@4NYAC;!D9X W?I';0UZG"GJ;!F%IQ6$6(4R!V02ONQ7,)&IOR[57,1'A4J4# MH=V_]-^H'.V6C$TUZWP':+B1035-2K.+:)M440KX;+=EGHRXM#02=5]S[W]^ M_PN1Q"*G:4C==4S.9^!@U(@=H'O8(!XUDT8,1MV,0.P<*2%5);=DY44:E66R M2N).:_M/V'MDN-3AQ&A[NAYWB,/%1>HEX;0@O//!(+Q/N0J_Z_\TOEJJ[E,B MQ8G+"'%WDG9CS&,C111EW,(+F^,G_[JX@8K/]DZ3;*E1+'2X[,8-3=D($WL.)3>R2! M,RE9FN)(J#3(\29T-9A>R:XNSS1+!UR#M#'?@2,P7WTNJV$/E[#O+EG4H\"?J MG@RFB7P[NA[5GM$646^&J7IE5>=!A&,E6@=D9S10>C?C38!C11]BP*5Y3[1# M63RPK.NJR)+G4RPW.2Y->6&U%IVZP_4>ZYY"8 M/J0GTU*G/9TMD0]&[2B$,Y%S4K/UJC:0WY@"HUU:D0_PK:_L8!V)ZD9A]3I4 M#ZRV7?GN,8JVO^LN:/>7WW\*K@ +(&VKSW\.U(V6#*Z&GQ%UJ F5%IO0T 3J MVDYX-S_R,?6P3H6HHQW@K)'IG'8F2G&&-VKFR7- ZSQE_K<\^1^P=",/(JUX M0W6,";X!$>2!E/1KD9D%VGJ4@:RXWBN:ZN!9B1!9M!V;?5NL2$/WN2@V#*;@[/6& M#(&=^Z"S][PLK_P]D/\0J/M5W7EI!3Q1D:G_372(#-\)SY!&B1,KTY\13H]# M [8ZLQ[D>/5A1#FLED[!V6#J42/ZFOT=(D>2;,=&KQS&>5:>TU5>T%99]:OG MJHCR8IED4?'"3\(:YJJ%F]1_L<*O,X?BMU\VK-M@243)H/D^;+ MY(%_6LW._.,STOT845]#:Y33;.M-F=A5/6E_E M,.G0+)2"NZ>S##T4]P3,-]ER)\H"&E7LPX=(R:/@ZF^VNT?1+?89:0D(I$)F M6XT-G^VC).6%%W)(<))G[8W^>50FL4F;(T4@4NQ4Y'I=S*KK)I-:&(Q1(8ZT MY&*>D?I?'6>9SM1 #%*VUISD"$8/S[H MS"6[^^0!2\@JKY:_++R-7F":U53@H,6B!Q^(EA*S)IXPE3XJ*C]_30T%&7N_ M8^EY&RR]'$>'+DB:L#7$@-]DUU%2B.H+JQ8JK)N)QV(HH881+:W+UAKIB@=-M7@FP7 LCDR>LQHL6 M&S$BY0UC-!>"E2SUCE)RA;M[B<$KIY=4_/,F8TY(OLNJ\H[&--GWUZ$Q?(BT M-0JNX2R/,Y'O%?L/A T])8$T(M H42]6[*=$G0^U$AUP/94H!J4408)&SEF: MUSQ"&JW(/BM^75H1CU)G(R6,1KG[99QR8'O'%ONH$*%6?,^M^93>G%@\S?& M;>HU5N"7?VY\&K0!798>P;N<%<@%\S?8N[P/EG2Y?G+YQ*V M.74$S%E<)7MKN+(_-Z*Y=0)HTYT'R"!*"'EX(=^#'#;+_D":^*%&5JA;2ID1 M;I'+<^3.+JK][LYX5^G-C4B_$T!K]Y8JCUZ5J_/W>L9"-%Y&@+4Z!E"AJF&&823VUD&? M^%B6QMK$)GD#!FY$NIP >J0W4(L*[\P#2O@?&-D^2BD_GRVK(HG9I $_,.>V M^X<6)=N%ICL( 1(W(5'Z:Y'OMHR#_7LKO(YC1@S9;N_]E8F?" M3EO2(0!??5C\"+N2_M\Z##4@HA 1#HESMD&UPG!#O2LUI$\OC0DX_#@0S5N> M0,T9X&>M$P;!27X+G(-#Y:ZUIT?1*!",\ %@EJR5X7N;O\/D=]EJ)^6JSV:E MQ:(!'XAZM*25)TAB$^VJ;2A=T" '%NWX S5>Z;LX0X: :SF.1?I0MC*S%9(! M3O84#OHD9--B,T$,HA7H$/3&0/-W(@VSW"*15@97!(FBNNNN6#0=(]2#')$J M?5#:/ GE/Z#1T'V\ILL=!'R![WJ=YD_WN^TVY884I>"@IGFY8UVXX.]57-J; M* J19@]M@390I3PXL.!; Q Y(VVAI"65.3K\'4]XJVC=E,Y7G:U4>X.E;ZB, M@WJB+$1V<7 3M C7SEZPMTLT; G9Q!'\[MI0H%$\(GUDALS^K4R6$JVQ*N4! M8A!9PB'HK74K6\)FI!%'.O(:$PAUWEG'PG_D+Z?X!/;OI%I_SO*'DA8\YO F MV^YX&",3Q["*\PSVG\PK98V"AXAEW0QKTK"C? B!?W^:]FE7'NQKZG5;ZX/D MB7V1M#])Q#=)]Z-PYB6_RA^2EBU##)H&;6HO6CKQGE95:G]'?KRO(9K=3M#( M$UHG<[0: ,'2%EB"87@:->/=GI,#D;%X C44EF\']G3C>F:$,X=*NAK'N\V. MWPE?TFU!8V%C[-]3*O?I9YN\J)*_^-]'Q7:]EFQ$!O#J33*\0%4?(.TOS$C] M#6X^[:_,<$:.72=94M$/R9X_J&6-3-B4)@[I6JUL-\2X"(V6@LA<#@!OB.)@ MHMYQ6:01)N/KX1%_8SAM@:%+6)B*$4,%XFO6T6>0PIH6-%I5AJ3JOLQ(,*TTU]'R^9NZ^F)KJM":^5;K_-B19,*[AUA,_Z\31RAJ*?\/B)C M"M)L5[1'&T8GY./AA1BC0@ ,7T+>"3PR8IZT$,U("Y,X+&E0O35[ET6)6R/V MTZY?Y>IH'T&PC!V_;4;9G&]!'>O5,BS@I MZ6V1Q,;;SQ-]^NLT5J\6G\R$%1HBX1"%AW! (6W[=4K @[.[6$>9NQ:\3_;? M0'BPC8+0W7"$H:%['/+Q7L40-@.G!DEJE.I>^ W[W[)Y5J_O)KNE16+.QGST MCWX-GO;HMAYS\G@>= M(GRS^4K^ O$9LA/\#?G5/XW>G(_7XI$O!)3)SGH.">'?FPE;+TGK@ZA?RUM\[^^JG 8/-O,.W0VO;/,M&*@=]P,6R2^TA%[EZR.%]\J+_ LO25:W MW.(I'L,[F0P&VS@(V@?']&8$.N7(<'R0H0O^W!LN5M_]ZQHH)SE5]/WVUS\, M[$T.9O5?SP'E<)^?^MSR,$3?U'#PZ@@<@^2;\J1:+0_O20V#^:;&#%I/JC-< M4'I24PZE9=L_Y3R[)UVJ0PRQ27S5:P#WI[Z&$W[/%A[3A.MO*[\'0F7$]]^Z M:?96TU\A^N>2#<'Z-=Q1K77PZU^C ?LW^F@VW3%IQ%[* =W]Y40SK^D[V'R+ M8S7O^&[#US?A=N_L3NH;N#_]%1GMV!:?Q'=0?R(U&ES&/64#,AA]T?/:7G4' M./;CV'R)D[8Y7&R+YCQ_O48^W9D.C.O;&AI!'?#QHT;SSSE@ HA)DT$DQ/NH MHT7MC8NE#(WE][\''SUHNL X8L)@^NK6&;$E.DK4Y,AO8]LKG++)X=8$>9*. M,YCR-7J\WAF%L7'M\]^$F=M;'<[2:TS!C5UF:! UPA?1LWS6?$XSNDJ,3_/= M'(A,RA.H]E98UO.59=,9(Y&LS?N*>7D\C4 \2:<^_ @U.PJV5;]<"K]\YW(PZWF":M^.-B%C5L+JFZ!I6%A:$PVH( MJ758P7A2&1-[8PV+ON \0WCY:9H_0=H_+YWI;)CUYD#KI;N:G]0"L.CO$W6N M76TZS!IJP_-2"12YS%@5.T!,;E\$JZF105HC[1-=1S/,M?HR>D\UN8FP=:*9S$AO(02%T.4G!F1DD@MBBA9.,I$NK(C.JFQ7*?Y@1PN%AD^[:'N M9)6BCC M]K0\CU*;<^G%B& #-PVO=KY]=4%4U;(9>?_3NQ__:70P2U7YF$N= M09;UG7&E:_^)C>,_V)_5G]C_P0$Y^\O_ 5!+ P04 " !AA']4Q$^C)@IG M YP8 %0 &ED>&R,V9B*F3G=5O\_,V1ORJZ[O=5F^MJO[GOW204N0S&Z*5(.DRSJ_?@&0E"B2 M !(4H4RI/3$S[;(!,%]()!+Y^*__]KJ,1B^,IV$2_^.K]W_[YJL1BZ?)+(P7 M__CJ\\.[\O<.L.XO+)XE_//]]6;=YRQ;I7__^NLO7[[\+4Y>@B\) M_R/]VS19PA9\R((L3S>K??/Z3?D_Q?3_BL+XC[_+__<4I&PDZ!6G?W]-PW]\ M);];?O;+MW]+^.+K#]]\\_[K__WIYF'ZS);!NS"6=)NRKZI9>]__OGG MK]5?JZ&MD:]//*J^\>W7%3B;E<5?0\/X&B1I^/=4@7>33(-,L=WZF9%VA/S7 MNVK8._FK=^\_O/OV_=]>T]E7%?$5!7D2L7LV'\G_"NYMOAK&&>.K8,HDQ[Z6 M?_WZ/!$2*4!5\YXYF__CJW#VNA#+?WC__D.Q^/^],RA;KX1DIJ$4K*]&7_?] M\%D022H]/#.6I38 .@?[ .0NX"S.GED63H/(":K.F0.!*+<-6XKET\E\LI); M7@'[(DND?STDT$_KQ@LW#:9BY &R8[@'8\R!]OHJ2 M+TZ\;TT:"+!;HZ[WD#HW+,IJW_F09W#?&:%VSIQ( _)F+Q\T1H'![;8.H:.Q 8%V$Z322B M.9O!E9%YUD"@704A5Z;%)Q:D0I;4!K!!9IPT$&!W/!$X9VLATI=_YN%*?L,& MEVG.8!*5S+Z$420^,1&JEE_'0G07X5/$QFD*.):A\P<"]T8PR*Y&=D<-IARR ML!"-.W'F U1"Y_"!@!&JAHMM=/FZ8K% M:+^31(OWHG!RYLP> JC, /HW!Y+ M#82$N)DLPTQM-O'5'9'#76Z)AD31M Z>)++ M6$[.CK$#@?%KP'D T*+-<8,9/\*\>BQVOW'20( ]BEV4AE)8*YUL@TH_8Z@] MF*_$ E+=!E%UEY!.';Z$[478],& ?4K9G[GXVN4+Q/K3C4>Z(_FZ*WFZ,[F" M\2A/J,&1VUW5ZS4'A@!DKL\K#PQ*P%2/UQ\8C/:9![H*P%A\)GF#&_/PV#23CB( M;0^#T64-;^8T#%3;O,.8UL#MXK*()S,;"JEIUE"@39_9+(_D!2WG\@VI.'HO M6!:$D1U$T&PD\[F$XE9J[BQ\L?N%!EK?PP.&*RJ0N8,+4+<=[RQ)H&4&!_XJ MC -A:P31=9QF/)?ZH33T9Y/XGDV%> N22IWLCE'_M8='L[K%%!M5!\;G.!&Z MA[](C7,=K_),_%E(D[ ?%3?<*>#CLX,3I^OZY(PJ8!&/]T171>&RQN#TOIZ) MKPGU6K![]^YW+KZ^%G*AI,:9"7U7'AS%ZHJ['SJ05897%;D\#B_3+!26$9N- MEPG/PG\%-2O/70VX+GD@=X7[\=IO/5^G5KR0D!1G9;PHO!9]3RG 6H.C\4E: M7LHUL8EI4F!L0%)@U#P8SLCM^X5!G4^NXF:>Y>?-WA5&X/3!14?MOX;ORUDZ M (L,#KATS#WN^N6E4^!3&X3)?*L&\"];*:?Y*?]N\P6FO_-R3E?(&2 -8F8W"WLJ7JWZ.!L<%AT=( M^G';CONQI.NB>%\\6]<&E4IP_"7@,W=DA_N83\[VWD+V-08'6YQ#O[ TDUZJ MO4"'K7,H\;L7H/!P*L!1)!5ZJ/&;SW&XAZKS\56_KW"NBM%QF<'Y6KZWG:T_ M!;\G_#Q/LV2ITBT<.05;Q\O#HOOE S)[^!<3P=XD+M)&-B^*Y?WAC,5L'KJ[ M#]W7'-Z/S^:,#NT>BPZ. MV.>8B^\MXO!?BK:E=*3W211=);R7E>"\Y.!(B:_^DP4\?;+)\;+0]I]H[NL-C@J8W&C M?C>3L1*"8 _R64EIE\O7:93/V.R*)TNI6_-,<5_LX(#'XIZU":APQG;@#QXD M\L15)ONMYC/JO(=I %]D>&W6"HQQUV&V)0X37 .%VVF5@>E]';[;WN/CV?_* M@RBR,G;#E?BNZYG060D5**DBUQ*B^,?.%/::L5CHC&HAB16X#$$69G)T M61KB_>B=K".A@@S$C\7($I(*EBB9[GP^DO46DD9=@ZIVA:JJD++IWQ;)R]CA,\8%S2OU@KX=(=G[7(4Y8BO5RI1_]WT.8PV[)Z+ MHT)'H9(:B0;0.K'$)PY'T;& 82;AN(J"13=)&T. -'V/0=1.;#"I>L'2*0]7 M]90?#7%W1@)I_ &5QAVX(9"ZVD?W;!%*F"4XFSH09AVAF0(D_K>86L.(+2(7 MQG$L3M=[MDJXA?B[(X$T_PZ3YEVX(9):F#%<6!31&D+MUF @P;_')+@&0T2: M;XUX"-';HX%4_P'5(-'@B$CVAV<61?(2'L0@:>\:#R3]CYBDU^-)A/@J@>%" M'#=P^M>F %GP$Q46M+!%Y,(=XV$R$T<]!]"_-1A(^9\Q*:_!$)WFE_$,2O'- M4/ ="9_@#?00R7T5IM,@*J"Z$K]+S23O& XE.\K=U(HF.NGE&PN8\+7!4+*C M7%5R MJD,*C;Z59R+.9/%C$XV;(Z%T1KF3FI!#H_6YP(G+=,09>_V?;&TB=FLHE-HH M=U$C>FCDON/A,N#KAW!J5R#ML5""H]Q S0BB4?PQ>*U2 (M2XG;":Z= Z8]R M_02AB\8&&=+"5TG-W7PNWTWY^CR9&56\92*4)2CW4@?4T1@SGLVXK'!0_.Y*WM1@Z;UG=)F@71_Q>N;%9F]W@HW1$ON"9$,1R3!?^E MDT,7KM08 J4QRIVV$QT,LDI.4YR0V^G+; MHZ"T1;EQZI#"4,0RDCG5JH':G\'1#JNHHJW)\$A8D#[=MU'9IW34.2FB42Z$>,00JWW$F.";13H)Q ?).TH(O&AE^2*!>4XBH E6OV@F8H ME.R(;Y$:]/#B/8N@ZLUY)#>D+EK?/ -*?,1'23.RB+%P&9-PAR_L(LB"$DH3 M#W0SH#Q ?* T(XL:P\_/Q6&T2,QO\8V!4(HCAN!VHH9&Z(=E$$55'R43H1L# MH81&C+7M1 V-T)=+QA="R7WDR9?LN,2(6B.J> QXW>:]%[EY M1NIWC 975$ DO19)S)(AFX9L#[)F>L UE#>-A](>-?%3CR@"]56KC+IMI0"Z M%O<[4T"%?1:4$RC76BC2>.=MK?J \;C=&0>E.>(%M@LQO#RN_"D*IU=1$ACM M]IUA4!HCWE8[T$(C\5D0_\'S539=W_%DRIA\ADDW.P]P:0(N &4+XCW6B11X MKH5DN90)3LGTCZ+.;ZV'B='!8)P'90]FDBD <43K*-TFH+'9V?I>UF"7(1"/ M[#4[$Q_[PVPL :9#>81:&0E,!@1674_G7#G,$S[.,I86I-,'*9C&0YF!T/HW>CS8NF M*K$=ITD4SN0),RKGC\H%]I:1>9 ^*0[DZ;M%$*R4H'S-HBRM?J/DY=TW[]^5 MQSL1=G?+:##Q MH)+V94=Y*X%RI34"[#,J_B,[>;X$D32&Q]E.!W$] M>X#3TW/? DV'KO1SE>,QRM+GD/+ADQ)L*5JOO'/9LR(4=/ M$;MEF94YYEEH=0^VZ'$EP@P@'_JQ8'A/ M8)^=8:&^@+UHA7A38*V%4(&7)5D0J9&X?+OCR8KQ;'TGKC:9.$+E\;F2)JS8 M]GHVFF>A555W,?0@B!/96VKS7PL"QHM0*.0"/2-_]#/0RJV[\,:&,!&^?$R2 MV9A>Q,A(G2>B(T:R'>Q&Q:D[%[VH9S,/Z>%7!@V@7D: M7CEVIZT P9T*G[9&RFT23QULLOIPO'KMSBI*ARL1?A3@V8PQS%+M[IZ9DS&\ M:DVRA?6AGIJ?DT@0.I662+:VN]G@*^ 5A=_?,>I*)R)[KP8VV&]JFH-7;[XO M'[1LI.UC_ KI_F>+S"]7"*=[M^NC$GPI[+Y2I*UHS=LTB^R;61 MU',*,!6O_GU?IH'I081_A=TTG?+7B%]/MR#D8)(FRK 3B97X3I*DF# MZ"-/\M5U/(UR&1\M22QE:][+XQ7P;\OXP>B)3W)<&&V,_^\ M>4;VX=^I>8.KU+?S9/DD['0E=4H.%P)+&0L3SDIAK(BPAMST]UP6KQE!7Q$9 MA(Y$-OBN!\J)[X"I>-T.AKG7@*E#A)LW0BXG\W.AF$*CHJZ/PFN+,-3=LXTS M%78D\>*1\>5MDK'JXF5@2^=HO/8) [''0 ,B;%*V>@U-L'M;,P>OY<) 6L]* M#R*,J\$(,DLQ.S,,[F@[&;-4IF.%F4KYD5%^E24U-7+5. FO#\0P7 90A,@. M?&1+F:'%UP5>543F>"E]C>,LX^%3GDF5_YCVF ,P\^C>;^J9<#:PLE;(_'Z:<"IW%:G7=@28<9X-E-/I4%T%X2S MZ_@\6(7B9*Y!;7B? LS%:]?1EV%PBA!AX3W+ G$-G5T&/):Y_N/I-%_FZLWF M@LUE#P<]"R%S\=J!]&4AG")$6/C(69#F? U1BEUC\1J)]&61'F/W*\7/Q94B M9@OU3HE_J6A3P\4DP>Q0TI>=>HSQ;HCA['6A./3^0\F?ZXO__5$?':7EE)QF MG877R\299R!\2.E'FVD,O_^EGU_ /P>S<\1S7&V3=H2<4\JMG>L:1.A>@H "8:('1ZU\__M$?!NRU"IT=,Z M2YLNQC[4(<+9QK.1,)TG7"$^4UZ<.\9564OP4YM^ >RB/F!V.I*$)B.+8J3C M/'M.>/BO[<7,RL#V1.SR/GT9IR,!98:IQDRNS*HF81]\^S%J%W7*3#+7-C;A MV*>ZL4) ':??C##09NQX0F',.I*#'//@19IR$73FH#[.('UTM M2&W'EG8"=@&@_LPA>5PYEN'7X=;GF/(61]6?172/J)WG\@)88(1 -1B[2A#< M>-"C2J'2\[8I[62^R9_4E'S^SO0(M5UHE,Q'M:40Q4QV/5BR#63V%R?M!-R MJ!<6Y^Q*B* ,7Y8 _1IFS^=YF@E@^>5KF0HKR[Z(_YT]!J^F"*D>BR$[HBQL M;$5+]287$>UXGJ399%[B83JV=H9A^Y?2G>[-]RX;_D08=2_H*("0A>(OA(:.$E7NU5WL ;>R3-40$LD4EARLE@2+= MKDS6HGLZ/H+B>BV/.@ KZX/1ZW_W= RT$3YZ9E[+MPR65O M[=N-G2:43\ \:Z!7&O=W 3/O.>L7G"63'N,7AEZ>6KP%[07-B)?*T> MR&7I,_D@ER@O:"7LML=83Q]%KU_NJAJ\,^ $+((2]W(/G;&8&9_PM!/02Z3W M$0XMXD>C0_91!03*FP^]HT]L8U:H=E9LESWK)G-CY(K;*NC%TO>1!AB)B.QK M 1;D/MT8AEZIW(T_G4@>_<;%]T[/4=AL]++E;HQV M(D(702Z7OH0#@A#IZ%5'5G*O2 M911V,B(BC'(APO8H*_ "Z,79W03"D3!$#FN[U2GP::!BR1C;8TGTXNZN3'0U MX2W$)"D49N-S3_'HN3AZJ?DA!64O A,1&0L]>A\'!.K-[\=J(&&(L/%7)MMD M"Z2$E1LLV&TN:Z],YJWT,?LQ[[X2>L%YM_.^+ZF.C-,6,]]Q&?0B]+VYUH_Y M.MN?(.?KAPLL3=9Y(?3J]GZY;Z,@W?1.0,'1[_OD>E(J/7H:N9\H(:LT#ER7 M>%4WWXK8QD])RK!K -?W9MV!U*SIO[,O?X#OR_J:_T^P2M+_'(VJM2G4!MW% M&M[S!C2=1/738Z\*W*-N_EM9X -PYNC+ I<]NI+E*HFEN@*6!NZ>=HS,Z<:$ M2HG@[9N&K1!MQU#L.@0@(=.7SB%9?W:GB(R-)YV#L2L4].&* 6LB?-$TU[)Q MR#(-N_I 'UZ!*$&$:\U^6C9VZ<9CUQ_HPRY%Q(ZET!GA+@6_9%_"YJB3T$$4NUE73E @[SL:L$V5GFB! V8_JS!+]\T&#,. Z= M68C,Y7(5)6O&BM8!.9\^!RF[BP)3DEKO!;$K"0US;-I)1IOQ2L]KD>AW0AJ6 M0R_^,\BY:*47$9YW5&%7=>2XL=F0:1)Z79]]*M W<:?()25?%:"RQ-\GECTG M4'9I9Z.7\.G'-PLU,%/1-&;1-GXG?4PTSP.7K[+R11ZFSV7 @>H(:31C]U\6 MO>H/S*(:BGY$]C8$G2+=,@N?(G;!GHJR_9L,S"L6R&L6)/!MWR^@UPV"M]X< MF*J>KD@0,.LA?I-Y4<-"=B2'2 !TOSA\ [V1*+'XL:"N-9LC)4T89,1*_W U/0:4,M4Q"]G8EA")$_@E%"P^6W\65XCK>%.W?#S-PA=Q M58"T<^NS%G)")(2=;?.])\6(6#!^[U>^.+4'V7T6$NS.9$7WU<@K?CP-([:# M[6,RV%[W\S7L>./!A,PG,XBHD0LFN#,-%6_$SQ%33(IGL!QYV&SL:&2O;$QZ M$(24!(@+/%=@EE6O!5&VC9VS>_$G7IRM3U&XL!68[K48=J3S >5C#V(3$1=% M _76D?"+)'_*YGE4^H",-6Y-L[#CG0\H !#R>7)@RB;A/ VBR?PLB?-4BF*^ M+5O3<%;J!F-'(1^"52;\\<-$!MK'5T'(BV"8#44G\U\#V6_.M)$MT[ CG@^X MDT$$)**T=U^NK\(X$'2)%Y:&N.99V/'4ASRU >3S%?$A%8^$NF@R93L&(\>37U K6RFF2=]K W4U_?=D_/LT]#CJ0^UB:$4])5E5G91WIAO MDWE-K6C89YN$'@I]*.;!J$?P:+THP:@U]M/PNG,D>B3SH1ALH-,)'+,?@S"6 MI)K$,I-R,A?$$N3)UE+]J.H_*TEA_;$+G8\>]'S 8]B-IB<@1&=Y&L8L3875 M\22N@I*G1<^2AO*2U5RJ2\6&2G.*NV2N'JJ[I]R$P5,8A=GZO5X* M#P8 >G#U <7XP%REXAB2SP[7RY4XSB4^ AV^,)6QT(U'C]L^I#?(2#,BC*W: M8D\%RHZ-P3NFH,>('Y"]5LJ=P!$F\)))L>R"%?\5=))8;XDE13P=Q[-*<86R M&A>L^/]^"Z,'OA]0T@;B A&-T\:F>M<45&3AB[F&.VPV>MC]4"RS"8*>=*>K M?PM)> #UOX*#RHB/@28I,I4OU M+EZK&G9U]'IMKGO0 TCOV1W2.]OY??F ^Q!$@2S%(1!2<3@:GZW#?/1>N0-S MT!']T][G$N<:V1RW>FLV>KO< ^YV#>D.MN%ODGB1,;XTLZ];VCOGHC? /4Z?F'I0$F0QK70F_0. MEP8)H!D1KY.P3ZN2.D51OYWG1Z%< :^Z+FN@]^+=@V-);ZQ/YD 1.$X9FZ57 M@JP=S]5 >7%9!)S\1E]@W&E'1$G 23#$B0#G^:'3K-UY[DZY4S4C-E'_ Y@1 MQK6@PN._@LG>9@2 9D0T1%VWR1+= FPFHSDVQ?AAIX%F*I2EWKR&>_!'?P88 MZ42:KW>58BJ:D,2SXA=,_+$7L^WK027 F]?1LP1 *>K)G50'ZB;I[#(@Q[6' M0?GBS<.W/U^Z$?-*;OF)ZI,:4N\.@9+9FR]N&#)WX>V1Q&7><]6Y76[2)BP/T;J9T Y[1?(S M=P'O+%0H)QC&0_EX:%>2XXZU4N0$MF_]?*T+[8T,&1?VK\ H!#J,#-/!=7#H M"H0;PK2N"B645PD7()=YB9.Y>K.SU2*%S(5R]]!.H1[UD45;A_83?UDA M[/)UJI*-[L7&N)S/F&@XH$+KOQ44W&>)PRLBA]U>R&_0O C359(&T4>> MY"LQ0_Q[JA+@JR0/HA7,3A/)S*]_AM8Y8D"J=U,VNG M>/]/HW^! MHO+N78WBF]IM0;3M2F!_Q1UH>=1TX'U0V$J'3<(>A0B?1<87M,-#@MR<8%#A M;.8J([&50G\2F1I9!_9!]C<*^$RCYGYNJKEB?EV5;5? +<==PE/4EI!:_9+S MA)\GXH2:JD,,4-C?:15<_XJNA9B$N81^DX^DQH1"D%<12-L,LSJR!NDC$BU? MS'!4IK#Y/R:J_JK @<>=^_W]-\W]KJ:,JCG'>A;_):R5A_Q)=JO+!&BJ1OKX M*/:K,QNZQTXE-<4K>75L#F M=EX(M;?,#DSUBWH'#EL6 C;W_BLC;_F> M'L-C,0@2EL^4U%T4\LD$ JY=:] MXS\T=[R<.U*31SNS*;17V (*V-[F623:1=0@ VQ4RS3D70AADJ[K@XD.%/93 ME9O3F9:SLYV^;6ZG:JIR^VTGX\;?="<:V;<48"IR9%$W>$[GH=LJR+L.S,QV M4)$SJ2CLQ(]),OL21I$ 687(7(N%XT7X%+%&\9V=7?E=^_Y:+*-VI5IHM%UI M5"Z%65MYBV83PYJGT;I?'9=!K28- 16P>UW70=Z_O1C=+!K=BW04=O.-#/30 M[-GOFWNV'#QD'?O-\L7:A@VERKEKAV-NG!LF.,TVM2@*T ;Q38/:V.8*=VY M 6 D&+BA,<(;3=704A[:FEWS0_MEIIHU*J9A1I'46LNH,(0*-);?U71#[E>C"^::_N24P*IUU9&*S*R*IPD56G MWNG*3NUL[A^;F[M<<50M63-GU:J/8M51?5GD!G_8;9Y/ZZZ7FBC MS-ZWHLQJ*R@5L+L&[HFO0\WQS'=9!C52%@(J8->[KH-_PKLSNAFZVHMT%'9P M(U%K9[.V8J7*P8@R6D!@WW;-<:AA#++RQ7,2"2E."[ADDK/3EG)8 GDW=3.H M&8W@2A$*.Z4S,[V^7SZT8HW4E%$U!_,)GCTYW51UXU'#"'9@@D0'Z"9@/_H; MF=%\VS=C36%CM)K=[VR*5ES.9K@7=VBU.M@AVIXP9)V(:G63N,J!'>-H>#%U M]*R7?M B>>Q^2W5.O7O2]I;>$?16.$HQ6W6F'NU,1XY *P!4Y=HV,)4%.\Z3 M-$M50VV%=)7A#PM(VV==Y/@T&.QG==AAX6G[+8Q]4 TB+.U@M2&H3>'@NVD?\K[Z648 9X' $%3-U#(-UX41RVR> M(M11PNGHN(#,1MZ4(*:UW!-PLE#86%U=QW=V52LJII@Q*J;@MJ,I('>Y;1DG M(3?7:0(&V$;F6Y>(@O669;%)ZQ[@Z3;OW M42M212VB'/'E,B.QSD@N-%HQ/BJ6PO3_!3P.X\4&+8 G4#L#=S\"2'#TCLA\M8I4 MP%@05>64KN-YPI<&AV0KUJ*^RD@N,Y+KC.H+H69[MW&\C*#I[K#9V(7()%1U M2-VRZ. K()]=+JSL* +F0B4*!YE,KF=_YF*]RQ=MNNJ'5C3%=MJHG(=<:Z&. M V3'Z69@UXRH0P4L$:&9@KZ/S$SI*/)@Q)W"9G&M5F>L6O=M.^2B5]6ZT;]5 M/_W[6TD8+R5A-.9K4QH4&]8V$]8ZZQ0KN8 0U^YSI->8+>IVSFX?*PRS@)SU M5CW?9Y$>"+V(L/:SK/1_F6:AN#>82MXWQT'[YAXC^[IIXJDQE'Q&YFG15>UA M%8493'/:IX$;U1X3AV"HD]IA9<'C9L%YL!:%30?WFCDF;KN1@!37'WDP8U5& M4)4Z)$N4"O"?(E8 K^WS(F^KJ&8 T\Z >4#6 M>>N@Z$T]@VDVL"^75+4?L'J'KP 4&&_]('WN=512K".,\8_PAF6=?!&7!LM!S.:!@>&L?Z5,P]J(P$2FY7JZ"D*L6&KRJ\#B9 MR^3XF_"%S0H=N2GVV"R?4^ &EB$O'P-*F+?&ECXES"-WB,B?(:?5P9<#7P/L MV3E&<7$G)A$I*,/590=/";5$\=

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end